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The cellular proto-oncogene c-Src is a non-receptor tyrosine kinase involved in 
cell growth and cytoskeletal regulation. Despite being dysregulated in a variety of human 
cancers, its precise functions are not fully understood. Identification of c-Src’s substrates 
remains a major challenge, as there is no simple way to directly stimulate its activity. 
Here we combine the chemical rescue of mutant c-Src and global quantitative 
phosphoproteomics to obtain the first high-resolution snapshot of the range of tyrosine 
phosphorylation events that occur in the cell immediately after specific c-Src stimulation. 
After enrichment by anti-phosphotyrosine antibodies, we identified 28 potential novel c-
Src substrate proteins. Tyrosine phosphopeptide mapping allowed the identification of 
382 non-redundant tyrosine phosphopeptides on 213 phosphoproteins. SILAC- based 
quantitation allowed the detection of 97 non-redundant tyrosine phosphopeptides whose 
level of phosphorylation is increased by c-Src. A large number of previously 
uncharacterized c-Src putative protein targets and phosphorylation sites are presented 
here, a majority of which play key roles in signaling and cytoskeletal networks, 
particularly in cell adhesion. Integrin signaling and focal adhesion kinase (FAK) 
signaling pathway are two of the most altered pathways upon c-Src activation through 
chemical rescue. In this context, our study revealed the temporal connection between c-
Src activation and the GTPase Rap1, known to stimulate integrin-dependent adhesion. 
Chemical rescue of c-Src provided a tool to dissect the spatiotemporal mechanism of 
activation of the Rap1 guanine exchange factor (Rap1GEF), C3G, one of the identified 
 iii 
potential c-Src substrates that plays a role in focal adhesion signaling. Phosphorylation of 
C3G on tyrosine 514 is known to increase activation of C3G. Translocation of C3G to the 
membrane by the adaptor protein Crk brings C3G to close proximity to its effector Rap1. 
Chemical rescue of c-Src allowed clarification of the timing and connection between both 
events as well as the identification of Crk phosphorylation as the possible event that lead 
to the observed C3G-Crk disassembly. In addition to unveiling the role of c-Src in the 
cell and, specifically, in the Crk-C3G-Rap1 pathway, these results exemplify a strategy 
for obtaining a comprehensive understanding of the functions of non-receptor tyrosine 
kinases with high specificity and kinetic resolution. 
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CHAPTER 1 – INTRODUCTION 
 
1. Signaling networks 
 
  Cells have the ability to communicate with the external environment through 
dynamic signaling pathways. These pathways receive signals from the external 
environment and from different regions of the cell. Signaling pathways generally 
interconnect to form signaling networks. This complex dynamic spatial organization 
results in a higher level of cellular coordination with the environment and other cells (1). 
 
1.1. Components of signaling networks 
 
1.1.1. Receptors and ion channels 
 
Cells receive external stimuli through cell surface molecules such as receptor 
proteins and ion channels. Receptors can be extracellular and intracellular. Extracellular 
receptors are integral transmembrane proteins that, upon ligand binding, change their 
intracellular conformation leading to a cascade of signaling events.  
An example of extracellular receptors is the G protein-coupled receptor (GPCR). 
The GPCRs are a large family of receptor proteins, which consist of seven 
transmembrane domains. These GPCRs interact with a heterotrimetric G protein and, 
when activated, lead to signaling events to several downstream effector proteins.  
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Receptor tyrosine kinases (RTKs), such as growth factor receptors (i.e. insulin 
receptor) are characterized by an intracellular kinase domain. Upon ligand binding, RTKs 
form dimers in the plasma membrane (2), which leads to autophosphorylation of 
tyrosines in opposite monomers. The resulting conformational change leads to kinase 
activation and a consequent signaling cascade. 
Integrin receptors (integrins) play a major role in cell attachment, both with other 
cells and with the extracellular matrix (ECM), as well as in the signaling resulting from 
ECM components such as fibronectin and collagen. After ligand binding, integrins 
undergo conformational changes that lead to clustering of integrin molecules at the 
membrane. Integrins do not have kinase activity. Instead, downstream signaling occurs 
through protein kinases and adaptors coordinated by integrin-linked kinase (3). Other 
relevant extracellular receptors include Toll-like receptors (TLRs) and ligand-gated ion 
channels. 
Intracellular receptors can be categorized as nuclear receptors, with the subclass of 
steroid receptors and the subclass of the retinoic acid receptors, and cytoplasmic 
receptors, such as the recently identified NOD-like receptors (NLRs) (4). 
 
1.1.2. Second messengers 
 
 Second messengers are molecules that transmit signals from receptors to target 
molecules inside the cell. Enzymes can synthesize, activate and break down secondary 
messenger networks (i.e. cyclases synthesize cyclic nucleotides). When ion channels 
open, they can also allow the influx of metal ions like Ca2+, which can be stored in 
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certain organelles and released at specific moments. The input and output of second 
messengers can be localized, allowing spatial and temporal compartmentalization of the 
signaling activity within the cell. Second messengers bind and activate other proteins 
continuing the signaling cascade. They are able to significantly amplify the strength of 
the extracellular signal. 
 A common mechanism of secondary messenger systems is the following: A 
neurotransmitter (first messenger) binds to a receptor protein. This binding leads to a 
conformational change that exposes a binding site for a G-protein (transducer). Upon 
binding to the receptor, the G-protein exchanges a GDP (guanosine diphosphate) for a 
GTP (guanosine triphosphate). The G-protein alpha subunit detaches from the beta and 
gamma subunits, and moves along the inner membrane, where it will eventually contact 
another protein bound to the membrane (primary effector). The primary effector produces 
a signal (second messenger), which is diffused in the cell and will eventually activate the 
secondary effector (Figure 1). 
 Second messengers can be classified in three major groups: Hydrophobic 
molecules, such as diaglycerol and phosphatidylinositols, that diffuse from the plasma 
membrane into the intermembrane, where they bind and regulate effector proteins that are 
associated to the membrane. Hydrophilic molecules locate in the cytosol, such as cAMP, 
cGMP, IP3, and Ca2+. Gases, such as nitric oxide (NO), a well-established signaling 
molecule, and perhaps carbon monoxide (CO) and hydrogen sulfide (H2S), can diffuse 
through the cytosol and across cellular membranes to transmit information. A few 




Figure 1: Mechanism of activation of second messenger signaling  
 
Representation of a common mechanism of secondary messenger signaling activation: 
The first messenger binds the receptor that will undergo a conformational change and 
expose a G-protein binding site. The G-protein will bind the receptor and exchange a 
GDP for a GTP. The alpha subunit will detach from the beta and gamma subunits. The 
alpha subunit will contact the primary effector that will lead to the transmission of a 





















transduction, are analyzed in more detail. Calcium is involved in many biological 
processes from muscle contraction to cell migration.  There are three main pathways that 
result in calcium activation: GPCR pathways, RTK pathways and gated ion channels. 
Calcium is released from the endoplasmic reticulum to the cytosol. There, it binds and 
activates signaling proteins, like calmodulin. Calcium is sequestered afterwards in the 
smooth endoplasmic reticulum and the mitochondria. 
 Lipophilic second messengers are formed when enzymes stimulated by activated 
receptors modify lipids from cellular membranes. Ceramide and diacylglycerol are such 
examples. Nitric oxide (NO) is synthesized by the NO synthase from arginine and 
oxygen. NO affects the biology of cells through different mechanisms such as oxidation 
of iron-containing proteins, activation of soluble guanylyl cyclase, ADP ribosylation of 
proteins, protein sulfhydryl group nitrosylation, or iron regulatory factor activation (5). 
NO can diffuse through the plasma membrane and affect surrounding cells.  
 
1.1.3. Intracellular signaling peptides and proteins 
 
These signaling components are found in the cytoplasm and transmit extracellular 
signals to intracellular effectors and regulate the activity of transcription factors. 
Signaling enzymes are proteins that catalyze chemical reactions and serve a broad variety 
of functions in living organisms as diverse as active transport (ATPases that constitute 
ion pumps in the cell membrane) or generation of movement (Myosin ATPases that 
contribute to muscle contraction). Enzymes are indispensable for signal transduction and 
cell regulation, often via post-translational modifications of proteins. Through these 
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modifications, cells can regulate post-translationally key cellular pathways. Among these 
post-translational modifications are phosphorylation (kinases and phosphatases), 
acetylation (acetyltransferase and deacetylases), methylation (methyltransferases and 
demethylases), ubiquitinylation, ADP-ribosylation and sumoylation (6). 
Considering the type of signal modulation that the signaling enzyme is 
responsible for within the signaling cascade, they can be classified as amplifiers or 
coincidence detectors. Amplifiers tend to increase the signal by producing large amounts 
of small intracellular second messengers or by activating a variety of downstream 
signaling proteins. Coincidence detectors are signaling enzymes that are only activated 
when several signals occur together. As an example, cAMP-generating adenylyl 
(adenylate) cyclases are modulated by G-proteins, forskolin, Ca2+/calmodulin, and other 
class-specific substrates. 
Adaptor proteins are non-catalytic multivalent binding proteins that serve as 
platforms for the assembly of signaling molecules (Figure 2) (7). Kinase-phosphatase 
signaling complexes modulate the phosphorylation state of their substrates. Signaling 
complexes related to tyrosine phosphorylation were identified first. Many tyrosine 
kinases and phosphatases function through adaptor proteins. These proteins contain SH2 
domains, which bind to certain phosphorylated tyrosines as part of the signaling process, 
and SH3 domains that bind to PXXP motifs in other signaling proteins including 
cytoskeletal components and small G-proteins (8). Signaling complexes of 
serine/threonine kinases form through two different types of adaptor proteins. Scaffold 
proteins simultaneously associate with several kinases of a signaling pathway in a way 






Adapted from Scott JD et al., Cell 1996 
 
Figure 2. Schematic of two types of adaptor proteins: Scaffold proteins and anchoring proteins 
Adaptor proteins: scaffold proteins serve as a dock for several kinases that are 
sequentially activated as part of a signaling pathway. Anchoring proteins localize proteins 















specific regions of the cell, and localize their bound proteins close to their site of action, 
providing a spatial dimension to signaling. 
 
1.2. Signaling domains 
 
Signaling proteins often have a modular organization formed by catalytic domains 
separated by regions that serve as docking or substrate sites for other signaling molecules. 
The Src homology 2 (SH2) domain is a compact domain of about 100 amino acids that 
bind phosphotyrosine-containing peptide motifs (9,10). Most proteins containing SH2 
domains are recruited to sites of tyrosine phosphorylation to help in the coordinated 
assembly of molecular machines (11). SH2 domains can also influence enzymatic activity 
in different ways. The SH2 domain of human FES cytoplasmic kinase stabilizes its 
activity since the kinase is only fully active when the SH2 domain is bound to a primed 
substrate (12). In other contexts, SH2 domains can also suppress tyrosine kinase activity, 
as in enzymes like Abl, Src, Lyn, and Fyn (13,14).  
 The smaller Src homology 3 (SH3) domain contains about 60 amino acids and 
binds proline-containing sequences capable of forming a polyproline type II helix (15). 
 Pleckstrin homology (PH) domains bind to phosphatidylinositol lipids that have 
been phosphorylated at particular positions on the head group. In this manner, PH 
domain-containing proteins can be recruited to activate signaling complexes at the 
membrane through interactions with phosphorylated PtdIns lipids (15). 
Many other types of domains have been identified, like EF hand domains or PDZ 
domains. There are specialized domains found in cell-surface adhesion and inflammatory 
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responses. Some of them are: cadherin repeats, carbohydrate-recognition domain (CRD), 
caspase recruiting domains, CARD domains, C-lectin domain (CTLD), death domain 
(DD), death effector domain (DED), Ffas-Associated Death domain (FADD), and zinc 
finger DNA binding domains.  
 
1.3. Cell signaling in space and time 
  
 The components of signaling pathways are organized in sophisticated regulatory 
mechanisms to ensure that signaling enzymes find their intracellular substrates in the 
correct place and time. Several mechanisms have emerged to ensure the accurate 
coordination of events in space and time. 
 
1.3.1. Signal-dependent formation of signaling complexes 
 
The flow of information commonly requires the dynamic formation of protein 
complexes, and this process can be initiated by posttranslational modifications or protein 
oligomerization that can generate pockets of increased enzyme activity. Different 
covalent modifications can be used by the cell to facilitate signal-dependent recruitment 
of proteins. 
In the case of tyrosine phosphorylation signaling, the building block of these units 
is usually a complex of adaptor proteins that recognize the activated receptor (through 
their SH2 domain in case of upstream RTKs) and bind other proteins through their other 
binding domains, such as SH3 domains. Adaptor proteins such as Grb2 (SH3-SH2-SH3) 
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or Nck (SH3-SH3-SH3-SH2) are examples of this strategy (16). As described in the 
previous section, SH2 domains can also stabilize or suppress tyrosine kinase activity. 
Other modular domains regulate serine or threonine phosphorylation events. Specifically 
these protein interactions occur through pThr and pSer binding molecules like WW and 
FHA (Forkhead homology-asociated) domains and 14-3-3 proteins (17) (18). Sometimes 
the assembly or disassembly of signaling complexes occurs in specific subcellular 
compartments. Certain domains have their ability to target the protein to certain 
subcellular regions through the recognition of phosphoinositides in particular membranes. 
As an example, protein kinase B (PKB) / Akt protein kinase and its regulator 
phosphoinositide-dependent protein kinase 1 (PDK1) both have PH domains that are 
selective for PI(3,4,5)P3 or PtdIns(3,4)P2 that recruit the kinase and its regulator to the 
membrane when PI3K is activated (16).  
 Ubiquitination of lysine residues is another posttranslational modification that 
aids in the formation of protein complexes (19). While polyubiquitination often leads to 
degradation of target proteins by the 26S proteasome, mono-ubiquitination and di-
ubiquitination also mediate other cellular functions. Ubiquitin-binding domains (UBDs) 
bind ubiquitin in a similar manner than in phosphotyrosine signaling (20) but with 
micromolar affinities (21). As a result UBD proteins usually control transient cellular 
processes.  
 Lysines can also be acetylated. This posttranslational modification is usually 
associated with changes in the activity of histones and transcription factors (22). 
Acetylated residues can recruit proteins containing bromodomains. Also, autoacetylation 
leads to conformational changes of proteins with intrinsic HAT activity (histone 
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acetyltransferases) as is the case with the transcriptional co-activator CBP/p300. In 
addition, acetylation can inhibit ubiquitination of the same side-chain, resulting in a 
prolonged half-life of the protein. An example of this last event is the tumor suppressor 
protein p53 (23). 
  
1.3.2. Signal processing through preassembled multiprotein complexes  
 
Another way to regulate intracellular communication is by the flow of signals 
through preassembled multiprotein complexes where successive enzymes of a 
transduction pathway are clustered in an orderly fashion. The molecular glue is a scaffold 
protein as described above. One example of this modulation is the clustering of the 
kinases involved in the MAPK (mitogen-activated protein kinase) pathway by scaffold 
proteins such as KSR and MP-1, which will be thoroughly discussed bellow. The benefit 
of this kind of modulation is that it enhances the precision and fidelity of signaling 
events.  
 
1.3.3. Signal regulation by subcellular localization 
 
 Another way of spatially restricting signaling events is by compartmentalizing 
enzymes in close proximity to their substrates. In this manner, many kinase- and 
phosphatase- binding proteins are recruited to sites where they can receive activating 
signals and are near their substrates (16). 
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 One family of anchoring proteins are AKAPs (A-kinase anchoring proteins). 
AKAPs organize protein kinase A (PKA) holoenzyme, guanine nucleotide exchange 
factors (Epac) and phosphodiesterases (PDE) into cAMP-inducible complexes. There are 
about 20 AKAP genes and about 75 alternately spliced transcripts that are targeted to 
different organelles within the cell. As a result PKA can anchor to different isoform 
targets in different localizations and restrict the action of PKA to only a few of its 
substrates. 
 
1.3.4. Temporal control of signal transduction 
 
 A different way to modulate cellular events is to induce changes in either the 
composition or the amount of enzyme complexes over time. This usually involves 
synchronized phosphorylation events, ubiquitin-mediated degradation, and translocation 
of signaling components. A good example is the activation mechanism of NF-kB (nuclear 
factor kB), which involves the phosphorylation and ubiquitination of several components 
(24). 
 




Protein tyrosine kinases (PTKs) catalyze tyrosine residue phosphorylation, by 
transferring the g-phosphoryl group of adenosine triphosphate (ATP) to the hydroxyl 
 13 
group in the substrate. Phosphotyrosine (pTyr or pY) modifications can modulate the 
enzymatic activity of target proteins and can also disrupt or stabilize protein-protein 
interactions. Many tyrosine kinases have the potential to cause cancer and are considered 
oncogenes (25). There are approximately 100 PTKs encoded in the human genome, from 
which about 40 are nonreceptor tyrosine kinases (NRTKs) and 60 are receptor tyrosine 
kinases (RTKs). 
 
2.2. Structure of protein tyrosine kinases 
 
Receptor tyrosine kinases are composed of a ligand binding extracellular domain, 
a transmembrane helix domain and an intracellular portion with tyrosine kinase activity 
(Figure 3) (15,26).  
 Non-receptor tyrosine kinases are mostly localized in the cytoplasm although 
some are anchored to the cell membrane through modifications such as myristoylation or 
palmitoylation. NRTKs possess a tyrosine kinase domain and can contain one or more 
different recruitment or regulatory domains that mediate protein-protein, protein-lipid, 
and protein-DNA interactions, such as SH2 domains, SH3 domains, or other subfamily-
specific domains. Some examples are an integrin-binding domain and a focal adhesion-
binding domain in focal adhesion kinase (FAK), or a nuclear localization signal, an F 
actin–binding domain and a DNA-binding domain in Abl kinase. Another common 
domain is the pleckstrin homology (PH) domain (Figure 4) (15). 
The structure of the kinase domain is highly conserved among all tyrosine kinases 





Hubbard SR and Till JH, Annual Review of Biochemistry 2000 
 
Figure 3. Domain organization for a variety of RTKs 
 
The horizontal double line represents the cell membrane. On top of it, the extracellular 
portion of the receptors is represented, whereas the cytoplasmic portion is on the bottom. 
The length of the receptor is to approximate scale. The tyrosine kinase symbol (red 





Hubbard SR and Till JH, Annual Review of Biochemistry 2000 
 
Figure 4. Domain organization for a variety of NRTK 
 
The NRTKs are shown from the amino terminus (left) to the carboxy terminus (right). 






lobe with catalytic residues and protein substrate recognition elements, and a deep cleft 
between both lobes where the active site responsible for catalysis is located. 
The ATP g-phosphate is oriented outward toward the active site entrance and the  
adenine is positioned inside a hydrophobic pocket. The ribose interacts with the kinase 
structure through hydrogen bonds. Mg2+ interacts with the two or three of the phosphates 
of ATP. A catalytic aspartate acts as a base that removes the proton from the hydroxyl 
group in the substrate tyrosine. There are several other conserved residues involved in 
substrate positioning and in coordinating the metal ions.  Most tyrosine kinases have an 
activation loop containing at least one regulatory tyrosine. When the tyrosine residue is 
unphosphorylated, it often interferes with catalysis and autophosphorylation of this 
tyrosine residue leads to a conformational change in the active site that facilitates 
activation of the kinase. 
 
2.3. Regulation of protein tyrosine kinases  
 
After decades of research, the developed model of RTK activation is that ligand 
binding to RTKs stabilizes dimer formation from receptor monomers. This facilitates 
intermolecular autophosphorylation of the kinases domains in the cytoplasmic region of 
the RTKs (27,28). Autophosphorylation of up to three tyrosine residues in the activation 
loop further stimulates the kinase activity (29). 
A signal induced from an RTK can be attenuated and terminated through different 
mechanisms such as inhibitory ligands (30), inactive RTKs with ability to hetero-
oligomerize with functional RTKs (31), certain RTK phosphorylation events (32), 
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receptor-mediated endocytosis (28), ubiquitin-directed proteolysis (33), and protein 
tyrosine phosphatases (34). 
Regulation of NRTKs can be modulated by phosphorylation of tyrosine sites in 
the activation loop or at other positions.  Other forms of regulation are dephosphorylation 







Prior to the identification of the src gene, a virus called the Rous sarcoma virus 
(RSV), was discovered by Peyton Rous, and was shown to be the causative agent for the 
development and transmission of chicken tumors called fibrosarcomas. RSV was later 
identified as a type of retrovirus and its molecular details were elucidated. Certain tumor-
causing retroviruses contain three genes: gag, pol, and env, in addition to a gene called v-
src that is required for the development of cancer (35). The v-src gene was the first 
oncogene identified. Bishop and Varmus discovered in 1979 that chickens contain a gene 
that is structurally related to v-src and it became known c-src, for cellular src (36). This 
discovery led to the groundbreaking realization that a gene that is normally present in the 
cell could cause cancer and was therefore classified as a proto-oncogene. Erickson, 
Sefton, and Hunter showed that Src was a protein tyrosine kinase (37).  
The gene v-src was first sequenced in 1980 (38). v-Src protein is not negatively 
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regulated as c-Src is, because it lacks a C-terminal inhibitory phosphorylation site 
(tyrosine 527). This explains why v-Src is constitutively active (oncogene) as opposed to 
c-Src (proto-oncogene), which is activated specifically in certain cellular stages. 
The Src family is composed of eleven tyrosine kinases with a high level of 
homology: Src, Fyn, Yes, Yrk, Blk, Fgr, Hck, Lck, Lyn, and the Frk subfamily proteins 
Frk/Rak and Iyk/Bsk. Members of this family are involved in several functions including 
cellular proliferation, differentiation, survival, adhesion and migration. The functions of 
Src family kinases are redundant (39). For example, Src, Fyn and Fgr are involved in 
cellular adhesion through integrins, cadherins, selectins, and focal adhesion kinase 
(FAK). Src, Yes and Fyn play roles in RTK activation pathways. Fyn, Hck, Fgr, Lck, 
Lyn, Src, and Yes are involved in cytokine receptor activation. 
 
3.2. Domains of Src 
 
Src is composed of the following domains, from N to C-terminus: SH4, unique 
domain, SH3, SH2, linker region, catalytic domain (SH1), and C-terminal tail, as shown 
in Figure 5.  
 The SH2 and SH3 domains cooperate in the auto-inhibition of the kinase domain. 
C-Src is phosphorylated on an inhibitory tyrosine near the C-terminus of the protein. This 
produces a binding site for the SH2 domain which, when bound, facilitates binding of the 
SH3 domain to a low affinity polyproline site within the linker between the SH2 domain 
and the kinase domain. Binding of the SH3 domain results in misalignment of residues 




Figure 5. Schematics of c-Src domains 
 
c-Src domain composition: From N to C-terminus: SH4, unique domain, SH3, 
SH2, linker region, catalytic domain (SH1), and C-terminal tail. C-Src is phosphorylated 
on Tyr-527, creating a binding site for the SH2 domain.  The SH3 domain binds to a low 
affinity polyproline motif included in the linker between the SH2 domain and the kinase 
domain, leading to the inactivation of the enzyme. C-Src can be activated by 
dephosphorylation of Tyr-527, binding of the SH2 domain to a competitive phospho-












mechanisms for c-Src activation: dephosphorylation of the C-terminal tyrosine by a 
protein tyrosine phosphatase, binding of the SH2 domain by a competitive phospho- 
tyrosine residue, as seen in the case of c-Src binding to focal adhesion kinase, or 
competitive binding of a polyproline binding motif to the SH3 domain, as seen in the case 
of the HIV NEF protein. 
The SH4 domain is essential for Src membrane association, which is key for the 
biological function of Src, since it allows the flow of signal from the membrane to 
downstream cytoplasmic substrates. This association occurs mainly through 
myristoylation (40), the concentration of basic residues in the SH4 domain and 
palmitoylation (41). This association is also promoted by several signaling pathways 
(39).The unique domain is the least conserved among the Src family members and its 
functions remains unclear to date. Ser/Thr kinase Cdc42 is thought to phosphorylate Thr-
34, Thr-46, and Ser-72 residues (42,43) in this domain. There may be specific functions 
associated with each Src family member related to this region. 
The β-barrel fold comprised of β-strands in the SH3 domain of Src binds to a left-
handed proline type II helix in the linker region of Src (44). The SH3 domain in Src has 
two functions. It helps maintain Src in its basal state, by maintaining its repressed 
conformation. It also provides a docking site for substrate binding and cellular 
localization. As described before, the consensus sequence in the proline rich region that 
binds to the SH3 domain contains the PXXP pattern (X being any amino acid).  Binding 
between Src’s SH3 domain and its peptide ligand has been measured by in vitro binding 
assays: a dissociation constant of 10 µM shows a moderate binding affinity (44), which 
can be higher with intact proteins due to cellular localization or other long-range proteins 
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interactions. SH3 domains are also commonly found in dozens of other signaling 
proteins.  
The SH2 domain of Src serves a dual function: it binds phosphorylated Tyr-527 
of the Src C-terminal tail to maintain Src in its repressed state. In addition, it serves as a 
docking site for substrates or adaptors by binding to phosphotyrosine containing proteins, 
such as focal adhesion kinase (FAK), p130Cas, the p85 subunit of PI3-Kinase, and 
p68Sam (45). The SH2-phosphotyrosine binding usually occurs through a two-pocket 
mode. The first pocket of the SH2 domain contains one or more Arg residues and binds 
the phosphotyrosine residue. The second pocket usually binds to a hydrophobic residue 
located at position +3 after the phosphotyrosine residue. The binding affinity of the 
binding between the SH2 domain and the phosphorylated tyrosine is in the range of 1.0 
µM. This affinity is strongly reduced (1000-fold or more) when tyrosine is 
unphosphorylated (46).  
The Src catalytic domain contains a small N-terminal lobe, an activation loop 
(residues 404 to 432), and large C-terminal lobe. The activation loop contains an 
autophosphorylation site (Tyr-416) that facilitates the activity of Src. When 
unphosphorylated, this tyrosine probably blocks the substrate binding to the catalytic site. 
Autophosphorylation relieves the inhibition and allows substrate binding (47). The Src 
catalytic domain is homologous to hundreds of other human protein kinase domains. 
Unlike v-Src, c-Src contains a C-terminal tail (48). This domain contains the key 
residue, Tyr-527. This residue is phosphorylated by Csk and Chk (49). Subsequently, 
Src’s SH2 domain binds phosphorylated Tyr-527 and locks Src in its inactive 
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conformation. However, phosphotyrosine-containing proteins may be able to displace the 
tail to open Src and enhance its activity. 
 
3.3. Crystal structure of Src 
 
c-Src is normally maintained in a repressed conformation by two main 
interactions (50).  The first one is the interaction between the phosphorylated Tyr-527 
and the SH2 domain and the second the interaction between the SH3 domain and short 
polyproline Type II helix in the linker between the SH2 domain and the kinase domain. It 
is thought that these two interactions might limit autophosphorylation of Tyr-416 in the 
activation loop. When Tyr-416 is not phosphorylated, it forms hydrophobic interactions 
with residues in the catalytic cleft, blocking substrate binding (50). 
 
3.4. The Role of Src in the cell: v-Src 
 
 The v-Src phenotype on cell biological function has been intensively studied. 
Infection or transfection of fibroblasts with the v-Src oncogene leads to several 
morphological changes: the cells that initially formed an ordered monolayer, lose the 
intercellular, integrin-based cytoskeletal attachments and, as a result they round up, 
disaggregate, and float in the media. These cells also have increased motility and 
invasiveness. After several weeks, when cells have lost their density inhibition, v-Src 







Adapted from Yeatman TJ, Nature 2004. 
 
Figure 6. Photomicrographs showing the v-Src phenotype  
 
Photomicrographs showing the transformed phenotype caused by v-Src transfection. A. 
Normal rat fibroblast culture stably transfected with a control vector. The cells are 
fusiform and show density inhibition. B. Transformed rat fibroblasts stably transfected 
with v-Src. Cells rounding up and detaching from the substratum eventually form visible 
foci. 
  
A. Mock-transfected fibroblasts  B. v-src-transfected fibroblasts 
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 Loss of contact inhibition is a hallmark of a cancer cell. In fact, v-Src transformed 
cells undergo processes that resemble metastatic cells when they disaggregate from the 
primary tumor, invade surrounding tissues, and travel to distant organs.  
In normal cells, v-Src increases the proliferation rate, reducing doubling times and 
increasing nutrient requirements in vitro. When cells are transfected in vivo, they grow 
faster than normal cells and form tumors a few days after injection. The tumors can 
metastasize both locally and to distant sites (51). 
 
3.4.1. Induced signaling in v-Src transformed cells 
 
 The transformational activity of v-Src is likely to be mediated by certain STAT 
proteins (Signal Transducers and Activators of Transcription). STAT3 promotes 
transcription of cell-cycle regulator D-type cyclins, cyclin E, p21WAF1/CIP1 and Myc. Myc 
synthesis is a critical feature in v-Src transformed cells (52). STAT3 activation also 
stimulates VEGF (Vascular Endothelial Growth Factor) in v-Src transformed cells (53). 
Another STAT, STAT5, may also contribute and is associated with cell cycle 
progression, cell survival, and anchorage-independent growth (54). 
 
3.4.2. v-Src and adhesion 
 
3.4.2.1. Stress fiber disorganization 
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As cells encounter an ECM that induces adhesion, cells form stress fibers, which are 
complex structures that comprise cytoskeletal structures and other cytoplasmic 
components. The cytoskeletal structures are formed by actin, which assemble into actin 
filaments (previously called microfilaments) that generate the actin cytoskeleton.  Actin 
filaments can assemble between two separated and stable adhesions into stress fibers that 
can generate high traction forces (55). Crosslinking proteins that bind two or more 
filaments together, and myosin II motors are the cytoplasmic components of stress fibers. 
The myosin motors move, sliding actin filaments past one another, allowing the fibers to 
contract. 
The fibers must be anchored in order for contraction to generate forces. Stress 
fibers are linked to the exterior through focal adhesions, which are formed by the 
assembly of many proteins. The contraction of the fibers against these fixed external 
substrates allows the traction forces generated by the myosin motors to modulate the 
mechanical homeostasis of the cell by moving and reshaping it (56). This process 
responsible for stabilizing the cell structure and transducing mechanical information from 
the cell exterior that leads to the production of force that promotes changes in cell shape 
and ECM remodeling (57). 
 Cofilin is an actin-binding protein that disassembles actin filaments through two 
different mechanisms: severing filaments (58) and increasing off-rate for actin monomers 
from the pointed end (59). Cofilin activity is regulated by the RhoA-ROCK-LIM kinase 
pathway, and the loss of stress fibers is thought to be associated with disruption of this 
pathway (60). Src also plays a role in cofilin activity by indirectly mediating cofilin 
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dephosphorylation on Ser-3, which leads to cofilin activation and subsequently actin 
filament disassembly.  
 
3.4.2.2. Focal adhesion disruption 
 
3.4.2.2.1. v-Src-induced proteolysis of FAK 
 
 One of the key features of v-Src transformed cells is the disruption of focal 
adhesions. This event will be discussed in detail below. As a brief introduction, v-Src 
mediates phosphorylation of FAK and its proteolysis by the calpain-calpastatin 
proteolytic system. Calpain promotes FAK proteolysis and thus induces focal adhesion 
turnover. Calpastatin is calpain endogenous inhibitor. V-Src can both increase the 
synthesis of calpain 2 and the degradation of calpastatin, therefore promoting the 
turnover of focal adhesions (61) (Figure 7). 
 
3.4.2.2.2. v-Src effects on integrin function 
 
 Integrins are key components on the linkage between the ECM and the 
cytoskeleton. Tyrosine phosphorylation of integrins can reduce cell adhesion. V-Src can 
induce tyrosine phosphorylation of certain integrins, such as b1A integrin on sites Tyr -
783 and Tyr-795 (62), or b3 integrin on sites Tyr-783 and Tyr-795 (63). Phosphorylation 





Figure 7. Schematics of the mechanism of v-Src –induced proteolysis of FAK 
 
v-Src-induced proteolysis of FAK by the calpain-calpastatin proteolytic system. Src is 
thought to promote calpain synthesis as well as calpastatin degradation. Calpastatin is a 
calpain inhibitor so its degradation enhances the effect of Src on calpain. Calpain 
promotes FAK proteolysis and the consequent focal adhesion turnover. 
 
  





cells, constitutively active Src might break this balance and promote focal adhesion 
disassembly.  
 Another way of regulating integrin function is by phosphorylation of the small 
GTPase R-Ras by v-Src (64), suppressing integrin activity and affecting cell-matrix 
adhesion. 
 
 3.4.2.3. Disruption of adherens junctions 
 
 Adherens junctions are cell-cell junctions that connect the actin cytoskeleton of 
two cells through protein complexes that contain, among other proteins, cadherins and 
catenins. Cadherins are transmembrane proteins that form homodimers in a calcium-
dependent manner with other cadherin molecules on adjacent cells.  
 v-Src can induce cadherin degradation in different ways: hakai is a Src-binding 
protein which functions as an E3 ligase that ubiquitylates C-cadherin promoting its  
degradation (65). P120CTN is tyrosine phosphorylated by Src (66) and modulates E-
cadherin (epithelial cadherin function), reducing cell-cell adhesion. Loss of E-cadherin 
complexes at cell-cell adhesions as well as enhancement of integrin-dependent cell-ECM 
contacts, are related to the induction of epithelial to mesenchymal transition (EMT), 
which is a key event in metastatic events. 
 
3.4.2.4. Disruption of Gap junctions 
 
  Gap junctions are intercellular junctions that connect the cytoplasm of two cells, 
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allowing the free interchange of molecules and ions between cells (67,68). Gap junctions’ 
channels are composed of two conexons (or hemichannels) which connect across the 
intercellular space (69). These hemichannels are primarily homo- or hetero-hexamers of 
conexins proteins. v-Src can phosphorylate connexin 43 on Tyr-247 and Tyr-265 leading 
to gap junction disruption (70). 
 
3.4.2.5. v-Src and FAK induced expression of MMPs (matrix metalloproteinases) 
 
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that 
degrade different types of ECM proteins as well as several bioactive molecules. They are 
known to have several functions including the cleavage of cell surface receptors, release 
of apoptotic ligands or chemokine/ cytokine activation (71). In addition, MMPs play 
important roles in cell proliferation, migration, differentiation, apoptosis and 
angiogenesis. 
v-Src induces FAK signaling to JNK (c-Jun N-terminal kinase), promoting the 
downstream expression of MMP2 and MMP9 (72,73). In addition, v-Src induces 
phosphorylation and activation of FAK, which recruits DOCK180 (a Crk-binding 
adaptor) and p130Cas to lamellipodial focal contacts (74). DOCK180 induces Rac 
activation through Crk/p130Cas complexes. Elevated activities of Rac1 and JNK promote 




 c-Src affects cell proliferation in fibroblasts. This event may be related to the fact 
that Src-family kinases are thought to play roles in mitosis, specifically in the progression 
from phase G2 to phase M during cell cycle (75). C-Src transfected cells experience 
decreased intercellular adhesion and increased invasion and motility, particularly in 
epithelial cells and in cancer cells in late stages of progression (76). 
 Among the Src family, c-Src is the member most often associated with cancer. 
Several cancer types have shown c-Src overexpression or an increase in its activity (77). 
Some examples are gastrointestinal-tract cancers such as colorectal cancer (78), 
hepatocellular, pancreatic, gastric and oesophageal (77), breast (79), ovarian (79,80), and 
lung cancers. C-Src is necessary for cell division in fibroblasts (75) and may also 
stimulate the proliferation of precancerous cells, playing a role in tumorigenesis 
(production of new tumors). However, it has also been shown that there is no correlation 
between Src activity and in vitro colon tumor cell proliferation rates or in vivo tumor 
growth rates. Instead, when c-Src is overexpressed in human colon cancer cells, it 
stimulates the assembly of integrin adhesions, which increase the ability of cells to spread 
on a substrate (81). In the same manner, the cooperation between c-Src and epidermal 
growth factor receptor (EGFR) is not associated with increased proliferation, but with 
enhanced invasiveness of cancer cells (82). A suggested explanation for these 
observations is that c-Src plays a role in cell proliferation during the initial process of 
tumorigenesis and enhances adhesion and invasiveness during later stages of tumor 
progression (76). It is important to note that the effects of c-Src are believed to be distinct 
in epithelial cells vs. fibroblasts.  
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3.5.1. Localization of c-Src in the cell 
 
The subcellular localization of Src influenced by three regions within the N-
terminus of Src. Amino acids 1-14 are responsible for Src myristoylation and attachment 
to cytoplasmic granules (83). Amino acids 38-111 promote the association to the plasma 
membrane and perinuclear membrane. Amino acids 204-259 facilitate the association 
with perinuclear membranes (84). C-Src localizes also at the membrane-cytoskeletal 
interface in focal adhesions, lamellipodia and filopodia as a result of the regulation 
mediated, in part, by the small G proteins RhoA, RAC1 and CDC42 (84,85). The 
recruitment of Src to focal adhesions by FAK will be described in the next section. 
 
3.5.2. Regulation of Src activity in the cell 
 
As described earlier, phosphorylation of Src’s C-terminal Tyr-527 leads to its 
intramolecular interaction with the Src SH2 domain, locking Src’s structure into its 
“inactive” form. Disruption of this intramolecular interaction by either removal of the 
phosphate group from Tyr-527 or by engagement of the SH2 and/or SH3 domains with 
other proteins can effect activation of Src. 
 
3.5.2.1. Phosphorylation on C-terminal tyrosine (Tyr-527) 
 
There are two known upstream tyrosine kinases responsible for Src C-tail 
phosphorylation. Csk (c-Src tyrosine kinase) and its homologue Chk (C-terminal Src 
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Kinase-homologous Kinase) (49). The reverse process (dephosphorylation) also occurs in 
the cell and is mediated by protein tyrosine phosphatases that remove the phosphate from 
Tyr-527, thereby activating Src (51). Several phosphatases have demonstrated to be able 
to promote this dephosphorylation, such as CD45 (86), PTP (protein tyrosine 
phosphatases)-a,  PTP-g, PTP1B, SHP-1 (SH2-containing phosphatases 1) and SHP-2 
(84,87,88). 
 
3.5.2.2. Interaction with binding partners 
 
 A number of proteins can bind to Src in the cell. These interactions generally 
occur through Src’s non-catalytic domains, particularly its SH2 and SH3 domains. As 
described in the previous section, FAK binds Src’s SH2 domain and p130Cas binds to 
Src’s SH3 domain (89,90). In this manner, FAK and p130Cas disrupt the inactive 
conformation and relieve Src autoinhibition. It is important to note that these interactions 
are also responsible for Src’s colocalization with substrate proteins in specific sites of the 
cell. The local concentration of the substrate proteins is an important determinant of Src 
substrate specificity.  
 
3.5.2.3. Receptor-mediated activation of Src 
 
When certain receptor tyrosine kinases become activated through phosphorylation 
on one or more tyrosine residues in their cytoplasmic regions, Src’s SH2 domain binds 
these phosphorylated tyrosines driving Src to its active conformation. Some of these 
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receptors are Epidermal Growth Factor Receptor (EGFR), Platelet-Derived Growth 
Factor Receptor (PDGFR), Human Epidermal growth factor Receptor 2 (Her2/Neu or 
ErbB2), Fibroblast Growth Factor Receptor (FGFR), colony-stimulating factor 1 and 
Hepatocyte Growth Factor Receptor (HGFR) (45,52,91-94) 
 
3.5.3. c-Src in signaling pathways 
 
3.5.3.1. Src-FAK complex 
 
The relationship between c-Src and FAK deserves special attention. Focal 
adhesion kinase (FAK) was one of the first discovered Src substrates (95). FAK’s 
association with Src is well studied and considered a key event in Src’s role in cell 
signaling (96). FAK is a non-receptor tyrosine kinase involved in cell-cycle progression 
(cell proliferation), cell survival, and cell migration, as well as growth-factor- and 
integrin-mediated cellular motility, adhesion and invasion (72,97). FAK localizes to focal 
adhesions, which are cytoskeletal structures responsible for cell-extracellular matrix 
(ECM) connections. In particular, integrins in focal adhesions link the actin cytoskeleton 
with the ECM (Figure 8). 
FAK is phosphorylated after cellular contact with the ECM and can be activated 
by both growth factors and integrins (98). Integrin clustering, actin polymerization and 
actomyosin contractility facilitate FAK autophosphorylation and activation (73). FAK 
associates with integrins through its COOH-terminal domain. FAK recruits Src to focal 
adhesions through binding of c-Src’s SH2 domain to FAK, forming a transient signaling  
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Figure 8. Schematics of the interactions of Src, FAK, p130Cas and paxillin in focal adhesions 
 
Integrin clustering, actin polymerization and actomyosin contractility facilitate FAK 
autophosphorylation and activation. Phosphorylated FAK binds Src in a transient 
complex and thus recruits it to focal adhesions. C-Src stimulates tyrosine phosphorylation 
and activation of FAK. As a result, Src promotes turnover of focal adhesions. Src’s SH3 
domain binds p130Cas. Src, FAK, and p130Cas form a trimeric complex, where the 
FAK-Src complex phosphorylates p130Cas and paxillin, creating heavily phosphorylated 
sites that serve as a recruitment dock for other molecules involved in signaling and actin 
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Recruitment of signaling molecules to FAs 
Actin cytoskeletal organization  
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complex with c-Src (99,100). This recruitment of Src to FAK promotes turnover of these 
junctions, contributing to cell motility. C-Src stimulates tyrosine phosphorylation and 
activation of FAK, which results in the loss of focal adhesions (100,101). Src also binds 
p130Cas through its SH3 domain. Src, FAK, and p130Cas form a trimeric complex that 
is stabilized through mutual interactions among the three proteins (99). The FAK-Src 
complex phosphorylates p130Cas and paxillin, creating heavily phosphorylated sites of 
recruitment for other molecules and therefore facilitating actin cytoskeletal organization 
(102). 
Quantitative assays to determine levels of kinase and adaptor molecules in focal 
adhesions have demonstrated that the FAK- c-Src complex, p130Cas, paxillin, 
extracellular signal-regulated kinase p42 (Erk) and myosin light-chain kinase (MLCK) 
are crucial for adhesion turnover at the cell front (101). Erk is a target of Src-FAK 
signaling (96) and it is also the upstream kinase of calpain. Activated calpain can induce 
proteolysis of FAK and promote the breakdown of focal adhesions (61). 
 
3.5.3.2. Src targets in adhesion, motility and invasion 
 
There are two main cytoskeletal structures that regulate adhesion, motility and 
invasion: focal adhesions and adherens junctions (51). Src is thought to enhance cellular 
motility by both disrupting adherens junctions and promoting focal adhesion turnover.  
Focal adhesions are the cytoskeletal structures responsible for cell-matrix 
attachments, and also play an essential role in regulating proliferation and gene 
transcription (96). As cells move along the extracellular matrix, focal adhesions are 
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disassembled and Src is believed to play a major role in disruption of focal adhesions and 
stress fibers (103). The current understanding of this connection is Src induced tyrosine 
phosphorylation of FAK and the subsequent degradation of FAK by the calpain-
calpastatin proteolytic system (61). 
In the context of adherens junctions, Src is also thought to play a role in the 
disruption of adherens junctions. Src’s contribution seems to be associated with its ability 
to phosphorylate E-cadherin, leading to E-cadherin’s ubiquitylation and subsequent 
displacement (65). An additional role of Src in adhesion is its ability to regulate 
metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteases (104), thus 
affecting their role in tissue remodeling.  
 
3.5.3.3. Src and the Ras/ MAPK pathway 
 
 In the classical MAPK pathway, RTKs are activated and Shc and SHP-2 recruited 
and phosphorylated by RTKs. The phosphorylation sites on Shc and/or SHP-2 recruit the 
complex formed between the adaptor Grb2 and its associated molecule Sos, a guanine 
exchange factor (GEF) for Ras. The Grb2/Sos complex can also be recruited to the 
membrane through phosphorylation sites in the C-terminal cytoplasmic region of the 
RTKs (105). Once Sos has been translocated to the membrane, it induces the GTP/GDP 
exchange and converts Ras to an active form (106). The GTP bound Ras has an enhanced 
ability to interact with its effectors, Raf, Ral-GEFs and PI3K (phosphatidylinositol 3-
kinase), and activate them for downstream signaling (107). Raf is part of the well-
established Raf/MEK/ERK pathway, which is known to be activated by Ras (108).  
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 Activated Raf first leads to the stimulation of the dual-specificity kinases MEK1 
and MEK2, also known as MAPKK or MAP2K 1 and 2 (mitogen-activated protein 
kinase kinases). MEK 1 and 2 phosphorylate the MAPK/Erk (mitogen-activated protein 
kinase/ extracellular signal-regulated kinases) proteins Erk1 (p44) and Erk2 (p42). This 
Ser/ Thr protein kinase cascade provides opportunities for feedback regulation and signal 
amplification.  
When Src is activated by RTK, it can phosphorylate FAK and recruit it. Tyr-925 is 
one of the residues in FAK that becomes phosphorylated upon Src activation and it 
constitutes a binding site for Grb2 (99). The activated Src/FAK complex stimulates Shc 
tyrosine phosphorylation (99,109). Another possible role for Src in this pathway is that 
Src is thought to phosphorylate Raf1 in its N-terminal domain that is responsible for Raf1 
autoinhibition, therefore inducing Raf1 activation (110-113). The Ras/Raf/MEK/Erk 
pathway regulates transcription, metabolism and cytoskeletal reorganization with 
downstream effects associated with cell growth, anti-apoptosis and cell differentiation 
(114). 
 
 3.5.3.4. Induction of DNA synthesis 
 
Several RTK activating growth factors such as EGF, PDGF, and CSF-1 require 
Src activity to induce DNA synthesis (115). As an example, PDGF-b mediated induction 
of myc transcription requires Src activity and can be block by a Src selective inhibitor 
(116). Several signaling molecules are known to be involved in Src-mediated DNA 
synthesis, such as Shc (117) or PI3K (118). 
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3.5.3.5. Degradation of Src 
 
c-Src can be ubiquitylated (74) and Cbk ubiquitin ligase (especially the Cbl-c E3 
ligase) appears to be responsible for Src ubiquitylation (119). Activated Src seems to be a 
better substrate for ubiquitylation than the tail-phosphorylated form. Upon ubiquitylation, 
Src can be degraded by the proteasome as a mechanism for attenuating Src signaling 
cascades. 
 
4. Methods for identification of tyrosine kinase substrates 
 
 Signaling pathways are extremely complex and dynamic. Signaling pathways are 
not independent units. Instead they are intricately interwoven. Different kinds of 
mechanisms alter signal flow, including feedback loops and amplifications mechanisms. 
An initial way to approach the dissection of such a daunting matrix of potential 
interactions is to determine the in vivo interactions/ substrates of a protein of interest. In 
the case of protein tyrosine kinases, this is particularly challenging given several reasons, 
among which are the apparent lack of a constant consensus sequence around the Tyr (as 
opposed to many Ser/Thr kinases), and the fact that many in vitro techniques are not 
applicable in vivo. We will next summarize some of the employed techniques that have 
been used towards the goal of tyrosine kinase substrate identification. 
 
4.1 Classical methods 
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4.1.1. Genetic methods 
 
 One broadly used method to identify substrates of tyrosine kinases is to perform 
genetic screens followed by subsequent analysis of genetic interactions. One 
disadvantage of such experiments is that it is difficult to infer any direct biochemical 
linkage. One example is the epistasis analysis perform in Drosophila melanogaster, where 
Daughter of Sevenless (Dos) was located downstream of the RTK Sevenless (120). 
 
4.1.2 Biochemical Fractionation 
 
 When the phosphorylation site is known and the upstream kinase is searched, it is 
possible to screen different fractions of the cell lysate using radioactive assays or with 
antiphosphotyrosine antibody blots in order to determine the upstream kinase. As an 
example, Src’s substrate p130Cas was identified in this manner (121).  
 
4.1.3. In vitro identification of kinase substrate 
 
4.1.3.1. Solid phase phosphorylation screening of phage expression libraries 
 
 Phage display is used for high-throughput screening of protein interactions. DNA 
from a cDNA library encoding the proteins or peptides of interest is ligated to genes that 
encode a coat protein. As a result, a whole library of protein or peptide sequences can be 
inserted into surface exposed coat proteins in a bacteriophage. 
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In the case of a phosphorylation screening, the immobilized bacteriophage can be 
phosphorylated by g-32P-ATP. The phage particles are screened and those that are 
efficient substrates can be isolated and enriched to produce more phage (by bacterial 
infection with helper phage). After infecting suitable bacteria, from which the plasmids 
can be collected, the DNA can be sequenced and identified. As an example, PI3 Kinase 
p85 was identified as an EGFR downstream substrate using this approach (122). 
 
4.1.3.2. Oriented peptide library screen of optimal substrate motifs 
 
 In peptide library screening, a synthetic peptide library is exposed to a tyrosine 
kinase and the phosphorylated peptides are selected by affinity chromatography. The 
selected pool can be sequenced by Edman degradation. From the pool of selected 
peptides, the sequence surrounding the phosphorylated Tyr can be analyzed and 
consensus sequences identified (11). 
 
4.1.4. In vivo identification of kinase substrates 
 
4.1.4.1. Two- dimensional gels 
 
 In this methodology, the kinase of study is either activated (i.e.: by 
overexpression in the cell, stimulation of upstream receptors) or inactivated (i.e.: by 
specific kinase inhibitors, injection of antibodies, knockouts, RNA interference). The [g-
P32] ATP labeled cell lysate is run in a two-dimensional gel by electrophoresis that 
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provides resolution based on isoelectric point and protein mass. It is unlikely that two 
proteins will share these identical properties and as a result, this method allows for 
favorable separation of proteins in the lysate that can be then identified by in gel-
trypsinization and mass spectrometry. 
 
4.1.4.2. Protein chips 
 
 This novel technology can be used to screen for potential kinase substrates in a 
high-throughput fashion. The technology was designed for high-through analysis of 
protein kinase activity over the kinome (123). As an example, Rim11p was identified as a 
novel tyrosine kinase that could use poly (Glu, Tyr) as substrate in radioactive assays. In 
vivo validation of its kinase activity on the substrate, Ime1p, was performed. 
 
4.1.4.3. Kinase-substrate crosslinking 
 
 In this approach, an ATP analog, with an UV activable crosslinking group azide 
in both the purine moiety and g-phosphate is applied in vivo. The adenine moiety of ATP 
usually bounds to the kinase active site during phosphorylation and the g-phosphate is 
usually close to the substrate protein. When using the described ATP analoge, the UV 
activatable crosslinking generates a ternary complex that can help the identification of the 
kinase substrate and can then be cleaved by phosphodiesterase. As an example, this 




4.1.4.4. ATP analog and mutant kinase pair 
 
 This methodology combines a kinase mutant with altered ATP binding proteins 
with an unnatural ATP analog (125). The use of a radioactive [g-P32] ATP analog allows 
for direct labeling of substrates in cell extracts, but not in the living cell, since ATP 
analogs are highly negatively charged and are therefore not cell permeable. However, it 
has received much interest and identified many kinase-substrate interactions for Src, 
Cdks, and other kinases. 
 
4.1.4.5. Phospho-motif specific antibodies 
 
 Based on the consensus sequences obtained using previously descried methods, 
novel site-specific phosphorylation site antibodies have been generated. These antibodies 
have been particularly helpful in validating potential novel substrates for specific kinases 
(126). Given the fact that consensus sequences seem to be more conserved in Ser/Thr 
kinases, only Ser/Thr kinases substrates have so far been achieved using this approach. 
 
4.1.4.6. Chemical Rescue 
 
 One of the critical steps in kinase substrate identification is the method employed 
for activation/ inhibition of the kinase. Specific modulation of a kinase in vivo is 
particularly challenging. Many of the commonly used methods to activate kinases or 
 43 
inhibit enzymes are non-specific  (i.e. stimulation of upstream receptors, many kinase 
inhibitors) or achieve their goal a few hours or even days (i.e. overexpression of the 
kinase in the cell, injection of antibodies, knockouts, RNA interference). In this context, 
chemical rescue has been of particular use. In this approach, the activity of an inactive 
mutant protein can be restored by chemical complementation by a small molecule with 
similar electronic or steric features than the side chain of the mutated amino acid. The 
activation of the kinase is therefore highly specific and the activation can be observed 
within minutes upon chemical rescue, providing a specific, rapid, and reversible method 
for kinase activation. Combining chemical rescue with other methodologies to identify 
changes in the phosphorylation pattern in the cell upon chemical complementation of the 
kinase can in principle provide many novel proteins/ residues being phosphorylated upon 
kinase activation. Chemical rescue will be thoroughly reviewed in the next section. 
 
5. Chemical Rescue 
 
5.1. Introduction of chemical rescue 
 
 In an effort to approach the study of protein structure and function, early efforts 
were focused on using group modifying agents to modulate the activity of 
macromolecules, like enzymes or proteins. Site-directed mutagenesis methodology 
followed (127). Both approaches were later combined in chemical complementation 
(128).  
 44 
 One of the first applications of chemical complementation was the study of serine 
proteases, endopeptidases in which serine acts as the nucleophilic amino acid at the active 
site (129). A common feature of most Ser proteases is a Ser-His-Asp catalytic triad (Asp-
102, His-57, Ser-195) (130). As mentioned before, Ser-195 is the nucleophile and His-57 
acts like the general base (and later, general acid). Asp-102 has a very low pKa of 2, and 
it is therefore mostly ionized. In that way, it helps stabilize the protonated imidazole ring 
of His-57 with its negative charge.  
 Subtilisin is a non-specific serine endopeptidase initially obtained from Bacillus 
subtilis, a Gram positive bacterium commonly found in soil. While performing site 
mutagenesis studies, it was found that the catalytic activity of H64A mutant subtisilin 
could be restored by a substrate that contains the lost histidine at the P2 position (131) as 
compared with the substrate that contains alanine at the P2 position (factor of 170). For 
the rescue, the imidazole ring of the His at P2 can almost superimpose on the catalytic 
His64 in subtilisin, mimicking the function of the catalytic histidine in the wild-type 
enzyme. In this manner, the activity of the mutant enzyme was restored. 
  Several studies followed, which not only optimized chemical rescue of different 
enzymes, but also revealed functionalities of different residues within the catalytic region 
of the enzymes allowing physicochemical analysis of the catalytic impact of a specified 
amino acid residue in the enzyme. As an example, site-directed mutagenesis studies of 
trypsin (132), revealed the important facilitating function of Asp-102 in the triad of serine 
protease.  
 Chemical rescue was further developed through the study of aspartate 
aminotransferase (AATase). AATase is a pyridoxal phosphate (PLP)-dependent 
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transaminase enzyme that catalyzes the reversible transfer of an α-amino group, 
facilitating the interconversion of the dicarboxylic amino and ketoacids. The inactive 
K258A AATase mutant contained a cavity in the catalytic site where several amines with 
different pKa values could fit, replacing the lost residue and partially rescue the activity 
of the AATase (133). 
  Chemical rescue has been extended to a number of enzymes to establish 
structure-activity relationships as well as to identify important catalytic residues. 
Depending on which amino acid is mutated, different small molecules are used for 
complementation. For example, amines are commonly used for lysine mutations, 
guanidines for arginine mutations, azide, formate, or fluoride for Glu or Asp mutations, 
imidazole for histidine mutations, and indole for enzymes with tryptophan mutations.  
 
5.2. Chemical rescue and signaling 
 
 Chemical rescue is one of the most efficient ways of manipulating enzyme 
activity with the use of small molecules or structurally altered substrates (131-133) that 
functionally substitute for the missing side chain.  
 The initial applications of chemical rescue were focused on the analysis of 
enzyme mechanisms and molecular recognition in vitro. However, one of the most 
advantageous aspects of chemical rescue is the fact that it facilitates the challenging 
spatio-temporal dissection and analysis of complex cellular pathways in the cell. One of 
the challenges to an in vivo application to chemical rescue is that the small molecules 
used as rescue agents need to be cell-permeable and non-toxic at the relevant 
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concentrations (sometimes up to molar quantities might be required). If these challenges 
are met, in vivo chemical rescue represents an enzyme activation methodology that is 
specific (only activates the mutated enzyme), rapid (activation can be less than a minute 
depending on the enzyme) and reversible (the enzyme can be deactivated by small 
molecule removal). 
Chemical rescue of an enzyme with an altered substrate has been applied to the 
study of specific G-proteins in cells. EF-Tu is a GTP regulatory protein. The fact that 
mutant D138N EF-Tu cannot bind GDP efficiently but instead can bind xanthosine 5’-
diphosphate efficiently, reveals that Asp138 probably interacts with C-2 of the purine 
ring. This approach has been used to study other GTPases involved in nuclear protein 
import. 
 
5.3. Chemical rescue of Src  
 
 Previous work in our laboratory used a chemical rescue strategy to learn more 
about the role of v-Src in the cell (134). The catalytic Arg-388 in all Src’s family 
members is located two residues upstream as compared with its position in other tyrosine 
kinases (Figure 9).  
 Src kinase was subjected to site-directed mutagenesis and rendered catalytically 
inactive. In particular, a set of Src Arg388 mutant recombinant proteins were generated 
and their potential for chemical rescue was examined. The maximal turnover rate (kcat) of 
the mutant R388A Src was 0.5% of the kcat of wild-type Src. The kcat after imidazole  
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SRC  382YVHRDLRAANILV394 
CSK     FVHRDLAARNVLV 
IRK     FVHRDLAARNCMV 
 
Adapted from Qiao Y et al., Science 2006 
 
Figure 9. Position of the catalytc Arg-388 of Src- family kinases as compared to other tyrosine 
kinases 
 
Selected sequences within the catalytic domain of selected tyrosine kinases. Numbers 
above sequences correspond to the equivalent residue position in Src. 
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treatment increased to 30-50% of the kcat of wild-type Src. In summary, Src’s activity 
could be restored by the addition of the cell permeable small molecule imidazole.The 
Michaelis-Menten constant (Km) for imidazole was approximately 2.5 mM, which is far 
below its toxic level. By specifically jump-starting v-Src kinase activity, the immediate 
contributions of v-Src to different signaling pathways could be identified. 
Encouraged by these positive results, the potential of chemical rescue of Src was 
assessed in living cells. For this purpose, an additional mutation, Y527F was incorporated 
in order to prevent down-regulation by Csk phosphorylation.  In this manner, SYF MEFs 
were stably transfected with R388A/Tyr-527Phe (Y527) Src to generate 8A7F cells. A 
control cell line was generated by stably transfecting SYF MEFs with Src Asp386Asn 
(D386N)/ Y527F (6N7F). This Src mutant is catalytically inactive and insensitive to 
imidazole. In this thesis, when describing the research conducted on c-Src rescue, we will 
refer to the mutation R388A as R390A, and the mutation D386N as D388N, just as a 
result of different nomenclature but the site of mutation is the exact same. 
8A7F cells were treated with 5 mM imidazole for 0 to 10 minutes and the changes 
in overall tyrosine phosphorylation level were analyzed by Western blot using the anti-
phosphotyrosine antibody 4G10. Some new bands appear and others intensified at 2.5 
minutes and plateau by 10 minutes. However, when the same treatment was applied to 
6N7F cells no changes were observed (Figure 10). 
Chemical rescue conditions were analyzed in greater detail by observing 
autophosphorylation on its activation-loop tyrosine, Tyr-416, with a site-specific 
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Figure 10. Time course of tyrosine phosphorylation induced by imidazole treatment of Src 
R388A/Y527F in SYF cells (8A7F) and Src D386N/Y527F in SYF cells (6N7F cells) 
 
Time course of tyrosine phosphorylation levels induced by 5 mM imidazole treatment of 
R388A/Y527F in SYF cells (8A7F cells) and D386N/Y527F in in SYF cells (6N7F 
cells). The lysates were analyzed by Western blot using a 4G10 anti p-tyr antibody and 
the loading control was performed using an anti-actin antibody. 
  
first proto-oncogene and tyrosine kinase dis-
covered, is involved in a myriad of cellular pro-
cesses, but many aspects of its function are still
poorly understood (9, 10). In Src and its eight
other family members, the catalytic Arg388 is
located two residues upstream relative to its
position in other tyrosine kinases (fig. S1). We
therefore generated a set of Src Arg388 mutant
recombinant proteins and examined their po-
tential for chemical rescue (11) (fig. S1). The
maximal turnover rate (kcat) of R388A Src was
about 0.5% of the kcat of wild-type Src but
increased to 30 to 50% of the kcat of wild-type
Src with imidazole. The rescued enzyme
showed less than threefold changes in the
Michaelis-Menten constant (Km) of two differ-
ent substrates (11) (fig. S1B). Encouragingly,
the Km for imidazole was È2.5 mM (fig. S3B),
well below its toxic level (12).
To assess the potential of chemical rescue of
R388A Src kinase activity in living cells, we
stably transfected R388A/Tyr527YPhe (Y527F)
Src in SYF (Src, Yes, and Fyn deleted) mouse
embryonic fibroblasts (13) to generate 8A7F
cells. The Y527F mutation was included to
prevent down-regulation by Csk phosphoryl-
ation (9, 10) and the SYF line was used because
of its low background of Src family member
expression. We also generated the control SYF
line containing Src Asp386YAsn (D386N)/
Y527F (6N7F), a catalytically defective form
of Src that we showed (with the use of
recombinant protein) to be insensitive to
imidazole (fig. S3C). Western blots with an
antibody to Src showed that the level of Src
expression in these transfected lines was similar
to that in human embryonic kidney (HEK) 293
cells (fig. S4A). 8A7F cells were exposed to
5 mM imidazole for 0 to 10 min, and then
lysates were analyzed by Western blot with a
sequence nonselective antibody to phosphotyro-
sine (4G10) (Fig. 1A). A variety of bands in-
tensify or freshly appear at 2.5 min and plateau
by 10 min. In contrast, when the control cell
line 6N7F was exposed to imidazole, no de-
tectable changes in antiphosphotyrosine blotting
were observed (Fig. 1B). That the bands seen in
imidazole-treated 8A7F cells were related to
rescued Src tyrosine kinase activity was also
supported by the finding that pretreatment with
the Src-selective inhibitor PP1 (14) blocked the
appearance of the tyrosine-phosphorylated pro-
teins (fig. S4B).
A more detailed analysis of the dose and
reversibility of Src chemical rescue involved ex-
amining autophosphorylation on its activation-
loop tyrosine, Tyr416 (9, 10), with a site-specific
antibody (Fig. 1, C and D). As expected, mod-
ification of this loop is rapid and readily
detected after 5 min of imidazole treatment.
About 50% maximal phosphorylation was
achieved with È2 mM imidazole exposure
with 8A7F cells (Fig. 1C). Despite the more
complex environment of the cellular milieu,
this dose-response correlation of imidazole-
Src rescue is in good agreement with that of
the in vitro kinase behavior. Control 6N7F
cells were insensitive to imidazole, as expected
(Fig. 1C). Washout experiments showed that
activation-loop phosphorylation was back to
background within 4 min of imidazole removal
(Fig. 1D). This experiment not only establishes
the rapid reversibility of kinase activity by
dilution of imidazole, but it also underscores
the rapid cellular kinetics of tyrosine phospha-
tase activity toward the Src activation loop.
To further analyze the scope and kinetics of
the chemical rescue process in 8A7F cells, we
transiently transfected 8A7F cells with a fluo-
rescent biosensor that shows a fluorescence
resonance energy transfer (FRET) change upon
Src phosphorylation (15) (Fig. 2A). Imidazole
induces a rapid (less than 60 s) FRET change in
cytoplasmic regions of the cell. The FRET
change plateaus by about 500 s, consistent with
an equilibrium being reached with phosphatase
action and also with the effects seen by
Western blot (Fig. 1). Pretreatment with the
Src-selective inhibitor PP1 abolished FRET
change (Fig. 2A).
Functional and longer term consequences of
chemical rescue were also studied with the use
of a cellular transformation assay (16) as well
as a matrigel invasion analysis (17) (Fig. 2).
Addition of imidazole to 8A7F cells but not
6N7F cells led to increases in the number of
transformed foci (Fig. 2B and fig. S4C) and
also enhanced the efficiency of invasion with
the use of a modified Boyden chamber assay
(Fig. 2C). These classical phenotypes associ-
ated with viral Src (v-Src)–carrying fibroblasts
suggest that chemical rescue of mutant Src in
cells can induce expected oncogenic properties.
To gain insight into the nature of the pro-
teins that are tyrosine phosphorylated by imid-
azole after treatment of 8A7F cells, we carried
out an affinity-based enrichment of tyrosine-
phosphorylated proteins using antibodies to phos-
photyrosine (18). Immunoprecipitated proteins
were separated on an SDS–polyacrylamide gel
electrophoresis and detected with silver stain-
ing, and bands that appeared to be enriched were
identified by tandem mass spectrometry (Fig.
3A). We also used stable isotope labeling
(SILAC) (18), which allows for relative quanti-
tation to identify those proteins whose tyrosine-
phosphorylation status is up-regulated upon
imidazole treatment (Fig. 3A and fig. S5). Of
the 24 proteins detected from either of the two
strategies, six are reported to be Src substrates
(19, 20), but the others had not previously been
linked to Src kinase action.
To validate the mass spectrometry results,
eight individual proteins were immunoprecipi-
tated and thenWestern blotted with the antibody
to phosphotyrosine (Fig. 3B). Western blots of
the proteins with type-specific antibodies were
used for loading controls. These eight proteins
reproducibly increased their phosphotyrosine
content after imidazole treatment of 8A7F cells
but not 6N7F control cells (Fig. 3B). Included
among these were five established Src sub-
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Fig. 1. Tyrosine phos-
phorylation induced by
imidazole treatment of
Src R388A/Y527F in SYF
cells. (A and B) Time
course of phosphoryl-
ation levels in 8A7F cells
(A) and 6N7F cells (B)
treated with 5 mM imid-
azole. Lysates were ana-
lyzed by blot with a
4G10 antibody. (C) Src
autophosphorylation
(Y416) in 8A7F and
6N7F cells as a function
of imidazole concentra-
tion. 8A7F cells received
5 min of treatment;
6N7F cells were treated
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min), and then imidazole-containing media was exchanged for imidazole-free media, and lysates were
analyzed 4 to 60 min later.
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Figure 11. Src autophosphorylation (Y416) induced by imidazole treatment of Src R388A/Y527F in 
SYF cells (8A7F) and Src D386N/Y527F in SYF cells (6N7F cells) 
 
Src autophosphorylation (Y416) in R388A/Y527F in SYF cells (8A7F cells) as a function 
of imidazole concentration after 5 min treatment (top two panels). Src 
autophosphorylation (Tyr-416) in D386N/Y527F in in SYF cells (6N7F cells) at the 
indicated concentrations and during the indicated treatment times (top two panels). The 
lysates were analyzed by Western blot using a phosphospecific antibody against Tyr-416 
in Src and the loading control was performed using an anti-actin antibody. 
  
first proto-oncogene and tyrosine kinase dis-
covered, is involved in a myriad of cellular pro-
cesses, but many aspects of its function are still
poorly understood (9, 10). In Src and its eight
other family members, the catalytic Arg388 is
located two residues upstream relative to its
position in other tyrosine kinases (fig. S1). We
therefore generated a set of Src Arg388 mutant
recombinant proteins and examined their po-
tential for chemical rescue (11) (fig. S1). The
maximal turnover rate (kcat) of R388A Src was
about 0.5% of the kcat of wild-type Src but
increased to 30 to 50% of the kcat of wild-type
Src with imidazole. The rescued enzyme
showed less than threefold changes in the
Michaelis-Menten constant (Km) of two differ-
ent substrates (11) (fig. S1B). Encouragingly,
the Km for imidazole was È2.5 mM (fig. S3B),
well below its toxic level (12).
To assess the potential of chemical rescue of
R388A Src kinase activity in living cells, we
stably transfected R388A/Tyr527YPhe (Y527F)
Src in SYF (Src, Yes, and Fyn deleted) mouse
embryonic fibroblasts (13) to generate 8A7F
cells. The Y527F mutation was included to
prevent down-regulation by Csk phosphoryl-
ation (9, 10) and the SYF line was used because
of its low background of Src family member
expression. We also generated the control SYF
line containing Src Asp386YAsn (D386N)/
Y527F (6N7F), a catalytically defective form
of Src that we showed (with the use of
recombinant protein) to be insensitive to
imidazole (fig. S3C). Western blots with an
antibody to Src showed that the level of Src
expression in these transfected lines was similar
to that in human embryonic kidney (HEK) 293
cells (fig. S4A). 8A7F cells were exposed to
5 mM imidazole for 0 to 10 min, and then
lysates were analyzed by Western blot with a
sequence nonselective antibody to hosphotyro-
sine (4G10) (Fig. 1A). A variety of bands in-
tensify or freshly appear at 2.5 min and plateau
by 10 min. In contrast, when the control cell
line 6N7F was exposed to imidazole, no de-
tectable changes in antiphosphotyrosine blotting
were observed (Fig. 1B). That the bands seen in
imidazole-treated 8A7F cells were related to
rescued Src tyrosine kinase activity was also
supported by the finding that pretreatment with
the Src-selective inhibitor PP1 (14) blocked the
appearance of the tyrosine-phosphorylated pro-
teins (fig. S4B).
A more detailed analysis of the dose and
reversibility of Src chemical rescue involved ex-
amining autophosphorylation on its activation-
loop tyrosine, Tyr416 (9, 10), with a site-specific
antibody (Fig. 1, C and D). As expected, mod-
ification of this loop is rapid and readily
detected after 5 min of imidazole treatment.
About 50% maximal phosphorylation was
achieved with È2 mM imidazole exposure
with 8A7F cells (Fig. 1C). Despite the more
complex environment of the cellular milieu,
this dose-response correlation of imidazole-
Src rescue is in good agreement with that of
the in vitro kinase behavior. Control 6N7F
cells were insensitive to imidazole, as expected
(Fig. 1C). Washout experiments showed that
activation-loop phosphorylation was back to
background within 4 min of imidazole removal
(Fig. 1D). This experiment not only establishes
the rapid reversibility of kinase activity by
dilution of imidazole, but it also underscores
the rapid cellular kinetics of tyrosine phospha-
tase activity toward the Src activation loop.
To further analyze the scope and kinetics of
the chemical rescue process in 8A7F cells, we
transiently transfected 8A7F cells with a fluo-
rescent biosensor that shows a fluorescence
resonance energy transfer (FRET) change upon
Src phosphorylation (15) (Fig. 2A). Imidazole
induces a rapid (less than 60 s) FRET change in
cytoplasmic regions of the cell. The FRET
change plateaus by about 500 s, consistent with
an equilibrium being reached with phosphatase
action and also with the effects seen by
Western blot (Fig. 1). Pretreatment with the
Src-selective inhibitor PP1 abolished FRET
change (Fig. 2A).
Functional and longer term consequences of
chemical rescue were also studied with the use
of a cellular transformation assay (16) as well
as a matrigel invasion analysis (17) (Fig. 2).
Addition of imidazole to 8A7F cells but not
6N7F cells led to increases in the number of
transformed foci (Fig. 2B and fig. S4C) and
also enhanced the efficiency of invasion with
the use of a modified Boyden chamber assay
(Fig. 2C). These classical phenotypes associ-
ated with viral Src (v-Src)–carrying fibroblasts
suggest that chemical rescue of mutant Src in
cells can induce expected oncogenic properties.
To gain insight into the nature of the pro-
teins that are tyrosine phosphorylated by imid-
azole after treatment of 8A7F cells, we carried
out an affinity-based enrichment of tyrosine-
phosphorylated proteins using antibodies to phos-
photyrosine (18). Immunoprecipitated proteins
were separated on an SDS–polyacrylamide gel
electrophoresis and detected with silver stain-
ing, and bands that appeared to be enriched were
identified by tandem mass spectrometry (Fig.
3A). We also used stable isotope labeling
(SILAC) (18), which allows for relative quanti-
tation to identify those proteins whose tyrosine-
phosphorylation status is up-regulated upon
imidazole treatment (Fig. 3A and fig. S5). Of
the 24 proteins detected from either of the two
strategies, six are reported to be Src substrates
(19, 20), but the others had not previously been
linked to Src kinase action.
To validate the mass spectrometry results,
eight individual proteins were immunoprecipi-
tated and thenWestern blotted with the antibody
to phosphotyrosine (Fig. 3B). Western blots of
the proteins with type-specific antibodies were
used for loading controls. These eight proteins
reproducibly increased their phosphotyrosine
content after imidazole treatment of 8A7F cells
but not 6N7F control cells (Fig. 3B). Included
among these were five established Src sub-
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cells. (A and B) Time
course of phosphoryl-
ation levels in 8A7F cells
(A) and 6N7F cells (B)
treated with 5 mM imid-
azole. Lysates were ana-
lyzed by blot with a
4G10 antibody. (C) Src
autophosphorylation
(Y416) in 8A7F and
6N7F cells as a function
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only 5 minutes. As expected from the previous results, control 6N7F were unresponsive 
to imidazole treatment. 
The reversibility of chemical rescue was then analyzed by performing washout 
experiments that showed that phosphorylation of the activation-loop tyrosine was back to 
background only 4 minutes after imidazole removal (Figure 12). This result is also an 
indication of the rapid cellular kinetics of tyrosine phosphatase activity towards Src’s 
tyrosine autophosphorylation site. 
The study included functional studies of v-Src’s chemical rescue as well as a 
proteomic study to identify novel v-Src substrates, the relevance of some of which was 
further explored. This work suggested that this strategy may be applicable to c-Src, the 
cellular form of c-Src, which is more relevant to human disease, as well to other disease-
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Figure 12. Reversible Src autophosphorylation (Y416) in R388A/Y527F in SYF cells (8A7F cells) 
after imidazole washout 
 
Reversible Src autophosphorylation (Y416) in R388A/Y527F in SYF cells (8A7F cells) 
after treatment with 5 mM imidazole for 5 minutes. Imidazole was removed by replacing 
the imidazole-containing media for imidazole-free media. Lysates were analyzed 4 to 60 
min later using a phosphospecific antibody against Tyr-416 in Src and the loading control 
was performed using an anti-actin antibody. 
first proto-oncogene and tyrosine kinase dis-
covered, is involved in a myriad of cellular pro-
cesses, but many aspects of its function are still
poorly understood (9, 10). In Src and its eight
other family members, the catalytic Arg388 is
located two residues upstream relative to its
position in other tyrosine kinases (fig. S1). We
therefore generated a set of Src Arg388 mutant
recombinant proteins and examined their po-
tential for chemical rescue (11) (fig. S1). The
maximal turnover rate (kcat) of R388A Src was
about 0.5% of the kcat of wild-type Src but
increased to 30 to 50% of the kcat of wild-type
Src with imidazole. The rescued enzyme
showed less than threefold changes in the
Michaelis-Menten constant (Km) of two differ-
ent substrates (11) (fig. S1B). Encouragingly,
the Km for imidazole was È2.5 mM (fig. S3B),
well below its toxic level (12).
To assess the potential of chemical rescue of
R388A Src kinase activity in living cells, we
stably transfected R388A/Tyr527YPhe (Y527F)
Src in SYF (Src, Yes, and Fyn deleted) mouse
embryonic fibroblasts (13) to generate 8A7F
cells. The Y527F mutation was included to
prevent down-regulation by Csk phosphoryl-
ation (9, 10) and the SYF line was used because
of its low background of Src family member
expression. We also generated the control SYF
line containing Src Asp386YAsn (D386N)/
Y527F (6N7F), a catalytically defective form
of Src that we showed (with the use of
recombinant protein) to be insensitive to
imidazole (fig. S3C). Western blots with an
antibody to Src showed that the level of Src
expression in these transfected lines was similar
to that in human embryonic kidney (HEK) 293
cells (fig. S4A). 8A7F cells were exposed to
5 mM imidazole for 0 to 10 min, and then
lysates were analyzed by Western blot with a
sequence nonselective antibody to phosphotyro-
sine (4G10) (Fig. 1A). A variety of bands in-
tensify or freshly appear at 2.5 min and plateau
by 10 min. In contrast, when the control cell
line 6N7F was exposed to imidazole, no de-
tectable changes in antiphosphotyrosine blotting
were observed (Fig. 1B). That the bands seen in
imidazole-treated 8A7F cells were related to
rescued Src tyrosine kinase activity was also
supported by the finding that pretreatment with
the Src-selective inhibitor PP1 (14) blocked the
appearance of the tyrosine-phosphorylated pro-
teins (fig. S4B).
A more detailed analysis of the dose and
reversibility of Src chemical rescue involved ex-
amining autophosphorylation on its activation-
loop tyrosine, Tyr416 (9, 10), with a site-specific
antibody (Fig. 1, C and D). As expected, mod-
ification of this loop is rapid and readily
detected after 5 min of imidazole treatment.
About 50% maximal phosphorylatio was
achieved with È2 mM im dazole exp sure
with 8A7F cells (Fig. 1C). Despite the more
complex environment of the cellular milieu,
this dose-response correlation of imidazole-
Src rescue is in good agreement with that of
the in vitro kinase behavior. Control 6N7F
cells were inse sitive to imidazole, as xpected
(Fig. 1C). Washout experiments showed that
activation-loop phosphorylation was back to
background within 4 min of imidazole removal
(Fig. 1D). This experiment not only establishes
the rapid reversibility of kinase activity by
dilution of imidazole, but it also underscores
the rapid cellular kinetics of tyrosine phospha-
tase activity toward the Src activation loop.
To further analyze the scope and kinetics of
the chemical rescue process in 8A7F cells, we
transiently transfected 8A7F cells with a fluo-
rescent biosensor that shows a fluorescence
resonance energy transfer (FRET) change upon
Src phosphorylation (15) (Fig. 2A). Imidazole
induces a rapid (less than 60 s) FRET change in
cytoplasmic regions of the cell. The FRET
change plateaus by about 500 s, consistent with
an equilibrium being reached with phosphatase
action and also with the effects seen by
Western blot (Fig. 1). Pretreatment with the
Src-selective inhibitor PP1 abolished FRET
change (Fig. 2A).
Functional and longer term consequences of
chemical rescue were also studied with the use
of a cellular transformation assay (16) as well
as a matrigel invasion analysis (17) (Fig. 2).
Addition of imidazole to 8A7F cells but not
6N7F cells led to increases in the number of
transformed foci (Fig. 2B and fig. S4C) and
also enhanced the efficiency of invasion with
the use of a modified Boyden chamber assay
(Fig. 2C). These classical phenotypes associ-
ated with viral Src (v-Src)–carrying fibroblasts
suggest that chemical rescue of mutant Src in
cells can induce expected oncogenic properties.
To gain insight into the nature of the pro-
teins that re tyrosine phosphorylated by imid-
azole after treatment of 8A7F cells, we carried
out an affinity-based enrichment of tyrosine-
phosphorylated proteins using antibodies to phos-
photyrosine (18). Immunoprecipitated proteins
were separated on an SDS–polyacrylamide gel
electrophoresis and detected with silver stain-
ing, and bands that appeared to be enriched were
identified by tandem mass spectrometry (Fig.
3A). We also used stable isotope labeling
(SILAC) (18), which allows for relative quanti-
tation to identify those proteins whose tyrosine-
phosphorylation status is up-regulated upon
imidazole treatment (Fig. 3A and fig. S5). Of
the 24 proteins detected from either of the two
strategies, six are reported to be Src substrates
(19, 20), but the others had not previously been
linked to Src kinase action.
To validate the mass spectrometry results,
eight individual proteins were immunoprecipi-
tated and thenWestern blotted with the antibody
to phosphotyrosine (Fig. 3B). Western blots of
the proteins with type-specific antibodies were
used for loading controls. These eight proteins
reproducibly increased their phosphotyrosine
content after imidazole treatment of 8A7F cells
but not 6N7F control cells (Fig. 3B). Included
among these were five established Src sub-
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ation levels in 8A7F cells
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Proteomics is the large-scale study of proteins, including their structures and 
functions (135,136). The term “proteomics” was conceived as a blend of “protein” and 
“genome”, to make an analogy with genomics (137). The proteome is the entire set of 
proteins expressed by a genome, including the modifications made to a particular set of 
proteins, produced by an organism or system in a given time under defined conditions 
(138). 
Proteomics is more complex than genomics due to the fact that an organism’s 
genome is relatively constant, whereas the proteome is more variable since distinct genes 
are expressed in particular cell types and specific stages of the cell cycle. In addition, the 
proteome is larger than the genome, especially in eukaryotes; there are more proteins than 
genes due to alternative splicing and post-translational modifications (PTMs). Alternative 
splicing has been estimated to expand the number of distinct mRNA sequences 
corresponding to the number of open reading frames (ORFs) by approximately three-fold 
(139). Even though the number of post-translational modifications is unknown, an 
average redundancy of four- to ten- fold has been estimated by considering combinatorial 
occupancies. As a result, it is reasonable that greater than one million different protein 
forms are present in human tissues (140). Moreover, there are at least two more levels of 
complexity in the proteome, as compared with the genome. The genome is encoded by 
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the sequence of nucleotides but the diversity of the proteome does not appear to 
correspond to a code. Moreover, proteins possess complex three-dimensional structures 
and engage in a plethora of subtle macromolecular interactions relative to the more 
monotonous conformations of DNA.  
In the past, the study of the proteome was primarily grounded in mRNA analysis. 
However, it has been found that this approach has limitations, since the analyzed specific 
mRNA level does not correlate tightly with protein abundance (141,142). Modern 
proteomics assays directly detect the presence and measure the quantity of individual 
proteins. 
In comparison to oligonucleotide and nucleic acid analytes, protein and peptide 
analytes show a broad array of solubility and chromatographic behavior, in addition to 
chemical complexity partly resulting from PTMs. Protein-protein interactions represent a 
key mechanism in signaling, but they are not accessible by conventional expression 
profiling.  As a result, differential profiling experiments require a combination of 
different strategies for the identification of proteins, the quantification of the relative 
expression and the assessment of covalent and noncovalent interactions (140). 
 
1.1. Proteomics Methods 
 
An early and still employed method for proteomics analysis involves the 
separation of proteins by two-dimensional gel electrophoresis (2DE). In the first 
dimension, the proteins are separated by isoelectric focusing (separation of different 
molecules by their ionic charge). In the second dimension, proteins are separated by 
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molecular weight using SDS-PAGE. This methodology reveals levels of protein 
expression and PTMs using protein staining intensities and electrophoretic mobility.  
Mass spectrometry has greatly expanded insights into proteomics.  A protein that 
is cleaved by proteases into short peptides can be identified by matching the observed 
peptide masses, which can be obtained by peptide mass fingerprinting, against a sequence 
database. Tandem mass spectrometry provides sequence information from individual 
peptides by isolating them, colliding them with a non-reactive gas, and labeling the 
fragment ions produced.  One of the most promising proteomics mass spectrometry 
approaches is multidimensional liquid chromatography coupled with tandem mass 
spectrometry (MudPIT, multidimensional LC-MS/MS) or ‘bottom up’ shotgun 
proteomics (Figure 13). In this strategy, a complex mixture of proteins is subjected to 
solution proteolysis. The resulting mixture of peptides is separated by multidimensional 
chromatography and analyzed by LC-MS/MS (143). An alternative methodology to 
analyze protein mixtures involves first separating the protein by SDS-PAGE followed by 
in-gel digestion (144). Current mass spectrometric software facilitates peptide sequencing 
through data dependent acquisition, by which ions are automatically selected and 
fragmented by MS/MS. As a result thousand of spectra can be collected from a single 
reversed phase run (145,146). 
The coverage of identified proteins by shotgun proteomics as compared to 2DE is 
much higher. The number of distinct ORFs detected in yeast, bacteria, and mouse by 2DE 
ranges from 1.5-5.1% of ORFs (147-149), whereas shotgun proteomics has led to the 




Figure 13. Schematics of MudPIT (multidimensional LC-MS/MS) or ‘bottom up’ shotgun proteomics 
 
Schematics of the flowtrough of MudPIT, multidimensional LC-MS/MS or ‘bottom up’ 
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resulting mixture of peptides is separated by multidimensional chromatography and 
analyzed by LC-MS/MS.   
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Deinococcus radiodurans, 46% of ORFs from Plasmodium falciparum and 15% of ORFs 
from human erythroleukemia cells (150-153). Moreover, shotgun proteomics detects 
hydrophobic proteins more efficiently, leading to a more successful detection of proteins 
from intracellular organelles (154,155). 
Quantifying peptide and protein abundances is a critical aspect of shotgun 
proteomics. A key difficulty is the fact that a peptide that ionizes inefficiently can show 
unreliable intensity when it coelutes with different peptides within a mixture showing 
charge competition (ion suppression). Such uneven ionization can be addressed by 
labeling peptides with differential isotopes or mass tags (Figure 14). After mixing and 
proteolyzing the lysates from both samples, the relative abundances of distinct peptides 
can be detected by comparing the intensities of their isotopically separable masses 
corresponding to the two (or more) different samples (156,157). 
Quantitation measured from MS peak intensities based on stable isotopes has 
been shown to be feasible. Peak intensities of peptide ions show good correlation with 
relative protein abundance as demonstrated with statistical modeling of peak intensities 
(158,159).  In the ICAT methodology (isotope-coded affinity tag), labeling is performed 
by covalently coupling the samples (typically through Cys or Lys residues) to isotopically 
labeled reactants (e.g. 12C vs. 13C). In the SILAC methodology (stable isotope labeling 
with amino acids in cell culture) lysates are metabolically labeled within normal cell 
growth in media containing isotopically distinguishable amino acids.   
 




Figure 14. Peptide labeling with isotopically labeled amino acids 
 
Isotopical labeling of amino acids allows distinguishing and comparing the intensities of 
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Shotgun proteomics combined with peptide quantitation by isotope labeling has 
been very helpful to unveil changes in the proteome as a result of signaling and cell 
regulation.  PTMs are difficult to detect in complex mixtures due in part to the fact that 
they are only present at low stoichiometry. Therefore, enrichment of modified proteins or 
peptides through affinity-based purification is an important strategy before LC-MS/MS.  
 
1.2.1. Phosphospecific antibodies 
 
Phosphospecific antibodies produced to detect and enrich tyrosine phosphorylated 
proteins and peptides have been especially helpful. However, antibodies for 
phosphorylated serine or threonine have been more difficult to generate, though certain 
antibodies that are specific for oligopeptides containing pSer/pThr have been successfully 




IMAC (immobilized metal affinity chromatography) can be used to enrich for 
phosphopeptides.  The mixture of proteins is run through a resin chelated with trivalent 
metals ions (i.e. Fe (III) or Ga (III)) that will adsorb phosphopeptides and 
phosphoproteins through ion pair interactions (161) (Figure 15). 
A limitation of this methodology is that the phosphorylated residues compete with 











capacity and high false-positive frequency. Enhanced methods to increase selectivity of 
phosphopeptide binding are needed.  
There are other methods to enrich for phosphopeptides that involve covalent 
modification (162-164). These strategies usually involve multiple steps of chemical 
derivatization and purification, which create reproducibility and recovery challenges.  
There is not a single method to analyze an entire proteome and its PTMs 
comprehensively. However, the methodology employed for the enrichment of modified 
peptides prior to LC-MS/MS analysis is helpful for improving breadth of protein sites 
identified. Still abundantly expressed proteins are easier to detect than scarce proteins. In 
fact, a comparison of the number of yeast ORFs that are quantifiable by Western blot 
analysis (and confirmed by microarray estimates) with the ORFs detected by mass 
spectrometry indicate that proteins represented in profiling studies are the mostly highly 
expressed proteins (165). 
   
1.2. Src proteomics 
 
Several biochemical and cellular strategies have been followed to identify direct 
and indirect tyrosine phosphorylated substrates of Src. Some of them involve 
immunoprecipitation of significant Src complexes (166), cDNA library screening (167), 
as well as in vitro determination of optimal peptide phosphorylation sequences (168). 
 
1.3.1. v-Src proteomics 
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Some of the cellular substrate identification studies have used the hyperactive, 
dysregulated form of Src, v-Src, which lacks normal downregulation by C-terminal 
phosphorylation on Tyr-527. V-Src’s direct substrates and mechanisms of cell 
transformation are still not fully understood (95). A chemical genetic screen for direct v-
Src substrates used a tagging method for specifically radiolabeling the direct cellular 
substrates of the oncoprotein v-Src (169). This strategy consisted of using a v-Src mutant 
capable of accepting a non-natural phosphate donor substrate (ATP= N6 (benzyl)ATP) 
that is weakly used  by wild-type kinases in vivo (125,170,171). In this way, the direct 
substrates of v-Src could be detected in cell lysates more cleanly. A global analysis using 
this technique in combination with 2DE and mass spectrometry led to the identification 
of 20 proteins that were phosphorylated by the v-Src mutant. After a focused screen with 
protein preparations enriched for potential direct substrates of v-Src (by isolating v-Src 
immune complexes), a restricted set of candidate direct v-Src substrates was revealed. 
Dok-1 was one of the identified proteins and the role of its direct phosphorylation by v-
Src was further studied. A disadvantage of this method is that it uses cell lysate as the 
pool of potential v-Src substrates. The cell lysate may not be representative for the 
phosphorylation events that occur in the living cell.  
A study from the Cole laboratory approached the search of v-Src substrates using 
the described strategy of chemical rescue that overcomes the limitation of having to use 
whole cell lysates as a starting material and allowed us to observe the effects of direct v-
Src activation in living cells (134). Chemical rescue of v-Src led to the rapid and specific 
activation of mutated v-Src. Tyrosine phosphorylation in the cell was detected by 
enriching the combined lysates from the control and treatment cell populations with 
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antiphosphotyrosine antibody and analyzing them by LC-MS/MS. Quantitation of the 
global changes in tyrosine phosphorylation upon v-Src activation was performed through 
two different methodologies. In the first one, immunoprecipitated proteins were separated 
on an SDS-PAGE gel and detected with silver staining. Bands that showed an apparent 
enrichment were identified by LC-MS/MS. The second strategy relied on metabolically 
labeling the control and treatment cell populations with different isotopically labeled 
amino acids. The combined results led to the identification of 24 proteins, 18 of which 
were unknown substrates at the time. The results were further validated by 
immunoprecipitation and Western blot and further studies were performed to explore the 
relevance of the phosphorylation by v-Src on some of the identified substrates.  
 
1.3.2. Proteomics using constitutively active c-Src mutants 
 
Several studies have used constitutively active Src mutants. In one of the studies, 
293T cells were transiently transfected with either an inactive form of c-Src (K298M) as 
a control or a constitutively active form of Src (Y527F) (172). Cells from both 
populations were labeled following the described SILAC methodology. Cells transfected 
with the constitutively active form of c-Src were harvested 12 or 24 hours after 
transfection. A more significant increase in phosphorylation was detected after 24 hours 
so this condition was selected. Lysates from the cells transfected with the inactive form 
of c-Src and the constitutively active form of c-Src were combined, enriched by 
immunoaffinity purification with an anti-phosphotyrosine antibody and analyzed by LC-
MS/MS. The study identified 10 known substrates and interactors of c-Src and Src family 
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kinases as well as 26 novel substrates. Four of the novel substrates were validated by in 
vitro kinase assays and cotransfection experiments. The study also used a c-Src specific 
inhibitor to demonstrate that three of the novel substrates contribute to PDGF signaling.  
 In a different study, p130Cas -/- mouse embryonic fibroblasts (MEFs) were 
either transformed with oncogenic Src-F529 or transfected with the empty retroviral 
vector (173). p130Cas expression was reconstituted by a separate retroviral vector. 
Phosphotyrosine peptides were enriched with an anti-phosphotyrosine antibody and 
analyzed by LC-MS/MS. A total of 867 peptides (563 distinct pTyr sites on 374 different 
proteins) were identified from the Src-transformed cells, while 514 peptides (275 pTyr 
sites on 167 proteins) were identified from nontransformed cells. Quantitation was 
performed by both spectral counting and SILAC and forty-three pTyr sites corresponding 
to 32 proteins were considered to be potential novel Src substrates. Interestingly, the 
proteins exhibiting increased phosphorylation in Src-transformed cells included many 
metabolic enzymes as well as RNA and protein synthesis processing machinery.
 Interestingly, v-Src forms are rarely found in human cells, even in cancer (174). 
Instead, it would be informative to pursue these studies focusing on the cellular proto-
oncogene c-src, which unlike the oncogene v-src, is regulated by Csk phosphorylation in 
the cell. This difference in activity regulation may confer different behavior of the kinase 
in the cell, including distinct substrates. 
 
1.3.3. c-Src proteomics 
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 There has been one previous proteomics study, which actually focused on 
mammalian c-Src (175). In this study NIH/3T3 fibroblasts were stimulated with PDGF in 
the presence or absence of the Src-family kinase inhibitor SU6656. A SILAC–based 
quantitative proteomic approach was combined with enrichment for tyrosine 
phosphorylated proteins and followed by LC-MS/MS analysis. The study detected 
changes in tyrosine phosphorylation patterns of 43 potential c-Src kinase substrates in 
PDGF receptor signaling. From the 23 known c-Src substrates, 7 had never been shown 
to play roles in PDGF signaling. From the 20 previously unknown substrates, 5 were 
reported as PDGF receptor signaling intermediates, while 15 have never been reported as 
players in PDGF receptor signaling. This study was particularly valuable in revealing the 
role of c-Src as a mediator of the mitogenic response to PDGF in fibroblasts. However, 
there may be benefits of analyzing cellular protein tyrosine phosphorylation targets of c-
Src using a proteomics strategy that can directly and specifically monitor c-Src kinase 
action rather than an indirect method such as the one performing growth factor 
stimulation.  
 One of the goals of this thesis was to achieve specific and rapid activation of c-
Src in living cells that will allow identification of substrates temporarily close to c-Src 
activation. An attractive strategy to pursue these objectives involves chemical rescue of 
mutant c-Src tyrosine kinase. Previous work in our lab combined chemical rescue of v-
Src and proteomics (134). In order to repeat this strategy for the mammalian c-Src, the 
first step would be to optimize the conditions for c-Src chemical rescue. After this was 
accomplished in living cells, we decided to combine c-Src chemical rescue with a 
shotgun proteomic strategy.  
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 By combining the specific and controlled activation of c-Src by chemical rescue 
with the ability of quantitative SILAC phosphoproteomics to provide the phosphorylation 
fingerprint of cells in different conditions, we have identified a number of potential novel 





2.1. Cell Culture and SILAC 
 
For regular tissue culture, Src-, Yes-, and Fyn- triple knockout mouse embryonic 
fibroblast cells (hereafter referred to as SYF cells) (ATCC) stably transfected with either 
R390A c-Src or D388N c-Src constructs as previously described (134) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) supplemented with 10% 
(v/v) qualified fetal bovine serum (FBS) (Invitrogen), 1% (v/v) of penicillin-
streptomycin-glutamine (PSG) (Invitrogen) and 300 µg/ml of Hygromycin B (Roche) and 
incubated at 37ºC in the presence of 5% CO2.  When starved, cells were cultured in the 
same medium lacking serum.  Chemical rescue experiments were performed from cells 
actively growing and motile at ~75% confluency.  Untransfected SYF MEFs cells and wt 
MEFs were grown as above without hygromycin treatment. 
For SILAC experiments, R390A c-Src SYF MEF cells (hereafter referred to as 
R390A/ SYF MEF cells) were adapted to the SILAC media. A detailed protocol for 
SILAC media preparation can be obtained from http://www.silac.org.  Arginine-, lysine-, 
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and tyrosine-free DMEM media were bought from Athena Enzyme Systems (SILAC 
experiment at the protein level) or from Invitrogen (SILAC experiment at the peptide 
level).  R390A/ SYF MEF cells were cultured in Arg-/ Lys-/ Tyr- free DMEM media 
supplemented with light (12C6 Arg/ 12C6 Lys/ 12C6 Tyr) amino acids from Sigma or heavy 
(13C6 Arg/ 13C6 Lys) amino acids from Cambridge Isotope Laboratories, Inc. “Light 
media” was supplemented with 12C6 Arg, 12C6 Lys, and 12C6 Tyr. “Heavy media” was 
supplemented with 13C6 Arg, 13C6 Lys, and 12C6 Tyr. A table with the used concentrations 
of stable isotopic amino acids used in SILAC media is included (Table 1). Both media 
contained 10% qualified FBS (Invitrogen), 1% PSG (Invitrogen) and 300 µg/ml of 
Hygromycin B (Roche).  The cells were adapted to the SILAC medium by growing them 
in these media for at least 5 replication cycles, as described earlier (176). When starved, 
cells were cultured in the same medium lacking serum.  The p-Tyr proteomes were 
assessed from cells actively growing and motile at ~75% confluency.   
 
2.2. Cell treatment  
 
For other chemical rescue experiments, including Western blots, 
immunoprecipitations and Western blots, and coimmunoprecipitations and Western blots, 
R390A/SYF cells and D388N/SYF cells were serum-starved for 16-20 hours. Cells were 
either treated with 10 mM imidazole, pH 7.5 for 5 minutes or left untreated (control) also 
for 5 minutes. Both cells sets were then washed once with ice cold PBS (Invitrogen) and 
immediately lysed in RIPA buffer (50 mM Tris-HCl pH 8.0, 0.25% Na-deoxycholate, 
150 mM NaCl, 1 mM EDTA, 1% NP-40 (Igepal), 1 mM Na3VO4, 1 mM NaF, 1 mM 
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PMSF, Complete protease inhibitor cocktail (Roche)), mixed for 30 minutes at 4°C.  The 
lysate was then cleared by centrifugation at 13,000 x g for 15 minutes and the supernatant 
collected. 
For SILAC experiments, approximately thirty 150-mm diameter plates of 
R390A/SYF cells (per condition) were serum-starved for 16 hours. Cells grown in 13C6 
Arg/ 13C6 Lys- containing media (heavy media) were treated with 10 mM imidazole, pH 
7.5 for 5 minutes, whereas cells grown in 12C6 Arg/ 12C6 Lys- containing media (light 
media) were left unstimulated and used as a control.  Both cells sets were then washed 
once with ice cold PBS (Invitrogen) and immediately lysed RIPA buffer (SILAC 
experiment at the protein level). In the SILAC experiment at the peptide level the lysis 
was perfomed with Urea lysis buffer (20 mM HEPES, pH 8.0, 9 M urea, 1 mM sodium 
orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM ß-glycerophosphate) by 3 bursts of 
ultrasonication (Duty cycle 40%, output control at 4, on Sonifier 250, Branson) at 4 °C.  
After sonication, the lysate was cleared by centrifugation at 20,000 x g for 15 minutes 
and the supernatant collected.   
 
2.3. SILAC experiment at the protein level 
 
SYF/MEF cells stably transfected with R390A c-Src were cultured, isotopically 
labeled and treated as described above. Phosphotyrosine protein profile with and without 
imidazole treatment was analyzed by immunoaffinity purification of phosphoproteins 
with 4G10 anti-phosphotyrosine antibody followed by Western blot using 4G10 anti-




Figure 16. Identification and quantitation of tyrosine phosphorylated proteins by SILAC and LC-
MS/MS.  Anti-phosphotyrosine immunoblot revealing chemical rescue. SDS-Page and colloidal 
Coomassie stained gels of immunoprecipitated eluates.  
 
A. Western blot against whole lysate of R390A/ SYF MEF cells using 4G10 anti-
phosphotyrosine antibody. Loading control was performed with anti-actin antibody. B. 
Phenylphosphate eluate run in a SDS-Page gel and stained with colloidal Coomassie. C. 




2.3.1. Tyrosine phosphoprotein enrichment and quantitative analysis 
 
Immunoaffinity purification of tyrosine-phosphorylated proteins was carried out 
as described previously (134). The agarose beads were eluted using two different 
procedures, one after the other. First, the beads were subjected to competitive elution 
with 100 mM phenyl phosphate. The eluate was concentrated and separated by SDS-Page 
(Figure 16.B.). Hereafter, the beads were treated with beta-mercaptoethanol and boiled at 
95ºC for 5 minutes. This sample was also separated by SDS-Page (Figure 16.C.). Both 
samples were processed independently from this step. The enriched tyrosine-
phosphorylated proteins were subjected to in-gel digestion as described previously (134). 
The resulting tryptic peptides were analyzed by reversed phase LC-MS/MS using a 
quadrupole-time-of-flight mass spectrometer (QSTAR Pulsar, MDS Sciex, Concord, 
Ontario, Canada) coupled to an 1100 series CapLC (Agilent, Santa Clara, CA). The raw 
data obtained from both analyses was first queried separately and then the raw data 
obtained from both analyses were combined and queried again. Queries were performed 
against the RefSeq protein database (v.26, containing 20311 entries) using MASCOT 
v.2.2.2 (Matrixscience, London, England). Quantitation of obtained SILAC data was 
conducted using MSQuant v1.4.3a39.  Acquired data were queried against the RefSeq 
mouse protein database using the following search parameters precursor and fragment 
ions mass tolerance of 1.1 and 0.1 Da, respectively. Carbamidomethylation of cysteines 
was set as a fixed modification while N-terminal acetylation, deamidation of asparagine 
and glutamine, oxidation at methionine, phosphorylation at serine, threonine and tyrosine 
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together with ‘heavy’ lysine and arginine was allowed as variable modifications. 
Quantitation was performed using MSQuant as described on 
http//msquant.sourceforge.net. As described before data from the two elutions were first 
treated separately and then merged, analyzed and quantitated together. 
 
2.4. SILAC experiment at the peptide level  
 
Three biological replicates were conducted.  Protein concentrations were 
determined by Bradford (Figure 17.A).  As a further loading control equal amount of 
lysates (50 µg) were mixed with SDS loading buffer and boiled at 95ºC for 5 minutes, 
analyzed by SDS-PAGE and stained with Colloidal Coomasie (Figure 17.B).  
Phosphotyrosine protein profile with and without imidazole treatment was 
analyzed by immunoaffinity purification of phosphoproteins with 4G10 anti-
phosphotyrosine antibody followed by Western blot using 4G10 anti-phosphotyrosine 
antibody (Figure 18).   
“Heavy” and “Light” lysates were mixed in protein concentration ratios 1:1.  As a 
result, a total amount of 35 mg (first biological replicate), 50 mg (second biological 
replicate) and 52 mg (third biological replicate) were generated for phosphotyrosine 
peptide profiling.  Two of the 3 biological replicates had two technical replicates with 
respect to LC-MS/MS.  LC-MS analysis of sample aliquots was performed to observe the 
equal mixing of heavy and light cell lysate proteins using a Micromass quadrupole time-








Figure 17. Site-specific mapping and quantification. Control 1 
 
Quality control studies of proteomics samples used for phosphotyrosine-site mapping.  A. 
Loading controls: protein concentrations were calculated by Bradford assay.  B. 50 µg 
samples from both the heavy and light lysates from each biological replicate were 





Figure 18. Site-specific mapping and quantification. Control 2 
 
Quality control studies of proteomics samples used for 
phosphotyrosine-site mapping.  Chemical rescue controls: Anti-phosphotyrosine 4G10 
Western Blot (WB) and immunprecipitation (IP/WB) of three biological replicates before 




Figure 19. Site-specific mapping and quantification. Control 3 
 
Quality control studies of proteomics samples used for phosphotyrosine-site mapping.  
Normalization controls: QTOF analysis of sample aliquots was performed to assure good 




0.9-1 0.9-1 0.9-1 
Biological Replicate 
 
       1                   2                    3 
 76 
2.4.1. Peptide preparation 
 
Proteins were reduced with DTT at a final concentration of 4.5 mM and alkylated 
with 10 mM iodoacetamide.  Lysates were diluted to a final concentration of 2 M urea, 20 
mM HEPES (pH 8.0).  1/100 vol/vol of 1 mg/ml trypsin- TPCK (Worthington 
Biochemical Corporation) was added to the diluted protein extracts and digestion was 
performed overnight at 25 ºC.  The lysates were analyzed before and after digestion as a 
control (Figure 20) using SDS-PAGE and colloidal Coomassie staining.  
The protein digests were acidified with trifluoroacetic acid (TFA) at a final 
concentration of 1%.  The acidified peptide solutions were centrifuged at 1,800 x g for 5 
minutes to remove the precipitate.  The clear supernatants were loaded onto Sep-Pak C18 
cartridges (Waters, cat no: WAT051910) previously wetted with 100% acetonitrile and 
equilibrated with 0.1% TFA. Acidified peptide samples were passed through cartridge by 
gravity and the cartridges were then washed with 0.1% TFA.  The peptides were eluted 
by 40% acetonitrile/ 0.1% TFA.  The eluted peptide solutions were lyophilized to remove 
residual TFA completely. 
 
2.4.2. Immunoaffinity purification of tyrosine phosphopeptides 
 
Anti-phospho-tyrosine antibody based immunoaffinity purification (IAP) of 
phosphopeptides was carried out according to the manufacturer’s protocol (177).  
Lyophilized peptides from each of the fractions (3 biological replicates, 2 technical 





Figure 20. Site-specific mapping and quantification. Control 4 
 
Quality control studies of proteomics samples used for phosphotyrosine-site mapping. 
Control of trypsinization of proteomic samples used for phosphotyrosine-site mapping.  
Samples from each biological control before and after trypsinization were separated on a 




sodium phosphate, 50 mM NaCl) aided by shaking and brief sonication. Solution was 
cleared by centrifugation for 5 minutes at 1,800 x g.  The phosphotyrosine antibody-
linked beads (Cell Signaling Technology) were washed with IAP buffer (1.4 ml IAP 
buffer, mix by invert 5 times) once and incubated with the cleared peptide solution for 30 
minutes at 4ºC with gentle shaking.  The phosphopeptide bound antibody beads were 
washed twice with IAP buffer and twice with water at 4ºC.  Phosphopeptides were eluted 
from the beads by incubation with 55 µl of 0.15% TFA at 20-25ºC for 10 minutes 
followed by second extraction with 45 µl of 0.15% TFA. 
The eluted phosphopeptides were desalted using Stage-Tip protocol described 
previously (178). The peptide eluate was then dried at 25ºC in Speed-Vac for mass 
spectrometry analysis. 
 
2.4.3. LC-MS/MS analysis of tyrosine phosphorylated peptides 
 
LC-MS/MS analysis of phosphopeptides enriched by IAP was carried out using a 
reversed-phase liquid chromatography system interfaced with Fourier transform LTQ-
Orbitrap Velos mass spectrometer (FT-MS) on a “high-high” mode (both MS and 
MS/MS analyses were carried out in FT-MS mode) (Thermo Scientific).  The reversed 
phase setup consisted of a trap column (2 cm × 75 µm, Magic C18 AQ material 5µm, 100 
Å) and an analytical column (10 cm × 75 µm, Magic C18 AQ material 5 µm, 100 Å).  
After concentration and desalting on the pre-column, peptides were eluted and separated 
on the analytical column using a gradient increasing from 100% solvent A/ 0% solvent B 
(Solvent A: 0.1% formic acid, solvent B: 100% acetonitrile, 0.1% formic acid) to 40% 
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buffer A/60% solvent B in 135 min. Each survey scan involved precursor scan from 350-
1600 m/z at 60,000 resolution and data dependent higher energy collision dissociation 
(HCD) MS/MS scans for the 10 most intense precursor ions at 7,500 resolution.  
Normalized collision energy was 35% and monoisotopic precursor selection enabled with 
isolation width of 1.9 m/z.  
 
2.4.4. Data analysis 
 
The acquired mass spectra were processed and searched using MaxQuant (version 
1.2) (179), Mascot (180) and Sequest (181) since these algorithms are complementary 
which can broaden protein and site identification (182). Searches using the latter two 
were submitted via Proteome Discoverer (version 1.3, Thermo Scientific), which allowed 
merging search results and quantitating the SILAC pairs.  All MS/MS spectra were 
searched against the RefSeq mouse protein database (v. 40, containing 31,183 entries). 
For all searches, two missed cleavages were allowed; carbamidomethylation of cysteines 
were set as a fixed modification. N-terminal acetylation, deamidation of asparagine and 
glutamine, oxidation at methionine, phosphorylation at serine, threonine and tyrosine 
together with the ‘heavy’ lysine and arginine were used as variable modifications. 
Monoisotopic peptide tolerance was set to 10 p.p.m. for precursors and 0.05 mDa 
for MS/MS fragment ions. Peptides fulfilling a FDR of 1% were reported. Peptides with 
inconsistent ratios or unusual high ratios were manually checked.  We established a 
threshold H/L ratio value of 1.2. Phosphopeptides showing an average (from the three 
biological replicates) SILAC ratio of 1.2 or above from Proteome Discoverer, MaxQuant, 
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or both were considered upregulated upon c-Src rescue. Four filtering criteria were used 
to obtain a high-confidence data set of quantified phosphotyrosine peptides. If manual 
validation was satisfactory and showed a rounded SILAC ratio of 1.2 or above, the 
peptides were included on the list. A detailed flow-chart of the process is included in 
Figure 21. 
 
2.5. Network Modeling and Literature Curation 
 
Phosphosite (http://phosphosite.org), Human Protein Research Database (HPRD) 
(22) (http://hprd.org), and literature curation were used to differentiate previously 
unidentified and known substrates from the list of proteins showing increased 
phosphorylation upon c-Src rescue. Phosphosite was used to establish the protein type 
classification of the detected proteins (Figure 26). The Ingenuity pathway analysis 
software (Ingenuity ® Systems, www.ingenuity.com) and literature curation were used to 
investigate previously observed connections between c-Src and the protein of study.  
The Ingenuity pathway analysis software was used to perform ontology and 
canonical pathway enrichment analysis of the proteins associated with the found tyrosine 
phosphopeptides experiencing an increase in their tyrosine phosphorylation level upon c-
Src rescue. The online web tool DAVID Bioinformatics Resources 6.7 
(http://david.abcc.ncifcrf.gov) (183) and the Ingenuity pathway analysis software were 
used to obtain a representation of the role of c-Src on focal adhesion pathways. The list of 





Figure 21. Flow-chart representing the complete data analysis process corresponding to the 
phosphopeptide enrichment by SILAC and LC-MS/MS 
 
Proteome Discoverer (v1.3) 
9187 redundant p-Tyr peptides 
(correspondent to 205 proteins) 
 
335 non-redundant p-Tyr peptides 
(correspondent to 205 proteins) 
 
MaxQuant (v1.2) 
931 redundant p-Tyr peptides 
(correspondent to 147 proteins) 
 
216 non-redundant p-Tyr peptides 




Four filtering criteria: 
 
High confidence peptides: 
 
1)!Peptides should show a SILAC ratio (H/L) equal or above 1.2 in at least two of the three biological 
replicates (obtained from Proteome Discoverer, MaxQuant, or both). If obtained from both Proteome 
Discoverer and MaxQuant the average H/L ratio in both should be equal or above 1.2 in both cases  
 
Peptides were subjected to manual validation when:  
2)   Peptide shows an average SILAC ratio (H/L) equal or above 1.2 Proteome Discoverer but the average 
SILAC ratio (H/L) is not above 1.2 in MaxQuant (or viceversa) 
3)   Peptide shows an average SILAC ratio (H/L) equal or above 1.2 (obtained from Proteome Discoverer, 
MaxQuant, or both), but the individual values of the SILAC ratio (H/L) from each biological replicate were 
not above 1.2 in two or more biological replicates. 
4)   Peptide shows an average SILAC ratio (H/L) equal or above 1.2 (obtained from Proteome Discoverer, 
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Threshold: Average H/L ratio ! 1.2 
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382 non-redundant  
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was uploaded in the DAVID tool, which incorporated the newly discovered proteins to 
the pathway. The pathway was completed using Ingenuity Systems. Both the known and 
the newly discovered potential c-Src phosphorylation sites were incorporated to the graph 
manually and validated with Phosphosite and HPRD.  
 
2.6. Immunobloting and Immunoprecipitations 
 
After imidazole treatment cells were washed once with PBS and lysed for 30 min at 
4ºC in RIPA buffer (Tris-HCl, 50 mM, pH 7.4, Na-deoxycholate 0.25%, NaCl, 150 mM, 
EDTA, 1mM, 1% NP-40), Na3VO4 1 mM, NaF 1 mM, PMSF 1 mM and protease 
inhibitor cocktail tablets (Roche), and centrifuged at 16,000 x g at 4ºC. The supernatants 
were collected for immunobloting and immunoprecipitation. For immunobloting the 
supernatants were mixed with SDS loading buffer and boiled at 95ºC for 5 minutes, 
analyzed by SDS-PAGE. The proteins were electroblotted onto nitrocellulose or PVDF 
membrane (Invitrogen). The membrane was blocked with 5% BSA in TBST for 1 hour at 
4ºC. The membrane was then probed with appropriate antibody, followed by incubation 
with the correspondent HRP- conjugated secondary antibody. Antibodies were used at the 
recommended concentration in the manufacturer’s instructions. Bands were visualized 
using SuperSignal West Pico chemiluminescent substrate (Pierce). For 
immunoprecipitation, the supernatants were pre-cleared with protein A or G agarose 
beads and subsequently incubated one hour with the antibody at 4ºC. Antibodies were 
used at the recommended concentration in the manufacturer’s instructions. Mixtures were 
treated with protein A or G agarose beads and then incubated at 4ºC overnight. The 
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agarose beads were subsequently washed three times by RIPA buffer, resuspended in 
SDS loading buffer with β-mercaptoethanol and boiled. The eluates were analyzed by 
SDS-PAGE and Western blot analysis.  
Antibodies were obtained as follows: Phosphotyrosine: (4G10) from Upstate 
Biotechnology. Both HRP-conjugated and non-HRP-conjugated 4G10 pTyr were used. 
FAK: 06-543 (FAK IP and WB) from Upstate Biotechnology. Paxillin: 05-417 (Paxillin 
IP and WB) from Millipore. Vimentin: ab8978 (Vimentin IP), ab58462 (Vimentin WB) 
from Abcam, Inc. C3G: sc869 (C3G IP and WB) from Santa Cruz Biotechnology. 
Tensin: sc28542 (Tensin IP and WB) from Santa Cruz Biotechnology.  Matrin 3: sc55724 
(Matrin IP and WB) from Santa Cruz Biotechnology. Nucleophosmin: ab10530 
(Nucleophosmin IP and WB) from Abcam. Gsk3β: CST9315 (Gsk3β IP) from Cell 
Signaling Technology, sc81462 (Gsk3β WB) from Santa Cruz Biotechnology. C3G: sc-
15359 (C3G IP and WB) from Santa Cruz Biotechnology. Western blots of experiments 
done with the rescuable cell lines (R390A/ SYF) were performed at least twice and 
results shown are representative except the IP-WB for tensin and matrin 3: tensin IP-WB 
in R390A/SYF cells have at least one reliable and clear immunoblot and one that is less/ 
non-reliable (poor quality blot, abundance of non-specific bands that make the 
interpretation difficult). However, the identification of upregulated tyrosine 
phosphorylation sites in the phosphopeptide search represents further validation of tensin 
as a c-Src substrate. In fact, the less/non-reliable anti-phosphotyrosine blot for the tensin 
IP was performed in the same membrane that another non-reliable duplicate of matrin 3 
which we will describe in detail in the Appendix 1 (Appendix 1 Figure 3.A). The IP-WB 
for matrin 3 was very challenging (specifically the anti-phosphotyrosine Western blot) 
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and, although attempted 5 times, we only obtained one reliable experimental repeat 
(Figure 28). FAK and paxillin IP-WB were only performed with the rescuable cell lines 
(R390A/ SYF) and only once (n=1). 
Western blots of experiments done with the non-rescuable cell lines (D388N/ 
SYF) were performed at least twice and results shown are representative, except in the 
IP-WB for tensin and matrin 3, where we only have one reliable biological replicate.  
The validation of matrin 3 through immunoprecipitation and Western blotting 
deserves further attention since the results obtained in the only valid biological replicate 
have modest quality, are ambiguous and present several caveats. The Appendix 1 is 
dedicated fully to the description of the methodology, results and interpretation of the 
matrin 3’s validation experiment and the modest evidence it provided, some of which 
supported the marginal increase in phosphorylation of matrin 3 upon c-Src rescue. 
Briefly, the initial experiment (Appendix 1 Figure 3.A) was performed following the 
standard protocol described above. We observed signal in the first attempt but the blot 
had bands that we suspect correspond to non-specific binding, making the interpretation 
unreliable, as we will explain in the Appendix 1. The next three repeats/ biological 
replicates (Appendix 1 Figure 3.B-D) were also performed following the standard 
protocol described above with slight modifications. Matrin 3 phosphorylation was very 
hard to detect, and the Western blot using phosphotyrosine antibody (4G10) showed no 
signal in these three experimental repeats. After three attempts when phosphorylation was 
not detected, we included some additional steps to be able to visualize phosphorylation. 
After incubation with the mouse HRP-conjugated 4G10 anti-pTyr antibody, we 
developed the blot and, as before, no phosphorylation was observed (Appendix 1 Figure 
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6). In order to detect matrin 3 phosphorylation, a sandwich reaction had to be performed 
(Appendix 1 Figure 7-8): we performed an incubation with an HRP-conjugated anti-
mouse secondary antibody. The first incubation with the secondary antibody (first 
sandwich reaction) was performed at 4ºC for approximately one hour. After washing the 
membrane we developed the membrane using SuperSignal West Femto 
chemiluminescent substrate (Pierce) diluted 1 to 10 in water (Appendix 1 Figure 7-8). 
We then washed the membrane again and developed (Appendix 1 Figure 9).  The 
membrane was then washed and incubated again with anti-mouse secondary antibody 
(second sandwich reaction). This second incubation was performed at 4ºC overnight as 
indicated in my notebook. After washing the membrane we developed the membrane 
using SuperSignal West Femto chemiluminescent substrate (Pierce) diluted 1 to 2 in 
water (Appendix 1 Figure 10-12). The resulting blot was very dark but could be scanned 
successfully with the help of an external lamp (Figures 28 and Appendix 1 Figure 11). 
The summarized workflow for the additional steps included to allow visualization of 
matrin 3 phosphorylation is presented in Appendix 1 Figure 4.  It should be noted that 
baseline values between rescuable and non-rescuable cells may not be the same due to 





3. 1. c-Src chemical rescue optimization 
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The chemical rescue of mutant v-Src provides precise temporal control of its 
intracellular kinase activity (134) and is a very useful tool to specifically activate v-Src in 
living cells.  In order to test whether we could observe similar results with cellular c-Src 
and combine this technique with a proteomics approach, we used SYF MEF cells stably 
transfected with R390A c-Src (R390A/SYF cells).  The triple knockout reduces the 
background from endogenous c-Src, as well as two other members of the Src kinase 
family, Yes and Fyn (184).  We observed that treatment of SYF MEF cells stably 
transfected with R390A c-Src using a range of 2.5-5 minutes and 2-10 mM imidazole 
induced a time- and dose-dependent increase in range and intensity of tyrosine-
phosphorylated protein bands as visualized by Western blot analysis of whole cell lysate 
with 4G10 anti-phosphotyrosine antibody (Figure 22 and 23).  After a series of 
optimization experiments, we selected 10 mM imidazole and 5 minutes exposure as 
favorable conditions for c-Src rescue in R390A/SYF cells. The imidazole-insensitive 
inactive c-Src mutant D388N/SYF cells were used as a negative control since they 
express an inactive Src kinase at similar levels (134) and should be most similar to the 
untreated R390A/SYF cells.  In prior studies (134), it was shown that D388N/SYF cells 
are unresponsive to imidazole.  We confirmed here that D388N/SYF cells showed no 
such change in protein tyrosine phosphorylation with 10 mM imidazole and 5 minute 
treatment, compared with the imidazole-sensitive R390A/SYF c-Src mutant (Figure 23), 
suggesting that the imidazole effect was specific.  The baseline Western blot differences 
(minus imidazole) between D388N/SYF and R390A/SYF cells likely represent subtle 





Figure 22.  Western blot experiment to optimize c-Src rescue conditions 
 
Optimization of c-Src rescue conditions. Time course imidazole treatment (2 mM and 5 
mM) of c-Src R390A SYF cells. Overall tyrosine phosphorylation level was performed 






Figure 23. Western blot experiment showing c-Src chemical rescue in R390A/ SYF cells but not in 
D388N/ SYF cells 
 
c-Src chemical rescue by imidazole.  Comparison of the phosphotyrosine profile of 
imidazole-treated cells compared to that of untreated cells. Tyrosine phosphorylation 
induced by imidazole treatment (10 mM, 5 minutes) of SYF cells stably transfected with 
c-Src R390A and D388N SYF (negative control). Cells were subjected to lysis and whole 




To further ensure that imidazole had no major effects on cellular tyrosine 
phosphorylation outside of chemical rescue under these conditions, we investigated its 
effect on SYF MEF and WT MEF cells.  As shown in (Figure 24), there were no 
appreciable changes in anti-pTyr Western blots of cell lysates treated with or without 
imidazole. 
 
3.2. Phosphoprotein identification and quantitation  
 
Since our goal was to identify the c-Src-induced phosphoproteome, we combined 
c-Src chemical rescue with mass spectrometry and stable isotope labeling with amino 
acids in cell culture (SILAC) (185).  R390A c-Src-expressing SYF cells were labeled 
with either 13C6-Arg/ 13C6-Lys (heavy) or 12C6-Arg/ 12C6-Lys (light).  “Heavy” cells were 
treated with 10 mM imidazole for 5 minutes and “light” cells were left untreated (control) 
to distinguish the c-Src induced tyrosine phosphorylation events from the background of 
steady-state tyrosine phosphorylated proteins in the cell. As an initial approach to test the 
combined advantages of chemical rescue and a proteomics analysis, protein enrichment 
was performed by immunoprecipitation with anti-phosphotyrosine antibody (Figure 25).  
The phosphotyrosine proteins were analyzed by tandem mass spectrometry. As 
described in the method section, two lists were generated after analyzing the two different 
elution samples (phenyl phosphate elution and boiled-beads elution) coming from the 
beads used in the phosphotyrosine protein enrichment. Both tables (Tables 2 and 3) are 






Figure 24. Control Western blot experiment showing no effects of c-Src chemical rescue in SYF MEF 
and MEF cells 
 
c-Src chemical rescue by imidazole.  Comparison of the phosphotyrosine profile of 
imidazole-treated cells compared to that of untreated cells. Tyrosine phosphorylation 
induced by imidazole treatment (10 mM, 5 minutes) of SYF MEF cells and MEF cells 
SYF MEF! MEF!
imidazole             -        +             -      +                  




(negative controls). Cells were subjected to lysis and whole lysates were subjected to 
Western blotting with 4G10 anti- phosphotyrosine antibody. 
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Figure 25.  Scheme of the experimental design of SILAC-based quantitative phosphoproteomic 
approach. Protein level 
 
R390A/SYF MEF cells were divided into two populations that were grown in ‘light’ or 
‘heavy’ medium. Heavy cells were treated with 10 mM imidazole for 5 minutes and 
‘light’ cells were untreated. Cell lysates were combined in equal proportions. The protein 
mixture was incubated with anti-phosphotyrosine antibodies for enrichment of tyrosine- 
phosphorylated proteins. The enriched fraction was subjected to in-gel trypsinization.  
The enriched sample was analyzed by LC- MS/MS. 
R390A c-Src SYF cells 
12C-Arg, 12C-Lys media 13C-Arg, 13C-Lys media 
IMIDAZOLE 
TREATMENT 
“Light” Lysate    “Heavy” Lysate 
Combine lysates 
 Immunoafinity purification 
of  pTyr-proteins 









The list of identified proteins resulting from analyzing the combined raw data is shown in 
Table 4 and Table 5 (simplified). A summary of fold change in phosphorylation upon c-
Src chemical rescue for all proteins included in Table 4 is included in Figure 26.   
We propose that many of the 35 proteins showing SILAC ratios equal to or above 1.2 are 
potential targets of c-Src-mediated tyrosine phosphorylation.  The cutoff of 1.2 was based 
on the standard deviation of the SILAC ratios as well as prior experience with this 
technique.  In fact, at least six of these 35 proteins are previously documented c-Src 
substrates. It could be assumed that larger SILAC ratios suggest greater confidence in 
undergoing c-Src-mediated phosphorylation. However, this is not necessarily the case.  
For example, the well-established c-Src substrate focal adhesion kinase (FAK) showed a 
modest ratio of 1.2.  The group of proteins that shows an increase in their 
phosphorylation level upon c-Src chemical rescue were sub-classified into five categories 
(Figure 26.B.) according to the Phosphosite bioinformatics resource 
(www.phosphosite.org) (186). The most highly represented cellular functions were 
signaling pathways (37%) – with proteins such as nucleophosmin, G3BP-2, Map kinase, 
C3G, and cullin 5 – and adhesion and cytoskeleton (26%) – vimentin, tensin 1, matrin 3, 
plectin 1, fibronectin 1, and myosin X.  A subset of the 29 potentially novel c-Src targets 
have been functionally linked to c-Src signaling pathways. They have never been 
identified as c-Src substrates, although the experiments here show unique evidence that 
they are closely temporally linked to c-Src kinase action. Two examples are vimentin 





Figure 26. Graph showing the distribution of identified and quantified phosphoproteins 
 
A. Summary of fold change in phosphorylation upon c-Src chemical rescue for all 
proteins in R390A/ SYF MEF cells. Known Src protein substrates within the group with 
increased phosphorylation level (H/L > 1.2) are indicated. Proteins with a heavy to light 
(H/L) ratio > 1.2 (red) increased their tyrosine phosphorylation level, and those with H/L 
ratio < 0.8 (green) decreased their tyrosine phosphorylation level. Proteins that showed 
no significant change in their tyrosine phosphorylation level (0.8 < H/L ratio < 1.2) are 
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regulated (H/L >1.2), constant (0.8 < H/L < 1.2) or down-regulated (H/L <0.8) tyrosine 
phosphorylation levels.  B.  Functional distribution of identified proteins with increased 




3.3. Validation of potential c-Src targets by immunoprecipitation-Western blot 
analysis 
We selected a set of identified proteins to confirm chemical rescue-induced 
tyrosine phosphorylation using an immunoprecipitation-Western blot approach in c-Src 
R390A/SYF cells.  The D388N/SYF cells serve as negative controls. As a positive 
control, we first selected two well-established c-Src’s susbtrates: paxillin and Fak showed 
imidazole-enhanced signal intensity when blotting with 4G10 anti-phosphotyrosine 
antibody after immunoprecipitation from R390A/SYF cells’s lysates (Figure 27). 
We then chose a set of representative potential new c-Src substrates from the 
different functional classes represented in our screening. We showed that C3G, vimentin, 
tensin 1, matrin 3 (n=1), nucleophosmin, and Gsk-3ß could be efficiently 
immunoprecipitated from SYF cells (Figure 28). The loading controls were performed 
by immunoprecipitation with a specific protein antibody followed by blotting with an 
antibody against the same protein.  Analysis of these immunoprecipitated proteins with 
anti-phosphotyrosine antibody showed an increase in the phosphorylation of each of 
these proteins from R390A/SYF but not D388N/SYF cells when treated with 10 mM 
imidazole for 5 minutes. These data suggest that tyrosine phosphorylation of each of 
these proteins depends on c-Src kinase activity, with a close temporal connection to c-Src 
rescue. The evidence obtained in the case of matrin 3 was not as strong as the one for 
other proteins. The quality of the blot was low given the extra steps we had to include to 
detect phosphorylation. Some of the evidence obtained supports matrin 3’s increased 
phosphorylation upon c-Src but we say they with reservations and recommend further  
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Figure 27. Validation of protein phosphorylation of known Src substrates Fak and paxillin upon c-
Src rescue 
 
Validation of protein phosphorylation of known Src substrates Fak and paxillin by 
immunoprecipitation- immunoblot analysis of R390A/ SYF cells after treatment with 10 
mM imidazole for 5 minutes. Immunoprecipitation was carried out with commercially 
available antibodies corresponding to the protein of interest and immunoblotting was 
carried out with the 4G10 pTyr-antibody as well as protein specific antibodies (n=1). 
Focal adhesion kinase and paxillin are two well-known studied c-Src substrates that were 
also found in ourexperiment. Validation of these two proteins was done once and was 
used as a control. Note that these results confirm Y Qiao et al. Science (2006). 
  
Focal Adhesion Kinase 
R390A 
imidazole      -        +            
IP: FAK     
WB: p-Tyr      
IP: FAK       
WB: FAK   
Paxillin 
R390A              
imidazole      -       +             
IP: Pax     
WB: p-Tyr    





Figure 28. Validation of six identified potential novel c-Src substrates 
 
Validation of protein phosphorylation by immunoprecipitation- immunoblot analysis of 
R390A and D388N c-Src SYF cells after treatment with 10 mM for 5 min. 
Immunoprecipitation was carried out with commercially available antibodies 
corresponding to the protein of interest and immunoblotting was carried out with the 
4G10 pTyr- antibody as well as protein-specific antibodies.  The blots were performed at 
least twice for R390A/ SYF MEF cells, except for matrin 3 and tensin where n=1. The 
blots were performed at least twice for D388N/ SYF MEF cells, except for matrin 3 and 
tensin where n=1. 
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validation with alternative methodologies to confirm the possibility that matrin 3 is a 
potential downstream target of c-Src. 
In fact, I would like to pay special attention to matrin 3. Matrin 3 was identified as 
one of the proteins that experienced an increase in its tyrosine phosphorylation level upon 
c-Src chemical rescue. The mass spectrometry data evidencing the identification and 
quantification of this protein is shown in Appendix 1 Figure 1 (MS/MS) and Appendix 
1 Figure 2 (MS).  Since matrin 3’s validation was particularly challenging, the 
procedure, results and interpretation have been thoroughly developed in the Appendix 1, 
created exclusively with the purpose of presenting the data obtained in an extensive and 
clear manner. See Appendix 1 for further details. 
  
3.4. Phosphosite mapping by chemical rescue of mutant c-Src 
 
Given the positive outcome of our preliminary attempt to combine c-Src chemical 
rescue and phosphoproteomics, we decided to perform an extensive phosphopeptide 
mapping  
and quantitation of phosphorylation changes in the cell upon c-Src rescue. The protocol 
described above for quantitative analysis of protein tyrosine phosphorylation was 
modified such that trypsin proteolysis of extracted proteins was performed prior to 
affinity based enrichment with anti-phosphotyrosine antibody (Figure 29).  
As described above, three biological replicates and two technical replicates were
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Figure 29. Scheme of the experimental design of SILAC-based quantitative phosphoproteomic 
approach.  Peptide level 
 
SYF MEF cells stably transfected with R390A c-Src were divided into two populations 
that were grown in ‘light’ or ‘heavy’ medium. The population of cells cultured in ‘heavy’ 
medium was treated with 10 mM imidazole for 5 minutes and the one cultured in ‘light’ 
media was left untreated. Cell lysates were combined in equal proportions. The protein 
R390A c-Src SYF cells 
12C-Arg, 12C-Lys media 13C-Arg, 13C-Lys media 
IMIDAZOLE 
TREATMENT 
“Light” Lysate    “Heavy” Lysate 
Combine lysates 
 Lysate trypsin digestion 





(No treatment)   
LC-MS/MS analysis 
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mixture was first digested with trypsin and then incubated with anti-phosphotyrosine 
antibodies for enrichment of tyrosine- phosphorylated peptides. The enriched sample was 




performed and analyzed using high resolution, high accuracy mass spectrometry (189).  
Mascot and Sequest led to the identification of an initial list of 9,187 tyrosine 
phosphopeptides spectrum matches (corresponding to 205 proteins). These translated into 
a list of 335 non-redundant peptide sequences (corresponding to 205 proteins).  In 
parallel, the quantitative proteomics software MaxQuant led to the identification of an 
initial list of 931 tyrosine phosphopeptide spectrum matches (corresponding to 147 
proteins). The tables containing all this information and raw data associated with the 
phosphopetide screening were uploaded to ProteomeCommons.org Tranche where they 
can be downloaded from, http://proteomecommons.org/tranche/, using the following hash 
code:04W8a1fu+GSc7GMzdx0PJMaHuN+TEK8OpXcdzz07rrnT9h7USvqudUouF1vSin
kQgXwrp+SA6WuF5IBCwMuF4oCtFDgAAAAAAAAJSg==. 
Combining the two sets of data, we assembled a proteome comprising 382 non-
redundant peptide sequences, corresponding to 334 tyrosine phosphorylation sites on 213 
proteins (Table 6).  
We again set a threshold value of 1.2-fold for SILAC ratio (heavy vs. light ≥ 1.2) 
to filter for tyrosine-containing peptides with increased phosphorylation level upon c-Src 
rescue.  A high-confidence data set of quantified phosphotyrosine peptides was obtained 
through a four filtering criteria described in the Methods section.  After manual validation 
we obtained a list of 97 non-redundant peptide sequences, revealing 85 tyrosine 
phosphorylation sites (corresponding to 52 proteins), as upregulated in response to 
chemical rescue of c-Src, suggesting that they may be downstream c-Src targets.  A 
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complete list of the mapped proteins with sites showing an increased phosphorylation 
level upon c-Src chemical rescue is provided in (Table 8).  
Several of these sites were identified in proteins that also showed an increased 
phosphorylation level at the protein level (such as C3G, tensin 1, Pard3 and Lpp), adding 
further confidence to their significance.  The proteins containing the tyrosine residues 
which showed an increased phosphorylation level upon c-Src rescue can be classified into 
several categories (Figure 30) including actin modeling, adaptor/scaffold, adhesion, 
guanine exchange factors/GTPase-activating proteins, non-receptor protein kinases, 
phosphatases, cell polarity, receptor tyrosine kinases, and a group of proteins with diverse 
functionalities.  
We analyzed the c-Src upregulated phosphoproteome with the Ingenuity 
Pathways Knowledge Software (Ingenuity ® Systems, http://www.ingenuity.com) and 
looked for enrichment of both canonical pathways (Figure 31. A) and ontology (Figure 
31.B).  Not surprisingly two of the most enriched pathways are the integrin and the focal 
adhesion signaling pathways. The ‘cellular movement’ category appears to be the 
functionality that is especially impacted upon c-Src activation.  The combination of 
integrin-mediated focal adhesion formation and adherens junction formation and focal 
adhesion disassembly (turnover) mediate cellular motility and are involved in cancer 
invasiveness and progression (51). A significant proportion of the identified sites are 
involved in cell adhesion, particularly in focal adhesion regulation, where c-Src plays a 
key role (190,191). In this context, several phosphosites are found in potential novel c-
Src substrates. Also, novel sites in well-established c-Src substrates show an increased 





Figure 30. Overview of identified phosphopeptides with upregulated tyrosine phosphorylation upon 
c-Src rescue in R390A c-Src SYF MEF cells 
 
All the detected upregulated phosphopeptides are shown whether they are novel (red) or 
known (red and black dot) c-Src substrate sites. As shown, the corresponding proteins 
span a wide variety of cellular functions, such as polarity, actin remodeling, adaptors, 




Figure 31. Ingenuity Pathway analysis of the c-Src upregulated phosphoproteome 
  
A. Enrichment plots of canonical pathways (x-axis) built on the list of 52 c-Src upregulated 
phosphoproteins. The right y-axis (line) represents the percentage enrichment (ratio between the number of 
c-Src upregulated proteins and the total number of proteins included in the pathway). The left y-axis (bars) 
represents the significance of the enrichment, which was calculated using the Benjiamini-Hochberg 
multiple testing correction, as –log10 of P-values. From the complete list of pathways obtained from the list 
of the c-Src upregulated phosphoproteins by Ingenuity Systems, the ones with a value of –log (BH-P) ≥ 6 
















































































































































































































































































































































































































































































































































































































































































































































phosphoproteins. The y-axis represents the significance of the enrichment, which was calculated using the 





Figure 32. Role of c-Src in focal adhesion signaling   
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The signaling pathways involved in focal adhesion activation by integrins and the resulting downstream 
signaling events are represented.  The biological functions resulting from focal adhesions are also 
summarized.  For each of the proteins involved the sites that are known substrates of c-Src are indicated.  
The modulation of phosphotyrosine sites that were identified in our experiment is indicated as significantly 
increased (black), not modulated (gray), or decreased (white). Among the identified sites some are known 




Although the tyrosine phosphoproteome provided here is not likely to include the 
entire c-Src phosphoproteome, it is the first snapshot of the tyrosine phosphorylation 
events that take place immediately (5 minutes) after c-Src specific activation and the first 




 As described above, previous studies have focused on the proteomic analysis of 
oncogenic v-Src and other dysregulated Src mutants (134,172,173), which may respond 
very differently to wild type c-Src in a cellular context.  Moreover, some of these studies 
have examined tyrosine phosphorylation patterns several hours or even days after Src is 
expressed, allowing chronic changes in phosphoproteins to be determined.  Such analyses 
are well-suited to identification of possible biomarkers in v-Src expressing tumors, which 
appear to be very rare, but likely reflect many secondary changes in cellular protein 
levels relating to Src’s well established effects on growth and gene expression.   
 The most recent study on Src proteomics did focus on cellular c-Src’s kinase 
action in response to treatment with SU6656 inhibitor and posterior stimulation with 
platelet-derived growth factor (PDGF) (175). Proteomic analysis after acute activation of 
tyrosine kinases by ligands such as growth factor have been particularly informative 
because they have revealed how a cascade of signaling is initiated in a temporal fashion. 
They also have provided information on how the kinase of study is involved in the 
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signaling pathways that are usually activated by such growth factors. However, this 
methodology is unlikely to reflect the effects of exclusively activating a single kinase.  
 In order to identify direct or temporally connected substrates of the proto-
oncogene c-Src, it would be ideal to use a method to rapidly and specifically switch on c-
Src activity in the cell.  In contrast to receptor tyrosine kinases, most non-receptor 
tyrosine kinases cannot be readily controlled in this fashion.  However, the chemical 
rescue of the R390A c-Src mutant provides a strategy that nicely fits this purpose since it 
provides a rapid, specific and reversible mechanism of c-Src activation, permitting the 
detection of the immediate effects of the restored c-Src activity in live cells (134). 
 Combining the power of chemical rescue with a proteomics approach that 
incorporates tyrosine-phosphorylated protein enrichment led to the identification of 28 
potential novel c-Src protein substrates. When the enrichment was done at the peptide 
level, we were able to identify 85 potential novel tyrosine phosphorylation sites 
(corresponding to 52 proteins), which showed an increased phosphorylation level upon c-
Src rescue.  It is reassuring that several of the putative protein substrates of c-Src that we 
have uncovered in this work have been linked to Src in prior studies.  However, only 16 
of the proteins found here using c-Src rescue were found among the 140 putative Src 
kinase targets identified in a combined list (Table 8) of the four prior mass spec 
phosphoproteomics studies (134,172,173,175) reported previously.  The lack of greater 
overlap is likely due in part to the divergent experimental approaches.   
It should be noted that even chemical rescue cannot unequivocally assign a 
protein as a direct kinase substrate of c-Src since the changes in phosphorylation we see 
can result from secondary effects, which can happen within the time frame used in our 
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observations (5 minutes).  Indeed, the class of proteins that show a decrease in tyrosine 
phosphorylation likely reflects examples of a secondary phenomenon where a protein 
tyrosine phosphatase is activated by phosphorylation. For example, protein tyrosine 
phosphatases SHP1 and SHP2 are known to be activated by tyrosine phosphorylation and 
such a mechanism could contribute to specific dephosphorylation events (192,193). 
Nevertheless, in order to define the characteristics of signaling networks, it is helpful to 
elucidate the temporal connections among phosphoprotein changes, even if the protein 
interactions are indirect. 
Activation of c-Src by growth factors or activating mutations leads to increased 
cellular proliferation, invasion and motility and decreased cell-cell (adherens junctions) 
and cell-matrix adhesion (focal adhesions) (51).  As revealed by the Ingenuity analysis 
(Figure 31), a significant number of the phosphopeptides detected in our chemical rescue 
analysis are involved in cell adhesion and, in particular, in focal adhesion pathways 
(Figure 32).  C-Src is known to play a role in the regulation and disassembly of focal 
adhesions, which link the extracellular matrix to the actin cytoskeleton (194) and are also 
involved in signaling pathways that regulate proliferation and gene transcription (195).  
Our work here provides a number of possible novel connections between c-Src and focal 
adhesion pathways. A network map that includes the role of c-Src in focal adhesions and 
highlights the novel proteins and phosphopeptides identified in our study is shown in 
Figure 32. 
Focal adhesions form when integrin connects the ECM to a complex of proteins 
that act as a link between integrins and the actin cytoskeleton.  These supramolecular 
complexes include structural cytoskeletal proteins like talin, vinculin and alpha-actinin, 
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as well as signaling molecules, including c-Src, FAK, p130Cas and paxillin (196). In fact, 
focal adhesions serve at least two significant cellular functions: transmitting force at 
adhesion sites in order to maintain strong attachments to the underlying ECM and acting 
as signaling centers from which several intracellular pathways originate and are involved 
in cell growth, survival and gene expression (197,198). Several tyrosine sites from 
cytoskeletal proteins that are part of this supramolecular structure and have not 
previously been described as c-Src substrates experienced an increase in their 
phosphorylation level include talin (Tyr-436), filamin B (Tyr-2502), tensin 1 (Tyr-1477, 
Tyr-1480, Tyr-1558), and tensin2 (Tyr-483, Tyr-705, Tyr-770, Tyr-791).  Tensin 3 is a 
recently discovered c-Src target (199) but the site found in this study, Tyr-584, has never 
been shown to be phosphorylated by c-Src.  
Regarding the effects of c-Src on the signaling molecules mentioned above, our 
study led also to interesting findings about potential novel c-Src tyrosine phosphorylation 
sites. C-Src is known to autophosphorylate on site Tyr-424 leading to an increase in its 
activation. We were able to detect this site, which indeed showed an increase in 
phosphorylation. However, we also identified a second phosphorylation site within the 
catalytic domain, Tyr-444 that was also detected in a previous study (173) and has no 
known role in Src activity or binding with other partners. It is established that c-Src 
phosphorylates and activates FAK at sites Tyr-614 and Tyr-615 promoting maximal FAK 
catalytic activity (200). Interestingly we detected a new FAK phosphorylation site, Tyr-5, 
which underwent a c-Src mediated increase in phosphorylation and has never been 
identified as a c-Src substrate. Similarly, p130Cas is a well-known substrate of active 
FAK-Src. Several known sites and a new phosphorylation site, Tyr-331, showed an 
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increased phosphorylation level upon c-Src rescue. 
The activation of the small GTP binding protein RhoA is one of the key events of 
focal-adhesion assembly (201).  C-Src blocks downstream signalling by RhoA through 
activation of p190-RhoGAP, leading to focal-adhesion disruption and increased motility. 
In this manner, c-Src regulates EGF-dependent actin cytoskeleton reorganization through 
phoshorylation of p190-RhoGAP (202). Two other RhoGAPs are known to be 
phosphorylated by c-Src: RhoGAP3 (Tyr-21 (203)), and RhoGAP5 (204) (Tyr-1091, 
1109).  Interestingly, we detected two other RhoGAPs that have never been described as 
c-Src substrates: RhoGAP42 (Tyr-342-unknown; Tyr-759-unknown) and RhoGAP32 
(Tyr-2025-unknown).  
Among other new sites identified, one is particularly worth mentioning since we 
will focus on its connection with c-Src through the next chapter. Previous studies have 
shown a correlation between C3G phosphorylation and different potential tyrosine 
kinases, including Src family kinases (205-207). However, we believe it is the first time 
that such a temporarily connected correlation has been established between c-Src and 
C3G in living cells. This connection was established through the above proteomic 
approach and revealed an increase in phosphorylation of the C3G protein, as well as a 
new site (Tyr-571), that has a remarkably high SILAC ratio upon c-Src chemical rescue. 
In addition, the work described in the next chapter has further explored the connection 
between c-Src-mediated C3G’s phosphorylation, its activation and the consequent 
ramifications in c-Src-Crk-C3G-Rap1 signaling. 
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C3G (for Crk SH3 domain-binding guanine nucleotide-releasing factor) or Rap1 
guanine exchage factor (Rap1GEF) is a guanine nucleotide exchange factor for the small 
G-proteins Rap1, Rap2, and R-Ras (208, 209). C3G was first identified as one of two 
major proteins that bind the SH3 domain of the adaptor Crk (210, 211). A 4.1-kb C3G 
cDNA containing a 3.2-kb open reading frame encodes a 121-kDa protein that has three 
major types of domains (Figure 33).  The C-terminal domain catalyzes the guanine-
nucleotide exchange reaction for Rap1, a Ras family protein (208).  Mutational analysis 
of C3G revealed that a 50-amino acid central region containing a proline-rich sequence is 
responsible for binding to Crk’s SH3 domain (211). The function of the amino-terminal 
region of C3G remains incompletely understood but p130Cas, a major Crk SH2-binding 
protein, binds this region in vitro (212). 
C3G, among other guanine exchange factors, is responsible for stimulating the 







Figure 33. C3G domain structure 
 
 The amino-terminal is known to bind p130Cas. The central region contains a proline-rich 
sequence that binds the SH3 domain of Crk. The carboxyl-terminal domain catalyzes the 
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p130Cas (Cas; crk-associated substrate) was identified as a highly phosphorylated 
protein of 130 kDa in v-Src and v-Crk transformed rat 3Y1 fibroblasts (214). p130Cas is 
a docking molecule that contains one NH2-terminal SH3 domain followed by a stretch of  
proline-rich sequences, a central substrate domain composed of a cluster of potential 
SH2-binding sites, and a COOH-terminal domain which contains consensus binding sites 
for the SH3 and SH2 domains of c-Src (215). The SH3 domain is known to bind focal 
adhesion kinase (FAK) (216) among other molecules, but C3G was also identified as a 
direct interactor both in vitro and in vivo. Analysis of several mutants revealed a proline-
rich Cas-binding site located NH2-terminal of C3G. The site is defined by the consensus 
sequence XXPXKPX, which is recognized by the p130Cas SH3 domain. As a docking 
molecule, p130Cas may serve to bring C3G to specific compartments within the cell 
(212). 
 
 1.3. Crk 
 
v-crk was identified first as an oncogene of CT10 avian sarcoma virus (10). Crk 
belongs to a group of adaptor-type SH2-containing molecules, together with GRB2/ASH 
and Nck proteins. The human crk gene is translated into two products by alternative 
mRNA splicing, CrkI and CrkII (217). v-Crk, its cellular homologs Crk II, Crk I, and the 
paralog CrkL, constitute a class of regulatory proteins that function as adaptors. These 
adaptors contain SH2 and SH3 domains that participate in the assembly of multiprotein 
complexes and act as convergence points in tyrosine kinase signaling (218). Figure 34 




Adapted from Birge RB et al. Cell Commun Signal, 2009 
 
Figure 34. Crk domain structure 
 
v-Crk is a viral protein containing a Gag, SH2 and SH3 domains. There are two splice forms of huan Crk, 
CrkI (containing one SH2 domain and one SH3 domain) and CrkII (containing one SH2 domain and two 
SH3 domains). The paralog CrkL shares CrkII’s domain structure. 
  
Figure 3.2 
Adapted from Birge RB et al. Cell Commun Signal 2009 
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Gag, viral group specific antigen.  
The SH2 domain of Crk binds to phosphotyrosine-containing proteins such as 
paxillin and p130Cas (214,218). Two major proteins bound to the amino-terminal SH3  
Domain, SH3(N), have been identified as C3G and DOCK180. Apart from these major 
binding proteins, Abl family tyrosine kinases and Sos, a guanine nucleotide exchange 
protein for Ras, are also known to bind to SH3 (N) (219-223). 
A peculiar feature of Crk (CrkII) is that unlike other adaptor proteins such as 
Grb2 and Nck, CrkII itself is phosphorylated on tyrosine. Tyr-221 (Crk) or Tyr-207 
(CrkL) are negative regulatory phosphorylation sites. Crk is negatively regulated by 
tyrosine phosphorylation on Tyr-221, which occurs as a result of various types of 
stimulation. C-Abl kinase binds to the first Crk SH3 domain and is proposed to 
phosphorylated Crk on Tyr-221 (Figure 35). The phosphorylation of c-Crk Tyr-221 
creates a binding site for the Crk SH2 domain. c-Crk lacking phosphorylation on Tyr-221 
can bind specifically to several proteins. It is likely that protein-binding activity of Crk is 
regulated by a mechanism similar to that of the Src family kinases. The intramolecular 
binding of phosphorylated Tyr-221 to the SH2 domain blocks SH3 (1)- dependent protein 
binding. The activation of Crk may be linked to the action of a cellular phosphatase. 
Once the first SH3 domain is unmasked, Crk forms a complex with specific proteins. It is 
currently unknown if the Crk SH2 domain has more than a negative regulatory function 




Adapted from Feller SM et al. EMBO J, 1994 
 
Figure 35. Crk negative regulation by phosphorylation on Tyr-221 by c-Abl 
 
 c-Abl binds to Crk’s SH3 domain, facilitating phosphorylation of Crk on Tyr-221. Phosphorylated Tyr-221 
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 Rap 1 is a small G-protein of the Ras family that antagonizes Ras activity by 
sequestering Raf-1, a common target, in the inactive form (224) and therefore 
competitively suppresses Ras-dependent transformation and ERK/ MAP kinase activation 
(225,226). Rap is implicated in a variety of biological processes that affect the 
cytoskeleton, adhesion molecules and/or intracellular trafficking. These functions of Rap 
include the regulation of integrin-mediated cell adhesion, cell–cell junction formation, 
establishment of cell polarity, exocytosis and cell proliferation (227). 
 Rap proteins have been shown to localize to multiple membrane compartments 
including the plasma membrane (PM), the perinuclear Golgi apparatus and endoplasmic 
reticulum, endocytic vesicles, secretory vesicles, and the nuclear envelope. Lipid 
modifications within the C-terminal tail are responsible for anchoring of Rap to the 
membrane (228). Rap is likely to be further compartmentalized at the membrane into 
distinct molecular complexes (229). The dynamic localization of Rap is partly controlled 
by post-translational modifications (228). 
 
1.5. THE SRC-CRK-C3G-RAP1 PATHWAY 
 
 The members of the Crk family are not just conduits for intracellular signal 
transduction: they can also regulate the amplitude of signaling (230): Crk-mediated 
transformation leads to an increase in p130Cas-associated activity of Src family kinases 
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(SFK) (231), phosphorylation of FAK by SFKs, and the recruitment of PI3K to FAK 
(232,233). It has been shown that Crk overexpression in tumor cells induces an increase 
in the tyrosine phosphorylation of p130Cas and the activation of an intracellular feedback 
loop that further increases Crk activity with the consequent increase in motility of cancer 
cells signaling (230) (Figure 36). 
 
1.6. C3G activation 
 
1.6.1. C3G- Crk binding and membrane recruitment 
 
 C3G activation occurs mainly through membrane recruitment (205, 234). Binding 
to the Crk/ CrkL SH2 domains to newly generated target sites on activated receptors and 
their substrate proteins leads to a redistribution of C3G within the cell, presumably to 
sites where Rap 1 is located. In fact, the adaptor protein Crk has been identified to 
mediate Src-dependent Rap1 activation (235). Expression of Crk in COS cells leads to 
C3G activation concomitant with its translocation to the cell membrane.  
Besides the relocation of this complex, some studies suggest Crk-C3G association itself 
may be regulated, thereby affecting downstream signaling (236). As described above, the 
binding sites of C3G for Crk and CrkL have been mapped as several P-x-x-P-x-K motifs 
in the center of the protein (237,238). CrkII is more abundant than CrkI in normal cells 
and is therefore the major adaptor for C3G (217). It was reported in a previous study that 
CrkII is constitutively associated with C3G (239). However, even though Crk and CrkL 
exist in constitutive complexes with C3G in many cell types, regulation of these  
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Adapted from Cabodu S, et al. Nature Reviews Cancer, 2010 
 
Figure 36. The Src-Crk-C3G-Rap1 pathway 
 
Growth factors activate RTKs. Crk’s SH2 domain binds to activated receptors or newly tyrosine 
phosphorylated proteins, such as p130Cas. The SH3 domain of Crk binds proline-rich-effector molecules 
such as C3G, which is redistributed to sites where its effector, Rap1, is located. C3G is tyrosine-
Figure 3.4 
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phosphorylated on Tyr-514 and this phosphorylation is thought to regulate its activity. This event may 
occur when C3G is close to the membrane and in the vicinity of activated tyrosine kinases. Activated Rap1 
recruits B-Raf, stimulating a signaling cascade. SFK: Src family kinases; SD: substrate domain; SRR: 




complexes has also been reported in response to a variety of stimuli such as insulin 
receptor activation and integrin stimulation (236,240,241). 
The requirement of the SH2 domain of Crk for the enhancement of guanine 
nucleotide exchange activity for Rap1 could be replaced by the addition of a 
farnesylation signal to Crk (234). These results suggest that Crk may be able to enhance 
the guanine nucleotide exchange activity of C3G by recruitment of C3G to the 
membrane.  
 
1.6.2. C3G phosphorylation 
 
Membrane recruitment may not be the sole mechanism of C3G activation by Crk. 
While a previous study showed that Crk did not stimulate the guanine nucleotide 
exchange activity of C3G for Rap1 in vitro (234), an indirect tyrosine phosphorylation 
mechanism has been proposed. It has been shown that an increase in the catalytic activity 
of C3G correlated with its tyrosine phosphorylation (206). In fact, C3G is the first 
example of a guanine nucleotide exchange factor for Ras family proteins that can be 
activated by tyrosine phosphorylation. 
It has been observed that activation of C3G by CrkI expression is accompanied by 
C3G tyrosine phosphorylation, playing a significant role in the activation of C3G (242). 
Several growth factors and cytokines stimulate the recruitment of the Crk-C3G complex 
to the membrane where tyrosine kinases are located, such that a C3G tyrosine residue 
may phosphorylated with a resultant increase in its GEF activity (205,206). 
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A previous study constructed a series of C3G deletion mutants in order to 
understand the mechanism by which C3G is phosphorylated and activated by Crk 
(Figure 37) (206). This 1999 study described a negative regulatory region within C3G. 
Deletion of the amino-terminal third had been shown to activate C3G to the level of C3G 
co-expressed with Crk, strongly suggesting the presence of a cis-acting negative 
regulatory function in the noncatalytic domain of C3G (206). When C3G was truncated 
to amino acid 390 (C3G-delta390), C3G showed the same level of activity as wild-type 
C3G before and after Crk coexpression. Deletion of the amino terminus of C3G to amino 
acid 579 (C3G-d579) increased GTP-bound Rap1 to the level of wild-type C3G in the 
presence of Crk, irrespective of the presence of Crk. As a result, Ichiba et al. concluded 
that C3G-delta579 is a catalytically active form and the negative regulatory region is 
located between residues 391 and 579.  
The Ichiba et al. study then defined the location of Crk-induced tyrosine 
phosphorylation. C3G-delta390 was still phosphorylated on tyrosine. C3G-d579 
exhibited significant reduction in the Crk-dependent tyrosine phosphorylation. As a 
result, Ichiba et al. deduced that the tyrosine phosphorylation sites on C3G are located 
between residues 391 and 579. Integrin stimulation-dependent tyrosine phosphorylation 
of C3G had been reported (237) but the exact site had not been mapped. In order to do so, 
Ichiba et al. substituted all seven tyrosine residues in this region for phenylalanine. The 
C3G-Y504F mutant was remarkably less activated and phosphorylated than the wild 
type. All the other substitution mutants were activated and tyrosyl-phosphorylated after 
the expression of Crk. The authors conclude that CrkI activates C3G by the 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































domain outside the catalytic region. When the amino-terminal region, including Y504 is 
deleted, the catalytic activity is intact. In wild type C3G, phosphorylation may be 
required for the suppression of cis-acting negative regulation. Previous studies have 
shown a correlation between C3G phosphorylation and activation of different potential 
tyrosine kinases: Activation of Src family kinase Hck increased C3G phosphorylation on 
Y504 (205). When NIH-3T3 cells were treated with growth hormone both JAK2 and c-
Src were activated (239). Tyrosine phosphorylation of C3G occurs in cells transformed 
by v-Crk or v-Src. When C3G comes into the vicinity of activated tyrosine kinases, 
phosphorylation of the regulatory tyrosine residue (Y504) could occur, although prior to 
this thesis research, C3G-Y504 phosphorylation had so far only been observed in certain 
oncogene-transformed cells with hyperactive tyrosine kinases (206). Src-dependent Rap1 
activation is indispensable for integrin-mediated cell adhesion and formation of focal 
adhesion structures (243).  
Growth hormone treatment stimulates tyrosine phosphorylation of C3G, and the 
increased phosphorylation level of C3G observed in these conditions required the 
combined activities of both JAK2 and c-Src (244). However, a systematic analysis of 
kinases that may have contributed to this phosphorylation has not been completed. 
In addition, a study showed that transfection of Src family kinases or pervanadate 
treatment of cells, which may mimic stimulation by growth factors, has also induced 
tyrosine phosphorylation of C3G at Y504 (207). Upon expression of Src family kinases 
or pervanadate treatment of cells, C3G phosphorylated on Y504 was predominantly 
located at the Golgi complex and the subcortical actin cytoskeleton unlike non-
phosphorylated C3G, which was largely cytosolic (207). 
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1.6.3. C3G binding to p130Cas 
 
p130Cas has been shown to bind directly to C3G (212). Pro-267 and Pro-270 of 
C3G are essential for the binding of the SH3 domain of p130Cas. When the prolines 
responsible for binding to the SH3 domain of p130Cas were deleted in the C3G-delta390 
mutant described above, C3G could not be activated effectively by the expression of Crk, 
even though C3G-delta390 is tyrosyl-phosphorylated to a similar extent as the wild-type 
C3G. Therefore, binding of p130Cas may be required for optimal activation of C3G after 
the phosphorylation of Tyr 504 (206). 
Therefore, there are three events that are hypothesized to occur in the process of 
C3G activation: C3G binding to Crk and consequent membrane recruitment, C3G 
phosphorylation, and C3G binding to p130Cas. All three events seem to contribute to 
C3G activation. However, the order or the possible connections between these events 
remains largely unknown. 
2. Methods 
 
2.1. Cell treatment and lysate preparation 
 
R390A/SYF cells and D388N/SYF cells were serum-starved for 16 hours. 
Different dishes from each cell line were either treated with 10 mM imidazole, pH 7.5 for 
5 minutes or left unstimulated and used as a control. Cells sets were then washed once 
 130 
with ice cold PBS (Invitrogen) and immediately lysed in RIPA buffer (Tris-HCl 50 mM, 
pH 7.4, Na-deoxycholate 0.25%, NaCl 150 mM, EDTA 1mM, 1% NP-40, Na3VO4 1 
mM, NaF 1 mM, PMSF 1 mM). The lysate was collected and transfer to pre-chilled 
micro centrifuge tubes.  The tubes were placed in a rotor at 4ºC during 30 minutes. The 
lysate was cleared by centrifugation at 13,000 rpm for 15 min at 4ºC and the supernatant 
collected. Protein concentrations were calculated by the Bradford method.   
 
 2.2. Immunobloting and Immunoprecipitations 
 
 For immunobloting a volume of the lysate corresponding to 10-30 µg was mixed 
with SDS loading buffer with β-mercaptoethanol, boiled at 95ºC for 5 minutes, and 
analyzed by SDS-PAGE. The proteins were electroblotted into PVDFs membrane 
(Invitrogen) using the iBlot system (program 3/ 5.5 minutes). The membrane was blocked 
with 5% BSA in 1X TBST for one hour at room temperature. After a quick rinse in 1X 
TBST, the membrane was probed with appropriate primary antibody, followed by 
incubation with the correspondent HRP-conjugated secondary antibody. Antibodies were 
used at the recommended concentration in the manufacturer’s instructions. Bands were 
visualized using SuperSignal West Pico chemiluminescent substrate (Pierce) and ECL 
film (GE Healthcare Amersham). 
 For immunoprecipitation, a volume corresponding to approximately 1 mg of 
lysate was cleared by incubating it with 40 µl of 50/50 protein A or G agarose magnetic 
bead slurry (Invitrogen) rotating for one hour at 4ºC. Using a magnet, the beads were 
separated from the supernatant. Beads were discarded and the supernatant was kept on 
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ice. 40 µl of 50/50 protein A or G agarose magnetic bead slurry were mixed with the 
volume of antibody corresponding to 10 µg 200 µl of RIPA modified buffer was added to 
facilitate mixing. Samples were incubated for one hour rotating at 4°C. Using a magnet, 
the bead-antibody complex was separated from the supernatant, which was discarded. 
The cleared lysate was added to the antibody-bead complex. Incubation was performed 
overnight rotating at 4ºC. Antibodies were used at the recommended concentration in the 
manufacturer’s instructions. The beads were subsequently washed six times with RIPA 
buffer, resuspended in SDS loading buffer with beta-mercaptoethanol and heated at 95-
100°C for 5 minutes. The eluates were analyzed by SDS-PAGE, electroblotted into 
PVDF membrane and subjected to Western blot analysis as described above.  
Antibody against C3G (C3G WB), sc-15359 from Santa Cruz Biotechnology; 
antibody against Tyr(P)-514 of C3G isoforms (Tyr(P)-514-C3G WB), sc32621 from 
Santa Cruz Biotechnology; C3G IP/ Crk WB: sc-15359 (C3G IP and WB) from Santa 
Cruz Biotechnology and 610035BD (Crk WB) from BD Transduction Laboratories; Crk 
(pTyr-221) WB,  ab76227 from Abcam. Antibody against tubulin (tubulin WB), ab44928 
from Abcam. The results shown are representative of the tendency observed in different 
experimental repeats. It should be noted that the timing at which increases where detected 
was not always the exact same but it was similar, and the tendency of the signal intensity 
of the bands of interest was similar throughout the biological replicates obtained. It 
should also be noted that baseline values between rescuable and non-rescuable cells may 
not be the same due to subtle alterations in the cell passage number, growth conditions, or 
Western blot conditions (such as exposure time). 
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2.3. Immunofluorescence and Confocal Microscopy 
 
Cells were seeded and grown in 8-well glass microscopy slides (Lab-Tek). Cells 
were processed for immunofluorescence staining in the following way: after imidazole 
treatment (10 mM, for 0, 1, 2.5, 5 and 10 minutes), cells were washed once with ice cold 
PBS. Cells were fixed with 4% formaldehyde (Tousimis Reserch Corporation) for 1 hour 
at 4°C followed by washing with 10 mM glycine in PBS. Permeabilization was 
performed with 0.1-0.2% (v/v) of Triton X 100 (or NP-40) in PBS for 5 minutes at room 
temperature. After washing with PBS, cells were incubated in blocking solution (10-20 
mg/ml BSA in PBS) for 1 hour. The primary antibodies used were rabbit polyclonal 
antibody against C3G (sc-15359 from Santa Cruz Biotechnology) and rabbit polyclonal 
antibody against pTyr514-C3G (sc-32621 from Santa Cruz Biotechnology). The 
secondary antibodies used were Alexa-Fluor 555 goat anti-rabbit (A-21430 from 
Invitrogen) and Alexa-Fluor 488 chicken anti-rabbit (A-21441 from Invitrogen), 
respectively. The slides were mounted with ProLong® Gold Antifade Reagent (With 
DAPI) from Invitrogen. Samples were acquired with the Zeiss Meta Confocal Laser 
Scanning Microscope System, utilizing AIM software version 4.0.  An argon laser 
excited at 488 nm and a red HeNe at 561 nm wavelengths was used to obtain optical 
sections. Narrow band emission filters (nm) were utilized to eliminate channel crosstalk 
and a 1.0 µm confocal aperture was used to obtain z-plane sections.  Slides were imaged 
with a 40x and 100x oil immersion Plan Apochromat objective lens (N.A. 1.4) through a 
Zeiss Axiovert inverted microscope.  For quantification, at least 40 cells were counted for 
each condition and scored according to whether or not they had peripheral staining   
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(Figure 38). Percent of cells with a peripheral staining was calculated for each 40x 
window. Averages and standard errors are shown and statistical analysis was done using 
the Student’s t test. 
  
2.4. FRET Microscopy 
 
R390A and D388N c-Src SYF MEF cells were plated to glass bottom dishes 
(MatTech Corp.) and transiently transfected with 2 µg Raichu-Rap1 (Figure 39) (245) 
reporter using lipofectamine (Invitrogen). The cells were starved for 16 hours. After 15 
hours cells were washed once and media was replaced with Hanks Balanced Salt Solution 
(HBSS). The dish was loaded onto the stage of an inverted Zeiss Axiovert 200M 
microscope controlled by METAFLUOR software (Universal Imaging, Downingtown, 
PA).  Dual emission ratio imaging was performed using a 420DF20 excitation filter and a 
450DRLP dichroic mirror and appropriate emission filters, 475DF40 for CFP and 
535DF25 for YFP. Images were captured with a MicroMAX BFT512 CCD camera 
(Roper Scientific, Trenton, NJ). Baseline values were captured every 30 seconds for 2 
minutes. Cells were treated with 10 mM imidazole at time zero and imaged for an 
additional 15-20 minutes. Images were quantified using the Metafluor software. Regions 
of interest were selected and average intensities of the pixels in each region for each 
channel were quantified. FRET ratios were calculated by dividing the yellow emission 




Figure 38. C3G and pTyr-514-C3G increased localization at the cell periphery after c-Src rescue 
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R390A/SYF and D388N/SYF cells were treated with 10 mM imidazole for 0,1,2.5,5, and 
10 minutes and immunostained against C3G or pTyr-514-C3G. Two representative 









Adapted from Mochizuki N, et al. Nature, 2001 
 
Figure 39. Schematic representation of the Raichu-Rap1 reporter bound to GDP or GTP 
 
 The difference in the FRET response allows evaluating the difference in the ability of 
C3G to activate Rap1. 
  
Figure 3.6 
















3.1. c-Src chemical rescue leads to Rap-1 activation 
 
We had observed in our proteomics study that C3G level of phosphorylation 
increases upon c-Src rescue. As described above, it is known that phosphorylation of 
C3G leads to an increase in its guanine exchange factor activity. In order to functionally 
evaluate the potential  effects of c-Src mediated phosphorylation of C3G on Rap1 in our 
system, we employed the cell-based reporter Raichu-Rap1 (245), which is designed to 
undergo a FRET change upon Rap1 activation.  
As shown in Figure 40, imidazole treatment of R388A Src/SYF cells revealed 
that chemical rescue of c-Src rapidly stimulates Rap1, manifested as an increase of 10-
11% FRET ratio. As a control, imidazole treatment of D386N Src/SYF cells did not show 
a significant increase.  
Rap1 is known to localize to the Golgi, lysosomal vesicles and cortical actin 
cytoskeleton (246). Consistent with expectation, the apparent c-Src-induced activation of 
Rap1 was mostly observed at the cell periphery where filopodia were formed. Rap1 
showed an increase in its activation level immediately after c-Src rescue, and reached the 
maximum level of activity 5 minutes after treatment.  
Once we tested the effects of Src activation on Rap1 activity, we were interested 
in analyzing possible intermediate steps in a spatio-temporal manner that may contribute 






Figure 40.  Detection of the effect of c-Src activation on C3G’s ability to activate Rap1 
 
 Rap1 activation upon c-Src rescue in R390A c-Src SYF cells (red) and D388N c-Src 
SYF cells (blue). The FRET-based GTPase sensor, Raichu-Rap1 showed a 10% increase 
in FRET (Rap1activation indicator) along the cell membrane after 8 min of treatment 
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3.2. Effects of c-Src activation on C3G phosphorylation 
 
As discussed above, we have previously detected increased phosphorylation levels of 
C3G in the cell after rescuing catalytically inactive c-Src. Based on previous reports  
where different members of the Src family of tyrosine kinases have shown an effect on 
C3G phosphorylation on Tyr-504 (human)/ Tyr-514 (mouse), we wanted to look for site- 
specific tyrosine phosphorylation with our chemical rescue approach. Using a 
commercially available anti pTyr514-C3G site-specific antibody, Western blot analysis 
revealed enhanced C3G modification with imidazole treatment of R388A Src/SYF cells, 
but not D386N Src/SYF cells (Figure 41). 
This increase was observed within 1 minute of imidazole exposure, supporting the 
possibility of direct targeting of C3G by c-Src. It must be noted that we detected an 
increase in one band that corresponds to a slightly smaller molecular weight than the 
strong band usually observed when we perform a Western blot against C3G or an 
immunoprecipitation with C3G antibody followed by Western blot against C3G. 
However, in previous immunoprecipitation with C3G antibody followed by Western blot 
against C3G, we have also observed a weaker lower band at around 120 kDa and we 
suggest that it may corresponds to one of the different known C3G isoforms, which are 
known to exist as a result of alternative spliced transcript variants. Figure 42 shows two 
biological replicates where the same observation was made. The figure includes the 
complete films obtained from Western blot experiments with the anti pTyr514-C3G site-
specific antibody. The blot shows multiple bands suggesting that the antibody specificity 





Figure 41. Detection of the effect of c-Src activation on C3G’s phosphorylation on Tyr-514 
 
 Western blot using anti pTyr514-C3G antibody showed an increase in the 
phosphorylation level of tyrosine 514 in a C3G isoform after 1 minute upon c-Src rescue 
in R390A c-Src SYF cells but not in D388N c-Src SYF cells. From the several bands 
observed in the blot against pTyr514-C3G, we detected an increase in one band that 
corresponds to a slightly smaller molecular weight than the strongest band usually 
observed when we perform a Western blot against C3G or an immunoprecipitation with 
C3G antibody followed by Western blot against C3G. However, we have also observed a 
weaker band just bellow the strongest band in C3G immunoprecipitation and western blot 
that we understand corresponds to one of the different C3G isoforms. The molecular 
weights are indicated in the blot to illustrate this point. Western blot using an antibody 
against C3G shows equal loading along the different time points in both R390A c-Src 




Figure 42. Biological replicates for the experiment to detect the effect of c-Src activation on C3G’s 
phosphorylation on Tyr-514 
 
 The entire anti-pTyr514-C3G immunoblot is shown for both repeats to show the entirety 
of bands appearing. In the case of the anti-C3G-immunoblot, the band presented was the 
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major and stronger band of the blot. Western blot using anti pTyr514-C3G antibody 
showed an increase in the phosphorylation level of tyrosine 514 in a C3G isoform after 1 
minute upon c-Src rescue in R390A c-Src SYF cells but not in D388N c-Src SYF cells. 
From the several bands observed in the blot against pTyr514-C3G, we detected an 
increase in one band that corresponds to a slightly smaller molecular weight than the 
strongest band usually observed when we perform a Western blot against C3G or an 
immunoprecipitation with C3G antibody followed by Western blot against C3G. 
However, we have also observed a weaker band just bellow the strongest band in some 
C3G immunoprecipitation and Western blot experiment. We interpret that this lower 
band corresponds to one of the different C3G isoforms. The molecular weights are 
indicated in the blot to illustrate this point. Western blot using an antibody against C3G 
shows equal loading along the different time points in both R390A c-Src SYF and 




could correspond to different C3G isoforms. In the anti pTyr514-C3G immunoblot we 
indicate two bands. One corresponds to the band at the molecular weight were we usually 
observe C3G in the C3G immunoblot. The other band is the one that consistently 
increases in intensity one minute upon c-Src rescue and that we believe corresponds to a 
C3G isoform. The molecular weights are indicated in the blot to illustrate this point.  
 
3.3. Effects of c-Src activation on C3G-Crk binding 
 
As mentioned above, it has been shown that different stimuli lead to an increase 
in C3G-Crk binding. In order to further dissect this signaling process and investigate 
whether c-Src specific activation can result in an increase in binding between C3G and  
Crk, we explored potential changes in protein-protein interactions between C3G and Crk.  
After imidazole treatment of R388A/SYF cells, C3G protein was 
immunoprecipitated and Crk binding was analyzed by Western blot (Figure 43).  
It was shown that increased Crk was pulled down by C3G immunoprecipitation 
after only 1 minute of rescue of R388A/SYF cells, but not in D388N/SYF cells. The peak 
binding of C3G and Crk was reached at 2.5 minutes and began to decrease by 5 minutes.  
It is important to warn that the exact timing at which these observations are made 
differs slightly from one biological replicate to the other but the pattern of an immediate 
increase and a consequent decrease is consistent. In the biological replicate shown in 
Figure 44, we performed two different co-immunoprecipitations. In one of them the 







Figure 43. Detection of the effect of c-Src activation on C3G- Crk binding 
 
 Co-Immunoprecipitation using C3G immunoprecipitation and Crk blotting showed an 
increase in C3G-Crk binding after 1 minute upon imidazole treatment which was 
sustained until 2.5 minutes and decreased at minute 5 in R390A c-Src SYF cells but not 








A. Co-Immunoprecipitation using C3G immunoprecipitation and Crk blotting showed an 
increase in C3G-Crk binding after 2.5 minutes upon imidazole treatment in R390A c-Src 
SYF cells but not in D388N c-Src SYF cells. B. Co-Immunoprecipitation using C3G 
immunoprecipitation and Crk blotting showed an increase in C3G-Crk binding after 2.5 
minute supon imidazole treatment which was sustained until 10 minutes and decreased at 
minute 20 in R390A c-Src SYF cells but not in D388N c-Src SYF cells. 
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for just one hour. In both of them we observed a mild increase in C3G-Crk binding after 
2.5 minutes upon c-Src chemical rescue. This increase was maintained until 10 minutes. 
The overnight-incubation experiment did not have a lane corresponding to 20-minute 
treatment due to a mistake, but the experiment where the incubation was performed for 
one hour showed a decrease in Crk-C3G binding 20 minutes upon c-Src rescue. We could 
therefore conclude that c-Src activation leads to an immediate increase in binding 
between C3G and Crk followed by a consequent decrease. 
 
3.4. Tyr-221 Crk phosphorylation and Crk-C3G complex dissociation 
 
It has previously been shown a that phosphorylation of Crk on Tyr-221 (241) is an 
important event that mediates for Crk-C3G dissociation after insulin-stimulation of 
Chinese hamster ovary cells. Phosphorylation of Crk on Tyr-221 (241) allows the 
intramolecular binding of Crk’s SH2 domain to Tyr-221 (223, 247). 
 In order to test if phosphorylation of Crk on Tyr-221 was responsible for 
the observed decrease in C3G-Crk binding, we measured the phosphorylation level of 
this particular site with a phosphospecific antibody (Figure 45) at the same time points 
used to observe C3G-Crk binding. We performed both experiments simultaneously from 
the same cell lysates to reduce experimental variability. Indeed, in Figure 45 
phosphorylation of Crk on Tyr-221 increases just after 1 minute and reaches a peak at 5 
minutes, which correlated with the time at which binding between C3G and Crk 
decreases.  









Figure 45. Detection of the effect of c-Src activation on Crk’s phosphorylation on Tyr-221  
 
Western blot using anti-pTyr-221in Crk showed a gradual increase in 
phosphorylation upon c-Src rescue reaching the highest level of phosphorylation at 
minute 5 in R390A c-Src SYF cells but not in D388N c-Src SYF cells. The maximum 






Figure 46. Biological replicates for the experiment to detect the effect of c-Src activation on Crk’s 
phosphorylation on Tyr-221 
 
Western blot using anti-pTyr-221in Crk showed a gradual increase in 
phosphorylation upon c-Src rescue reaching the highest level of phosphorylation at 






phosphorylation of Crk. 
 
3.5. Effects of c-Src activation on C3G subcellular localization 
 
As discussed above, in addition to C3G phosphorylation, C3G activation occurs 
mainly through membrane recruitment (205,234). To further examine the connections 
between c-Src and C3G, we explored the subcellular localization of C3G using 
immunocytochemistry and confocal microscopy after chemical rescue (Figure 47).  
As shown, upon imidazole treatment of R390A/SYF cells but not D388N/SYF 
cells, there is an apparent movement of C3G protein to the cell periphery from the 
cytosol.  This movement occurs within 1 minute and persisted for at least 5 minutes and 
then began showing a decrease about 10 minutes after c-Src rescue.  
 
4. Discussion  
 
The Rap1 guanine exchange factor, C3G, was first detected in our SILAC experiment as 
a protein with increased phosphorylation upon c-Src rescue. It was further validated by 
immunoprecipitation and Western blot and showed a clear increase in tyrosine 
phosphorylation. A phosphopeptide from C3G was subsequently detected in our mass 
spectrometric phosphopeptide screening, Tyr-571, and showed an apparent 2.5-fold 
increase in its phosphorylation level that was consistent among the three biological 
replicates.  






Figure 47. Detection of the effect of c-Src activation on C3G’s subcellular localization 
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R390A c-Src/SYF cells were treated with 10 mM imidazole for various time points 
before being fixed. Localization of both C3G and pTyr514-C3G was detected by staining 
with C3G (Rhodamine) and pTyr514-C3G (FITC) and nuclei stained by DAPI. Images 
were acquired by confocal microscopy. Representative images at 100x magnification are 
shown. Cells (n>40) were categorized according to phenotype (cytosolic vs peripheral) 
and quantified. Quantitative analysis of C3G and pTyr514-C3G cellular localization was 
measured as a function of imidazole treatment time. Images were captured by confocal 
microscopy at 40x magnification. Six representative images (at least 40 cells) were 
quantified for each condition. Each cell was scored for whether it had peripheral staining. 
The fraction of cells with peripheral staining was calculated for each image and averages 
were calculated by combining the six images for each condition. Each time point was 
normalized to time zero and standard errors are shown. Statistical significance (p<0.05) 






and strongly implicated in the control of integrin-mediated cell adhesion. Recent 
evidence indicates that Rap1 also plays a key role in formation of cadherin-based cell-cell 
junctions. Rap1 has been reported to play an essential role in the spatial and temporal 
control of adhesion. It is therefore not surprising that several Rap1 GEFs, such as C3G, 
have been implicated in the regulation of adhesion complexes (248,249). 
Despite the considerable interest in understanding the process of C3G activation, 
the spatiotemporal regulation of this process has been largely unclear. The ability of c-Src 
chemical rescue to specifically and rapidly activate c-Src allowed us to gain greater 
insight into the spatiotemporal process of C3G activation, as well as to propose a 
molecular mechanistic pathway for Rap1 control. After we found that c-Src activation led 
to an increase of GTP-bound Rap1 in the cell periphery within 5 minutes, we pursued this 
molecular mechanism in greater detail. 
Although it has been reported that Crk is constitutively associated with C3G 
(239), it has also been shown that this association can be induced by different stimuli 
(236,240,241). We show that rapid activation of c-Src enhances interaction between C3G 
and Crk by 1 minute.  Such regulation of this complex may account for reported 
responses after the stimulation of cells by insulin, integrin engagement, and other natural 
triggers. Presumably, as the adaptor protein Crk forms a complex with C3G, it recruits 
C3G to the cell periphery, where we detected C3G rapidly after c-Src rescue. 
Interestingly, the binding between C3G and Crk began to decrease approximately 5 
minutes post stimulation, possibly initiating retrograde signaling in this pathway. In 
support of this idea, a previous study reported that both insulin and epidermal growth 
factor (EGF) stimulation of cells resulted in a time-dependent dissociation of the Crk-
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C3G complex (240).  
Crk is negatively regulated by tyrosine phosphorylation on Tyr-221. The 
intramolecular binding of phosphorylated Tyr-221 to the SH2 domain blocks SH3 
dependent protein binding responsible for the formation of the C3G-Crk complex (223). 
Pretreatment of the cells with genistein (tyrosine kinase inhibitor), decreased the tyrosine 
phosphorylation of Crk that correlated inversely with the amount of Crk that was 
immunoprecipitated with C3G (240). We showed that the level of phosphorylation of Crk 
on Tyr-221 increases upon c-Src activation.  Interestingly the observed decrease in Crk-
C3G binding occurs when phosphorylation of Crk on Tyr-221 reaches a maximum level. 
There thus seems to be an inverse correlation between Crk phosphorylation on Tyr-221 
and C3G-Crk binding. Subsequently, Rap1 activation appears to be indirectly modulated 
downward in a fashion that is also correlated with Crk phosphorylation on residue Tyr-
221.   
Since Rap1 suppresses Ras signaling by sequestering its common target, Raf1, it is 
logical that the ability of growth factors to activate the Ras/Raf/MEK/ERK cascade 
requires a mechanism for the inactivation of Rap1 function. Phosphorylation of Crk on 
Tyr-221 and the consequent dissociation of the C3G-Crk complex may well contribute to 
this negative regulation of Rap1 activity. In fact, a similar negative feedback loop 
involving another aspect of the same pathway has been reported already and a parallel 
can be made with our pathway of study (Figure 48).  Sos is a RasGEF that associates 
with the adaptor Grb2. A kinase downstream of MEK or maybe MEK itself, can 
phosphorylate Sos on serine/threonine (250,251). As a result, the ability of Sos to activate 






Figure 48. Hypothetical parallelism between the phosphorylation of the RasGEF Sos and the adaptor 
protein Crk as events for the regulation of the Raf/MEF/ERK cascade 
 
Sos associates with the adaptor Grb2 and activates Ras leading to an activation of the 
Raf/MEF/ERK cascade. However, when Sos is phosphorylated, its ability to both bind 
Grb2 and to activate Ras decreases. Crk’s phosphorylation on Tyr-221 by Abl seems to 
decrease its ability to serve as an adaptor of C3G, leading to a downstream inactivation of 







































phosphorylation of Crk may be the key event of a similar feedback mechanism. 
Abl kinase has been identified as a Crk upstream kinase that can phosphorylate 
Tyr-221 (252).  In this regard, our phosphopeptide mapping revealed that site Tyr-439/ 
393 of Arg (Abl2)/Abl, which has additive effects on Abl activation (253) and has not 
been described previously as a c-Src substrate, experienced a significant increase in its 
phosphorylation level 5 minutes after c-Src chemical rescue. In this way, tyrosine 
phosphorylation on Tyr-221 of Crk, may regulate MAPK activity through Crk-C3G 
formation. In support of this idea, oncogenic Bcr-Abl may lead to constitutive 
phosphorylation of Crk, dissociation of the Crk-C3G complex and reversal of the 
suppressive effects of RAP on ERK activity. This would contribute to the oncogenic 
effects of Bcr-Abl. It is worth mentioning one more study that supports this idea of a 
feedback mechanism mediated by phosphorylation of Tyr-221 on Crk in a different 
context: Tyr-221 was reported to also be phosphorylated by other tyrosine kinases, such 
as epidermal growth factor (EGF) receptor upon EGF stimulation. This phenomenon was 
also detected in a c-Abl-deficient cell line. Tyrosine-phosphorylated Crk was detected at 
the periphery of the cells, where ruffling is prominent, suggesting that signaling to Crk 
may be involved in EGF-dependent cytoskeletal reorganization. Moreover, recombinant 
Crk protein was phosphorylated in vitro by EGF receptor. These results suggested that 
EGF receptor may directly phosphorylate Crk. Mutational analysis revealed that the 
Crk’s SH2 domain was essential for the phosphorylation of Crk by EGF receptor but not 
by c-Abl, arguing that these kinases phosphorylate Crk by different phosphorylation 
mechanisms. This may be due to the fact that the SH2 is required for recruiting Crk to the 
proximity of EGFR, but not for cytosolic Abl. It was also found that Crk initiated 
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dissociation from EGF receptor within 3 minutes even with sustained tyrosine 
phosphorylation of EGF receptor. This led to the conclusion that the phosphorylation of 
Tyr-221 of Crk correlated with its dissociation from the EGF receptor, implicating the 
phosphorylation of Tyr-221 in the negative feedback of the SH2-mediated binding of Crk 
to EGF receptor (252). Previous studies have provided some evidence that PTP1B may 
be able to dephosphorylate Crk (236,241) and have a role in the regulation of the Crk-
C3G complex formation. In addition, PTP1B has been shown to bind to p130Cas, 
allowing it to locate near potential substrates, such as Crk (254). In fact, phosphorylation 
of p130Cas may also be important, as this is required to create an SH2-docking site for 
Crk as well as c-Src and other kinases that may be involve in the phosphorylation of C3G 
and other components of the signaling complex.  
It was known previously that C3G is phosphorylated on tyrosine 514 and this PTM 
has been suggested to influence its ability to activate Rap1. We observed an increase in 
Tyr-514 phosphorylation level within 1 minute after activation of c-Src. Indeed, 
increased phosphorylation of C3G on Tyr-514 facilitate C3G’s activity to catalyze GTP 
exchange on Rap1 in our system, as revealed in our live cell reporter assay, which also 
showed a maximum level of activity at 5 min.   
Interestingly, a previous study revealed that even the C3G-Y504F mutant was also 
activated slightly by Crk expression (206). Because the C3G-Y504F mutant was still 
phosphorylated weakly on tyrosine, it is possible that phosphorylation of other tyrosine 
residue(s) may replace the function of Y504F phosphorylation. In this regard, it is also 
noteworthy that rescue induced an ~3-fold increase in phosphorylation of a new site, Tyr-




Figure 49. Novel tyrosine phosphorylation site in C3G (Tyr-571) as evidenced by MS/MS 
 
Tyr-571 showed upregulated phosphorylation level upon c-Src’s activation as evidenced 






Supplementary Figure 7 
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site, similar to Tyr-514, is located between two proline rich regions in C3G that bind the 
SH3 domain of Crk.  
The preferred binding motif for the Crk SH2 domain is pY-x-x-P. This preference 
was initially identified by an in vitro approach (255) and subsequently confirmed by 
mutational analyses of several Crk SH2 domain-binding partners. Multiple pY-x-x-P 
motifs are present in prominent Crk SH2 domain binding partners like paxillin (256,257) 
or p130Cas (214,258). Interestingly, the newly discovered phosphorylation site in C3G 
fits the sequence of this preferred binding motif (Figure 50).  
  It would be informative to reveal whether or not C3G phosphorylation and Crk-
C3G complex formation are interdependent. Growth factor stimulation leads to the 
formation of a large multiprotein signaling and Crk plays a major role in recruiting some 
of these proteins. An increase in the association between FAK, c-Src and JAK2 has been 
reported (239). Crk may facilitate the formation of this triple kinase complex together 
with C3G. As a result, it could be the case that increased Crk binding to C3G, and the 
consequent C3G translocation to the membrane, facilitated phosphorylation of C3G by 
Src due to the local proximity. However, it is also possible that phosphorylation of C3G 
leads to an increase in binding with Crk.   
Both phosphorylation of C3G on Tyr-514 and C3G-Crk binding showed an 
increase after only 1 minute upon c-Src rescue in our system, showing that both 
phenomena are temporarily related. However, it is not clear whether the occurrence of 
one phenomenon depends on the other or both phenomena are independent.  In fact, 
while both C3G phosphorylation and C3G-Crk binding experience a significant increase 






Figure 50. Schematics of a hypothetical C3G-Crk interaction based on Tyr-571 phosphorylation 
 
pY-x-x-P is the preferred binding motif for the Crk SH2 domain and is included in many 
Crk SH2 binding partners. The newly discovered and upregulated phosphorylation site in 







follow the trend of C3G-Crk binding. C3G-Crk association decreases after 2.5 minutes 
(although this phenomenon can be detected later since there is some experimental 
variability) and reaches a minimum at 5 minutes, when Crk’s phosphorylation on Tyr-
221 reaches a maximum level. It is worth emphasizing that the timing is variable but 
experiments shown in Figue 43 and Figure 45 were performed from the same sample 
coming from the same experimental repeat so the timing between these two events can be 
compared in a more convincing way, since we are avoiding experimental variability.  
If both phenomena were interdependent, further research would hopefully allow 
dissecting which of the two events occurs first and facilitates the second. 
This leaves us with two possible mechanisms of C3G activation and consequent 
Rap activation, as represented below (Figure 51). Both phosphorylation of C3G on Tyr-
514 and recruitment to the membrane by Crk are needed but we cannot conclude from 
our data if one of these events is required or facilitates the occurrence of the other. The 
figure also summarizes all the observations made in this study and suggests a mechanism 
of Crk-C3G dissociation caused by Crk’s phosphorylation on Tyr-221 (likely by c-Abl) 
as a hypothetical retrograde signaling in this pathway. 
Additional phosphorylation of C3G may play a role in its activation. We have 
identified a novel site that shows a significant increase in phosphorylation at the time 
GTP-bound Rap1 signal reaches its highest level. Either this or other unknown tyrosine 
or serine/ threonine phosphorylations might affect C3G’s ability to interact with Crk.  




Figure 51. Schematics of the observations made on the Crk-C3G-Rap1 pathway 
 
 C3G is activated by both phosphorylation on Tyr-514 and by binding to Crk, which then 
recruits C3G to the membrane. There is an increased localization of C3G in the 
peripheral region and an increased in Rap1 activity which is known to be mediated by 
C3G. The figure also represents the hypothetical retrograde signaling that takes place 
when Crk becomes phosphorylated on Tyr-221 by Abl leading to a disruption of C3G-

























Rap1 C3G activation: 
-" Phosphorylation of Tyr-514 
-" Binding to Crk and translocation 
to the membrane 
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signaling events that would otherwise have been difficult to obtain. In principle, this 
technique can be applied to other non-receptor PTKs to provide a more complete portrait 























































Table 2. List of identified proteins from the SILAC experiment at the protein level. 
Phenylphosphate elution. 
 




1 gi|9506909 239143 Myosin X 2.6 0.34 
2 gi|94365254 144931 PREDICTED: similar to tensin 2.3 0.4 
3 gi|27370424 108910 Hypothetical protein LOC244895 2.1 0.25 
4 gi|21281693 62198 Paxillin isoform alpha 2.0 0.31 
5 gi|6754632 41648 Mitogen activated protein kinase 1 2.0 0.18 
6 gi|31981796 52789 Docking protein 1 2.0 0 
7 gi|31982290 67339 LIM domain containing preferred 
translocation partner in lipoma 
1.9 0.13 
8 gi|27476057 84520 Discoidin, CUB and LCCL domain 
containing 2 
1.8 0.14 
9 gi|31560712 51254 c-src tyrosine kinase 1.7 0.04 
10 gi|40254593 94455 Breast cancer anti-estrogen resistance 1 1.7 0.25 
11 gi|31980859 73497 Rho guanine nucleotide exchange factor 
(GEF7) 
1.6 0.15 
12 gi|21489933 43381 mitogen activated protein kinase 3 1.6 0 
13 gi|51921285 86046 G protein-coupled receptor kinase-
interactor 1  
1.6 0.17 
14 gi|70794809 60366 Rous sarcoma oncogene isoform 2 1.5 0.39 
15 gi|31982755 53712 Vimentin 1.5 0.17 
16 gi|84875504 136510 Rap guanine nucleotide exchange factor 
(GEF) 1 isoform 2 
1.5 0.06 
17 gi|6679741 119939 PTK2 protein tyrosine kinase 2 1.3 0.13 
18 gi|10092590 41489 Mitogen activated protein kinase 14 1.3 0.19 
19 gi|9790077 47194 Glycogen synthase kinase 3 beta 1.3 0 
20 gi|46849812 276017 Fibronectin 1 1.3 0 
21 gi|51766344 32925 PREDICTED: similar to 40S ribosomal 
protein SA (p40) (34/67 kDa laminin 
receptor) 
1.1 0.08 
22 gi|6679321 81601 Phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 2 (p85) 
1.1 0 
23 gi|70608146 87806 X kin of IRRE like 1 1.1 0.03 
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24 gi|32484983 110265 Eph receptor A2 1.1 0.23 
25 gi|68299809 53708 phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1 isoform 1 
1.1 0.14 
26 gi|6681273 50764 Eukaryotic translation elongation factor 
1 alpha 2 
1.0 0.15 
27 gi|94387987 74363 PREDICTED: similar to heat shock 
protein 8  
1.0 0.1 
28 gi|7106439 50095 tubulin, beta 5 1.0 0.07 
29 gi|9845265 15004 Ubiquitin A-52 residue ribosomal 
proteína fusion product 1 
1.0 0.17 
30 gi|31981722 72492 Heat shock 70 kD protein 5 (glucose-
regulated protein) 
1.0 0.04 
31 gi|9507003 57723 Polypyrimidine tract binding protein 2 1.0 0 
32 gi|82993679 70418 PREDICTED: similar to Heat shock 70 
kDa protein 1B (HSP70.1) isoform 5 
1.0 0 
33 gi|6671509 42052 Actin, beta, cytoplasmic 1.0 0.05 
34 gi|6678469 50562 tubulin, alpha 6 1.0 0.02 
35 gi|94392981 198322 PREDICTED: pleckstrin homology 
domain containing, family H (with 
MyTH4 domain) member 1 isoform 1 
1.0 0 
36 gi|66841385 431301 cardiomyopathy associated 3 1.0 0 
37 gi|94363502 43081 PREDICTED: similar to non-catalytic 
region of tyrosine kinase adaptor protein 
2 isoform 2 
0.9 0.04 
38 gi|7948995 117788 Tyrosine kinase, non-receptor, 2 0.9 0.05 
39 gi|34328187 43092 non-catalytic region of tyrosine kinase 
adaptor protein 1 
0.9 0.07 
40 gi|82887378 50313 PREDICTED: molybdenum cofactor 
synthesis 3 
0.9 0 
41 gi|94377125 293560 PREDICTED: similar to Filamin-C 
(Gamma-filamin) (Filamin-2) (Protein 
FLNc) (Actin-binding-like prot 
0.9 0 
42 gi|39841025 82811 FCH and double SH3 domains 2 0.9 0.07 
43 gi|6753620 73455 DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 3, X-linked 
0.9 0 
44 gi|46560563 189575 SH3 domain protein 1B 0.9 0.04 
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45 gi|68989251 60110 tweety 2 0.9 0 
46 gi|49258190 79207 NCK interacting protein with SH3 
domain 
0.8 0 
47 gi|40556608 83571 Heat shock protein 1, beta 0.8 0 
48 gi|47059093 110370 Eph receptor B4 0.8 0.09 
49 gi|7305295 223983 Myosin, heavy polypeptide 11, smooth 
muscle 
0.8 0.05 
50 gi|33598964 229824 Myosin heavy chain 10, non-muscle 0.7 0.04 
51 gi|66955868 18368 hypothetical protein LOC67288 0.7 0 
52 gi|86262157 56249 hypothetical protein LOC239796 0.7 0.03 
53 gi|91598596 68147 Sorting nexin associated golgi protein 1 0.6 0.02 
54 gi|23956222 47783 ARP3 actin-related protein 3 homolog 0.6 0 
55 gi|6680920 15556 Centromere autoantigen A 0.5 0 
56 gi|13386452 13986 Histone 3, H2ba 0.4 0 
57 gi|70778882 71740 Chaperone, ABC1 activity of bc1 
complex like 
0.2 0.06 






Table 3. List of identified proteins from the SILAC experiment at the protein level. 
Boiled beads elution. 
 




1 gi|70794809 59853 Rous sarcoma oncogene isoform 2  3.32 0 
2 gi|31982755 53655 Vimentin  2.63 0.51 
3 gi|24429590 149489 DEAH (Asp-Glu-Ala-His) box 
polypeptide 9  
2.39 0.69 
4 gi|6754632 41249 Mitogen activated protein kinase 1  1.83 0.22 
5 gi|25141233 94572 Matrin 3  1.79 0 
6 gi|21313308 77597 Heterogeneous nuclear 
ribonucleoprotein M  
1.75 0.07 
7 gi|51921285 85247 G protein-coupled receptor kinase-
interactor 1  
1.64 0.12 
8 gi|7949051 87837 Heterogeneous nuclear 
ribonucleoprotein U  
1.58 0.28 
9 gi|40254593 94227 Breast cancer anti-estrogen resistance 1  1.55 0.19 
10 gi|31980859 72984 Rho guanine nucleotide exchange factor 
(GEF7)  
1.53 0.09 
11 gi|6679108 32540 Nucleophosmin 1 1.53 0.31 
12 gi|46849812 272368 Fibronectin 1 1.5 0.02 
13 gi|21281693 60772 Paxillin isoform alpha  1.49 0.18 
14 gi|41322927 506145 Plectin 1 isoform 4  1.47 0.3 
15 gi|28316750 14228 Histone 1, H2ba  1.47 0.75 
16 gi|21450625 46125 Eukaryotic translation initiation factor 
4A1 
1.47 0 
17 gi|31980648 56265 ATP synthase, H+ transporting 
mitochondrial F1 complex, beta subunit 
1.43 0 
18 gi|6671509 41710 Actin, beta, cytoplasmic 1.41 0.15 
19 gi|7305237 71375 LIM domains containing 1 1.35 0.08 
20 gi|94370505 14540 PREDICTED: similar to heterogeneous 
nuclear ribonucleoprotein H2 
1.29 0.04 
21 gi|7305075 51797 Ras-GTPase-activating protein SH3-
domain binding protein 
1.27 0 
22 gi|6679741 119141 PTK2 protein tyrosine kinase 2 1.26 0.09 
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23 gi|23956078 71736 ATP-binding cassette, sub-family F 
(GCN20), member 2 
1.26 0 
24 gi|10946928 49168 Heterogeneous nuclear 
ribonucleoprotein H1 
1.23 0.06 
25 gi|31982757 54055 Ras-GTPase-activating protein 
(GAP120) SH3-domain binding protein 
2 isoform a 
1.21 0 
26 gi|15809050 148969 Partitioning-defective protein 3 homolog 
isoform 3 
1.21 0 
27 gi|13195690 17939 Ribosomal protein S27a 1.2 0.03 
28 gi|6754524 36475 Lactate dehydrogenase 1, A chain 1.17 0.31 
29 gi|10092590 41261 Mitogen activated protein kinase 14 1.16 0.12 
30 gi|86990450 128483 Myosin IB 1.15 0.51 
31 gi|8394460 39478 Tropomodulin 3 1.14 0 
32 gi|47271404 111785 Rho/rac guanine nucleotide exchange 
factor (GEF) 2 
1.14 0 
33 gi|33598964 228855 Myosin heavy chain 10, non-muscle 1.11 0.54 
34 gi|31542366 34085 Cell division cycle 2 homolog A 1.11 0.08 
35 gi|6677805 29579 Ribosomal protein S4, X-linked 1.11 0.24 
36 gi|7242171 28766 Proliferating cell nuclear antigen 1.11 0.12 
37 gi|31981690 70827 Heat shock protein 8 1.09 0.31 
38 gi|6679937 35787 Glyceraldehyde-3-phosphate 
dehydrogenase  
1.09 0.02 
39 gi|31560030 32689 Tropomyosin 1, alpha 1.08 0.19 
40 gi|6680748 59716 ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit, isoform 1 
1.08 0 
41 gi|31980798 70256 Nuclear RNA export factor 1 1.07 0 
42 gi|82993679 70133 PREDICTED: similar to Heat shock 70 
kDa protein 1B (HSP70.1) isoform 5 
1.06 0.11 
43 gi|83816893 69223 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 5 
1.06 0.07 
44 gi|6678097 42571 Serine (or cysteine) proteinase inhibitor, 
clade B, member 6a 
1.06 0.48 
45 gi|9506843 52620 Lamin A isoform C2 1.06 0.03 
46 gi|12963531 54564 Non-POU-domain-containing, octamer 1.05 0 
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binding protein 
47 gi|6997239 36861 Poly(rC) binding protein 2 1.05 0 
48 gi|6755002 95950 Programmed cell death 6 interacting 
protein 
1.05 0 
49 gi|6679321 81201 Phosphatidylinositol 3-kinase, 
regulatory subunit, polypeptide 2 (p85) 
1.05 0 
50 gi|68533246 108114 Thyroid hormone receptor associated 
protein 3 
1.05 0.07 
51 gi|6753620 73056 DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 3, X-linked 
1.04 0.17 
52 gi|6755372 26657 Ribosomal protein S3 1.03 0.09 
53 gi|86262142 69406 RNA binding motif protein 14 1.03 0.12 
54 gi|6680047 35055 Guanine nucleotide binding protein (G 
protein), beta polypeptide 2 like 1 
1.03 0.06 
55 gi|23956214 75394 Splicing factor proline/ glutamine rich 
(polypyrimidine tract binding protein 
associated) 
1.02 0.07 
56 gi|6678986 118082 Myosin IC isoform b 1.02 0 
57 gi|31560686 69599 Heat shock protein 2 1.01 0 
58 gi|6681273 50422 Eukaryotic translation elongation factor 
1 alpha 2 
1 0.14 
59 gi|6754256 73483 Heat shock protein 9A 0.99 0.2 
60 gi|40556608 83229 Heat shock protein 1, beta 0.99 0.4 
61 gi|34328251 72372 Drebrin 1 0.99 0.22 
62 gi|31560560 32893 Laminin receptor 1 0.96 0.03 
63 gi|31981562 57808 Pyruvate kinase 3 0.95 0.11 
64 gi|61743961 603866 AHNAK nucleoprotein isoform 1 0.95 0 
65 gi|19526792 40957 CD34 antigen 0.94 0 
66 gi|33859482 95253 Eukaryotic translation elongation factor 
2 
0.93 0.2 
67 gi|7305295 223128 Myosin, heavy polypeptide 11, smooth 
muscle 
0.92 0.08 
68 gi|31981722 72378 Heat shock 70 kD protein 5 (glucose-
regulated protein) 
0.91 0.09 
69 gi|6671672 32947 Capping protein (actin filament) muscle 
Z-line, alpha 2 
0.91 0.08 
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70 gi|23956398 40730 Protein-L-isoaspartate (D-aspartate) O-
methyltransferase domain containing 2 
0.91 0.08 
71 gi|76677817 60183 Fuse-binding protein-interacting 
repressor isoform a 
0.91 0.11 
72 gi|6678465 49928 Tubulin, alpha 1 a 0.87 0.12 
73 gi|6754994 37474 Poly(rC) binding protein 1 0.86 0 
74 gi|7948995 116761 Tyrosine kinase, non-receptor, 2 0.84 0.06 
75 gi|6753262 30609 Capping protein (actin filament) muscle 
Z-line, beta 
0.81 0.29 
76 gi|49258190 78523 NCK interacting protein with SH3 
domain 
0.79 0 
77 gi|21536246 69733 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 41 
0.68 0.04 
78 gi|91598596 67748 Sorting nexin associated golgi protein 1 0.63 0.02 
79 gi|23956222 47327 ARP3 actin-related protein 3 homolog 0.61 0 
80 gi|6753226 192750 Complement component 4 (within H-2S) 0.39 0 
81 gi|19111160 36193 prostasin 0.3 0.1 
82 gi|28395018 81749 Junction plakoglobin 0.29 0.1 
83 gi|10946866 78269 Solute carrier organic anion transporter 
family, member 1c1 
0.27 0.1 
84 gi|31982171 165193 Murinoglobulin 1 0.25 0.21 
85 gi|6678083 45825 Serine (or cysteine) proteinase inhibitor, 
clade A, member 1c 
0.21 0.13 
86 gi|94419105 105453 PREDICTED: similar to Development 
and differentiation-enhancing factor 2 
(Pyk2 C-terminus associate) 
0.15 0.08 
87 gi|50363232 207000 Nestin 0.13 0.14 
88 gi|94390864 93809 PREDICTED: similar to Y39A1A.9 
isoform 1 
0.13 0.09 
89 gi|6753220 26701 Complement component 1, q 
subcomponent, B chain 
0.12 0.19 
90 gi|6671684 85416 Catenin (cadherin associated protein), 
beta 1, 88 kDa 
0.12 0 
91 gi|83008262 13646 PREDICTED: similar to Ig heavy chain 
V region 108A precursor 
0.11 0.13 
92 gi|94377464 12891 PREDICTED: similar to Ig kappa chain 0.11 0.08 
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V-VI region NQ2-17.4.1 
93 gi|27370470 85462 Phosphatidylinositol-3-phosphatase 
associated protein  
0.09 0.02 
94 gi|94385430 21645 PREDICTED: similar to Myosin light 
polypeptide 6 (Myosin light chain alkali 
3) (Myosin light chain 
0.06 0.14 
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Table 4.  List of identified proteins from the SILAC experiment at the protein level. 









































1 1 2.55 0.29 gi|9506909 237319 myosin X YSGMLETVR 531.2703 2 23 
1 2           VEGQEFIVR 541.7942 2 60 
1 3           TSFLEGTLR 515.2854 2 42 
1 4           TIVADVLAK 468.2754 2 21 
1 5           TFTPYER 460.238 2 34 
1 6           QLLAEKR 435.2859 2 35 
1 7           LLNEATR 411.7417 2 38 
1 8           IVDYLLEK 499.7991 2 35 
1 9           EIEDLQR 454.7456 2 37 
2 1 2.44 0.65 gi|31982755 53655 vimentin VEVERDNLAEDIMR 572.9616 3 36 
2 2      VEVERDNLAEDIMR 572.9659 3 22 
2 3      TYSLGSALRPSTSR 499.2764 3 42 
2 4      TYSLGSALRPSTSR 503.3027 3 20 
2 5      SYVTTSTR 460.7439 2 38 
2 6      SYVTTSTR 460.7411 2 41 
2 7      SYVTTSTR 460.7541 2 35 
2 8      SSVPGVR 351.1989 2 52 
2 9      SSVPGVR 354.2128 2 45 
2 10      SSVPGVR 354.2181 2 37 
2 11      SLYSSSPGGAYVTR 725.8761 2 55 
2 12      QVDQLTNDKAR 433.9129 3 24 
2 13      QVDQLTNDKAR 429.9083 3 42 
2 14      QQYESVAAK 512.2586 2 25 
2 15      QQYESVAAK 515.2666 2 62 
2 16      QQYESVAAK 515.2819 2 56 
2 17      QQYESVAAK 515.2888 2 35 
2 18      QQYESVAAK 515.2856 2 30 
2 19      QDVDNASLAR 547.7911 2 84 
2 20      NLQEAEEWYK 658.3205 2 45 
2 21      NLQEAEEWYK 658.3316 2 39 
2 22      
MFGGSGTSSRPSSN
R 519.2566 3 36 
2 23      
MFGGSGTSSRPSSN
R 515.2534 3 32 
2 24      
LQDEIQNMKEEMA
R 593.6254 3 29 
2 25      
LQDEIQNMKEEMA
R 593.6412 3 32 
2 26      LLEGEESR 466.7409 2 58 
2 27      LLEGEESR 469.7498 2 66 
2 28      LLEGEESR 469.7574 2 33 
2 29      KVESLQEEIAFLK 515.9863 3 45 
2 30      KLLEGEESR 358.2197 3 30 
2 31      ISLPLPTFSSLNLR 782.4772 2 38 
2 32      ILLAELEQLKGQGK 517.9962 3 38 
2 33      ILLAELEQLKGQGK 518.0084 3 47 
2 34      
FADLSEAANRNND
ALR 596.9824 3 33 
2 35      FADLSEAANR 550.2779 2 63 
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2 36      FADLSEAANR 550.2895 2 59 
2 37      EYQDLLNVK 564.3161 2 37 




polypeptide 9 YTQVGPDHNR 398.2154 3 20 
3 2           LPIEPR 365.7411 2 27 
3 3           LGGIGQFLAK 505.3134 2 29 
3 4           ILTTEGR 398.2441 2 27 
3 5           DFVNYLVR 516.2927 2 22 
4 1 2.26 0.36 gi|94365254 144475 
PREDICTED: 
similar to 
tensin SYVESVAR 458.7536 2 30 
4 2      SYVESVAR 458.7574 2 33 
4 3      LLSGFGVDR 485.3182 2 22 
4 4      LFGFVAR 408.257 2 30 
4 5      LFGFVAR 408.2612 2 24 
4 6      HFLIETGPR 538.3086 2 27 
4 7      GAYGLAMK 416.7264 2 24 
4 8      GAYGLAMK 416.728 2 23 
5 1 2.16 0.15 gi|27370424 107827 
hypothetical 
protein 
LOC244895 VQEFNNCLNR 650.3205 2 56 
5 2           STSSPYHASNLLQR 522.9381 3 31 
5 3           SSVKVPETHK 375.2175 3 25 
5 4           SPNLSEIK 447.2591 2 24 
5 5           SPNLSEIK 447.2527 2 47 
5 6           SAPTSPTATNISSK 684.3675 2 55 
5 7           
LVTSAQSEPPPPFPP
PR 608.3553 3 31 
5 8           IQRPTQEPAGK 412.919 3 32 
5 9           IQRPTQEPAGK 412.9093 3 36 
5 10           
IQKDPSTKPVTSPPS
K 428.2498 4 26 
5 11           IAVHTEKPESK 417.5839 3 26 
5 12           EIAGLEATPPVR 629.8547 2 69 
5 13           ANTLSPVR 472.2493 2 36 
6 1 2.01 0 gi|31981796 52390 
docking 
protein 1 VGQAQDILR 503.288 2 64 
6 2      
TWAVLYPASPHGV
AR 544.2989 3 40 






YVATR 743.9977 3 51 
7 2           NYLLSLPHK 364.2256 3 29 
7 3           LKELIFEETAR 454.2658 3 52 
7 4           LFPNADSK 449.2416 2 33 
7 5           ISPFEHQTYCQR 524.5866 3 32 
7 6           ICDFGLAR 476.2466 2 40 
7 7           GQVFDVGPR 490.7686 2 48 
7 8           GQVFDVGPR 490.7845 2 31 
7 9           ELIFEETAR 557.292 2 27 
7 10           
DLKPSNLLLNTTCD
LK 619.6872 3 50 
7 11           APEIMLNSK 512.786 2 31 
7 12           APEIMLNSK 509.7607 2 40 
7 13           APEIMLNSK 512.7877 2 56 
7 14           ALDLLDK 397.2494 2 48 
7 15           ALDLLDK 394.2411 2 33 




SSAK 655.0199 3 50 
8 2      VVTALDR 387.2331 2 37 
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8 3      VVTALDR 390.248 2 26 
8 4      VVTALDR 387.2401 2 55 
8 5      VVTALDR 387.2314 2 29 
8 6      VVTALDR 390.2406 2 48 
8 7      VVTALDR 390.232 2 20 
8 8      VVTALDR 390.2472 2 36 
8 9      VVTALDR 387.2248 2 23 
8 10      
RGSLCSGCQKPITG
R 419.985 4 45 
8 11      NFFER 356.6888 2 24 
8 12      NFFER 359.6998 2 21 
8 13      NFFER 356.6857 2 24 
8 14      NFFER 359.6857 2 23 
8 15      LGVATVAK 379.7341 2 31 
8 16      LGVATVAK 382.7609 2 48 
8 17      LGVATVAK 382.7617 2 55 
8 18      LGVATVAK 382.7657 2 36 
8 19      LGVATVAK 379.7287 2 38 
8 20      LGVATVAK 379.7227 2 39 
8 21      LGVATVAK 379.712 2 25 
8 22      LGVATVAK 382.7594 2 35 
8 23      LGVATVAK 379.7498 2 34 
8 24      LGVATVAK 379.7517 2 42 
8 25      KPIAGQVVTAMGK 439.2709 3 57 
8 26      KPIAGQVVTAMGK 443.2617 3 30 
8 27      KPIAGQVVTAMGK 439.2684 3 60 
8 28      KPIAGQVVTAMGK 443.2543 3 26 
8 29      KFHPEHFVCAFCLK 458.7491 4 37 
8 30      KDYFDMFAPK 430.5607 3 57 
8 31      KDYFDMFAPK 425.2324 3 50 
8 32      ISASSATR 399.7402 2 24 
8 33      GSLCSGCQKPITGR 511.598 3 41 
8 34      GSLCSGCQKPITGR 511.6095 3 57 
8 35      
ELDELMASLSDFKF
MAQGK 735.3865 3 25 
8 36      ELDELMASLSDFK 757.3842 2 58 
8 37      DYHSLFSPR 376.5365 3 24 
8 38      DYFDMFAPK 578.2772 2 27 
8 39      DYFDMFAPK 567.2712 2 31 
8 40      
DGQPYCEKDYHSLF
SPR 525.5088 4 30 
8 41      AGEEEHVYSFPNK 504.921 3 43 





partner in       
lipoma YAPVVAPKPK 361.2409 3 32 
9 2           STGEPLGHVPAR 409.5754 3 33 




ein M MGPAIER 398.2191 2 55 
10 2      MGPAIER 395.205 2 30 
10 3      MGLVMDR 430.2266 2 33 
11 1 1.71 0 gi|25141233 94572 matrin 3 LAEPYGK 392.2341 2 35 




containing 2 YSTSEVSHLSAR 448.254 3 26 
12 2      FTQVLQPR 497.799 2 38 





13 2           VLGQLAAA 371.7258 2 37 
13 3           
TQQGLYQAPGPNP
QFQSPPAK 754.0436 3 69 
13 4           
TKAPGPGPEGSSSL
HPNPTDK 522.2858 4 29 
13 5           
TKAPGPGPEGSSSL
HPNPTDK 519.2798 4 50 
13 6           TGGLGPSDR 433.2392 2 49 
13 7           RVLGQLAAA 452.7907 2 31 
13 8           RPGPGTLYDVPR 447.2675 3 37 
13 9           RPGPGTLYDVPR 443.2494 3 44 
13 10           QGKGQLELQQLK 461.2806 3 40 
13 11           QGIVPGNR 420.7412 2 22 
13 12           QGIVPGNR 423.7416 2 38 
13 13           LVFIGDTLSR 563.8469 2 58 
13 14           LVFIGDTLSR 563.8301 2 57 
13 15           LVFIGDTLSR 563.8427 2 29 
13 16           
HLLAPGPQDIYDVP
PVR 631.686 3 56 
13 17           GWEGTKPPAK 357.529 3 24 
13 18           
GSPGFTPEDLDRLV
ACSR 663.6592 3 40 
13 19           GSPGFTPEDLDR 648.821 2 55 
13 20           GQLELQQLK 531.8093 2 33 
13 21           GAVSNATHTSDR 407.8735 3 45 
13 22           GAVSNATHTSDR 407.8778 3 31 
13 23           ASSIQSRPLPSPPK 492.9652 3 33 
13 24           ASSIQSRPLPSPPK 492.961 3 42 
13 25           
ALYDNVAESPDELS
FR 609.3046 3 67 
13 26           
ALYDNVAESPDELS
FR 916.4366 2 52 
13 27           
AAALQYPSPSAAQD
MVDR 638.311 3 77 




3 NYLQSLPSK 528.3014 2 45 
14 2      ALDLLDR 408.2391 2 46 
14 3      ALDLLDR 411.2538 2 41 




synthesis 3 VPPPPLAPR 475.3003 2 53 
15 2           VPPPPLAPR 475.3145 2 26 
15 3           VPPPPLAPR 475.3088 2 25 
16 1 1.62 0.07 gi|31560712 50684 
c-src tyrosine 
kinase SVLGGDCLLK 534.2907 2 28 
16 2      NVLVSEDNVAK 597.3231 2 48 





interactor 1 YQMLAFVHK 386.8891 3 26 
17 2           VNSSLSDELRR 425.901 3 42 
17 3           TPIDYAR 421.2411 2 37 
17 4           TPIDYAR 418.232 2 33 
17 5           TGNLETCLR 535.2849 2 57 
17 6           SLSSPTDNLELSAR 745.4058 2 66 
17 7           SLSSPTDNLELSAR 748.4102 2 60 
17 8           
SAVPFLPVNPEYSA
TR 877.489 2 30 
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17 9           
SAVPFLPVNPEYSA
TR 877.48 2 31 
17 10           RPALEPVR 469.2943 2 40 
17 11           QLVTITTR 460.7959 2 36 
17 12           QLHSSVR 408.2427 2 40 
17 13           QAGHHELAER 379.5361 3 34 
17 14           NIQELLR 446.285 2 29 
17 15           NIQELLR 446.287 2 36 
17 16           NIQELLR 446.2642 2 33 
17 17           LVECQYELTDR 716.3648 2 45 
17 18           LQALSNR 404.2555 2 39 
17 19           LQALSNR 404.2518 2 43 
17 20           LQAENLQLR 542.8238 2 56 
17 21           LQAENLQLR 545.8197 2 41 
17 22           LPCRDDDGVTAK 453.5799 3 20 
17 23           
LLSLGAQANFFHPE
K 559.9899 3 36 
17 24           
LLSLGAQANFFHPE
K 559.9986 3 22 
17 25           LLNASAYR 457.2814 2 40 
17 26           LLNASAYR 457.2737 2 49 
17 27           LLNASAYR 457.2621 2 21 
17 28           LAFYLCGR 503.2966 2 22 
17 29           LAFYLCGR 500.2734 2 40 
17 30           LAFYLCGR 503.2868 2 24 
17 31           KLQALSNR 471.3139 2 45 
17 32           GVLVCDECCSVHR 532.9268 3 44 
17 33           GTTPLHVAAK 497.7983 2 45 
17 34           
AEHTLMGPGGSTH
R 368.9472 4 42 
18 1 1.58 0 gi|28076981 90916 cullin 5 LVHAER 365.7453 2 27 




factor (GEF7) VIEAYCTSAK 574.2993 2 51 
19 2           VGGCFLSLMPQMR 767.3954 2 27 
19 3           TGWFPSNYVR 616.8285 2 52 
19 4           STAALEEDAQILK 697.9097 2 68 
19 5           SPPKGFDTTAINK 459.2687 3 41 
19 6           SNGQTVIEEK 553.2873 2 81 
19 7           
SLVDTVYALKDEV
QELR 664.0517 3 58 
19 8           SLEEEQRAR 377.2228 3 25 
19 9           NLSAQCQEVR 605.8151 2 52 
19 10           NAFEISGSMIER 685.3394 2 56 
19 11           NAFEISGSMIER 688.3584 2 24 
19 12           NAFEISGSMIER 680.359 2 47 
19 13           MSGFIYQGK 566.7582 2 44 
19 14           MSGFIYQGK 566.7609 2 36 
19 15           LPTTGMTITK 542.8077 2 64 
19 16           LPTTGMTITK 542.8257 2 35 
19 17           LPTTGMTITK 542.824 2 32 
19 18           LPTTGMTITK 542.8106 2 48 
19 19           LPTTGMTITK 534.8231 2 49 
19 20           LDKYPTLLK 368.2464 3 38 
19 21           LDKYPTLLK 368.2398 3 28 
19 22           LDKYPTLLK 368.2329 3 40 
19 23           KPSDEEFAVRK 441.9297 3 36 
19 24           KPSDEEFAVR 397.2208 3 41 
19 25           IIVEETK 419.2689 2 33 
19 26           GFDTTAINK 486.7646 2 40 
 178 
19 27           GFDTTAINK 483.7627 2 39 
19 28           GDVIHVTR 448.7604 2 66 
19 29           
GASSPGILVLTTGLS
KPFMR 683.4067 3 49 
19 30           
ESAPQVLLPEEEKII
VEETK 765.0932 3 22 
19 31           ELELQILTEPIR 730.437 2 55 
19 32           EIKPSEKPVSPK 452.9625 3 38 
19 33           EIKPSEKPVSPK 446.9509 3 25 




factor (GEF) 1 
isoform 3       VAVVAPMSR 476.274 2 28 
20 2      VAVVAPMSR 476.2654 2 32 
20 3      RQSAPSPTR 506.7647 2 29 
20 4      RQSAPSPTR 506.7586 2 38 
20 5      RQSAPSPTR 506.7602 2 32 
20 6      RQSAPSPTR 506.7627 2 43 
20 7      RQSAPSPTR 506.7599 2 34 
20 8      RQSAPSPTR 506.7662 2 34 
21 1 1.55 0.32 gi|6679108 32540 
nucleophosmi
n 1 VTLATLK 373.2528 2 23 
21 2           GPSSVEDIKAK 377.5513 3 31 
21 3           GPSSVEDIK 469.2599 2 49 
22 1 1.5 0.02 gi|46849812 272368 fibronectin 1 LTAGLTR 369.2423 2 26 
22 2      LGVRPSQGGEAPR 445.9319 3 35 
22 3      LGVRPSQGGEAPR 445.9337 3 26 
22 4      APITGYIIR 505.3098 2 33 




factor 4A1 VLITTDLLAR 560.8733 2 37 
24 1 1.46 0.41 gi|70794809 59853 
Rous sarcoma 
oncogene 
isoform 2 VADFGLAR 427.7443 2 63 
24 2      
LTTVCPTSKPQTQG
LAK 614.6861 3 53 
24 3      LLLNAENPR 523.3054 2 43 
24 4      LIEDNEYTAR 615.3117 2 71 
24 5      KLDSGGFYITSR 452.5897 3 30 
24 6      GPSAAFVPPAAEPK 669.8598 2 47 
24 7      EVLDQVER 497.2609 2 23 
24 8      EVLDQVER 494.2589 2 60 
24 9      EVLDQVER 497.2573 2 25 
24 10      EVLDQVER 497.287 2 41 
24 11      DAWEIPR 446.7387 2 26 




ein U NGQDLGVAFK 527.7952 2 69 
25 2           NGQDLGVAFK 528.2864 2 40 
25 3           LNTLLQR 432.2828 2 60 
25 4           FIEIAAR 410.2494 2 35 





F1 complex,       
beta subunit ILQDYK 393.2238 2 23 
26 2      IGLFGGAGVGK 491.2992 2 33 
27 1 1.35 0.16 gi|41322927 506145 
plectin 1 
isoform 4 VPLDVAYAR 505.2954 2 28 
27 2           VPGAQDGVR 449.7492 2 32 
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27 3           VLADPSDDTK 533.7846 2 23 
27 4           QLAEGTAQQR 551.2933 2 32 
27 5           LTVDEAVR 454.7751 2 46 
27 6           LSVAAQEAAR 511.2928 2 58 
27 7           LRAETEQGEQQR 486.27 3 33 
27 8           LQAEEVAQQK 575.323 2 30 
27 9           LLEAAAQSSK 512.2999 2 39 
27 10           LLAEENQR 489.7771 2 27 
27 11           LKAEVTEAAR 363.216 3 38 
27 12           LAAISEATR 469.2878 2 47 
27 13           EVAEADSVR 488.2538 2 42 
27 14           ATVSAPFGK 442.2648 2 46 
27 15           AGVVGPELHEK 381.2187 3 21 




K 737.4149 2 68 
28 2      GAGNNPEFEETRR 492.9147 3 25 
28 3      DSGLGYEASGR 556.2725 2 55 
28 4      DSGLGYEASGR 559.2823 2 46 
29 1 1.29 0.1 gi|6679741 119141 
PTK2 protein 
tyrosine 
kinase 2 YMEDSTYYK 608.2519 2 41 
29 2           YMEDSTYYK 608.2626 2 45 
29 3           VYENVTGLVK 564.318 2 29 
29 4           VKHVACYGFR 416.8988 3 47 
29 5           
TLLATVDETIPALPA
STHR 669.3861 3 50 
29 6           
TLLATVDETIPALPA
STHR 669.3689 3 50 
29 7           THLGTGMER 501.2454 2 32 
29 8           SYWEMR 439.2053 2 25 
29 9           SNYEVLEK 491.2509 2 47 
29 10           SNYEVLEK 491.2644 2 35 
29 11           
SNDKVYENVTGLV
K 522.6277 3 67 
29 12           
SNDKVYENVTGLV
K 526.6223 3 79 
29 13           
SNDKVYENVTGLV
K 522.9644 3 41 
29 14           SLLDSVK 381.235 2 22 
29 15           SLLDSVK 384.2428 2 25 
29 16           SLLDSVK 381.2245 2 40 
29 17           SLLDSVK 384.2417 2 28 
29 18           SFLQVR 375.2272 2 22 
29 19           SFLQVR 375.2353 2 39 
29 20           SFLQVR 378.2399 2 39 
29 21           SFLQVR 378.2307 2 37 
29 22           SFLQVR 375.2254 2 35 
29 23           
SEEVHWLHVDMGV
SSVR 498.0016 4 52 
29 24           
SDYMQEIADQVDQ
EIALK 704.665 3 68 
29 25           
QQQEMEEDQRWLE
KEER 577.5194 4 26 
29 26           
QQQEMEEDQRWLE
KEER 764.001 3 50 
29 27           
QQQEMEEDQRWLE
KEER 764.693 3 38 
29 28           
QMLTAAHALAVDA
K 487.9323 3 47 
29 29           
QMLTAAHALAVDA
K 487.9519 3 38 
29 30           
QMLTAAHALAVDA
K 482.6054 3 47 
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29 31           
QMLTAAHALAVDA
K 722.9066 2 81 
29 32           
QMLTAAHALAVDA
K 722.8778 2 
10
1 
29 33           
QMLTAAHALAVDA
K 714.8811 2 82 
29 34           QFANLNREESILK 778.9328 2 47 
29 35           QFANLNR 434.7376 2 31 
29 36           QFANLNR 431.7459 2 25 
29 37           NVLVSSNDCVK 620.8313 2 68 
29 38           NVLVSSNDCVK 617.8247 2 54 
29 39           NVLVSSNDCVK 617.8077 2 48 
29 40           NNDVIGR 394.2032 2 45 
29 41           NNDVIGR 397.2296 2 44 
29 42           NLLDVIDQAR 581.8312 2 53 
29 43           NLLDVIDQAR 578.8368 2 56 
29 44           NLLDVIDQAR 578.8269 2 63 
29 45           NLLDVIDQAR 578.8079 2 53 
29 46           NLLDVIDQAR 578.8351 2 57 
29 47           MLGQTRPH 478.2532 2 52 
29 48           LVNGATQSFIIRPQK 558.3307 3 46 
29 49           LVNGATQSFIIRPQK 558.3252 3 49 
29 50           LVNGATQSFIIRPQK 558.3038 3 33 
29 51           LVNGATQSFIIRPQK 558.0133 3 35 
29 52           
LQPQEISPPPTANLD
R 592.6669 3 26 
29 53           
LQPQEISPPPTANLD
R 594.6568 3 61 
29 54           
LQPQEISPPPTANLD
R 594.6668 3 73 
29 55           
LPMPPNCPPTLYSL
MTK 664.6544 3 44 
29 56           LLNSDLGELISK 651.3829 2 78 
29 57           LLNSDLGELISK 651.368 2 84 
29 58           LLNSDLGELISK 654.368 2 66 
29 59           LLNSDLGELISK 651.3825 2 65 
29 60           LKMLGQTRPH 403.579 3 31 
29 61           LKMLGQTRPH 403.5744 3 35 
29 62           LIQQTFR 456.2809 2 58 
29 63           LIQQTFR 453.2551 2 49 
29 64           LIQQTFR 453.7579 2 35 
29 65           LIQQTFR 453.3102 2 47 
29 66           LGDFGLSR 432.7419 2 63 
29 67           LGDFGLSR 432.7485 2 52 
29 68           LGDFGLSR 432.7402 2 51 
29 69           LGDFGLSR 432.7271 2 57 
29 70           LGDFGLSR 435.75 2 35 
29 71           LGDFGLSR 435.7479 2 32 
29 72           LGDFGLSR 435.7474 2 32 
29 73           LGDFGLSR 432.7485 2 59 
29 74           LGCLEIRR 508.7903 2 46 
29 75           LGCLEIR 430.7483 2 49 
29 76           LGCLEIR 433.7438 2 55 
29 77           LGCLEIR 402.2566 2 23 
29 78           
LAQQYVMTSLQQE
YKK 662.7009 3 35 
29 79           
LAQQYVMTSLQQE
YKK 662.6783 3 45 
29 80           
LAQQYVMTSLQQE
YKK 657.3598 3 44 
29 81           
KSNYEVLEKDVGL
KR 445.2536 4 38 
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29 82           KSNYEVLEK 370.5394 3 32 
29 83           KSNYEVLEK 370.5458 3 21 
29 84           
KQMLTAAHALAVD
AK 532.6475 3 46 
29 85           KGMLQLK 409.2516 2 47 
29 86           IQPAPPEEYVPMVK 540.6401 3 21 
29 87           IQPAPPEEYVPMVK 540.6217 3 37 
29 88           IQPAPPEEYVPMVK 538.632 3 29 
29 89           IQPAPPEEYVPMVK 535.2964 3 53 
29 90           HVACYGFR 508.248 2 42 
29 91           GMLQLK 356.2077 2 24 
29 92           
GMGQVLPPHLMEE
R 544.6077 3 27 
29 93           
GMGQVLPPHLMEE
R 544.6231 3 20 
29 94           FLQEALTMR 565.8173 2 44 
29 95           FLQEALTMR 565.8158 2 51 
29 96           FLQEALTMR 562.7865 2 48 
29 97           FLQEALTMR 565.8122 2 34 
29 98           FLQEALTMR 554.7934 2 55 
29 99           FLKPDVRLSR 437.573 3 21 
29 
10
0           FLKPDVR 437.7733 2 40 
29 
10
1           FLKPDVR 443.7825 2 49 
29 
10
2           FFEILSPVYR 635.8618 2 44 
29 
10
3           FFEILSPVYR 635.8451 2 45 
29 
10
4           FFEILSPVYR 635.859 2 36 
29 
10
5           FDKECFK 493.2589 2 20 
29 
10
6           FDKECFK 493.2356 2 20 
29 
10
7           EVGLALR 382.2463 2 36 
29 
10
8           EVGLALR 379.2449 2 24 
29 
10
9           EVGLALR 379.2347 2 42 
29 
11
0           EVGLALR 379.2416 2 50 
29 
11
1           EVGLALR 379.2311 2 41 
29 
11
2           EVGLALR 382.2387 2 34 
29 
11
3           EVGLALR 379.2272 2 37 
29 
11
4           EVGLALR 382.231 2 32 
29 
11
5           EVGLALR 379.2429 2 50 
29 
11
6           ERIELGR 442.7718 2 27 
29 
11
7           
EKYELAHPPEEWK
YELR 555.0383 4 50 
29 
11
8           EKFLQEALTMR 465.2693 3 23 
29 
11
9           EKFLQEALTMR 465.2597 3 32 
29 
12
0           EIEMAQK 427.7414 2 32 
29 
12
1           EESILK 359.7129 2 23 
29 
12




3           DYEIQR 415.2064 2 29 
29 
12
4           DYEIQR 412.2118 2 28 
29 
12
5           CWAYDPSR 530.7433 2 40 
29 
12
6           AVIEMSSK 435.7382 2 36 
29 
12
7           
AQLSTILEEEKVQQ
EER 681.3852 3 72 
29 
12
8           
AQLSTILEEEKVQQ
EER 681.3603 3 77 
29 
12
9           
AQLSTILEEEKVQQ
EER 677.3695 3 57 
29 
13
0           ALPSIPK 366.2539 2 40 
29 
13
1           ALPSIPK 366.243 2 31 
29 
13
2           ALPSIPK 366.2549 2 26 






binding       
protein 2 
isoform a VDAKPEVQSQPPR 488.2873 3 30 




14 TLFPGTDHIDQLK 497.6111 3 46 
31 2           TIWEVPER 518.28 2 27 
31 3           TIWEVPER 518.2925 2 24 
31 4           NYIQSLAQMPK 657.8442 2 55 
31 5           NYIQSLAQMPK 657.8666 2 42 
31 6           MLVLDSDKR 368.881 3 22 
31 7           LVGTPGAELLKK 409.2551 3 36 
31 8           LVGTPGAELLKK 409.2693 3 22 
31 9           LVGTPGAELLK 549.3185 2 32 
31 10           LVGTPGAELLK 552.3599 2 23 
31 11           ILDFGLAR 455.783 2 36 
31 12           ILDFGLAR 455.7818 2 35 
31 13           DLLIDEWK 519.283 2 28 
31 14           DLLIDEWK 519.2944 2 30 





member 2 MMASGLTER 514.2493 2 41 





isoform 2 TLGLLVK 372.2589 2 21 
33 2           LNIQLK 364.7349 2 25 
33 3           INDGDLR 401.7284 2 33 




nuclear       
ribonucleoprot
ein H2 YVEVFK 392.7164 2 22 
34 2      YVEVFK 392.7282 2 23 
34 3      YIEIFK 406.7357 2 23 
34 4      
HTGPNSPDTANDGF
VR 564.2916 3 54 
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ein H1 VHIEIGPDGR 366.8919 3 29 
35 2           IQNGAQGIR 481.795 2 32 
35 3           FIYTR 350.1983 2 22 






protein       EAGEPGDVEPR 581.2846 2 39 
37 1 1.14 0.05 gi|31542366 34085 
cell division 
cycle 2 
homolog A SPEVLLGSAR 514.8035 2 59 
37 2           NLDENGLDLLSK 668.874 2 90 
37 3           LADFGLAR 434.7629 2 37 
37 4           IGEGTYGVVYK 633.308 2 54 
37 5           EISLLK 351.7317 2 32 
37 6           AFGIPIR 387.2455 2 37 
38 1 1.14 0 gi|8394460 39478 
tropomodulin 
3 LVEVNLNNIK 581.3741 2 50 
38 2      LLSYLEK 433.2575 2 22 
38 3      LLSYLEK 433.2693 2 30 
39 1 1.12 0.1 gi|32484983 108782 
Eph receptor 
A2 YSEPPHALTR 392.8831 3 25 
39 2           VVQMSNEDIKR 445.5759 3 31 
39 3           VIGAGEFGEVYK 637.8506 2 69 
39 4           TLADFDPR 470.7593 2 58 
39 5           
TASVSINQTEPPKV
R 546.9796 3 41 
39 6           SEQLKPLK 477.8206 2 31 
39 7           NILVNSNLVCK 640.3728 2 63 
39 8           NILVNSNLVCK 637.3386 2 46 
39 9           NGVSGLVTSR 498.2881 2 64 
39 10           MVGPLTR 395.2299 2 27 
39 11           LPSTSGSEGVPFR 667.3509 2 67 
39 12           LNVEER 380.2139 2 40 
39 13           LNVEER 380.2088 2 34 
39 14           LEGVVSK 369.234 2 23 
39 15           IFIELK 381.7519 2 24 
39 16           IFIELK 381.7482 2 35 
39 17           IAYSLLGLK 489.3087 2 61 
39 18           GELGWLTHPYGK 455.2599 3 40 
39 19           FTTEIHPSCVAR 475.2596 3 28 
39 20           FADIVSILDK 563.8411 2 66 
39 21           EVVLLDFAAMK 626.3525 2 52 
39 22           
EKDGEFSVLQLVG
MLR 617.0149 3 23 
39 23           EIPVAIK 388.2584 2 36 
39 24           AINDGFR 396.7117 2 35 
39 25           ACSPGFFK 460.2363 2 45 
40 1 1.1 0.16 gi|31560030 32689 
tropomyosin 
1, alpha SLEAQAEK 441.2482 2 47 
40 2      SIDDLEEK 474.7457 2 43 
40 3      QLEDELVSLQK 654.3726 2 61 
40 4      LATALQK 375.7515 2 26 
40 5      LATALQK 375.7502 2 30 
40 6      HIAEDADR 466.7405 2 23 




e VVDLMAYMASKE 697.8499 2 47 
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41 2           VGVNGFGR 403.719 2 20 
41 3           LTGMAFR 406.2206 2 31 
41 4           
GAAQNIIPASTGAA
K 685.3845 2 36 





F1 complex,       
alpha subunit, 
isoform 1 LTELLK 358.7469 2 22 
42 2      AVDSLVPIGR 513.7972 2 23 
42 3      AVDSLVPIGR 513.8113 2 22 
42 4      APGIIPR 362.2389 2 28 





box       
polypeptide 3, 
Y-linked VGSTSENITQK 582.3038 2 67 
43 2           VGSTSENITQK 585.3131 2 28 
43 3           VGSTSENITQK 585.323 2 84 
43 4           VGSTSENITQK 585.3143 2 87 
43 5           SSFFGDR 408.2038 2 38 
43 6           SPILVATAVAAR 587.8849 2 50 
43 7           QSSGASSSSFSSSR 681.3143 2 76 
43 8           IVEQDTMPPKGVR 495.9441 3 32 
43 9           HAIPIIK 399.2762 2 44 
43 10           HAIPIIK 396.2625 2 21 
43 11           GLDISNVK 423.2533 2 28 
43 12           FSGGFGAR 402.7222 2 26 
44 1 1.07 0 gi|12963491 47095 
enolase 1, 
alpha non-
neuron YNQILR 406.7444 2 20 
44 2      YNQILR 406.7519 2 21 
44 3      TIAPALVSK 450.2858 2 24 
44 4      IGAEVYHNLK 383.8834 3 23 
44 5      IGAEVYHNLK 381.8761 3 25 
44 6      IEEELGSK 455.7547 2 41 
45 1 1.07 0 gi|31980798 70256 
nuclear RNA 
export factor 1 NASPEEIQR 522.2729 2 32 




SH3 domain LSDLQATLR 508.8013 2 44 
46 2      ALYAFR 370.7254 2 21 
46 3      AIEAVHNTAMR 410.2281 3 22 
46 4      AAAETVVPR 457.2728 2 65 
46 5      AAAETVVPR 457.2672 2 71 
47 1 1.07 0.11 gi|7106439 49639 tubulin, beta 5 YLTVAAVFR 523.313 2 41 
47 2           TAVCDIPPR 514.7689 2 67 
47 3           LAVNMVPFPR 580.3126 2 57 
47 4           LAVNMVPFPR 580.3341 2 33 




polypeptide 5 TIVFVETK 471.8016 2 42 
48 2      TIVFVETK 468.7826 2 41 
48 3      TGTAYTFFTPNNIK 790.9148 2 31 
48 4      TAQEVDTYRR 413.5605 3 26 
48 5      TAQEVDTYRR 413.5576 3 23 
48 6      QVSDLISVLR 568.3588 2 39 
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48 7      LMEEIMSEKENK 504.918 3 25 
48 8      LMEEIMSEKENK 504.9179 3 24 
48 9      LLQLVEDRGSGR 452.2819 3 23 
48 10      LLQLVEDR 496.3127 2 62 
48 11      LLQLVEDR 493.2965 2 60 
48 12      APILIATDVASR 613.8734 2 62 
48 13      APILIATDVASR 613.8695 2 51 
49 1 1.06 0 gi|47271396 -1 
GNAS 
complex locus 
isoform a LLLLGAGESGK 529.3407 2 71 





protein), beta       
polypeptide 2 
like 1 VWQVTIGTR 533.3165 2 43 
50 2      LWDLTTGTTTR 635.859 2 63 
51 1 1.06 0.13 gi|82993679 70133 
PREDICTED: 
similar to Heat 
shock 70 kDa 
protein 1B       
(HSP70.1) 
isoform 5 YKAEDEVQR 379.8723 3 23 
51 2           VQVNYKGESR 397.9071 3 31 
51 3           VQVNYK 375.7211 2 28 
51 4           SAVEDEGLK 474.257 2 46 
51 5           NALESYAFNMK 652.3189 2 31 
51 6           LSKEEIER 502.2883 2 29 
51 7           DNNLLGR 401.2392 2 27 
51 8           DAGVIAGLNVLR 599.3729 2 45 
51 9           DAGVIAGLNVLR 599.3623 2 46 
51 10           
ATAGDTHLGGEDF
DNR 561.2862 3 39 
52 1 1.06 0.03 gi|9506843 52620 
lamin A 
isoform C2 LSPSPTSQR 489.7752 2 36 
52 2      LSPSPTSQR 489.7767 2 49 
52 3      LSPSPTSQR 486.7678 2 48 








NNR 534.9006 3 58 
53 2           ALIEMEK 428.2463 2 24 
53 3           AFNLEK 361.2105 2 25 
54 1 1.05 0.1 gi|51766344 32640 
PREDICTED: 
similar to 40S 
ribosomal 
protein SA 
(p40) (34/67       
kDa laminin 
receptor) LLVVTDPR 456.785 2 30 
54 2      LLVVTDPR 456.7848 2 46 
54 3      FAAATGATPIAGR 605.3592 2 57 
54 4      FAAATGATPIAGR 605.3329 2 67 
54 5      FAAATGATPIAGR 602.3388 2 49 




LNPK 652.0387 3 38 
55 2           
VAPEEHPVLLTEAP
LNPK 652.02 3 23 
55 3           
VAPEEHPVLLTEAP
LNPK 654.0398 3 46 
55 4           
SYELPDGQVITIGNE
R 597.65 3 33 
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55 5           
SYELPDGQVITIGNE
R 898.9823 2 57 
55 6           RGILTLK 400.7818 2 27 
55 7           QEYDESGPSIVHR 508.2675 3 69 
55 8           MQKEITALAPSTMK 527.616 3 38 
55 9           
LDLAGRDLTDYLM
K 547.3163 3 20 
55 10           IKIIAPPERK 388.9293 3 34 
55 11           IKIIAPPER 350.244 3 33 
55 12           IKIIAPPER 518.8471 2 27 
55 13           IIAPPERK 462.2967 2 31 
55 14           IIAPPERK 462.2843 2 25 
55 15           IIAPPER 401.2602 2 38 
55 16           IIAPPER 401.2442 2 25 
55 17           IIAPPER 401.2438 2 39 
55 18           IIAPPER 398.2346 2 20 
55 19           IIAPPER 398.2513 2 50 
55 20           HQGVMVGMGQK 396.5437 3 41 
55 21           GYSFTTTAER 566.7815 2 46 
55 22           GYSFTTTAER 566.7631 2 41 
55 23           GYSFTTTAER 569.7852 2 22 
55 24           GYSFTTTAER 566.7782 2 54 
55 25           EITALAPSTMK 589.3176 2 36 
55 26           EITALAPSTMK 589.303 2 38 
55 27           EITALAPSTMK 589.3063 2 34 
55 28           EITALAPSTMK 592.3389 2 32 
55 29           EITALAPSTMK 581.3286 2 50 
55 30           EITALAPSTMK 581.3058 2 48 
55 31           DSYVGDEAQSKR 452.2229 3 55 
55 32           DSYVGDEAQSKR 452.2328 3 44 
55 33           DSYVGDEAQSK 599.7844 2 65 
55 34           DSYVGDEAQSK 602.7911 2 56 
55 35           
DLYANTVLSGGTT
MYPGIADR 746.3755 3 46 
55 36           DLTDYLMK 510.7622 2 30 
55 37           DLTDYLMK 507.7349 2 23 
55 38           DLTDYLMK 510.7722 2 27 
55 39           DLTDYLMK 499.7562 2 39 
55 40           CDVDIRK 453.2381 2 31 
55 41           AVFPSIVGRPR 404.26 3 21 
55 42           AVFPSIVGRPR 400.2615 3 33 
55 43           AVFPSIVGRPR 400.2671 3 28 
55 44           AVFPSIVGRPR 404.2584 3 23 
55 45           AVFPSIVGRPR 400.2543 3 27 
55 46           AVFPSIVGRPR 400.2607 3 23 
55 47           AGFAGDDAPR 488.7405 2 72 
55 48           AGFAGDDAPR 491.7354 2 54 
55 49           AGFAGDDAPR 488.7237 2 44 
55 50           AGFAGDDAPR 491.7491 2 47 
55 51           AGFAGDDAPR 488.7461 2 47 
56 1 1.05 0.21 gi|6754524 36475 
lactate 
dehydrogenas
e 1, A chain VTLTPEEEAR 572.8052 2 57 
56 2      LVIITAGAR 460.3051 2 41 
57 1 1.05 0.05 gi|6755372 26657 
ribosomal 
protein S3 TQNVLGEK 447.7643 2 34 
57 2           TEIIILATR 518.3447 2 47 
57 3           QGVLGIK 357.741 2 43 
57 4           LLGGLAVR 402.7864 2 31 
57 5           
GGKPEPPAMPQPVP
TA 795.4161 2 27 
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57 6           FIMESGAK 449.7381 2 34 
57 7           ELAEDGYSGVEVR 715.3662 2 93 
57 8           AELNEFLTR 549.81 2 56 
58 1 1.05 0.06 gi|86262142 69406 
RNA binding 
motif protein 
14 INVELSTK 455.2817 2 52 
58 2      AQPSVSLGAPYR 626.3545 2 62 
58 3      AQPSVSLGAAYR 613.3488 2 34 
59 1 1.03 0.09 gi|31981690 70827 
heat shock 
protein 8 VQVEYKGETK 394.2254 3 31 
59 2           VQVEYKGETK 394.2253 3 22 
59 3           VQVEYKGETK 394.2285 3 33 
59 4           VQVEYKGETK 394.227 3 20 
59 5           VQVEYK 383.2176 2 23 
59 6           VEIIANDQGNR 614.8315 2 56 
59 7           VEIIANDQGNR 617.8396 2 57 
59 8           VEIIANDQGNR 614.8253 2 40 
59 9           VCNPIITK 475.7948 2 27 
59 10           VCNPIITK 475.7927 2 30 
59 11           
TVTNAVVTVPAYF
NDSQR 663.3573 3 37 
59 12           TTPSYVAFTDTER 744.3718 2 68 
59 13           TTPSYVAFTDTER 744.383 2 67 
59 14           
STAGDTHLGGEDFD
NR 566.6011 3 65 
59 15           SQIHDIVLVGGSTR 496.6311 3 38 
59 16           SFYPEEVSSMVLTK 544.943 3 41 
59 17           SFYPEEVSSMVLTK 816.9095 2 36 
59 18           RNTTIPTK 471.8095 2 31 
59 19           
QATKDAGTIAGLN
VLR 543.3184 3 20 
59 20           NTTIPTK 390.7358 2 31 
59 21           NTTIPTK 387.7278 2 42 
59 22           NTTIPTK 390.7409 2 22 
59 23           NSLESYAFNMK 660.3191 2 54 
59 24           NSLESYAFNMK 652.3191 2 71 
59 25           
NQVAMNPTNTVFD
AKR 607.9936 3 83 
59 26           
NQVAMNPTNTVFD
AK 833.4086 2 51 
59 27           MVQEAEKYK 381.208 3 21 
59 28           MKEIAEAYLGK 427.5876 3 55 
59 29           MKEIAEAYLGK 418.2365 3 58 
59 30           LSKEDIER 495.2707 2 52 
59 31           LSKEDIER 495.2768 2 56 
59 32           LLQDFFNGKELNK 522.959 3 34 
59 33           LLQDFFNGK 544.3138 2 47 
59 34           
LDKSQIHDIVLVGG
STR 617.3713 3 44 
59 35           ITITNDKGR 509.2966 2 66 
59 36           ITITNDK 405.7428 2 23 
59 37           
IINEPTAAAIAYGLD
KK 596.6945 3 67 
59 38           
IINEPTAAAIAYGLD
KK 596.6845 3 62 
59 39           
IINEPTAAAIAYGLD
K 555.9947 3 74 
59 40           GTLDPVEK 429.752 2 24 
59 41           GTLDPVEK 432.7507 2 42 
59 42           FELTGIPPAPR 599.342 2 41 
59 43           FEELNADLFR 630.3428 2 75 
59 44           EIAEAYLGK 497.2781 2 49 
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59 45           DAGTIAGLNVLR 600.3571 2 64 
59 46           DAGTIAGLNVLR 603.3608 2 39 
59 47           DAGTIAGLNVLR 600.346 2 62 
59 48           ARFEELNADLFR 494.2704 3 68 
60 1 1.03 0.1 gi|34328251 72372 drebrin 1 MAPTPIPTR 500.2608 2 34 
60 2      LSNGLAR 368.7387 2 34 
61 1 1.03 0 gi|6678986 118082 
myosin IC 
isoform b LGTEEISPR 501.286 2 63 





subunit,       
polypeptide 2 
(p85 beta) ILLNSER 425.7624 2 33 
62 2      DGTFLIR 411.2411 2 35 
62 3      APGPGPPSAAR 492.2877 2 48 
63 1 1.03 0.06 gi|6754256 73483 
heat shock 
protein 9A VQQTVQDLFGR 645.8472 2 67 
63 2           VLENAEGAR 479.7657 2 60 
63 3           VLENAEGAR 479.7595 2 55 
63 4           TTPSVVAFTADGER 728.8831 2 68 
63 5           RYDDPEVQKDTK 374.2107 4 27 
63 6           RYDDPEVQKDTK 504.6137 3 27 
63 7           
QAVTNPNNTFYAT
KR 579.6545 3 26 
63 8           QAASSLQQASLK 619.3526 2 79 
63 9           QAASSLQQASLK 619.3498 2 51 
63 10           
ETGVDLTKDNMAL
QR 569.6374 3 32 
63 11           
ETGVDLTKDNMAL
QR 569.6408 3 36 
63 12           ETGVDLTK 431.7466 2 30 
63 13           DAGQISGLNVLR 621.8638 2 70 
63 14           DAGQISGLNVLR 624.8701 2 40 
63 15           ASNGDAWVEAHGK 450.2343 3 33 
63 16           AQFEGIVTDLIKR 497.2994 3 52 
64 1 1.03 0 gi|7242171 28766 
proliferating 
cell nuclear 
antigen YLNFFTK 469.7731 2 43 
64 2      MPSGEFAR 455.7145 2 43 





ne       tract 
binding 
protein 
associated) YGEPGEVFINK 626.8255 2 39 
65 2           LAQKNPMYQK 412.9043 3 22 
65 3           
FGQGGAGPVGGQG
PR 671.3613 2 48 
65 4           FATHAAALSVR 381.8959 3 35 
65 5           AVVIVDDRGR 367.2188 3 22 
65 6           AVVIVDDR 443.7702 2 41 
65 7           AELDDTPMR 535.2614 2 28 
66 1 1.01 0 gi|29336026 227620 
myosin, heavy 
chain 14 LKQLKR 393.2847 2 26 
67 1 1.01 0.08 gi|6677805 29579 
ribosomal 
protein S4, X-
linked YALTGDEVK 501.2826 2 37 
67 2           TIRYPDPLIK 405.9167 3 24 
67 3           LTIAEER 419.2457 2 49 
67 4           LSNIFVIGK 495.8141 2 31 
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67 5           LSNIFVIGK 495.8065 2 54 
67 6           LIYDTK 376.7213 2 33 
67 7           IGVITNR 389.7529 2 41 
67 8           DANGNSFATR 527.2525 2 66 
68 1 1 0 gi|31560686 69599 
heat shock 
protein 2 GTLEPVEK 439.7622 2 27 




1 isoform 2 VTNLLMLK 474.281 2 46 
69 2           
NSSTSAGVYANGN
DNKK 870.3868 2 22 




factor 2 VNFTVDQIR 549.3087 2 58 
70 2      VFSGVVSTGLK 550.3269 2 69 
70 3      GGGQIIPTAR 488.3006 2 21 
70 4      GEGQLSAAER 512.2792 2 58 
70 5      FSVSPVVR 445.7717 2 34 
71 1 0.99 0.26 gi|40556608 83229 
heat shock 
protein 1, beta FYEAFSK 449.2491 2 27 
71 2           ALLFIPR 418.2828 2 32 
71 3           ALLFIPR 418.2843 2 23 
71 4           ADLINNLGTIAK 624.8822 2 36 





subunit,       
polypeptide 1 
isoform 1 TAIEAFNETIK 618.8433 2 68 
72 2      ISEIIDSR 466.7634 2 61 
72 3      DGTFLVR 404.229 2 29 
73 1 0.97 0.09 gi|31981562 57808 
pyruvate 
kinase 3 VNLAMDVGK 484.7779 2 46 
73 2           GDLGIEIPAEK 571.3262 2 34 










prot LVSIDSK 384.2351 2 28 
74 2      IQQNTFTR 504.2669 2 47 
75 1 0.95 0.19 gi|13195690 17939 
ribosomal 
protein S27a TLSDYNIQK 541.2917 2 35 
75 2           TLSDYNIQK 541.2766 2 53 
75 3           TLSDYNIQK 541.28 2 37 
75 4           TLSDYNIQK 541.287 2 35 
75 5           TLSDYNIQK 544.2968 2 21 
75 6           TLSDYNIQK 544.3009 2 39 
75 7           MQIFVK 391.2389 2 31 
75 8           MQIFVK 391.2248 2 40 
75 9           MQIFVK 391.2197 2 30 




ein K ILLQSK 351.2382 2 27 
76 2      DLAGSIIGK 440.2657 2 24 
76 3      DLAGSIIGK 437.271 2 26 
77 1 0.95 0.02 gi|6678469 49877 tubulin, alpha LSVDYGKK 455.2587 2 40 
 190 
6 
77 2           DVNAAIATIK 511.3023 2 48 
77 3           DVNAAIATIK 508.2953 2 31 
77 4           DVNAAIATIK 508.2955 2 37 
77 5           DVNAAIATIK 508.3018 2 42 




factor 1 alpha 
2 TIEKFEK 447.7486 2 41 
78 2      TIEKFEK 447.7502 2 40 
78 3      TIEKFEK 447.7604 2 37 
78 4      QTVAVGVIK 457.7913 2 55 
78 5      QLIVGVNK 438.791 2 28 
78 6      LPLQDVYK 488.2808 2 47 
78 7      LPLQDVYK 488.2891 2 44 
78 8      LPLQDVYK 488.2881 2 62 
78 9      IGGIGTVPVGR 513.3025 2 65 
78 10      IGGIGTVPVGR 516.3175 2 77 
78 11      IGGIGTVPVGR 513.3235 2 67 
78 12      IGGIGTVPVGR 516.327 2 68 
78 13      IGGIGTVPVGR 513.3197 2 35 
78 14      IGGIGTVPVGR 516.3341 2 23 
79 1 0.95 0 gi|66841385 427993 
cardiomyopat
hy associated 
3 QDNDLRK 444.73 2 38 





tyrosine       
kinase adaptor 
protein 2 
isoform 2 VQLVDSVYCIGQR 768.8876 2 66 
80 2      TGYVPSNYVER 642.8039 2 57 
80 3      NLKDTLGLGK 353.5428 3 36 
80 4      LWLLDDSK 495.2716 2 43 
80 5      KAPIFTSEHGEK 448.5749 3 45 
80 6      IYDLNIPAFVK 646.8628 2 45 
80 7      HQAECALNER 409.858 3 41 
80 8      GVEGDFLIR 503.2789 2 54 
80 9      GQVGLVPK 402.252 2 36 
80 10      
FAYVAEREDELSLV
K 590.3101 3 43 
80 11      FAYVAER 428.2284 2 20 
80 12      EWYYGNVTR 597.2802 2 28 
80 13      DTLGLGK 355.2128 2 20 
80 14      DSESSPSDFSVSLK 745.848 2 76 
80 15      APIFTSEHGEK 407.8797 3 38 










isoform 1 TLQSHLQK 480.8007 2 39 
81 2           SPSDVIR 390.2322 2 26 




kinase adaptor TGFVPSNYVER 634.8114 2 38 
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protein 1       
82 2      FAGNPWYYGK 601.7896 2 50 





beta       
isoform b SVQTFADK 451.2484 2 36 
83 2           STLNEIYFGK 589.324 2 78 
83 3           LVEDMENKIR 421.5656 3 23 






PYD       
containing 4A VKTLISK 400.7743 2 28 
85 1 0.92 0 gi|19526792 40957 CD34 antigen SWSPTGER 460.243 2 41 





protein) VYEGERPLTK 397.9032 3 25 
86 2      
SQIFSTASDNQPTVT
IK 612.9986 3 28 
86 3      
QATKDAGTIAGLN
VMR 554.6504 3 28 
86 4      NTVVPTK 379.7303 2 28 
86 5      
NQLTSNPENTVFDA
KR 611.9937 3 50 
86 6      NGRVEIIANDQGNR 519.6215 3 34 
86 7      MKETAEAYLGK 423.5796 3 21 
86 8      
LYGSGGPPPTGEED
TSEKDEL 726.68 3 28 
86 9      LTPEEIER 493.772 2 44 
86 10      LTPEEIER 493.7709 2 53 
86 11      ITPSYVAFTPEGER 783.9114 2 43 
86 12      ITITNDQNR 537.7893 2 65 
86 13      IQQLVK 364.7468 2 20 
86 14      IQQLVK 364.749 2 24 
86 15      ELEEIVQPIISK 699.4099 2 41 
86 16      EFFNGKEPSR 404.2243 3 32 
86 17      DAGTIAGLNVMR 620.3358 2 40 
86 18      DAGTIAGLNVMR 620.3283 2 49 





alpha 2       TSVETALR 441.7675 2 53 
87 2           LLLNNDNLLR 599.3524 2 68 




muscle RQQQLTAMK 373.8745 3 36 
88 2      QQQLTAMK 485.2673 2 46 
88 3      QQQLTAMK 477.28 2 44 
88 4      
QLLQANPILEAFGN
AK 578.3381 3 49 
88 5      
QLLQANPILEAFGN
AK 855.4749 2 46 
88 6      
QLLQANPILEAFGN
AK 863.9884 2 41 
88 7      QKLNVSTK 499.7529 2 24 
88 8      QKLNVSTK 499.7549 2 22 
88 9      NTDQASMPDNTAA 538.9279 3 36 
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QK 
88 10      
NTDQASMPDNTAA
QK 804.3607 2 47 
88 11      LEVNMQALK 531.2921 2 23 
88 12      
ERNTDQASMPDNT
AAQK 635.6515 3 25 
88 13      EQADFAIEALAK 653.3592 2 58 
88 14      EQADFAIEALAK 653.3587 2 70 
88 15      ATDKSFVEK 512.7883 2 37 
88 16      
AQTKEQADFAIEAL
AK 578.6559 3 59 
89 1 0.91 0.06 gi|7948995 116761 
tyrosine 
kinase, non-
receptor, 2 VEQLFGLGLRPR 462.285 3 30 
89 2           VEQLFGLGLRPR 462.2864 3 32 
89 3           TVSVAVK 355.2343 2 35 
89 4           TVSVAVK 352.2273 2 31 
89 5           TVSVAVK 352.2253 2 33 
89 6           TVSVAVK 355.2377 2 36 
89 7           TLCVGPFPR 523.7915 2 30 
89 8           TLCVGPFPR 526.7951 2 27 
89 9           TLCVGPFPR 523.7769 2 31 
89 10           NLLLATR 403.7726 2 35 
89 11           NLLLATR 403.7772 2 45 
89 12           NLLLATR 403.7632 2 37 
89 13           NLLLATR 403.7727 2 34 
89 14           LYGVVLTLPMK 625.3834 2 50 
89 15           LRDDLNITR 372.5543 3 35 
89 16           LGDGSFGVVR 506.7896 2 
10
0 
89 17           LGDGSFGVVR 503.7812 2 88 
89 18           LGDGSFGVVR 503.7711 2 20 
89 19           LGDGSFGVVR 506.7847 2 58 
89 20           DFLLEAQPTDMR 729.3608 2 28 
89 21           
ANFSTNNSNPGARP
PSLR 633.9971 3 61 
89 22           AGPCILPIVR 551.3339 2 45 
89 23           AGPCILPIVR 548.3347 2 31 
89 24           AGPCILPIVR 551.3438 2 53 
90 1 0.91 0 gi|7949150 32243 
syndecan 
binding 
protein SLMDHTIPEV 579.2948 2 29 
90 2      ITMTIR 375.7246 2 26 






ase       
domain 
containing 2 TDLVEQAFR 542.8052 2 46 
91 2           LVQLPPPAVR 545.3489 2 46 
91 3           LPLPDPLK 446.7926 2 32 
91 4           EAQYIR 393.2187 2 35 
92 1 0.89 0.13 gi|33598964 228855 
myosin heavy 
chain 10, non-
muscle YLFVDR 406.7248 2 22 
92 2      
VVSSVLQFGNISFK
K 555.6835 3 29 
92 3      VLQQVK 360.7486 2 21 
92 4      VLAYDKLEK 364.2382 3 25 
92 5      VLAYDKLEK 364.2231 3 24 
92 6      VKPLLQVTR 355.9259 3 56 
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92 7      VIQYLAHVASSHK 365.4758 4 24 
92 8      VIQYLAHVASSHK 363.9677 4 23 
92 9      VIQYLAHVASSHK 486.9536 3 40 
92 10      VDYKADEWLMK 475.9286 3 37 
92 11      TVGQLYKESLTK 456.2724 3 35 
92 12      TVGQLYK 407.7509 2 22 
92 13      QLEEAEEEATR 652.822 2 62 
92 14      QKLQLEK 441.2888 2 22 
92 15      QKLQLEK 443.7241 2 29 
92 16      QIVSNLEK 465.7792 2 52 
92 17      QGFPNR 362.7061 2 24 
92 18      QGFPNR 362.7099 2 27 
92 19      QGFPNR 362.6962 2 26 
92 20      NTNPNFVR 484.2774 2 35 
92 21      NTNPNFVR 484.2582 2 37 
92 22      NTNPNFVR 484.2726 2 41 
92 23      NTNPNFVR 481.2566 2 28 
92 24      NTNPNFVR 484.2693 2 35 
92 25      NTNPNFVR 481.2602 2 30 
92 26      LVWIPSER 500.294 2 29 
92 27      LQELEGAVK 496.803 2 55 
92 28      LMATLR 355.7296 2 22 
92 29      LMATLR 355.7297 2 25 
92 30      LDPHLVLDQLR 440.2723 3 37 
92 31      LDPHLVLDQLR 442.283 3 33 
92 32      KFDQLLAEEK 407.5716 3 54 
92 33      KFDQLLAEEK 411.5875 3 46 
92 34      KEEELQGALAR 415.2276 3 27 
92 35      IVFQEFR 469.7748 2 42 
92 36      IVFQEFR 469.7689 2 46 
92 37      IVFQEFR 469.7682 2 30 
92 38      GGPISFSSSR 497.7659 2 41 
92 39      FDQLLAEEK 549.8076 2 53 
92 40      FDQLLAEEK 549.8133 2 47 
92 41      EQEVAELK 473.2856 2 65 
92 42      EQADFAVEALAK 646.3439 2 59 
92 43      ELDDATEANEGLSR 763.366 2 67 
92 44      ATISALEAK 452.2696 2 45 
92 45      ATISALEAK 455.2806 2 60 
92 46      ASRDEIFAQSK 417.8981 3 31 
92 47      AMVNKDDIQK 393.215 3 36 
92 48      AMVNKDDIQK 393.2136 3 25 
92 49      ALELDPNLYR 602.3375 2 41 
92 50      
AGVLAHLEEERDL
K 395.7314 4 26 
92 51      AGVLAHLEEER 410.5658 3 36 
92 52      AGVLAHLEEER 410.5699 3 46 
92 53      
AGKLDPHLVLDQL
R 525.6611 3 37 
92 54      ADFCIIHYAGK 432.2336 3 22 
92 55      ADFCIIHYAGK 432.2298 3 20 





isoform a YAMEQSIK 496.2565 2 40 
93 2           QAFAPFGPIK 541.3192 2 43 
94 1 0.87 0.06 gi|39841025 82355 
FCH and 
double SH3 
domains 2 VGQVGYVPEK 538.3059 2 47 
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94 2      SSQFFPR 434.7373 2 32 
94 3      NFISEPAR 467.2594 2 43 
94 4      LSLFQSR 428.7669 2 33 
94 5      LASQYLK 411.7495 2 25 
94 6      INICENYK 527.2686 2 43 
95 1 0.87 0 gi|54607098 72539 
succinate 
dehydrogenas
e Fp subunit TEDGKIYQR 370.5381 3 22 
95 2           AFGGQSLK 407.2423 2 28 






member       
6a TGTQYLLR 476.2467 2 26 
96 2      TGTQYLLR 476.286 2 47 
96 3      QHINTWVAK 368.2255 3 24 
96 4      QGLFLSK 388.2346 2 29 
96 5      MTYIGEIFTK 612.829 2 47 
96 6      LGMTDAFGGR 520.7599 2 47 
96 7      ILGEDSSK 427.7395 2 48 
97 1 0.86 0 gi|6754994 37474 
poly(rC) 
binding 
protein 1 QGANINEIR 507.7834 2 79 
98 1 0.85 0.04 gi|46560563 188662 
SH3 domain 
protein 1B TLQDTLNPK 515.2957 2 42 
98 2      TGIFPSNYVRPK 460.2796 3 32 
98 3      QLLNER 386.7312 2 25 
98 4      QLLNER 386.7335 2 26 
98 5      LQDVQIR 436.2649 2 20 
98 6      LQDVQIR 439.2721 2 27 
98 7      LLGPSSER 432.7581 2 36 
98 8      LIYLVPEK 487.818 2 43 
98 9      ITRYPLLIR 382.2509 3 38 
98 10      ALYPFEAR 483.762 2 40 
99 1 0.85 0 gi|68989251 58969 tweety 2 LSEIIAAR 436.7845 2 47 





kinase NTLISASQQLK 603.3207 2 28 
101 1 0.8 0.09 gi|47059093 108831 
Eph receptor 
B4 VDTVAAEHLTR 404.5648 3 37 
101 2           TGWVPR 358.2139 2 44 
101 3           SSPCTTPPSAPR 629.3171 2 46 
101 4           ILASVQHMK 521.7994 2 52 
101 5           FPQVVSALDK 552.309 2 54 
101 6           DLVEPWVAIR 599.3489 2 44 
102 1 0.74 0 gi|22122825 44732 
actin-related 
protein 2 ILLTEPPMNPTK 685.3574 2 35 






se       
activation 
protein, theta 
polypeptide VISSIEQK 452.2675 2 34 
104 1 0.7 0 gi|6996913 38652 annexin A2 LMVALAK 384.2522 2 28 
105 1 0.66 0.03 gi|21536246 69733 
DEAD (Asp-
Glu-Ala-Asp) 




105 2           GITYDDPIK 511.2823 2 26 
105 3           ALMSVKEMAK 380.5422 3 24 
106 1 0.66 0.03 gi|86262157 55621 
hypothetical 
protein 
LOC239796 TAIEHVK 399.232 2 36 
106 2      SDPAEHLR 462.7326 2 41 
106 3      KLQQLVTENPGK 452.2701 3 42 
106 4      AISPYHLR 478.7738 2 37 
107 1 0.64 0 gi|31980969 86382 SEC23B YINTEHGGSQAR 446.8966 3 27 
108 1 0.64 0 gi|66955868 18140 
hypothetical 
protein 
LOC67288 LQALQEKR 493.7989 2 52 
109 1 0.63 0.06 gi|91598596 67748 
sorting nexin 
associated 
golgi protein 1 VGQSFR 350.2074 2 33 
109 2           SYISYK 383.7145 2 37 
109 3           SYISYK 380.7053 2 26 
109 4           
SGGEAFVLGEASGF
VK 777.9042 2 62 
109 5           SENPGEISLR 551.2916 2 60 
109 6           SDLSLGSR 417.7287 2 55 
109 7           SDLSLGSR 417.7137 2 36 
109 8           SDLSLGSR 420.7434 2 42 
109 9           LVPTHTQVPVHR 463.9467 3 70 
109 10           
LAEKFPVISVPHLPE
K 454.7905 4 36 
109 11           
GVSAPPAHQASGA
K 428.5754 3 38 
109 12           
GVSAPPAHQASGA
K 426.5717 3 34 
109 13           
GVSAPPAHQASGA
K 428.58 3 49 
109 14           GLFPASYVQVIR 678.4085 2 58 
109 15           FSTFVK 364.715 2 33 
109 16           FSTFVK 364.7142 2 27 
109 17           FEEDFISKR 390.8731 3 42 
109 18           FEEDFISK 507.7547 2 42 
109 19           
APEPGPPADGGPGA
PAR 505.2667 3 77 
109 20           
APEPGPPADGGPGA
PAR 507.2765 3 43 
109 21           
APEPGPPADGGPGA
PAR 757.384 2 72 
109 22           ALYDFK 378.7112 2 32 
110 1 0.61 0 gi|23956222 47327 
ARP3 actin-
related protein 
3 homolog LSEELSGGR 474.246 2 48 
110 2      LSEELSGGR 474.2648 2 33 
110 3      HNPVFGVMS 502.2539 2 36 
111 1 0.33 0 gi|31982171 165193 
murinoglobuli
n 1 YGAVTFSR 450.7459 2 42 
111 2           SSGSLFNNAMK 586.2876 2 39 
111 3           ITNKLIFLK 363.9241 3 37 
111 4           FSTSQSLPASQTR 705.3749 2 57 
111 5           FQVENSNR 497.2462 2 20 
112 1 0.11 0.11 gi|50363232 207000 nestin TLLEAENSR 517.2705 2 29 
112 2      TLLEAENSR 517.2693 2 28 
112 3      TLLEAENSR 517.2814 2 27 
112 4      TLLEAENSR 517.2715 2 32 
112 5      TLLEAENSR 517.2751 2 28 
112 6      TLLEAENSR 517.2807 2 48 
112 7      TLLEAENSR 517.2747 2 33 
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112 8      TLLEAENSR 517.2831 2 35 
112 9      TLLEAENSR 517.2761 2 33 
112 10      TLLEAENSR 517.2691 2 33 
112 11      TLLEAENSR 517.2578 2 36 
112 12      TLLEAENSR 517.2612 2 32 
112 13      TLLEAENSR 517.2638 2 35 
112 14      TLLEAENSR 517.2736 2 37 
112 15      TLLEAENSR 517.2657 2 33 
112 16      TLLEAENSR 517.2691 2 31 
112 17      TLLEAENSR 517.2726 2 43 
112 18      TLLEAENSR 517.2692 2 35 
112 19      TLLEAENSR 517.278 2 36 
112 20      TLLEAENSR 517.2709 2 33 
112 21      TLLEAENSR 517.2854 2 36 
112 22      TLLEAENSR 517.2827 2 34 
112 23      TLLEAENSR 517.2784 2 26 
112 24      TLLEAENSR 517.2814 2 31 
112 25      TLLEAENSR 517.2778 2 28 
112 26      TLLEAENSR 517.2731 2 46 
112 27      TLLEAENSR 517.277 2 34 
112 28      TLLEAENSR 517.2737 2 35 
112 29      TLLEAENSR 517.2769 2 31 
112 30      TLLEAENSR 517.2724 2 28 
112 31      TLLEAENSR 517.2812 2 35 
112 32      TLLEAENSR 517.283 2 48 
112 33      TLLEAENSR 517.2776 2 22 
112 34      TLLEAENSR 517.2713 2 23 
112 35      TLLEAENSR 517.2826 2 25 




Table 5. Simplified list of identified proteins from the SILAC experiment at the 
protein level. Phenylphosphate and Boiled beads elutions combined. 
 


















gi|9506909 Myo10  myosin X  2.55 0.29 
gi|31982755 Vim vimentin  2.44 0.65 
gi|24429590 Dhx9  DEAH (Asp-Glu-Ala-His) box polypeptide 9  2.35 0.93 
gi|94365254 Tns1  PREDICTED: similar to tensin  2.26 0.36 
gi|27370424 
C230081
A  hypothetical protein LOC244895  2.16 0.15 
gi|31981796 Dok1 (*) docking protein 1  2.01 N/A 
gi|6754632 Mapk1  mitogen activated protein kinase 1  1.95 0.25 
gi|21281693 Pxn (*) paxillin isoform alpha  1.92 0.37 
gi|31982290 
Lpp  LIM domain containing preferred translocation partner 
in lipoma  1.84 N/A 
gi|21313308 Hnrnpm  heterogeneous nuclear ribonucleoprotein M  1.73 0.13 
gi|25141233 Matr3  matrin 3  1.71 N/A 
gi|27476057 Dcbld2  discoidin, CUB and LCCL domain containing 2  1.69 0.31 
gi|40254593 Bcar1 (*) breast cancer anti-estrogen resistance 1  1.67 0.23 
gi|21489933 Mapk3  mitogen activated protein kinase 3  1.66 0.02 
gi|82887378 Mocs3  PREDICTED: molybdenum cofactor synthesis 3  1.66 0.5 
gi|31560712 Csk  c-src tyrosine kinase  1.62 0.07 
gi|51921285 Git1  G protein-coupled receptor kinase-interactor 1  1.59 0.15 
gi|28076981 Cul5  cullin 5  1.58 N/A 
gi|31980859 
Arhgef7 
(*) Rho guanine nucleotide exchange factor (GEF7)  1.56 0.11 
gi|6679108 Npm1 nucleophosmin 1  1.55 0.32 
gi|16905083 
Rapgef1 Rap guanine nucleotide exchange factor (GEF) 1 
isoform 3  1.55 0.05 
gi|46849812 Fn1 fibronectin 1  1.5 0.02 
gi|21450625 Eif4a1 eukaryotic translation initiation factor 4ª1  1.47 N/A 
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gi|70794809 Src (*) Rous sarcoma oncogene isoform 2  1.46 0.41 
gi|7949051 Hnrnpu heterogenous nuclear ribonucleoprotein U  1.41 N/A 
gi|31980648 Atp5b ATP synthase, H+ transporting mitochondrial F1 
complex, beta subunit  
1.39 N/A 
gi|41322927 Plec1 plectin 1 isoform 4  1.35 0.16 
gi|7305237 Limd1 LIM domains containing 1  1.34 0.11 
gi|9790077 Gsk3b Glycogen synthase kinase 3 beta 1.3 N/A 
gi|6679741 Ptk2 (*) PTK2 protein tyrosine kinase 2  1.29 0.1 
gi|31982757 G3bp2 Ras-GTPase-activating protein (GAP120) SH3-domain 
binding protein 2 isoform a  
1.26 N/A 
gi|10092590 Mapk14 mitogen activated protein kinase 14  1.21 0.1 
gi|23956078 Abcf2 ATP-binding cassette, sub-family F (GCN20), member 
2  
1.21 N/A 




PREDICTED: similar to heterogeneous nuclear 
ribonucleoprotein H2  1.2 N/A 
(*)  Prior evidence of direct c-Src phosphorylation 
 
Proteins with fold change in phosphorylation level < 1.2 
gi|10946928 Hnrnph1 heterogeneous nuclear ribonucleoprotein H1  1.19 0.01 
gi|7305075 
G3bp1 ras-GTPase-activating protein SH3-domain binding 
protein  1.16 N/A 
gi|31542366 Cdk1 cell division cycle 2 homolog A  1.14 0.05 
gi|8394460 Tmod3 tropomodulin 3  1.14 N/A 
gi|32484983 Epha2 Eph receptor A2  1.12 0.1 
gi|31560030 Tpm1 tropomyosin 1, alpha  1.1 0.16 
gi|6679937 Gapdh glyceraldehyde-3-phosphate dehydrogenase  1.1 0.04 
gi|6680748 Atp5a1 
 
ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit, isoform 1  1.1 N/A 
gi|94407081 Ddx3x 
 
PREDICTED: similar to DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y-linked  1.08 0.07 
gi|83816893 Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5  1.07 0.07 
gi|49258190 Nckipsd NCK interacting protein with SH3 domain  1.07 0.26 
gi|7106439 Tubb5 tubulin, beta 5  1.07 0.11 
gi|31980798 Nxf1 nuclear RNA export factor 1  1.07 N/A 
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gi|12963491 Eno1 enolase 1, alpha non-neuron  1.07 N/A 
gi|82993679 Hspa1b 
 
PREDICTED: similar to Heat shock 70 kDa protein 1B 
(HSP70.1) isoform 5  1.06 0.13 
gi|47271396 Gnas GNAS complex locus isoform a  1.06 N/A 
gi|9506843 Lmna lamin A isoform C2  1.06 0.03 
gi|6680047 Gnb2l1 guanine nucleotide binding protein (G protein), beta 
polypeptide 2 like 1  1.06 N/A 
gi|6671509 Actb actin, beta, cytoplasmic  1.05 0.18 
gi|6755372 Rps3 ribosomal protein S3  1.05 0.05 
gi|51766344 LOC4325
48 
PREDICTED: similar to 40S ribosomal protein SA 
(p40) (34/67 kDa laminin receptor)  1.05 0.1 
gi|86262142 Rbm14 RNA binding motif protein 14  1.05 0.06 
gi|12963531 Nono non-POU-domain-containing, octamer binding protein  1.05 N/A 
gi|6754524 Ldha lactate dehydrogenase 1, A chain  1.05 0.21 
gi|31981690 Hspa8 heat shock protein 8  1.03 0.09 
gi|6754256 Hspa9 heat shock protein 9ª  1.03 0.06 
gi|6679321 Pik3r2 
 
phosphatidylinositol 3-kinase, regulatory subunit, 
polypeptide 2 (p85 beta)  1.03 0.03 
gi|6678986 Myo1c myosin IC isoform b  1.03 N/A 
gi|7242171 Pcna proliferating cell nuclear antigen  1.03 N/A 
gi|34328251 Dbn1 drebrin 1  1.03 0.1 
gi|23956214 Sfpq 
 
splicing factor proline/glutamine rich (polypyrimidine 
tract binding protein associated) [Mus muscu 1.02 0.03 
gi|29336026 Myh14 myosin, heavy chain 14  1.01 N/A 
gi|6677805 Rps4x ribosomal protein S4, X-linked  1.01 0.08 
gi|31560686 Hspa2 heat shock protein 2  1 N/A 
gi|33859482 Eef2 eukaryotic translation elongation factor 2  0.99 0.14 
gi|68299809 Pik3r1 phosphatidylinositol 3-kinase, regulatory subunit, 
polypeptide 1 isoform 1  0.99 0.19 
gi|30039680 Rod1 ROD1 regulator of differentiation 1 isoform 2  0.99 N/A 
gi|40556608 Hsp90ab1 heat shock protein 1, beta  0.99 0.26 
gi|94377125 Flnc 
 
PREDICTED: similar to Filamin-C (Gamma-filamin) 
(Filamin-2) (Protein FLNc) (Actin-binding-like prot 0.97 0.21 
gi|31981562 Pkm2 pyruvate kinase 3  0.97 0.09 
gi|94363502 Nck2 
 
PREDICTED: similar to non-catalytic region of tyrosine 
kinase adaptor protein 2 isoform 2 [Mus musc 0.95 0.06 
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gi|6681273 Eef1a2 eukaryotic translation elongation factor 1 alpha 2  0.95 0.07 
gi|6678469 Tuba1c tubulin, alpha 6  0.95 0.02 
gi|13195690 Rps27a ribosomal protein S27a  0.95 0.19 
gi|94392981 Plekhh1 
 
PREDICTED: pleckstrin homology domain containing, 
family H (with MyTH4 domain) member 1 isoform 1 [ 0.95 N/A 
gi|66841385 Xirp2 cardiomyopathy associated 3  0.95 N/A 
gi|13384620 Hnrnpk heterogeneous nuclear ribonucleoprotein K  0.95 0.01 
gi|34328187 Nck1 non-catalytic region of tyrosine kinase adaptor protein 1  0.94 0.08 
gi|6753262 Capzb capping protein (actin filament) muscle Z-line, beta 
isoform b  0.93 0.11 
gi|94379397 Nalp4d 
 
PREDICTED: similar to NACHT, leucine rich repeat 
and PYD containing 4ª  0.93 N/A 
gi|7305295 Myh11 myosin, heavy polypeptide 11, smooth muscle  0.92 0.08 
gi|31981722 Hspa5 heat shock 70kD protein 5 (glucose-regulated protein)  0.92 0.07 
gi|6671672 Capza2 capping protein (actin filament) muscle Z-line, alpha 2  0.92 0.07 
gi|19526792 Cd34 CD34 antigen  0.92 N/A 
gi|7948995 Tnk2 tyrosine kinase, non-receptor, 2  0.91 0.06 
gi|7949150 Sdcbp syndecan binding protein  0.91 N/A 
gi|33598964 Myh10 myosin heavy chain 10, non-muscle  0.89 0.13 
gi|23956398 Pcmtd2 protein-L-isoaspartate (D-aspartate) O-
methyltransferase domain containing 2  0.89 0.1 
gi|76677817 Puf60 fuse-binding protein-interacting repressor isoform a  0.88 0.12 
gi|39841025 Fchsd2 FCH and double SH3 domains 2  0.87 0.06 
gi|54607098 Sdha succinate dehydrogenase Fp subunit  0.87 N/A 
gi|6678097 Serpinb6a serine (or cysteine) proteinase inhibitor, clade B, 
member 6ª  0.86 0.15 
gi|6754994 Pcbp1 poly(rC) binding protein 1  0.86 N/A 
gi|46560563 Itsn2 SH3 domain protein 1B  0.85 0.04 
gi|68989251 Ttyh2 tweety 2  0.85 N/A 
gi|6680942 Chuk conserved helix-loop-helix ubiquitous kinase  0.81 N/A 
gi|47059093 Ephb4 Eph receptor B4  0.8 0.09 




monooxygenase activation protein, theta polypeptide  0.73 N/A 
gi|6996913 Anxa2 annexin A2  0.7 N/A 







15Rik hypothetical protein LOC239796  0.66 0.03 
gi|66955868 Srek1ip1 hypothetical protein LOC67288  0.64 N/A 
gi|31980969 Sec23b SEC23B  0.64 N/A 
gi|91598596 Snx18 sorting nexin associated golgi protein 1  0.63 0.06 
gi|23956222 Actr3 ARP3 actin-related protein 3 homolog  0.61 N/A 
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Table 6. Complete set of tyrosine phosphorylated peptides quantitated by SILAC at 
the peptide level.   
The proteome is comprised of 382 non-redundant peptide sequences, corresponding to 














































     1.605 1.42 1.419 1.481 0.107 




     1.557 
 
1.6 1.621 1.593 0.033 
Abl2 Arg (Abelson 
tyrosine-protein 



























198 GySFTTTAER  0.864 0.877 0.871 0.009   0.894 0.894 N/A 
Actg1 Actin, cytoplasmic 
2 
53 DSyVGDEAQS
K 1.014 0.951 
 0.983 0.044      
Actn1  Alpha-actinin-1 193 HRPELIDyGK 
  





















1-like 2 isoform 3) 
68 IESPEGYyEEA
EPFDR 




     1.158  0.991 1.074 0.118 
Agfg1 AGFG1 (arf-GAP 








     0.941   0.941 N/A 
Anks1 ANKS1 (Ankyrin 







 4.24  4.24 N/A  6.81  6.81 N/A 
Anxa1 Annexin A1 21 FLENQEQEyVQ
AVK 
0.895 1.071 1.279 1.082 0.192 0.813 1.14 1.014 0.989 0.165 
Anxa 
2  
Annexin A2 199 ELyDAGVK   0.688 0.688 N/A      
238 SYSPyDMLESI
KK 
0.747 1.094 0.746 0.862 0.201  1.06 0.826 0.943 0.165 
275 LyDSMK  1.299 1.119 1.209 0.127      
316 SLyYYIQQDTK  0.992  0.992 N/A      
 203 
317 SLYyYIQQDTK  0.868  0.868 N/A 0.586 1.28  0.933 0.491 
Anxa5 annexin A5 92 LYDAyELKHAL
K 














      1.21  1.21 N/A 
Arhga
p42  
Arhgap42 342 EPIyTLPAIISK       1.45 1.166 1.308 0.201 
342 LWLEAMDGKE
PIyTLPAIISK 
     1.27  1.349 1.309 0.056 
759 LDTASSNGyQr
PGSVVAAK 
     1.25 1.27 1.355 1.292 0.056 
759 LRLDTASSNGy
QRPGSVVAAK 






































      0.87  0.87 N/A 
Axl Tyrosine-protein 
kinase receptor 
UFO isoform 1 
precursor 
697 KIYNGDYyR        0.855 0.855 N/A 
696 KIYNGDyYR      0.75 0.86 0.813 0.808 0.055 



















     0.603 0.64 0.619 0.621 0.019 








 2.66  2.66 N/A  3  3 N/A 
238 VGQGYVYEAA
QTEQDEyDTPR 
     1.748 1.69 1.542 1.66 0.106 
253 HLLAPGPQDIy
DVPPVR 
 2.218 1.611 1.915 0.429 2.822 2.7 2.221 2.581 0.318 
271 GLLPNQYGQE
VyDTPPMAVK 
1.841 2.081 2.01 1.977 0.123 2.101 2.17 2.391 2.221 0.151 
291 GPNGRDPLLD
VyDVPPSVEK 
     6.293 3.65 3.071 4.338 1.718 
310 GLLSSSHHSVy
DVPPSVSK 
     9.496 2.61 2.111 4.739 4.127 
331 EETyDVPPAFA
K 
1.791   1.791 N/A      
391 RPGPGTLyDVP
R 









  0.754 0.754 N/A      
Calm1 Calmodulin 100 VFDKDGNGyIS
AAELR 






















     1.154 1.08 1.148 1.127 0.041 
Cav-1 Caveolin-1 14 YVDSEGHLyTV
PIR 
     1.05 0.98 1.027 1.019 0.036 
Cbl CBL (E3 ubiquitin-
protein ligase C) 
672 IKPSSSANAIyS
LAARPLPMPK 
      0.94  0.94 N/A 








     0.664 1.25 0.936 0.95 0.293 
15 IEKIGEGTyGVV
YK 
     1.051 1 0.992 1.014 0.032 
15 IGEGtyGVVYK 0.913 1.055 0.969 0.979 0.071      
15 IGEGTyGVVYK
GR 
     0.995 1.01 1.026 1.01 0.016 
15 IGEGTYGVVyK
GR 




effector protein 1) 
349 HyTEMDAR 
 
 0.851  0.851 N/A      
Cdk2 Cdk2 (Cell 
division protein 
kinase 2 isoform 
1) 
15 VEKIGEGtyGVV
YK 0.949 1.055 0.958 
0.987 0.058 0.778 1.16 1.012 0.983 0.193 
15 VEKIGEGTyGV
VYK 
     1.021 1.04 1.022 1.028 0.011 
19 IGEGTYGVVyK
AK 
     1.012 1.06 1.035 1.036 0.024 





0.979 1.068 1.005 1.017 0.046 1.089 1.04 1.025 1.051 0.033 





     0.996 0.98  0.988 0.011 
Cdk17 Cell division 
protein kinase 17 
203 LGEGTyATVYK 1.122 1.055 1.064 1.08 0.036      
Cdk18 cell division 
protein kinase 18 
132 LGEGTyATVFK 
 









     0.949 0.98 0.986 0.972 0.02 








0.7 1.093 1.093 0.962 0.227 0.59 1.04 1.025 0.885 0.256 
Clf1 Cofulin-1 117 MIyASSK  0.89  0.89 N/A      
140 HELQANCyEEV
KDR 
     0.899 0.9 0.893 0.897 0.004 




0.825   0.825 N/A      
Cobll1 COBLL1 (cordon-




      0.99  0.99 N/A 




 1.07 0.97 1.02 0.071   1.123 1.123 N/A 















     0.807 0.9 0.817 0.841 0.051 














































 1.094 0.958 1.026 0.096      




     1.128 1.07 1.108 1.102 0.029 












 2.062  2.062 N/A  1.83 3.135 2.483 0.923 
361 LTDSKEDPIyD
EPEGLAPAPPR 




     2.887 1.51 1.565 1.987 0.78 
450 GFSSDTALySQ
VQK 
1.904 1.437  1.67 0.33 1.775 1.74  1.758 0.025 
Drp2 DRP2 
(dystrophin-
related protein 2) 











     0.934 0.99 1.123 1.016 0.097 
145 VYNDGYDDDN
yDYIVK 
1.118 1.11 1.24 1.156 0.073 1.161 1.17  1.166 0.006 
321 IYQyIQSR      1.043 1.03 1.036 1.036 0.007 








      1.18  1.18 N/A 












29 STTTGHLIyK 1.01 1.013 1.021 1.015 0.006 0.934 0.93 0.943 0.936 0.007 
141 EHALLAyTLGV
K 
0.919 0.943 0.879 0.914 0.032 0.942 0.96 0.912 0.938 0.024 















      0.91  0.91 N/A 








     0.709 0.94  0.825 0.163 
Eif4a1 Eif4a1 (Eukaryotic 
initiation factor 





      0.96 1.04 1 0.057 
 206 








     0.614 0.92 0.791 0.775 0.154 
Eno1 ENO1 (Enolase 1) 44 AAVPSGASTGI
yEALELR 
 0.933  0.933 N/A      
Epha2 EPHA2 (Ephrin 





     0.964   0.964 N/A 
595 TYVDPHTyEDP
NQAVLK 







0.870 0.884 0.924 0.893 0.028  0.88  0.88 N/A 
773 VLEDDPEATyT
TSGGK 
0.891 1.015 0.957 0.954 0.062 0.847 0.97 0.91 0.909 0.062 
773 VLEDDPEATyT
TSGGKIPIR 
      0.96 0.941 0.951 0.013 
Epha5  EphA5 (ephrin 








4.1-like protein 2) 
606 VDGDNIyVR 
 
     0.704 0.69 0.685 0.693 0.01 
Ephb3 EPHB3 (Ephrin 
type-B receptor 3 
precursor) 





0.798 0.887 0.783 0.112 0.554 0.89 1.02 0.821 0.24 
Ephb4 EPHB4 (Ephrin 




     0.748  0.925 0.837 0.125 







0.933 1.024 0.965 0.974 0.046 0.95 0.85 1.061 0.954 0.106 
614 EIDVSyVK 1.143 
 
0.99 1.089 1.074 0.078      
774 FLEENSSDPTy
TSSLGGK 
0.623 0.76 0.737 0.707 0.073 0.643 0.76 0.705 0.703 0.059 
774 FLEENSSDPTy
TSSLGGKIPIR 





LAP2 isoform 2) 
109
7 
RTEGDyLSYR      0.783 0.81 0.788 0.794 0.014 
109
7 
TEGDyLSYR 0.942   0.942 N/A 0.811 0.85 0.806 0.822 0.024 


































     0.703 0.73 0.789 0.741 0.044 
715 QEDGGVySSS
GLK 
 1.014  1.014 N/A  0.93  0.93 N/A 
Fgfr1 FGFR1 (growth 
factor receptor 1 
isoform 2) 
653 DIHHIDyYKK 0.904 1.082 1.308 1.098 0.202 0.897 1.01 1.067 0.991 0.087 
653 DIHHIDyYK       1.05  1.05 N/A 
Fhl2 FHL2 (Four and a 
half LIM domains 
protein 2) 




     0.91 1.11  1.01 0.141 
Flnb FLNB (Filamin-B) 250 SSTETCySAIPK       1.2  1.2 N/A 
 207 
2 
Flnc FLNC (Filamin-C) 266
6 
GASySSIPK  0.936  0.936 N/A      
268
4 
TPCEEVyVK  1.021  1.021 N/A      






      0.94  0.94 N/A 
349 RPALLNyENLP
SLPPVWEAR 















     0.985   0.985 N/A 
Gab1 Gab1 (GRB2-
associated 
binding protein 1) 
259 LTSVSGESSLy
NLPR 
     0.939 1.09 1.056 1.028 0.079 
407 DASSQDCyDIP
R 
1.276 1.482 1.154 1.304 0.166 1.283 1.24 1.1 1.208 0.096 
Gab2 GAB2 (GRB2-
associated-















      0.7  0.7 N/A 

















 2.044  2.044 N/A  2.2  2.2 N/A 















































216 GEPNVSyICSR      0.976 0.81 0.939 0.908 0.087 
216 GEPNVsyICSR  0.94  0.94 N/A      












409 IIEDNEyTAR  1.712  1.712 N/A      





132 VVQDTyQIMK 1.132 1.032  1.082 0.071      
216 VCEPCyEQLNK 
 



























      1.27  1.27 N/A 
159 SRPPYtDyVST
R 
      0.95  0.95 N/A 







     0.711 0.83 0.951 0.831 0.12 
27 IKEEyEVAEMG
APHGSASVR 
     0.73 0.92 1.007 0.886 0.142 
















      0.94  0.94 N/A 
Igf1r IGF1R (Insulin-









      0.79  0.79 N/A 
116
7 
DIYETDyYRK      0.838  0.932 0.885 0.066 
116
7 
DIYETDyYR       0.81  0.81 N/A 
116
8 
DIYETDYyR       0.83  0.83 N/A 
















     1.107 1.22 1.011 1.113 0.105 
671 SDDyMPMSPT
SVSAPK 




     0.881 1.03 0.92 0.944 0.077 























     1.012 0.95  0.981 0.044 
570 EVGDyGQLHK
TEVLLK 0.992 1.028 1.128 
1.049 0.07  1.03 1.216 1.123 0.132 
570 EVGDyGQLHK      0.931 0.9 1.068 0.966 0.089 
Kirrel 
1 





 1.575  1.575 N/A  1.48  1.48 N/A 
637 EEYEMKDPTN
GyYNVR 
     1.006 0.99 0.963 0.986 0.022 
657 AVLyADYR      0.944 0.89  0.917 0.038 
660 AVLYADyRAPG
PTR 







1.049   1.049 N/A      
679 LSHSSGyAQLN
TYSR 
     0.862   0.862 N/A 
685 LSHSSGYAQL
NTySR 
       0.848 0.848 N/A 
753 TPyEAYDPIGK 1.597 1.979 2.331 1.969 0.367      
 209 
756 TPYEAyDPIGK      1.205 1.38 1.485 1.357 0.141 
762 TPYEAYDPIGK
yATATR 
      0.65  0.65 N/A 
777 FSYTSQHSDyG
QR 










0.858 0.902 0.971 0.91 0.057      
10 IGyPAPNFK  0.782  0.782 N/A      






     0.951 1.02 0.866 0.946 0.077 











     4.122 2.49 2.338 2.983 0.989 
298 YyEPYYAAGPS
YGGR 
     1.513  1.703 1.608 0.134 
301 YYEPyYAAGPS
YGGR 
















WW and PDZ 
domain-
containing protein 
1 isoform c)  
373 IEDPVyGVYYV
DHINRK 









     3.321 2.83 2.562 2.904 0.385 
185 VADPDHDHTG
FLTEyVATR 









     2.72 2.15 2.06 2.31 0.358 
205 IADPEHDHTGF
LtEyVATR 


























































     1.111 0.9 1.03 1.014 0.106 









     
Met TeM (Tyrosine 100 SVSPTTEMVSN      0.426   0.426 N/A 
 210 





0.569 0.605 0.602 0.592 0.02  0.49  0.49 N/A 
Mllt4 Afadin  123
0 











1.623 1.596 1.429 1.549 0.105  1.53  1.53 N/A 
377 SESVVyADIR  1.856  1.856 N/A      
377 INKSESVVyADI
R 
     1.67  1.67 1.67 0 





 1.092  1.092 N/A      
149 CQyLQAEK  1.227  1.227 N/A  1.03  1.03 N/A 
140
7 






















and SH3 domain 
protein 1 





























      0.92  0.92 N/A 





  1.087 1.087 N/A 0.939 0.93  0.934 0.006 
Pabpc
2 





       1.104 1.104 N/A 
Pacsi
n2 
protein kinase C 
and casein kinase 
substrate in 













 0.923  0.923 N/A  0.95  0.95 N/A 
719 ISHSLySGIEGL
DESPTR 










1.335 1.183  1.259 0.107 1.425 1.22  1.322 0.145 
120
1 














      1.68  1.68 N/A 
998 DGRPLSPDHLE
GLyAK 
      1.47  1.47 N/A 





















     0.765 1.65 0.853 1.089 0.488 
754 EVSKySDIQR      0.88 1.03  0.955 0.106 
762 SLyDRPASYK       0.9  0.9 N/A 












     0.677 1.08  0.879 0.285 
















and LIM domains 












 0.393  0.393 N/A      
Pfn1 Profilin-1 129 CyEMASHLR        0.974 0.974 N/A 
Pgk1 PGK1 
(Phosphoglycerat
e kinase 1) 
196 ELNyFAK 
 





e mutase 1) 
92 HyGGLTGLNK      1.015 0.97 0.955 0.98 0.031 
92 HyGGLTGLNK
AETAAK 





alpha isoform 1) 
467 ESQGLyVVYNK
K 
1.083 1.052 1.095 1.08 0.022      
508 YSKEyIEK  1.289  1.289 N/A      
580 DQyLMWLTQK 
 








     1.254 1.25  1.252 0.003 








      1.2  1.2 N/A 















      0.79 0.71 0.75 0.057 
481 NNYALNTAATY
AEPyRPVQYR 
     0.765   0.765 N/A 
486 NNYALNTAATY
AEPYRPVQyR 











0.866 0.787 0.783 0.812 0.047 0.774 0.79 0.747 0.77 0.022 

















1.075 0.952  1.014 0.087      



























adhesion kinase 1 
isoform 1)  
5 AAAyLDPNLNH
TPSSSTK 




     1.094 0.53 1.247 0.957 0.378 
614 YMEDSTyYK      1.426 1.51 1.351 1.429 0.08 
614 YMEDSTyYKAS
K 
      2.21  2.21 N/A 
615 YMEDSTYyK      1.424 1.5 1.416 1.446 0.046 
615 YMEDSTYyKAS
K 






     10.24
9 













11 isoform a) 
62 IQNTGDyYDLY
GGEK 
1.018 1.014 0.922 0.985 0.054 0.981 0.99 0.893 0.955 0.054 
546 GHEyTNIK      0.913 0.95  0.932 0.026 
546 KGHEyTNIK 0.909 0.993 1.101 1.001 0.96      
584 VyENVGLMQQ
QR 
































1.135 0.992 1.126 1.084 0.08      
Ptrf PTRF 















     0.72 0.83 0.693 0.748 0.073 
Pxn Paxillin 88 YAHQQPPSPL
PVySSSAK 




     4.519 6.15  5.335 1.153 
118 AGEEEHV
ySFPNK 






















































      1.53 1.221 1.375 0.218 
Rasa1 Rasa1 (RAS p21 
protein activator 
1) 
451 EIyNTIR  1.192  1.192 N/A      





      0.94  0.94 N/A 
151 YSGGNYRDNy
DN 
     0.782 0.76  0.771 0.016 





     0.894 1.11 1.098 1.034 0.121 





  1.157 1.157 N/A   1.178 1.178 N/A 
Rpl15 60S ribosomal 
protein L15 
59 QGyVIYR 1.03 1.045  1.038 0.011  1.05  1.05 N/A 
81 GATyGKPVHH
GVNQLK 
















0.968 1.037 1.05 1.018 0.044 1.027 1.04 0.98 1.015 0.032 






     1.043 0.94 0.985 0.99 0.052 
Scarf2 Scarf2 (scavenger 






     0.737 0.71 0.716 0.721 0.014 
Sdc2 syndecan-2 
precursor 
201 APTKEFyA  1.094 1.302 1.198 0.147  0.99 1.147 1.069 0.111 
Sdc4 syndecan-4 
precursor  
197 KAPTNEFyA  1.075 1.115 1.095 0.028   1.084 1.084 N/A 













     1.139 0.98 1.001 1.04 0.086 
632 VPIVINPNAyDN
LAIYK 




















0.717 0.978 0.862 0.852 0.131 0.76 0.94 0.859 0.853 0.09 
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Shb SHB (SH2 
domain-
containing 
adaptor protein B) 
113 LDyCGGGGGG
DPGGGQR 
     0.961 0.81 0.838 0.87 0.08 
240 DKVTIADDySD
PFDAK 
     1.019 1.22 1.026 1.088 0.114 
240 VTIADDySDPF
DAK 
0.995 1.281 1.064 1.113 0.149 1.074 1.11 1.039 1.075 0.036 
268 AGKGESAGyM
EPYEAQR 
     0.969 1.06 0.976 1.002 0.051 
268 GESAGyMEPY
EAQR 
     1.132 1.11 1.085 1.109 0.024 
330 LPQDDDRPAD
EyDQPWEWNR 
0.9   0.9 N/A 1.273 0.85  1.061 0.299 
Shc1 SHC1 (SHC-
transforming 
































      1.1  1.1 N/A 
916 LAQDPyRLGH
DPYR 














424 LIEDNEyTAR      1.602 1.79 1.887 1.76 0.145 
444 WTAPEAALyG
R 




of tumorigenicity 5 
protein) 
498 ENPyEDVDLK 1.208 1.562 1.47 1.413 0.184      











     0.911 0.95 1.008 0.956 0.049 




isoform 3) iso 3 
705 YCRPESQEHP
EADPGAAPyLK 
      0.95 1.012 0.981 0.044 









0.556 1.275 1.241 1.024 0.406  1.08  1.08 N/A 








0.838 1.196 1.305 1.113 0.244 0.807 1.07 1.069 0.982 0.152 
Ston1 Stonin-1 2 MySTNPGSWV
TFDDDPAFQSS
QK 
 0.748  0.748 N/A  1  1 N/A 
Synrg Synrg (synergin 
gamma isoform 1) 
506 ASTDKyAVFK 
 













     3.123 2.65 2.432 2.735 0.353 
705 LALPTAALyGL
R 
2.548   2.548 N/A 3.538  3.018 3.278 0.368 






      2.2  2.2 N/A 
Tjp2 ZO2 (Tight 





















     >50   >50 N/A 
Tnk2 Ack (Activated 






 1.384  1.384 N/A  1.07  1.07 N/A 
533 KPTyDPVSEDP
DPLSSDFKR 
      0.96  0.96 N/A 
874 VSSTHyYLLPE
RPPYLER 
      0.92 0.863 0.892 0.04 
874 KVSSTHyYLLP
ERPPYLER 
       0.878 0.878 N/A 
875 KVSSTHYyLLP
ERPPYLER 
      1.16  1.16 N/A 














2.353 2.295 2.314 2.321 0.03 2.292 2.2 2.204 2.232 0.052 
Tns3 Tensin 3 584 KPSAPTPVQAY
GQSNySTQTW
VR 
     2.196 1.43  1.813 0.542 
Tjp1 ZO-1 (tight 
junction protein 












      0.34  0.34 N/A 
114
5 










     2.07 1.73  1.9 0.241 
Tln1 talin-1 26 TMQFEPSTMVy
DACR 
      0.95  0.95 N/A 
70 ALDyYMLR       1.01  1.01 N/A 
436 STVLQQQyNR        1.88 1.88 N/A 
436 KSTVLQQQyN
R 
     1.6 1.83  1.715 0.163 














     1.317 1.13  1.224 0.132 




















 1.944  1.944 N/A      
Vars Valyl-tRNA 
synthetase 
468 LHEEGVIyR 0.489   0.489 N/A      






822 SFLDSGyR      0.953 0.94 0.933 0.942 0.01 
Vim Vimentin 53 SLySSSPGGAY
VTR 
     1.007 0.89 0.97 0.956 0.06 







253 VIyDFIEK 0.691 0.817 0.753 0.754 0.063 0.693 0.77 0.766 0.743 0.044 
253 ETSKVIyDFIEK      0.657 0.73 0.672 0.686 0.039 
Wee1 Wee1-like protein 
kinase 
19 VGAAySLR 1.076   1.076 N/A 0.611 0.92 0.762 0.765 0.154 
170 AMDDPCSPQP
DyPSTPPHK 




family member 2) 
74 GSSGGyGPGA
AALQPK 
















      2.08  2.08 N/A 
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Table 7. Set of c-Src- induced tyrosine phosphorylated peptides quantitated by 






















  1.481 0.107 
Abi2 Abi2 (abl interactor 2) 207 TLEPVRPPVVPNDyVPSPT
R 
  1.593 0.033 
Abl2 Arg (Abelson tyrosine-protein 
kinase 2)  
439 LMTGDTyTAHAGAK 
 
5.333 0.616 5.51 N/A 
Ablim1 abLIM1 (actin-binding LIM 
protein 1 isoform 1) 
401 TSSESIySRPGSSIPGSPG
HTIYAK 
  1.46 N/A 
Anks1 ANKS1 (Ankyrin repeat and 
SAM domain containing 1) 
472 IQSSAPQEEEEHPyELLLT
AETK 
4.24 N/A 6.81 N/A 
Arhga
p32 
RICS (RhoGAP involved in the 
beta-catenin-N-cadherin and 
NMDA receptor signaling) 
2025 QSSMTVVSQyDNLEDYHS
LPQHQR 
  1.21 N/A 
Arhga
p42  
Arhgap42 342 EPIyTLPAIISK   1.308 0.201 
342 LWLEAMDGKEPIyTLPAIIS
K 
  1.309 0.056 
759 LDTASSNGyQrPGSVVAA
K 
  1.292 0.056 
Bcar1 p130Cas (breast cancer anti-
estrogen resistance protein 1) 
132 TQQGLyQAPGPNPQFQSP
PAK 
2.66 N/A 3 N/A 
238 VGQGYVYEAAQTEQDEyD
TPR 
  1.66 0.106 
253 HLLAPGPQDIyDVPPVR 1.915 0.429 2.581 0.318 
271 GLLPNQYGQEVyDTPPMA
VK 
1.977 0.123 2.221 0.151 
291 GPNGRDPLLDVyDVPPSV
EK 
  4.338 1.718 
310 GLLSSSHHSVyDVPPSVS
K 
  4.739 4.127 
331 EETyDVPPAFAK 1.791 N/A   
391 RPGPGTLyDVPR   2.858 0.37 
414 VLPPEVADGSVVDDGVyA
VPPPAER 
  1.59 N/A 
Crkl Crkl (crk-like protein) 251 RVPCAyDK   2.802 0.158 
Dcbld2 DCBLD2 (discoidin, CUB and 
LCCL domain-containing 
protein 2 precursor) 
710 TAGTQPHALVGTyNTLLS
R 
  1.971 0.511 
727 TDSCSSGQAQyDTPK 1.821 0.094 1.52 N/A 






  2.83 N/A 
314 TDSCSSGQAQyDTPK 2.062 N/A 2.483 0.923 
361 LTDSKEDPIyDEPEGLAPA
PPR 
  2.054 0.156 
408 LKEEGYELPYNPATDDyA
VPPPR 
  1.987 0.78 
450 GFSSDTALySQVQK 1.671 0.33 1.758 0.025 
Epha5  EphA5 (ephrin type-A receptor 
5) 
672 VLEDDPEAAyTTR   1.793 0.335 
Erbb3 HER3 (receptor tyrosine-
protein kinase erbB-3 
precursor) 
1325 SLEATDSAFDNPDyWHSR   1.222 0.11 
Flnb FLNB (Filamin-B) 2502 SSTETCySAIPK   1.2 N/A 
Gab1 Gab1 (GRB2-associated 
binding protein 1) 
407 DASSQDCyDIPR 1.304 0.166 1.208 0.096 





  1.749 0.199 





2.044 N/A 2.2 N/A 




  2.06 N/A 
Hck Hck (Tyrosine-protein kinase 
HCK) 
409 IIEDNEyTAR 1.712 N/A   
Hgs Hgs (Hepatocyte growth 
factor-regulated tyrosine 
kinase substrate isoform 2) 
216 VCEPCyEQLNK 
 
1.081 0.075 1.291 0.254 
Ick ICK (serine/threonine-protein 
kinase ICK) 
159 SRPPYTDyVSTR   1.27 N/A 




  1.28 N/A 
Kirrel 1 KIRREL 1 (Kin of IRRE-like 
protein 1 precursor) 
604 AIySSFKDDVDLK 1.575 N/A 1.48 N/A 
753 TPyEAYDPIGK 1.969 0.367   
756 TPYEAyDPIGK   1.357 0.141 
Lpp LPP (lipoma-preferred partner 





  2.983 0.989 
298 YyEPYYAAGPSYGGR   1.608 0.134 
301 YYEPyYAAGPSYGGR   1.846 0.416 
333 EAAyAPPASGNQNHPGM
YPVSGPK 
2.612 0.331   
Magi1 MAGI (membrane associated 
guanylate kinase, WW abd 
PDZ domain-containing 





  6.9 N/A 
Mapk1 ERK2 (Extracellular signal-
regulated kinase 2) 
185 VADPDHDHTGFLtEyVATR   2.904 0.385 
185 VADPDHDHTGFLTEyVAT
R 
  2.203 0.384 
Mapk3 ERK1 (Extracellular signal-
regulated kinase 1) 
205 IADPEHDHTGFLTEyVATR    2.31 0.358 
205 IADPEHDHTGFLtEyVATR   2.571 0.381 
Mpzl1 
 
PZR (myelin protein zero-like 
protein 1 isoform a) 
355 SPPSAGSHQGPVIyAQLD
HSGGHHSGK 
1.549 0.105 1.53 N/A 
377 SESVVyADIR 1.856 N/A   
377 INKSESVVyADIR   1.67 0 
Nedd9 Cas-L (Enhancer of 
filamentation 1 isoform 1) 
165 TGHGYVyEYPSR 1.82 N/A 1.546 N/A 
316 HQSFSLHHAPSQLGQSG
DTQSDAyDVPR 
  1.226 0.025 
Pard3 PARD3 (partitioning defective 
3 homolog isoform 3) 





defective 3 homolog B) 
953 GLVDYATAVTGPVHDMDD
DEMDPNyAR 
  1.68 N/A 










92 HyGGLTGLNKAETAAK   1.479 N/A 
Pik3r2 PIK3R2 (phosphatidylinositol 
3-kinase regulatory subunit 
beta) 
458 SREYDQLyEEYTR   1.252 0.003 
599 INEWLGIKNETEDQySLME
DEDALPHHEER 
  1.2 N/A 
Ptk2 
 
FAK (focal adhesion kinase 1 
isoform 1)  
5 AAAyLDPNLNHTPSSSTK 1.848 0.302   
614 YMEDSTyYK   1.429 0.08 
614 YMEDSTyYKASK   2.21 N/A 
615 YMEDSTYyK   1.446 0.046 





  9.627 0.88 
614, 
615 
YMEDSTyyKASK   8.658 1.49 
Ptpra PTPRA (receptor-type 
tyrosine-protein phosphatase 






1.399 0.035 1.359 0.045 
Pxn Paxillin 88 YAHQQPPSPLPVySSSAK   3.269 0.114 
88 YAHQQPPsPLPVySSSAK   5.335 1.153 
118 AGEEEHVySFPNK   3.046 0.87 




C3G (Rap guanine nucleotide 
exchange factor 1) 
571 HMLAYMQLLEDySEPQPS
MFYQTPQSEHIYQQK 
2.854 0.168 3.204 0.223 
Raph1 Raph1 (Ras association 
(RalGDS/AF-6) and pleckstrin 
homology domains 1) 
603 SyTSLMPPLSPQTK   1.375 0.218 
Rpl15 60S ribosomal protein L15 81 GATyGKPVHHGVNQLK 1.302 N/A   
Shc1 SHC1 (SHC-transforming 
protein 1 isoform a) 
423 ELFDDPSyVNIQNLDK 
 
1.392 0.116 1.365 0.104 
Src proto-oncogene tyrosine-
protein kinase Fyn isoform b 
424 LIEDNEyTAR   1.76 0.145 
444 WTAPEAALyGR 
 
  1.311 0.072 
St5 
 
St5 (Suppression of 
tumorigenicity 5 protein) 
498 ENPyEDVDLK 1.413 0.184   
Tenc1 Tensin2 483 GPLDGSPyAQVQR   2.735 0.353 
705 LALPTAALyGLR 2.548 N/A 3.278 0.368 
770 VGEEGHEGCSyAVCSEGR 2.313 N/A 2.864 0.176 
791 YGHSGYPALVTYGyGGAV
PSYCPAYGR  
  2.2 N/A 
Tjp1 ZO-1 (tight junction protein 
ZO-1 isoform 2) 
1177 YRPEAQPySSTGPK   1.9 0.241 
Tln1 talin-1 436 STVLQQQyNR   1.88 N/A 







1.44 N/A 1.379 0.1 
Tnc Tenascin 1341 LIQtIFTTIGLLyPFPR   >50 N/A 
Tns1 Tensin 1 1477 HAAyGGYSTPEDR   2.096 0.057 
1480 HAAYGGySTPEDR   2.27 N/A 
1558 AGSLPNyATINGK 2.321 0.03 2.232 0.052 
Tns3 Tensin 3 584 KPSAPTPVQAYGQSNyST
QTWVR 
  1.813 0.542 
Trp53 p53 (cellular tumor antigen 
p53 isoform a) 
228 HSVVVPYEPPEAGSEYTTI
HyK 
  1.224 0.132 
Ttyh2 TTYH2 (Protein tweety 
homolog 2) 














Table 8. Combined list of Src substrates (140) from prior proteomics studies. 
 
Actin, alpha skeletal muscle (Y93)  
Alpha enolase (Y43) 
Alpha-1 catenin (Y619) 
Anaphase promoting complex subunit 2 (Y825) 
ANKS1/Odin (Y471) 
Annexin A2 (Y23, 237) 
ATP citrate lyase 
ATP synthase 
A-kinase anchor protein 8 
Arsenate resistance protein ARS2 
Ataxin 2 related protein 






Cdc42 GTPase-inhibiting protein 
CDV3A/B (Y213) 
Chaperonin 
Chromosome 20 open reading frame 77 
Clathrin heavy chain (Y899) 




Cytidine 5’-triphosphate synthase 
Cytoplasmic FMR1 interacting protein 1 
Cytosolic phospholipase A2 
 221 
DOK1** (Y314,361,408) POSITIVE 
DNA damage-binding protein 1 (Y718) 
Double-stranded RNA-binding protein Staufen homolog (Y404) 
eEF1A1/2 (Y29,141) 
eEF2 
Elongation complex protein 3 (Y329) 
Ephrin receptor A2 
Ephrin receptor B1 
Ephrin receptor B3 
Ephrin receptor B4 
Eps15 
Eukaryotic translation initiation factor 3, subunit 4 
Eukaryotic translation initiation factor 3, subunit 6-interacting protein (Y72) 
Eukaryotic translation initiation factor 3, subunit 8 
Ewing sarcoma breakpoint region 1 
Ezrin 
FAK* (Y576,577) POSITIVE 
Fibronectin POSITIVE 
FUSE binding protein* 
FUSE binding protein 2 
FUS interacting protein (serine/arginine-rich) 1 
FUS/TLS oncogene 
Fyn 
Fyn binding protein 
GAPDH (Y315) 
GTP-binding protein Ran/TC4 
GEF eIF-2B 
GIT1 (Y554) POSITIVE 
G6PDH X (Y400) 
GMP synthetase 


















Lipoma preferred partner, LPP (Y245, 301,302) POSITIVE 
Map kinase Erk2 POSITIVE 
Moesin 
Myosin heavy chain IX 
NCK1 (Y105) 
NEFA-interacting nuclear protein 
Nice-4 
Non-muscle myosin chain 10 
OTUd4 (Y458) 
p190 RhoGAP (Y943) 
p120 catenin (Y96, 228) 
p130cas* (Y253, 271, 414) POSITIVE 
p120(ctn) (Y96) 
Paxillin* (Y118) POSITIVE 
PDGF receptor beta 
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Phospholipase C, gamma1 
PI3K regulatory subunit, p85a** (Y467) 
PI3K regulatory subunit, p85b POSITIVE 
Plectin 1 (Y3250) POSITIVE 
Polymerase I and transcript release factor (Y310,Y158) 
Procollagen, type III, a1 
Prolyl endopeptidase (Y71) 
Proteasome 26S non-ATPase subunit 2 
Proteasome activator subunit 3 
Proteasome subunit beta type 5 precursor (Y165) 
PSMA2 (Y56,75) 
Pyruvate kinase 3 





RNA binding motif protein 4B 
RNA binding motif 10 
SAK269 (Y632,638) 
Septin-2 (Y17) 
Seryl-aminoacyl-tRNA synthetase 1 
SHC1 (Y423) POSITIVE 
SHIP2 (Y987) 
SHP-2* (Y62) 
Similar to Zinc finger CCCH-type domain-containing protein 6 
Splicing factor, arginine/serine-rich 3 (Y32) 
Splicing factor, arginine/serine-rich 9 
Splicing factor 3B subunit 2 
Splicing factor proline/glutamine-rich 
Src** (Y418,438) POSITIVE 
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Stress-induced phosphoprotein 1 
Talin 1 (Y26, 70) POSITIVE 
Thioredoxin reductase 1, cytoplasmic (Y131) 
Threonyl-tRNA synthetase 
Thyroid hormone receptor associated protein 3 
Tight junction protein ZO-1 (Y1164, 1521) 
Trk-fused gene 




U1 snRNP 70 kDa (Y126) 
Valosin containing protein 
VASP (Y39) 
Vimentin (Y52) POSITIVE 
Vps35 
Xanthine dehydrogenase 




(Proteins with * , were identified in two prior reports; proteins with ** , were identified in 










Matrin 3 was identified in our first SILAC and LC-MS/MS experiment performed 
to identify and quantify tyrosine-phosphorylated proteins upon c-Src chemical rescue. 
Matrin 3 was identified among the group of proteins that were eluted after boiling the 
beads used for enrichment of tyrosine-phosphorylated proteins by immunoprecipitation 
with antiphosphotyrosine antibody. By mass spectrometry, matrin 3 showed an increase 
in its tyrosine phosphorylation level upon c-Src chemical rescue with a Heavy/ Light 
ratio of 1.79 (Std. Dev.: n/a) (Table 3). When the two sets of raw data obtained from both 
the phenyl-phosphate and boiled beads elutions were combined and searched again, 
matrin 3 showed a Heavy/ Light ratio of 1.71 (Std. Dev.: n/a) and the score of the matrin 
3 peptide was 35. Matrin 3 was identified by the identification of the peptide LAEPYGK. 
Matrin 3 was detected in MSQuant data analysis software, but not in Scaffold when the 
same Mascot data file was used as protein-peptide data file. The lists of proteins 
identified with 95% and 85% confidence by Scaffold are shown in Appendix 1 Tables 1 
and 2. Matrin 3 was not found by Scaffold with 50% confidence either but, as described it 
was detected in MSQuant data analysis softwar and further manual annotation of MS/MS 
spectra confirmed the sequence. The mass spectrometry data evidencing the identification 








Appendix 1 Figure 2 (MS). The experiment detailed in this appendix was 
performed to validate the results obtained in the SILAC experiment. 
Unlike the other proteins selected for validation, it was difficult to detect 
phosphorylated matrin 3, despite the fact that matrin 3 is tyrosine phosphorylated. Tensin 
phosphorylation was also hard to detect but increasing the amount of lysate used in the 
immunoprecipitation was sufficient to overcome the challenge. The methodology that 
worked for visualization of phosphorylation of C3G, vimentin, GSK-3β, nucleophosmin 
and, ultimately tensin, did not reveal the expected bands for matrin 3 phosphorylation, 
and therefore some extra steps were added to the process. We have only one biological 
replicate of this experiment that showed the appearance of phosphorylated matrin 3, 
although the experiment was performed 5 times (and an additional attempt to repeat it 
recently). This led to data of modest quality revealing a borderline result about matrin 3 
phosphorylation before and after c-Src chemical rescue, which we explain in detail here, 
and recommend that it be interpreted with caution. We believe the limitations of the assay 
for matrin 3 have led to the difficulties that will be next described.  
The data obtained about matrin 3 phosphorylation (IP with matrin 3 antibody and 
Western blot with anti-phosphotyrosine antibody) is complex and ambiguous since 
multiple blots were obtained from the experiment and they show results by eye that are 
ambiguous is some cases and inconsistent in one particular blot. All of them have caveats 
I will thoroughly describe. The different blots obtained through the experimental process 
used to detect matrin 3 phosphorylation indicate either a borderline increased intensity by 
eye (and we say this with reservations we thoroughly describe here), a lack of response or 




Appendix 1 Figure 2. MS spectrum showing the increase in intensity between the “light” and the 
“heavy” (isotopically labeled) forms of the peptide (LAEPYGK) from matrin 3. 
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describe here in detail). We tried employing the Image J methodology to measure the 
intensity of the bands but the high background and the non-optimal signal-to-noise made 
this very difficult in some cases and sometimes reflected changes that differ from what 
one can observe by eye. I believe one of the reasons for this is that the program needs an 
area of measurement that contains a substantial amount of background to be taken into 
account for its calculations. The program seems to work optimally when the band is clear 
and the signal relatively strong and the background is clear and homogeneous. In our 
case, having to choose such a large area makes it difficult to select areas where there is no 
heterogeneous background that affects the calculations. In addition, we observe that the 
methodology used to obtain the images may an effect in the quantitation. We used 
different methodologies to obtain the images and we believe the best images we obtained 
resulted from scanning the films. We believe we were successful in obtaining 
representative quantitation in some cases, even though other caveats were present. Some 
of the evidence in the experiment supports the mass spectrometry data, but some 
concerns are present. The few observations that, at least by eye (and not taking into 
consideration quantitations we believe are not representative of what can be observed by 
eye), don’t show an increase in intensity (and maybe even a decrease), also present 
caveats. However, we must warn about the limited quality of the evidence due to the fact 
that this assay was particularly challenging to validate matrin 3 as a potential c-Src target. 
Some extra steps had to be added to the experimental process for visualization of matrin 
3 phosphorylation and they led to some concerns and limitations. I believe the possible 
increase in phosphorylation of matrin 3 upon c-Src rescue is borderline and data is not 
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completely unequivocal/ convincing. Therefore, further validation through alternative 




The general methods were described in Chapter 2 but additional details are 
provided here.   
After imidazole treatment (10 mM, 5 minutes), cells were washed once with PBS 
and lysed for 30 min at 4ºC in RIPA buffer (Tris-HCl 50 mM, pH 7.4, Na-deoxycholate 
0.25%, NaCl 150 mM, EDTA 1mM, NP-40 1%, Na3VO4 1 mM, NaF 1 mM, PMSF 1 
mM), and centrifuged at 13,000 x g at 4ºC for 15 minutes. The supernatants were 
collected for immunoprecipitation.  
The supernatants were pre-cleared with protein G agarose. The precleared lysates 
were mixed with the antibody and incubated for 1 hour at 4ºC. Protein G agarose beads 
were then added to the mixture that was subsequently incubated overnight at 4ºC. 
Antibodies were used at the recommended concentration provided in the manufacturer’s 
instructions. The protein G agarose beads were subsequently washed three times with 
RIPA buffer, resuspended in SDS loading buffer with β-mercaptoethanol and boiled for 5 
minutes at 95ºC. The eluates were analyzed by SDS-PAGE and Western blotting.  
The antibodies used were obtained as follows: Phosphotyrosine: 4G10 
(phosphotyrosine WB) from Upstate Biotechnology. In most cases HRP-conjugated anti-
phosphotyrosine antibody was used. Other times (i.e. D388N/ SYF cells) we used non-
HRP-conjugated anti-phosphotyrosine antibody. Matrin 3: sc55724 (Matrin IP and WB) 
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from Santa Cruz Biotechnology. Western blots of experiments done with the rescuable 
cell lines were attempted 5 times (plus a recent attempt with non satisfactory loading 
control and poor visualization of matrin 3 phosphorylation), but we only obtained one 
experimental repeat where we believe we detected phosphorylated matrin 3 (Figure 28).  
The initial experiment (Appendix 1 Figure 3.A) was performed following the standard 
protocol described in Chapter 2. We observed signal in the first attempt but the blot 
presented bands that we suspect correspond to non-specific binding (Appendix 1 Figure 
3.A), making the interpretation unreliable, as we will explain in the result section. The 
next three repeats/ biological replicates (Appendix 1 Figure 3.B-D) were performed with 
slight modifications to the protocol, but these Western blots using anti-phosphotyrosine 
antibody (4G10) showed no signal in these three experimental repeats.  
In the fifth matrin 3 immunoblot experiment, we included some additional steps 
to be able to visualize phosphorylation. After incubation with the mouse HRP-conjugated 
4G10 anti-pTyr antibody, we developed the blot and, as before, no phosphorylation was 
observed (Appendix 1 Figure 6). A sandwich reaction then had to be performed 
(Appendix 1 Figure 7-8): We did a second incubation with an HRP-conjugated anti-
mouse secondary antibody. The first incubation with the secondary antibody (sandwich 
reaction) was performed at 4ºC for approximately one hour as indicated in my lab 
notebook. After washing the membrane, we developed the membrane using SuperSignal 
West Femto chemiluminescent substrate (Pierce) diluted 1 to 10 in water (Appendix 1 
Figure 7-8).  Even though there is the concern that the process of the sandwich reaction 
may lead to non-specific binding, it is actually a perfectly acceptable technique to 
increase the signal in a Western blot. Also, the first sandwich reaction was performed for 
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a short time (4ºC for one hour as I indicated in my notebook, but the exact period of time 
was not recorded), and exposed for a very short time (seconds to a few minutes).  We 
used a high concentration of substrate for development of the film (1 to 10 femtomolar 
ECL), which can make the blots very dirty with high background. This is expected and 
does not necessarily represent a problem but makes the washing and the visualization 
very difficult.  
We then washed the membrane again and developed it with 1 to 10 femtomolar 
ECL solution. I have a blot (Appendix 1 Figure 9) with a clearer background than those 
showing in Appendix 1 Figure 7-8 (Even though blots corresponding to Appendix 1 
Figure 8 and Appendix 1 Figure 9 may have been inadvertently switched in my lab 
notebook, the pattern of the background suggests that the order of the two blots is as the 
presented here). 
The membrane was then washed and incubated again with anti-mouse secondary 
antibody. This second sandwich reaction was performed at 4ºC overnight (as indicated in 
my notebook although the exact period of time was not recorded). After washing the 
membrane, we developed the membrane using SuperSignal West Femto 
chemiluminescent substrate (Pierce) diluted 1 to 2 in water (Appendix 1 Figure 9). A 
sandwich reaction may lead to reduced specificity and artifacts I am not aware of, but it 
was the only way I could visualize phosphorylation of matrin 3.  The resulting blot was 
very dark but could be scanned using different methodologies (Figures 28 and 
Appendix 1 Figure 10-12). After the second sandwich reaction, we also had problems 
with what we believe is loss of signal (or “clearing”) that will be described in the Results 
section.  
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It should be noted that baseline values between rescuable and non-rescuable cells 
may not be the same due to subtle alterations in the cell passage number, growth 
conditions, and/or immunoblot conditions. 
 
 The images were acquired through different methodologies: They were scanned 
with or without the help of a halogen desk lamp that was carefully placed so that it 
homogeneously illuminated the blot or region of interest. Some of the films we also 
scanned through translucent scanning, which provided extra illumination to dark blots.. 
The blots were also placed on top of a light box and pictures were taken with a low-
resolution camera in some cases (to get a whole image of a dark blot) or with a Cyber-
shot Sony camera. We also took pictures with an Imager  (Gel Logic 100, Imaging 
system) and a white lamp diffuser on top of a UV lamp (Fotodyn lamp). We used a white 
light diffuser on top of the UV light to attempt homogenous illumination. Images were 
acquired using Carestream MI GL100. Different images were obtained for different blots 
depending on the characteristics of the blots. 
 Images were quantified using Image J with these settings (Set measurements: 
Area/ Mean Gray Value/ Integrated density; Set Scale: 600 pixel; background was either 
not subtracted or subtracted with rolling ball radious of 50 or 100, depending of the 
image).  If the orginal image had color they were converted to gray scale by changing the 





3.1. First attempt 
 
The first attempt to validate matrin 3 through immunoprecipitation and 
immunoblot was initially considered successful even though the anti-phosphotyrosine 
immunoblot was dark and some unexpected bands appeared that we couldn’t initially 
explain (Appendix 1 Figure 3.A). However, we later realized that it might not be reliable 
due to the following reasons: I believe these bands correspond to a significant amount of 
non-specific proteins pulled down in the immunoprecipitation experiment that are being 
co-purified or retained with matrin 3. I believe the signal from these non-specific proteins 
in the anti-phosphotyrosine immunoblot is quite prevalent and may overlap/ interfere 
with any band that might show matrin 3’s phosphorylation. This was concluded after we 
observed some evidence for these non-specific proteins as a strong band at around 60 
kDa in the immunoprecipitation lane as well as in the lysate lane (to which no antibody 
was added). Initially it was thought that this band corresponded to the antibody heavy 
chain (55 kDa) but obviously that cannot appear in the lysate, making us concerned that 
that band represented a non-specific protein carried in the immunoprecipitation. The fact 
that the band appears at the same molecular weight in the immunoprecipitation lane and 
the lysate lane reaffirm the concern. Also, I can clearly see the two bands corresponding 
to the heavy chain at molecular weight of 50 kDa in the lanes corresponding to the lysates 
subjected to immunoprecipitation. Also, the pattern of bands observed in the lysate lane 
in the anti-phosphotyrosine immunoblot clearly resembles the pattern of bands observed 
in the lanes corresponding to immunoprecipitation, adding weight to the conclusion that 





Appendix 1 Figure 3. Repeats of the immunoprecipitation- Western blot experiments to validate the 
mass spectrometry results that revealed matrin 3 as a potential c-Src substrate.  
The control and imidazole treated cells were lysed and immunoprecipitation was performed using 
matrin 3 antibody. Western blot against matrin 3 was used as a loading control and Western blot against 
phosphotyrosine was used to detect tyrosine phosphorylation. A. Initial attempt where phosphorylation was 
observed at molecular weights of 60 kDa and 120 kDa, making it difficult to discern whether the top band 
corresponds to matrin 3 and or a cluster of proteins that was non-specifically bound to matrin 3 and are 
phosphorylated. B, C, and D. These biological replicates all successfully led to satisfactory loading controls 
(Matrin 3 western blot) but tyrosine phosphorylation of matrin 3 was not detected. 
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replicate we performed. In the loading control experiment (immunoprecipitation and 
Western blot with matrin 3 antibody) we observed two major bands that we believe 
correspond to matrin 3. One was located at about 150 kDa and the other one at 110-120 
kDa. The band that appeared in the phosphotyrosine immunoblot was considered as 
matrin 3, since it corresponds (has the approximate molecular weight) to the lower band 
observed in the loading control. However, we then realized that this band in the 
antiphoshotyrosine Western blot is at the same molecular weight as a strong band in the 
lane corresponding to the lysate. This was an indication that this band is also very likely a 
non-specific protein or group of proteins that was pull-down with matrin 3 during the 
immunoprecipitation the same way we described for the band at 60 kDa. It has actually 
been observed that these two strong bands usually appear at the approximate molecular 
weight of 60 kDa and 120 kDa when a whole lysate is blotted using anti-phosphotyrosine 
antibody (see Figure 23).  
In addition to the concern about non-specific binding, our initial experiment may 
have uneven loading. The amount of increase that can be observed in the band at 120 kDa 
between the control and treatment immunoprecipitated lysates is very similar to the 
amount of increase observed in the band at 60 kDa between the control and treatment 
immunoprecipitated lysates, suggesting that it might not be a real increase but a slight 
difference in loading. The loading control (immunoprecipitation with matrin 3 antibody 
and Western blot with matrin 3 antibody) is however satisfactory.  
Another concern has to do with the molecular weight of the band initially thought 
to be matrin 3. The immunoprecipitation effectively retained the matrin 3 protein, as can 
be observed in the immunoblot against matrin 3 after the immunoprecipitation with 
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matrin 3 antibody (loading control). As described, in this control blot, matrin 3 can be 
observed in this blot as a doublet of two strong bands (a stronger upper band and a lower 
band that is actually a doublet itself). However, in the anti-phosphotyrosine immunoblot, 
I only can see a band corresponding approximately to the lower molecular weight where 
the lower doublet was observed. This makes us question even more whether this band is 
really matrin 3, because one might expect both bands to be detected (band at 120 kDa and 
doublet at 110 kDa), especially since the top band is the strongest one in the matrin 3 
immunoblot. 
 
3.2. Three following unsuccessful attempts 
 
When I tried to reproduce this experiment (3 times)  (Appendix 1 Figure 3.B-D), 
I could always detect matrin 3 in the matrin 3 immunoprecipitation and matrin 3 
immunoblot. However, I could not detect phosphorylation in the lanes corresponding to 
immunoprecipitated lysate in the blot against phosphotyrosine. I had two positive 
controls in most of the membranes (the lanes corresponding to the lysate and the lanes 
corresponding to the supernatant after immunoprecipitation) and in one case (Figure 3.C) 
phosphorylation was observed in these lanes, indicating that the antibody and 
immunoblot protocol were correct. I consider these three repeats as unsuccessful as they 
do not provide any interpretable results. These three unsuccessful repeats further cause us 
to question the results of the initial experiment. It is unlikely that I detected 
phosphorylation in the first attempt but not in the next three attempts when I was 
optimizing the technique. These three unsuccessful attempts lead us to believe that, for 
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some reason, matrin 3 phosphorylation is very hard to detect. This may be due to the high 
molecular weight of the matrin 3 protein, which may contribute to inefficient transfer but 
this is unlikely because the same assay has been used successfully to validate targets with 
very similar molecular weight. Matrin 3 might not be highly phosphorylated (as I 
observed for tensin, for example), although it has several tyrosine phosphorylation sites.  
 
3.3. Final attempt- R390A/ SYF cells 
 
In our final repeat, I incorporated several steps to be able to detect 
phosphorylation. These steps are described in the methods section and represented in 
Appendix 1 Figure 4. After I followed these steps, I could observe bands at the correct 
molecular weight for the first time in the anti-phosphotyrosine immunoblot after matrin 3 
immunoprecipitation. 
 
3.3.1. Matrin 3 loading control (R390A/ SYF cells) 
 
The loading control (matrin 3 immunoprecipitation and matrin 3 immunoblot) is 
satisfactory (Appendix 1 Figure 5). The amount of sample loaded for this matrin 3 blot 
and the anti-phosphotyrosine blot is exactly the same. I performed one 
immunoprecipitation with lysate coming from treated cells and another one with lysate 
from untreated cells. The sample from each immunoprecipitation was divided in two, 
regardless of the total volume resulting from the immunoprecipitation. One of the gels 





Appendix 1 Figure 4. Workflow of the process to obtained the different blots in the last attempt to 





Appendix 1 Figure 5. Matrin 3 loading control of the final experimental repeat in the rescuable cell 
line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
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Western blot against matrin 3 was used as a loading control. A. Images and quantitations obtained by 
scanning the image. B. Images and quantitations obtained by translucent scanning. Two blots 




blotted against phosphotyrosine.  I loaded exactly the same volume of samples for both 
the matrin 3 immunoblot and the phosphotyrosine immunoblot (35 µl for untreated cells 
and 39 µl for treated cells). Special attention was paid to the loading process for accuracy 
and equal loading for both blots. However, because the loading control and the 
experiment are on separate gels, it is theoretically possible that there could be a manual 
mistake in the loading of the gels. However, the careful process of loading makes this 
unlikely. 
The matrin 3 loading control blot always reveals an upper more intense band 
around 160 kDa, a doublet around 110 kDa, and antibody chains around 55 kDa. We 
observed no change in intensity in the upper more intense band (if any, I think a very 
slight decrease in intensity may be observed by eye in the right blot corresponding to a 
shorter exposure time). The doublet seems a bit more intense in the treated R390A/SYF 
cells, but it is also true that the band is somewhat narrower in the treated R390/SYF cells, 
and this could account for/ justify the minimal increase in intensity in the doublet bands. 
Overall, I consider the loading control satisfactory. We quantitated the upper bands in the 
blots and obtained what we believe are representative values from the two different 
exposures from images obtained from translucent scanning (1/ 1 and 1/1.03, no 







3.3.2. Anti-phosphotyrosine Western blot before the sandwich reaction 
 
Before the sandwich reaction (Appendix 1 Figure 6), the anti-phosphotyrosine 
immunoblot only showed bands in the lanes corresponding to the lysate and the 
supernatant, as we had observed in previous repeats. The image was obtained from 
scanning the blot. 
 
3.3.3. Anti-phosphotyrosine Western blot after the first sandwich reaction 
 
Blots shown in Appendix 1 Figures 7-12 correspond to the same biological 
replicate, where the blot was subjected to different additional steps in a sequence that is 
described here (Appendix 1 Figure 4). After the additional steps described in the 
methods, bands appeared in the lanes corresponding to the immunoprecipitated lysates. 
The bands in that blot appear at the correct molecular weight for matrin 3, based on 
where it was observed in the matrin 3 immunoblot (Appendix 1 Figure 5). In addition, 
both the upper more intense band and the lower less intense doublet show in the blot, as 
opposed to our first attempt (Appendix 1 Figure 3.A) where the upper band was not 
detected.  
Appendix 1 Figure 7 shows the appearance of the blot after the first sandwich 
reaction and the development of the blot as indicated in the methods. The bands 
corresponding to matrin 3 are indicated with white arrows. We will mostly consider the 
upper band, because the matrin 3 immunoblot had a more intense band at this molecular 







Appendix 1 Figure 6. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. R390A/ 
SYF cells. Anti-phosphotyrosine Western blots before first sandwich reaction 
 
Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 





Appendix 1 Figure 7.1. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. R390A/ 
SYF cells. Anti-phosphotyrosine Western blots after the first sandwich reaction. 
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Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction. First exposure. A. 
Scans of the entire blot. The one in the left represents the intact scan and the one in the right the scan after 
the indicated adjustments in the levels. B. Image obtained by translucent scanning. C. The panel bellow 
shows a scan taken with the help of a lamp and the gray version of it after different adjustments in the 
levels. Quantitation of the bands corresponding to matrin 3 phosphorylation from the original image was 
attempted using different setting in Image J and results are shown. The arrows show bands of interest. 
White arrows indicate bands corresponding to matrin 3 phosphorylation. Red arrows indicate bands that 
show an increase in their intensity.  Green arrows indicate bands that show a decrease in their intensity. 




Appendix 1 Figure 7.2. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. R390A/ 
SYF cells. Anti-phosphotyrosine Western blots after the first sandwich reaction (cont.) 
 
Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction. First exposure. D. 
Representative pictures taken with a camera and the help of a light box. Different pictures correspond to 
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different adjustment in the brightness in the camera. E. Representative pictures bellow were taken with an 
imager and a lamp. Different pictures correspond to different adjustment in the light aperture.The arrows 




scanning the blot with translucent scanning, scanning the area of interest with the help of 
a halogen lamp (Appendix 1 Figure 7.1), taking a picture with the help of a light box, as 
well as representative pictures obtained with the imager, a UV lamp and a white light 
diffuser (Appendix 1 Figure 7.2). Quantitation was attempted from the scanned image 
and the image obtained by translucent scanning but the low signal, and possibly the 
heterogeneous background, made this impossible. 
Quantitation was performed from the image obtained scanning the area of interest 
with the help of a halogen lamp and the result is shown. However, due to the low signal 
and heterogeneous background we believe the quantitation is not representative of what 
can be observed by eye. A series of quantitation plots are shown and reveal that the 
characteristics of the blot are not optimal for quantitation. 
 
Limitations:  
One issue worth mentioning is that the sandwich reaction should lead to a stronger 
intensity of the bands. Indeed, I see new bands appearing in the immunoprecipitation  
lanes that did not appear before the sandwich reaction. However, the intensity of the 
bands that were present in the lysate and the supernatant lanes do not increase in intensity 
the same way the bands that appear in the immunoprecipitation lanes do for unknown 
reasons. We speculate that the fact that the phosphorylation signal in the lysate and 
supernatant may be already saturated may contribute to this observation.  
Another concern is that multiple bands appear after the sandwich reaction. This 
could mean that the sandwich reaction may have led to non-specific binding of one of the 
antibodies used in the immunoblot to a contaminant protein of low abundance in the 
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samples. However, a sandwich reaction is a perfectly acceptable technique to increase the 
signal in a Western blot. Also, the conditions under which it was performed included a 
short incubation with the anti-mouse HRP-conjugated secondary antibody (4ºC for 
approximately one hour as I indicated in my notebook, but the exact period of time was 
not recorded) and very short exposure time (seconds to a few minutes). The short 
incubation period and exposure time should minimize the appearance of non-specific 
bands. A sandwich reaction may lead to reduced specificity and artifacts, but allowed us 
to visualize phosphorylation of matrin 3. 
Also, in this particular blot, I see that some of the bands that appear below matrin 
3 show an increase in intensity (red arrows) upon treatment of the cells with imidazole. 
The careful handling of the loading and the satisfactory loading control (Appendix 1 
Figure 5) should be a good indicator of equal loading in the phosphotyrosine blot. 
However, the fact that this increase in intensity in some lower bands may be similar to a 
borderline possible increase that may be observed by eye in the band corresponding to 
matrin 3, suggests that there is a possibility of a human error in loading. This would mean 
that a possible increase in intensity in the band corresponding to matrin 3 could be a 
result of imprecise loading. However, there could be other explanations for this 
observation. Maybe the lower bands are proteins that are retained in the 
immunoprecipitation non-specifically and they increase their tyrosine phosphorylation 
level upon c-Src rescue. It is worth mentioning though that there are bands that show a 
decrease in intensity (green arrows), which would go against the argument of an overall 
imprecise loading favoring a possible stronger band of matrin 3 phosphorylation in the 
case of cells treated cells. Theoretically, there could still be a decrease even if there was 
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imprecise loading. c-Src rescue could lead to a decrease in phosphorylation of that 
protein that is pulled down non-specifically with matrin 3. This decrease could still be 
apparent even after having loaded more immunoprecipitated lysate from treated cells. 
However, the described measures taken for precise loading and the satisfactory loading 
control make the possibility of imprecise loading unlikely.  
Also, these changes in intensity of the lower bands of the blot upon imidazole 
treatment are not consistent among all the blots obtained along the process followed in 
this experiment, as I will describe (and this is also the case of the bands corresponding to 
matrin 3 phosphorylation, which shows slightly different intensity changes in some 
blots). This raises the possibility that maybe some of the changes in the intensity of the 
bands may not be real in the worst case.   
 Another concern is that the blots are quite dirty and have a heterogeneous 
background and this may interfere with the evidence (bands) observed and the 
interpretation made. I used a high concentration of substrate for development of the film 
(1 to 10 femtomolar ECL or 1 to 2 femtomolar ECL) to increase the signal. These high 
concentrations of ECL can make the blots very dirty. This kind of background is 
expected but it can lead to a difficult process of washing and visualization of the bands. 
The bands corresponding to phosphorylated matrin 3 are quite faint, and thus signal-to-
noise is a valid concern. If the resulting blot is not washed enough, it can lead to non-
homogeneous background. Therefore, a possible apparent marginal increase in intensity 
or matrin 3 and/or some of the non-specific proteins may be a result of the heterogeneous 
background or be affected by it. This is hard or impossible to determine.  
 Taken together, we have lingering concerns that are very hard or impossible to 
 253 
explain. We therefore wish to caution readers about the modest quality of the evidence 
this IP-WB experiment provided in the case of matrin 3. 
 
Image acquisition: 
The blot was scanned entirely first. It was also scanned by translucent scanning. 
The area of interest was scanned with the help of a halogen desk lamp. Results are shown 
in Appendix 1 Figure 7.1. The lamp was used to get a clearer image of the bands from a 
blot with high background. The lamp was carefully placed on top of the area of interest 
and we aimed to obtain a homogeneous illumination of the area of interest that was 
scanned. This did not seem to be a problem since the selected area was very small. 
However, this method was not specifically designed for this purpose. The levels were 
processed as indicated in the figure (approximate numbers). This type of illumination did 
not provide a very good image of the entire blot in some cases. For this reason, we took 
pictures of the entire blot with both a low-resolution camera and a Sony Cyber-shot 
camera (Appendix 1 Figure 7.2) on top of a light box. We also used an imager and a 
white light diffuser on top of the UV light to attempt homogenous illumination, although 
this may not be the optimal procedure either. All these images are shown in Appendix 1 
Figure 7.1 and Appendix 1 Figure 7.2. The scanned images seem to have better quality 
than the ones taken with the cameras and the help of a light box and the translucent 
scanning is thought to provide the most homogeneous illumination that may be needed to 





 The bands are not clearly defined or sharp. They are also very faint. The 
background is strong and heterogeneous. 
 By eye, I believe I may see a borderline increase in intensity but I have to say this 
is very ambiguous: the left band (untreated cells) looks a bit more intense than the right 
band (treated cells) in the left part of the band, but the right band seems more solid and 
seems to have a more homogeneous intensity through the band. However, the observed 
heterogeneous background may affect either one or both bands. For example, there is a 
dark region bellow the right band and a diagonal clear band also close to the right band. 
However, the signal is so faint, it is hard to distinguish. 
 The blots were scanned and are shown here. We attempted quantifying the 
differences in intensity between both bands but it was not possible (area plots alsmot 
indistinguishable) in the original scans, the adjusted images or the scan obtained with 
translucent scanning.  
 When the film was scanned with a lamp, we attempted to measure the change in 
intensity again. The result is shown but we believe it is not representative of what can be 
observed by eye. This may be due to the heterogeneous background and the fact that 
Image J requires a large selected area to make the quantitations. As a result, we could not 
avoid including some areas that show heterogeneous background in our film that may 
affect the reading. Another reason could be the low signal in the blots. However, the area 
plots and the quantitation graphs are presented here to show the discrepancy between 
what can be observed by eye and what the quantitation indicates if these limitations are 
present.  
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Representative pictures made with the Cybershot Sony camera and a light box are 
also included and shown in Appendix 1 Figure 7.2. Representative pictures made with the 
imager are also included in Appendix 1 Figure 7.2. but quantitation was not possible. 
 
3.3.4. Anti-phosphotyrosine Western blot after the first sandwich reaction. Second 
exposure. 
 
The blot was then developed during a longer exposure time (Appendix 1 Figure 
8) and the observations and concerns are very similar to the previous exposure 
(Appendix 1 Figure 7). The bands are a bit stronger and the background is more 
apparent too.  
 
Observations: 
By eye, the observations are similar than with the previous blot but an increase is 
even less apparent or non existent. The left band (untreated) is sharper or better defined 
and more solid now. The right band seems a bit wider. If there is an increase, it is easier 
to detect this with the lower exposure. It is important to mention that the background is 
more visible, its heterogeneity more obvious, and its possible effect more apparent. A 
lighter diagonal stripe observed mostly in the right side may affect the bands, maybe the 
right one, but this is ambiguous and hard to determine. Bellow the right area there is a 
small darker area that could affect it. The background seems stronger but it is also strong 
in the top left side of the left band. Overall, the high and heterogeneous background 
makes it hard to make conclusions and quantitate the blot. 
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Appendix 1 Figure 8.1. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. R390A/ 
SYF cells. Anti-phosphotyrosine Western blots after the first sandwich reaction. Second exposure. 
Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
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Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction. Second exposure. 
A. Image obtained by translucent scanning. Quantitation of the bands corresponding to matrin 3 
phosphorylation from the original image was attempted using different setting in Image J and results are 
shown. B. The panel bellow shows a scan taken with the help of a lamp and the gray version of it after 
different adjustments in the levels. Quantitation of the bands corresponding to matrin 3 phosphorylation 
from the original image was attempted using different setting in Image J and results are shown. The arrows 
show bands of interest. White arrows indicate bands corresponding to matrin 3 phosphorylation. Red 
arrows indicate bands that show an increase in their intensity.  Green arrows indicate bands that show a 




Appendix 1 Figure 8.2. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. R390A/ 
SYF cells. Anti-phosphotyrosine Western blots after the first sandwich reaction. Second exposure 
(cont). 
Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
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Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction. C. Representative 
picture taken with a low-resolution camera and the help of a light box D. Representative pictures taken with 
a camera and the help of a light box. Different pictures correspond to different adjustment in the brightness 
in the camera. E. Representative pictures bellow were taken with an imager and a lamp. Different pictures 
correspond to different adjustment in the light aperture. The arrows show bands of interest. White arrows 
indicate bands corresponding to matrin 3 phosphorylation. Red arrows indicate bands that show an increase 
in their intensity.  Green arrows indicate bands that show a decrease in their intensity. Grey arrows indicate 





blot was too dark to be visualized by scanning without the help of a lamp. The scanned 
images obtained with the help of a lamp are shown for both the entire blot and the region 
of interest. We attempted quantifying the differences in intensity between both bands. 
The results are shown (Scan with halogen lamp: Image converted to 32-bit: Background 
not subtracted: 1/0.74; Background subtracted-100 rolling ball radius: 1/0.76. Image 
converted to 8-bit: Background not subtracted: 1/0.82; Background subtracted-100 rolling 
ball radius: 1/0.82) but we believe the heterogeneous background and the fact that Image 
J requires a large selection surface (apparently to be able to take into consideration/ allow 
removin the effect of the background for the calculations) may limit it. In fact, we could 
not avoid including some areas that show heterogeneous background in our film that may 
affect the reading. We also attempted quantitation from the image obtained through 
translucent scanning. The value also does not show an increase (Translucent scan. 
Background not subtracted: 1/0.63; Background not subtracted-100 rolling ball radius: 
1/0.57), but the same limitations for quantitation are present. I believe the result of this 
quantitations do not represent what can be observed by eye and therefore I don’t think 
these quantitations are informative for this film. 
A low-resolution photograph was taken of the blot on top of a light box with the 
purpose of being shown in Appendix 1 Figure 8.2. Representative pictures made with the 
Cybershot Sony camera and a light box are shown in Appendix 1 Figure 8.2. 
Representative pictures made with the imager are also included. We attempted to 
quantify the changes of intensity of these images that showed a tendency to decrease, but 




Blots corresponding to Appendix 1 Figure 8 and Appendix 1 Figure 9 may have 
been inadvertently switched in my lab notebook, but the pattern of the background 
suggests that the order of the two blots is as the presented here.  
 
3.3.5. Anti-phosphotyrosine Western blot after the first sandwich reaction. After 
washing and developing again. 
 
The blot was then subjected to washing as indicated in the methods section, with 
the aim of cleaning up the background.  
 
Limitations: 
The resulting blot obtained after developing is shown in Appendix 1 Figure 9. As 
described for Appendix 1 Figure 7-8, several bands appear in the lanes corresponding to 
the immunoprecipitation, which were not present before the sandwich reaction (Appendix 
1 Figure 5).  
This blot is theoretically cleaner than the ones shown in Appendix 1 Figures 7-8. 
If washing reduces the background, the bands observed should theoretically be less 
affected by the heterogeneity of the background. It is therefore a concern that for this 
particular blot (obtained after washing to remove background and developing again), we 
did not observe an increase in the intensity of the band corresponding to matrin 3 upon c-
Src chemical rescue. We observe that the signal does not change in intensity or that it 
even decreases very slightly (This is shown more clearly in some of the high-resolution  
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Appendix 1 Figure 9.1. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. R390A/ 
SYF cells. Anti-phosphotyrosine Western blots after washing and redeveloping.  
Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
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untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction, washing again 
and redeveloping. A. Image obtained by translucent scanning. Quantitation of the bands corresponding to 
matrin 3 phosphorylation from the original image was attempted using different setting in Image J and 
results are shown. B. The panel bellow shows a scan taken with the help of a lamp and the gray version of 
it after different adjustments in the levels. Quantitation of the bands corresponding to matrin 3 
phosphorylation from the original image was attempted using different setting in Image J and results are 
shown. The arrows show bands of interest. White arrows indicate bands corresponding to matrin 3 
phosphorylation. Red arrows indicate bands that show an increase in their intensity. Grey arrows indicate 




Appendix 1 Figure 9.2. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. R390A/ 
SYF cells. Anti-phosphotyrosine Western blots after washing and redeveloping (cont).  
Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
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Western blot against phosphotyrosine after washing and performing a sandwich reaction, washing again 
and redeveloping. C. Representative picture taken with a low-resolution camera and the help of a light box 
D. Representative pictures taken with a camera and the help of a light box. Different pictures correspond to 
different adjustment in the brightness in the camera. E. Representative pictures bellow were taken with an 
imager and a lamp. Different pictures correspond to different adjustment in the light aperture. Quantitation 
of the bands corresponding to matrin 3 phosphorylation from the original image was attempted using and 
results are shown. The graphs with red columns indicate that the background has been subtracted (rolling 
ball radius: 50 pixels). The arrows show bands of interest. White arrows indicate bands corresponding to 
matrin 3 phosphorylation. Red arrows indicate bands that show an increase in their intensity.  Green arrows 




pictures taken with the Cybershot Sony camera). 
The blot background seems more homogeneous but the top part is much lighter/ 
clearer than the lower part, when comparing Appendix 1 Figure 9 with Appendix 1 
Figure 7-8.  I cannot explain why this is the case but it is a concern that this phenomenon 
may distort the real intensity of the bands making it difficult to interpret the results. In 
fact, some of the bands in the top part of the blot that show strong intensity in Appendix 1 
Figures 7-8, are also strong in Appendix 1 Figure 9, whereas other show a much lower 
intensity suggesting that the background is not entirely homogeneous or that the reason 
that causes that the top of the film is much clearer may also have an effect in the intensity 
of the bands. 
It is also important to consider that from comments obtained from colleagues, it is 
sometimes expected to observe different results when the blot has been washed and 
redeveloped, as compared to the initial development, and in this case it has been washed 
and developed twice (the first wash being after the initial incubation with HRP-
conjugated anti-phosphotyrosine antibody and before sandwich reaction was attempted, 
the second this last wash). The washing also may have had an effect in partly removing 
the secondary antibody added in the first sandwich reaction. 
It is also worth mentioning that one of the lower bands in the blot that showed an 
increase in Appendix 1 Figure 7-8, stills shows it in Appendix 1 Figure 9, but another of 
the lower bands that showed an increase in Appendix 1 Figure 7-8 does not show such a 
change now. Also, the bottom band, which showed a decrease in intensity in Appendix 1 
Figure 7-8, does not show such a change in Appendix 1 Figure 9. This may indicate that 
either the increase in the bands observed in the previous blot was real and for some 
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reason does not show now or that it was a result of a heterogeneous background and now 
that this has been reduced the increase does not appear. If in the earlier exposure some 
bands seemed to show a change in intensity as a result of a heterogeneous background, 
this would explain why in this cleaner exposure no longer shows that change and this 
situation would be particularly worrisome. However, as mentioned, the appearance/ 
background of the blot obtained after washing is not optimal (very light on the top part as 
compared with the bottom of the blot) and conclusions are difficult to make. There is a 
possibility that there was excessive or uneven washing. Also, the change in pattern of the 
bands observed in the top part of the lysate lane shown in Appendix 1 Figure 7-8 
compared with the one shown in Appendix 1 Figure 9 increases the suspicion that even 
the background of the top part of the film in Appendix 1 Figure 9 is not homogeneous. 
It is true that in some occasions the lack of a visible increase may be due to a 
saturation of the signal, but the signal of the bands corresponding to phosphorylated 
matrin 3 in Appendix 1 Figure 9 does not seem saturated or at least, it is hard to tell given 
the fact that the top of the blot, for some reason, appears much clearer than the bottom.  
It is therefore very hard to discern which of these increases are real due to the 
difficulty of using this assay for matrin-3 and the modest quality of the evidence. 
 
Image acquisition: 
The blot was too dark to be scanned without a lamp. For that reason, the entire 
film was also scanned by translucent scanning. The entire film and the area of interest 
were scanned with the help of a halogen desk lamp. Results are shown in Appendix 1 
Figure 9. The lamp was used to get a clearer image of the bands from a blot with high 
 268 
background. The lamp was carefully placed on top of the area of interest and we aimed to 
obtain a homogeneous illumination of the area of interest that was scanned. This did not 
seem to be a problem since the selected area was very small. The scanned images seem to 
have better quality than the ones taken with the cameras and the help of a light box 
(Appendix 1 Figure 9.1). In addition, pictures were taken with a low-resolution camera 
and a light box. Representative pictures made with the Cybershot Sony camera and a 
light box are shown. We also took pictures using imager and white light diffuser on top 




 The bands are now defined and the background is clearer. This will facilitate the 
measurement of the changes in intensity since these are conditions that are necessary for 
correct measurement by ImageJ. However, the film is not completely homogeneous and 
the top part of the film is much clearer than the bottom. This is worrisome and we cannot 
explain why. 
 By eye, I believe I don’t see a change in intensity in the bands. There may be a 
slight decrease in the intensity but I think the right band is slightly broader and this may 
account for the possible decrease. 
  Quantitation was also performed from the image obtained by translucent 
scanning and the result is similar (Translucent scan. Background not subtracted: 1/ 0.98; 
Background subtracted-50 rolling ball radius: 1/1.04). The film was scanned with a lamp. 
We attempted to measure the change in intensity in the blot that scanned the area of 
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interest with the help of a lamp, and we observed a minor change (Scan with halogen 
lamp: Image converted to 32-bit: Background not subtracted: 1/1.05; Background 
subtracted-50 rolling ball radius: 1/1. Image converted to 8-bit: Background not 
subtracted: 1/1; Background subtracted-50 rolling ball radius: 1/1). We believe the 
quality of the image obtained through scanning is the best within the ones shown. We 
believe the results from the quantitation are representative of the observation made by 
eye and this is probably due to the fact that this film seems to have the appropriate/ 
necessary characteristics for quantitation. 
 The pictures of the blots show a similar trend. We did not attempt to quantify 
them because we have better resolution images.   
 Representative pictures made with the imager are also included and quantitation 
was performed (Background subtracted-50 rolling ball radius: 1/0.92; 1/1.13; 1/15). 
The overall results indicate that there is not a significant change in intensity 
between both bands.  
 
3.3.6. Anti-phosphotyrosine Western blot after the second sandwich reaction. First 
exposure. 
 
The blot was then subjected to a second sandwich reaction, with overnight 
incubation time (most likely an overnight reaction, although the exact incubation time 





Adding further steps to the process possibly led to an increased probability of 
observing non-specific bands. 
Many of the lower bands are no longer visible since the signal was being lost in 
some areas in the left-top and in the mid-bottom part of the blot, that were very clear and 
interfered with the lower bands observed in previous blots. This shows that this final 
attempt is problematic, since the strong signal and the strong background may interfere 
with the visualization of the bands and the interpretation of the result, as happens here 
with the lower bands of the blot. The resulting blot is shown in Appendix 1 Figure 10.  
We again observed that the sandwich reaction has probably led to an increase in 
the signal of the bands in the immunoprecipitation lanes, but not in the lanes 
corresponding to the lysate and the supernatant.  
The signal is faint and the blot is dirty, although the background immediately 




 The blot was first scanned and the levels were modified as indicated. The blot was 
also scanned with translucent scanning (Appendix 1 Figure 10.1). 
Representative pictures made with the Cybershot Sony camera and a light box are 
shown in Appendix 1 Figure 10.2. Pictures were taken with the imager and a lamp and 
representative pictures with different apertures are shown. In both cases, the signal was 
too low to allow quantification by Image J.  
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Appendix 1 Figure 10.1. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. 
R390A/ SYF cells. Anti-phosphotyrosine Western blots after second sandwich reaction. First 
exposure. 
Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
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Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction, washing again 
and redeveloping, and performing a second sandwich reaction. First exposure. A. Image obtained by 
scanning the film. The following films show the image resulting from adjusting the levels as indicated. 
Quantitation of the bands corresponding to matrin 3 phosphorylation from the original image was 





Appendix 1 Figure 10.2. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. 
R390A/ SYF cells. Anti-phosphotyrosine Western blots after second sandwich reaction. First 
exposure (cont).  
Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction, washing again 
and redeveloping, and performing a second sandwich reaction. First exposure. C. Representative pictures 
taken with a Cybershot camera and the help of a light box. Different pictures correspond to different 
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adjustment in the brightness in the camera. E. Representative pictures bellow were taken with an imager 







As described, the blot is starting to become clearer in some areas of the blot and 
signal is being lost. One concern is that this may have an effect in the intensity of the 
band corresponding to phosphorylated matrin 3 from the untreated cells (left band). 
However, the area in the blot that is starting to clear is probably not large enough to have 
a major interference with the band although it may have a small effect. The only other 
band that is still visible (and is located below the two bands corresponding to matrin 3) 
does not seem to experience a change in intensity. 
 By eye, I believe there may be a potential borderline increase in the bands 
corresponding to matrin 3,  (specially if the apparent larger area of the right band is taken 
into account) although this is ambiguous and may be limited by the eye perception. 
 The lightness of the signal made it impossible to make any quantitations by 
ImageJ with the intact images since the peak corresponding to the band was almost 
impossible to distinguish from the area plots. When the levels were adjusted to 40.1.110, 
we could visualize a peak but the quality of the area plots is not optimal (even more so 
after the background in subtracted) as can be seen in Appendix 1 Figure 10.1. The results 
are shown (Scan with halogen lamp: Background not subtracted: 1/1.26; Background 
subtracted-100 rolling ball radius: 1/0.81). We also performed quantitation after adjusting 
the levels to 36.1.104 and results are shown (Scan with halogen lamp: Background not 
subtracted: 1/1.35; Background subtracted-100 rolling ball radius: 1/0.8). We believe the 
heterogeneous background but mostly the lightness of the band may have limited the 
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quantitations. In fact, we could not avoid including some areas that show heterogeneous 
background in our film that may affect the reading. I believe the light intensity of the 
band makes it hard to quantitate this film. A slight increase may be slightly more 
representative to the observation by eye, but given the nature of the film (presence of 
background and low signal) this is hard to conclude.  
 
 There is a lower band in the gel, which seems to show no increase in intensity 
(very hard to determine), as was also shown in Appendix 1 Figure 9. 
 
3.3.7.  Anti-phosphotyrosine Western blot after the second sandwich reaction. 
Second exposure. 
 




The background is very strong and the area where the background is getting 
clearer is larger than in Appendix 1 Figure 10. In fact, looking at the size of this clear 
area (which seems to increase with time), I believe this blot was maybe obtained after the 
one shown in Appendix 1 Figure 12.   
One concern is that the background is very strong and, unlike the previous blot 
(Appendix 1 Figure 10), it looks a bit more heterogeneous (or the signal is getting 




Appendix 1 Figure 11.1. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. 
R390A/ SYF cells. Anti-phosphotyrosine Western blots after second sandwich reaction. Second 
exposure. 
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Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction, washing again 
and redeveloping, and performing a second sandwich reaction.Second exposure. A. Image obtained by 
translucent scanning. Quantitation of the bands corresponding to matrin 3 phosphorylation from the 
original image was attempted using different setting in Image J and results are shown. B. The panel bellow 
shows a scan taken with the help of a lamp and the gray version of it after different adjustments in the 
levels. . The image was converted into greyscale and the levels adjusted to make the picture shown in 
Figure 28.  Quantification of the bands corresponding to matrin 3 phosphorylation was performed from the 
image obtained by scanning with the help of a lamp and results are shown. Quantitation of the bands 
corresponding to matrin 3 phosphorylation from the original image was attempted using different setting in 





Appendix 1 Figure 11.2. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. 




Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction, washing again 
and redeveloping, and performing a second sandwich reaction. Second exposure. C. Representative picture 
taken with a low-resolution camera and the help of a light box D. Representative pictures taken with a 
camera and the help of a light box. Different pictures correspond to different adjustment in the brightness in 
the camera. E. Representative pictures bellow were taken with an imager and a lamp. Different pictures 
correspond to different adjustment in the light aperture. Quantitation of the bands corresponding to matrin 3 
phosphorylation from the original image was attempted using and results are shown. The arrows show 
bands of interest. White arrows indicate bands corresponding to matrin 3 phosphorylation. Red arrows 
indicate bands that show an increase in their intensity.  Green arrows indicate bands that show a decrease in 




darker than in the rest of the blot. However, except for the area that is getting clear at the 
left side of the left band, the background seems quite homogeneous in the area 
immediately around the matrin 3 bands. 
Some of my main concerns about this blot are that the blot is being subjected to 
several additional steps (two sandwich reactions), which may lead to the appearance of 
artifacts but may also be of advantage in seeing weak bands. 
Another concern, as described in Appendix 1 Figure 10, is that the blot looks 
clearer in certain areas, and this clearing may interfere with the intensity of the bands 
corresponding to phosphorylated matrin 3. Specifically, the band corresponding to the IP 
from untreated cells is near an area of the blot that is clearer. The lower intensity of the 
background and/or the band may be a result of, or may be partially affected by, the 
effects of this clearer area of the blot, which may make the intensity band itself appear 
weaker. It seems like the background around the left band is lighter and this may make 
the left band weaker in intensity too. It could also make it appear darker. This is hard or 
impossible to determine. The bigger the clearing the most likely it is that it affects the 
background. The background is more affected in the left part of the left band. However, 
even taking this last factor into account, it is possible that the increase is still apparent if 
we look at the right part of both bands. The right part of the left band is less likely to be 
affected by the clearing of the blot (loss of signal) and the clearing is therefore less likely 
to affect the intensity of the left band and the background around it. 
I believe Image J would take into consideration the background for its 
calculations and in fact it is possible to subtract it as I have done for this Appendix. 
However, even if this is the case, this may only account for the graphic aspect of the 
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image, once it is obtain, but may not cover the fact that the clearing may affect the signal 
and/ or the background in a way we can not approach (maybe even related with the 
linearity of the signal in the film), even through ImageJ considerations of the background 
or even the visualization by eye. 
Also, it is conceivable that the halogen lamp is somehow illuminating selectively 
in a way that has a much higher illuminating effect in the already clear background areas 
(left band) than in the darker ones. Maybe the illumination from the halogen lamp affects 
differently different backgrounds and even Image J cannot take this into account but we 
also have quantitation from images scanned by translucent scanning which is an optimal 




The film was scanned through translucent scanning. The blot was then scanned 
with a halogen lamp on top of the blot. The lamp only illuminated a small part of the blot 
and it was therefore located so that it could illuminate the region of interest and so that 
the light was homogeneously illuminating the selection of interest. I tried using a light 
diffuser but I believe it did not make a difference because the light seemed homogeneous 
in the selected area without the light diffuser. The selected area was scanned and 
converted into greyscale. The levels were adjusted to 20/1/220 (approximate numbers). In 
an attempt to be consistent, the exact same adjustments were done in the Western blot 
against phosphotyrosine with the D388N/SYF cells that will be described later. The 
approximate flow of the performed image processing is indicated in the figure. It may not 
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be exhaustive/ complete but is definitively representative. This blot was used to make the 
figure shown in Figure 28 and in the paper (Martinez-Ferrando, MCP, 2012).  
The first picture shown was taken with a low-resolution camera and placing the 
film on top of a light box. Representative pictures made with the Cybershot Sony camera 
and a light box are shown in Appendix 1 Figure 11.2. We also took pictures using imager 
and white light diffuser on top of the UV light.  
 
Observations: 
 The bands are very sharp and the background around them is relatively 
homogeneous and low facilitating the quantification. The only aspect that interferes with 
visualization is the clearing of the blot at the left of the band correspondent to untreated 
cells. 
By eye, I believe a mild increase is observed in the intensity of the band 
corresponding to phosphorylated matrin 3. The clear area in the left side of the blot may 
have an effect but I believe that, even if we look at the right side of the bands, where the 
clearing is less prevalent (in the left band), the increase is still visible. In addition, the 
surface area of the right band (treated cells) seems to be equal or slightly greater than the 
one in the left (untreated cells). 
Quantitation was performed from the image obtained by translucent scanning and 
the results are shown (Translucent scan. Background not subtracted: 1/ 1.22; Background 
subtracted-50 rolling ball radius: 1/2). The film was scanned with a lamp. We attempted 
to measure the change in intensity in the blot that scanned the area of interest with the 
help of a lamp, and we observed a minor change (Scan with halogen lamp: Image 
 284 
converted to 32-bit: Background not subtracted: 1/1.14; Background subtracted-50 rolling 
ball radius: 1/1.42. Image converted to 8-bit: Background not subtracted: 1/16; 
Background subtracted-50 rolling ball radius: 1/1.41). We believe the quality of the 
image obtained through scanning is the best within the ones shown. We believe the 
results from the quantitation may representative of the observation made by eye and this 
is probably due to the fact that this fild seems to have better characteristics for 
quantitation than other films which did not lead to representative values when 
considering the observation made by eye. 
I was recommended to subtract the background by an experience colleague and I 
have attempted to provide results before and after subtracting the background. The results 
are slightly different but the tendency is the same. The quantitation values were slightly 
different  when the image was obtained by translucent scanning or by scanning with the 
help of a lamp. The type of illumination may explain part of this difference. It is hard to 
determine which is most appropriate. The lamp included in the imager was used with a 
light diffuser, but special care was put in the scanned images to illuminate the region of 
interest homogeneously. Also, we believe the resolution of the scanned images is superior 
to the rest. The process of translucent scanning is optimal both in resolution and in 
illumination homogeneity.  
Although these are not the optimal images, quantitation was also performed from 
representative images obtained from the imager. After subtracting the background the 
values obtained are (1/1.02, 1/1.3, 1/1.16).  
In any case, the tendency to increase seems consistent from the quantitation. 
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 Since this is the film we used for the paper, we decided to further analyze the 
change in intensity of the bands by comparing it with the matrin 3 loading control. We 
compared images that were obtained exactly the same way (translucent scan) and 
processed the same way (either the background was not subtracted or it was with a rolling 
ball radius of 50 pixels). We compared the image for this exposure with the two films 
obtained through different exposures in the matrin 3 loading control (Appendix 1 Figure 
6). Once we take into consideration the loading, the results show that the tendency to 
increase in signal is more apparent, based on the calculations and taking into account all 




	   	   	   	   	  Background	  no	  subtracted	  
	   	   	   	   	  









1	   (-) imidazole 2353.409	   1.00	   15398.785	   1.00	   1.00 
2	   (+) imidazole 2865.489	   1.22	   15415.028	   1.00	   1.22 
Background	  subtracted	  
	   	   	   	   	  









1	   (-) imidazole 5751.489	   1.00	   14331.238	   1.00	   1.00 
2	   (+) imidazole 11498.459	   2.00	   14700.238	   1.03	   1.95 
MATRIN2-­‐light	  
	   	   	   	   	  Background	  no	  subtracted	  
	   	   	   	   	  









1	   (-) imidazole 2353.409	   1.00	   16053.078	   1.00	   1.00 
2	   (+) imidazole 2865.489	   1.22	   15093.886	   0.94	   1.29 
Background	  subtracted	  
	   	   	   	   	  









1	   (-) imidazole 5751.489	   1.00	   14423.359	   1.00	   1.00 
2	   (+) imidazole 11498.459	   2.00	   13823.116	   0.96	   2.09 
 
 
Appendix 1 Figure 11.3. Change in phosphorylation of matrin 3 upon c-Src when using the 
quantitation from the image obtained from the translucent scan of the blot obtained after the second 





3.3.8. Anti-phosphotyrosine Western blot after the second sandwich reaction. Third 
exposure. 
 
An extra image of the blot was obtained with a different exposure time 
(Appendix 1 Figure 12). 
 
Limitations: 
 The background is even stronger than in Appendix 1 Figure 11. It is also a bit 
heterogeneous in the edges. The clearing is less intense. 
 
Image acquisition: 
The blot was scanned by translucent scanning. In the figure, we show an example 
of how the halogen lamp was placed on top of the blot to help visualize the bands with a 
dark background. As noted before, this type of image seems to have better quality than 
the ones taken with the low-resolution camera by placing the film on top of a light box. 
Pictures were taken with a low-resolution camera and placing the film on a light 
box. Representative pictures made with the Cybershot Sony camera and a light box are 
shown in Appendix 1 Figure 12.2. Representative pictures taken with the help of a lamp 
are also shown. 
Observations: 
The observations are similar from the ones made in Appendix 1 Figure 11, 




Appendix 1 Figure 12.1. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. 




Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction, washing again 
and redeveloping, and performing a second sandwich reaction. Third exposure. A. Image obtained by 
translucent scanning. Quantitation of the bands corresponding to matrin 3 phosphorylation from the 
original image was attempted using different setting in Image J and results are shown. B. The panel bellow 
shows a scan taken with the help of a lamp and the gray version of it after different adjustments in the 
levels. Quantification of the bands corresponding to matrin 3 phosphorylation was performed from the 




Appendix 1 Figure 12.2. IP-WB experiment to validate matrin 3 as a potential c-Src substrate. 
R390A/ SYF cells. Anti-phosphotyrosine Western blots after second sandwich reaction. Third 
exposure (cont). 
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Matrin 3 phosphorylation of the final experimental repeat in the rescuable cell line R390A/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
Western blot against phosphotyrosine after washing and performing a sandwich reaction, washing again 
and redeveloping, and performing a second sandwich reaction. Third exposure. C. Representative pictures 
taken with a low-resolution camera and the help of a light box D. Representative pictures taken with a 
camera and the help of a light box. Different pictures correspond to different adjustment in the brightness in 
the camera. E. Representative pictures bellow were taken with an imager and a lamp. Different pictures 
correspond to different adjustment in the light aperture. Quantitation of the bands corresponding to matrin 3 
phosphorylation from the original image was attempted using and results are shown (background not 





By eye, a very borderline increase can be observed again, with the darker band 
corresponding to rescue of c-Src. The effect of the clearing in the left side of the blot on 
the left band (untreated cells) seems to be smaller than in the previous blot but still 
apparent. 
Quantitation was performed from the image obtained by translucent scanning and 
the results are shown (Translucent scan. Background not subtracted: 1/ 1.16; Background 
subtracted-50 rolling ball radius: 1/1.7). Both results show an increase but the ratios are 
different. We think that the film is darker than the one in Appendix 1 Figure 11.1 and 
therefore the background is interfering more with the quantitation process. The film was 
scanned with a lamp. We attempted to measure the change in intensity in the blot that 
scanned the area of interest with the help of a lamp (Scan with halogen lamp: Image 
converted to 32-bit: Background not subtracted: 1/1.06; Background subtracted-50 rolling 
ball radius: 1/0.44. Image converted to 8-bit: Background not subtracted: 1/1.24; 
Background subtracted-50 rolling ball radius: 1/0.41). We must warn, however, that the 
background was strong and not ideal for the calculations. There is a clear difference in 
the ratios obtained when the background was not subtracted (showing an increase) and 
when it was subtracted (showing a stron decrease). I believe this blot is not optimal for 
quantitation. When the background is subtracted the quality of the area plot dimisnihes 
and we chose the areas being the most conservative (in an attempt to avoid any bias). 
When the area plots look like the ones shown, it is easy to obtain a very diiferent result 
by chosing the area in a slighty different way. The area plot is just not smooth and this 
causes this effect. Since we were conservative, we ‘favored’ a decrease. Therefore, I 
don´t believe these values are representative of the observation by eye. The area plots 
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obtained from the quantitation of the image from the translucent scan are much smoother 
and, even having been conservative as can be observe in the figure, we obtained an 
increase. 
Although these are not the optimal images, quantitation was also performed from 
representative images obtained from the imager. The appearance of the images obtained 
from the imager is quite different from the appearance if the images obtained with the 
scanner and the lamp and what can be observed by eye which suggest that maybe this 
type of illumination from the UV and the white light diffuser is not optimal. After 
subtracting the background the values obtained are (1/0.81, 1/1.01, 1/0.85). The results 
from the quantitation of the images from the imager are inconsistent maybe due to the 
effects of a non-optimal illumination or due to the high background of the darker images, 
which makes it hard to use Image J for this purpose. However, we are showing the results 
obtained to illustrate this hypothesis. 
The type of illumination may explain part of the difference in quantifitation in the 
image obtained from the scanner with the help of a halogen lamp and the translucent 
scanning versus the one obtained from the imager. The lamp included in the imager was 
used with a light diffuser, but special care was put in the scanned images to illuminate the 
region of interest homogeneously. Also, we believe the resolution of the scanned images 
is superior to the rest. We also believe that both the resolution and the illumination 
homogeneity of the translucent scanning is optimal and it supports an increase.  
 
 We have only this biological replicate for the IP-WB to validate matrin 3’s mass 
spectrometry evidence as a potential c-Src substrate in rescuable cells (R390A/ SYF). 
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3.4. Final attempt- D398N/ SYF cells. Anti-matrin 3 Western blot and anti-
phosphotyrosine Western blot  
 
 The similar experiment was performed with the non-rescuable cell line D388N/ 
SYF. As in the case of tensin, we performed the control experiment (the one done with 
the non rescuable cell line) several times but we could visualize phosphorylation of the 
protein only once. The loading control is shown in Appendix 1 Figure 13.  
In the matrin 3 Western blot, the intensity of the band corresponding to matrin 3 
decreases slightly but it is also true that the band corresponding to the cells treated with 
imidazole is slightly broader. Also, when I verified the volume loaded in the gel used for 
the matrin 3 immunoblot (but not the anti-phosphotyrosine immunoblot), I made the 
observation that the sample corresponding to immunoprecipitated lysate from untreated 
cells had 10 µl more than the volume of the same sample added in the gel that was 
transferred and incubated against the phosphotyrosine antibody, so this may explain the 
higher intensity of the left band in the loading control immunoblot (but not in the anti-
phosphotyrosine immunoblot).  
Unlike the experiment with rescuable cells, the control using non-rescuable cells 
was performed with a different anti-phosphotyrosine antibody. For the non-rescuable 
control, the primary 4G10 anti-phosphotyrosine antibody was not HRP-conjugated, and 
was detected using an HRP-conjugated anti-mouse secondary antibody, without use of 
sandwich reaction. This may have been the reason why phosphorylation was visualized 
without the need of a sandwich reaction. 
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 The blot was quite dark and was therefore scanned with a halogen lamp on top of 
the blot (Appendix 1 Figure 13). The selected area was scanned, cropped, and converted 
into greyscale. The levels were adjusted to 20/1/220 (approximate numbers). Special 
attention was taken for making the same adjustments for this blot than those that were 
done in the Western blot against phosphotyrosine with the R390A/SYF cells that were 
described before. The approximate flow of image processing is indicated in the figure. 
This blot was used to make the figure shown in the paper.  
By eye, the intensity of the signal does not seem to experience a significant 
increase, but there is high background which clearly darkens partly the right band in its 
right half. Quantification was performed from the images obtained after scanning the film 
with the help of a lamp. The quantitation made from the image obtained from the 
translucent scan showed an increase in intensity (1/1.39). Quantitation with background 
subtraction was not possible due to the quality of the area plots. We believe that this 
strong increase revealed in some quantitations from these images does not correspond to 
the observation made by eye. However, we are showing the results obtained to illustrate 
this hypothesis. Another quantitation (done trying to avoid the heterogeneous background 
more) showed a value of 1/1.13, which is more consistent with our observation by eye. 
As mentioned before we believe that the resolution of the scanner, the illumination 
provided by the translucent scanning and the methodology used for Image J quantitation 
make this quantitation one of the most reliable potentially. The variability observed is a 
result of the heterogeneity of the background and the low signal. 
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Appendix 1 Figure 13. Matrin 3 loading control of the final experimental repeat in the non-rescuable 
cell line D388N/SYF. 
Immunoprecipitation- Western blot experiment to validate matrin 3 as a potential c-Src substrate. The 
untreated and the treated cells were lysed and immunoprecipitation was performed using matrin 3 antibody. 
A. Western blot against matrin 3 was used as a loading control. Two blots corresponding to two different 
exposure times are presented. Translucent scans of the films are also shown and quantitation is shown. B. 
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Western blot against phosphotyrosine antibody non-conjugated to HRP followed by incubation with 
secondary antibody showed weak signal of phosphorylated matrin 3. The top two pictures are scans of the 
entire blot obtained after developing during different exposure times. The bottom blot shows scan of the 
left blot taken with the help of a lamp. The image was converted into grey, cropped and different 
adjustments in the levels were made. This workflow represents the way the correspondent image in Figure 
28 was acquired. A translucent scan was perfomed and the image is shown. Two different quantitations 








We have only one biological replicate for the immunoprecipitation-Western blot 
experiment (IP-WB) to validate matrin 3’s mass spectrometry evidence as a potential c-
Src downstream substrate both in rescuable cells (R390A/ SYF) and in non-rescuable 
cells (D388N/ SYF). In the one replicate performed in rescuable cells matrin 3 
phosphorylation seems to show a marginal increase in some of the exposures from some 
of the blots obtained at different stages during the experimental process to which we 
subjected the blots for visualization of phosphorylation. This observation by eye was 
validated for 2 of the films obtained after the second sandwich reaction (Appendix 1 
Figure 11 and 12) by quantitation, which seemed to favor the possibility of an increase 
when the image was obtained by translucent scanning. When the image was obtained 
with a scanner and the help of a halogen lamp there was one occasion when we observe a 
decrease instead of an increase (Appendix 1 Figure 12), but we believe this does not 
represent the observation made by eye and may be due to the limited quality of the blot 
for quantitation). We have lingering concerns about the evidence obtained in this 
experiment that are complex and hard to explain. We therefore wish to caution readers 
about the modest quality of the IP-WB evidence in the case of matrin 3. I would like to 
first summarize some of our observations as well as their caveats, which make us 
cautious about interpreting these data.   
One concern is the possibility that the process of the sandwich reaction (a 
conventional and accepted technique used to amplify the signal in a Western blot) may 
lead to non-specific binding or other artifacts. Nevertheless, it was the only way we 
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were able to visualize matrin 3’ phosphorylation. For the first sandwich reaction, we 
chose a short incubation period and exposure time in order to minimize the appearance of 
non-specific bands.  The band correspondent to matrin 3 phosphorylation may have a 
borderline increase in intensity by eye in our initial blots (Appendix 1 Figure 7 and 8), 
especially in the lighter exposure, but the ambiguity of this observation, the 
heterogeneous background and the fact that the quantitation does not reveal an increase 
makes us question the increase itself. We must note, however, that the heterogeneous 
background would make any quantitation very difficult. Besides the bands at the 
molecular weight of matrin 3, several non-matrin 3 bands appeared in the 
immunoprecipitation lanes, which may correspond to proteins that were non-specifically 
pulled down with matrin 3 during the immunoprecipitation. The second sandwich 
reaction was performed for a longer period of time, making the possibility of non-specific 
binding (or other caveats) stronger.  However, no obvious additional bands seemed to 
appear, although this is hard to tell due to the appearance of clear or lighter areas in some 
parts of the blot that prevents us from visualizing the bands in the lower part of the blot. 
The figure corresponding to matrin 3 validation for rescuable cells shown in Figure 28 
results from imaging the blot obtained after the second sandwich reaction with the help of 
a halogen lamp.  
Another concern is the possibility of a loading inconsistency due to a human error 
in loading.  This was suggested as a result of the observation that some non-matrin 3 
bands showed a slight increase in intensity upon imidazole treatment. If this increase was 
due to imprecise loading, a possible similar increase in the intensity of the band 
corresponding to matrin 3 phosphorylation could also be the result of imprecise loading 
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and the increase will be unreliable. However, the precise technique during the loading 
process, as well as a satisfactory even loading control should be good indicators of equal 
loading. 
Another concern is the strong and heterogeneous background due to the 
sandwich reaction process and/or the high concentration of ECL substrate used (1 to 10 
femtomolar or 1 to 2 femtomolar). A dark background from such a concentrated substrate 
solution is expected and is not a problem by itself, but makes the washing of the blots and 
the visualization of the bands very difficult. A heterogeneous background may interfere 
with our bands of interest and make the visualization and/or the quantitation of the 
difference in intensity difficult or impossible to determine. Interpretation of the results is 
hard to make and, in fact, a heterogenous background could be a conceivable explanation 
of an apparent increase in the intensity of matrin 3 and/or other non-matrin 3 bands. 
Nevertheless, it is possible that in the anti-phosphotyrosine immunoblot the non-matrin 3 
bands that show an increase in intensity upon c-Src rescue could be proteins that also 
have an increase in phosphorylation after c-Src rescue, and therefore should not be 
considered evidence of uneven loading or contamination by high background.  However, 
all such concerns that could question a possible increase in the intensity of the bands are 
challenged (but not completely overruled) by an inconsistent behavior of bands other 
than matrin 3 in different blots developed at different stages of the process. For 
example, one of the non-matrin 3 bands that increases in intensity upon c-Src rescue in 
some of the blots (Appendix 1 Figure 7 and 8), still shows an increase when the blot was 
washed and developed again (Appendix 1 Figure 9), while another band that also showed 
an initial increase does not show this increase when blot was washed and developed again 
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(Appendix 1 Figure 9). Another non-matrin 3 band, which initially shows a decrease in 
intensity (Appendix 1 Figure 7 and 8) shows no change in intensity upon c-Src rescue 
after washing and developing again (Appendix 1 Figure 9). We must also note that matrin 
3 phosphorylation shows a borderline increase by eye in some blots obtained in this 
biological replicate (with reservations and limitations), but in one occasion (Appendix 1 
Figure 9) matrin 3 phosphorylation showed no change or even a slight decrease in 
intensity upon c-Src rescue.  In summary there is an inconsistency in the pattern of 
change of these bands and we cannot really explain this observation. This inconsistency 
challenges the possibility that possible increases in intensity of the bands may be caused 
by imprecise loading or strong background (darker in the right area, where the bands 
corresponding to the treated cells are). If imprecise loading was the only responsible 
factor for a possible increase in the intensity of the bands from treated cells, the tendency 
of the bands to increase, remain or decrease in intensity would remain the same after 
washing the blot, and the pattern of change between bands correspondent to untreated and 
treated cells will be constant among the blots. Also, one of the lower non-matrin 3 bands 
shows a decrease in its intensity upon treatment, contradicting the possibility of a higher 
load in the lane corresponding to treated cells. If darker background (darker in the right 
region of the blot where the bands corresponding to the treated cells are) was responsible 
for the detection of an increase in intensity of several bands, washing the blot and 
reducing the background would lead to a cleaner blot where the bands will be equally 
affected by the washing. This is not the case in our experiment, where some bands appear 
clearer after washing while others keep their intensity (Appendix 1 Figures 7 and 8 vs 
Appendix 1 Figure 9). However, it is also possible that the background was very 
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heterogeneous through the blot that affected different bands differently and washing led 
to an homogeneous background that will allow visualization of the real tendency of the 
band to decrease, maintain, or increase in intensity. This could be worrisome because it 
may suggest that some of the potential increases observed may not be real, but caused by 
heterogeneous background, since washing, further incubations, etc, lead to changes in 
their tendency to increase, maintain or decrease in intensity.  
After developing the blot resulting from the first sandwich reaction, the blot was 
washed further and developed again, with the expectation of a reduced and more 
homogeneous background that facilitates visualization of the real tendency of the 
intensity of the bands.  The bands showed no change in intensity both by eye and by the 
quantitations made (which makes sense since this blot seems more appropriate for 
quantitation by Image J). However, this brought another concern, since the top part of the 
blot was inexplicably much clearer than the bottom (Appendix 1 Figure 9), which makes 
it hard to determine if the pattern observed in this area of the blot is reliable. In the blot, 
matrin 3 phosphorylation showed no increase or even a slight decrease. This is obviously 
worrisome, although excessive or uneven washing, uneven background or other factors 
related to the clearer aspect of the top part of the blot might account for this.  
An additional type of concern related to the blots obtained after the second 
sandwich reaction (Appendix Figures 10-12) is that the areas of the blot that are 
getting clearer likely interfere with the matrin 3 control band (no imidazole) and 
make it look a bit lighter (less intense) that what it really is. Some of this clearing/ fading 
occurs in an area of the blot near the band corresponding to untreated cell, and may 
contribute to the lighter intensity of this band as compared with the one showing matrin 3 
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phosphorylation after imidazole treatment. We hope that Image J, which is a very 
established way to quantitate blots and takes into account the background, and has been 
used in two different recommended ways, covers this issue during its calculations but we 
don´t have the certainty that the clearing may cause effects that ImageJ can not address. 
 Another issue I have mentioned through the text and worth discussing again here 
is the methodology used for scanning the very dark films: The way I initially scanned 
the films was using a desk halogen lamp illuminating the film and this may not be the 
most appropriate/ homogeneous way to illuminate the film in order to be able to scan it, 
although I was very careful in selecting the area of interest and applying homogenous 
illumination to it. The images shown in Figure 28 come from images taken following this 
methodology and adjusting the levels as indicated. It is encouraging to see that when the 
technique of translucent scanning, which has optimal resolution and homogeneous 
illumination, was used, the same tendency was revealed in the quantitations regarding the 
intensity changes in matrin 3’s phosphorylation. 
Another related issue is the variability of the quality and sometimes even the 
appearance of the figures depending on the methodology used to capture them. If the 
blots had a strong signal and a clear background I just scanned them with the help of a 
halogen lamp or by translucent scanning. If the blots were light and the signal weak, I 
scanned them, sometimes using a halogen lamp to obtain a clear image (less 
background), scanned them by translucent scanning, or I used an imager and a lamp. 
When the images were dark, I often had to use a halogen lamp to scan them and then I 
did scan them by translucent scanning. In order to get a picture of the whole film, I often 
used a low-resolution camera and a light box or an imager and a lamp. Sometimes the 
 304 
images obtained through these last two methods showed slightly different appearances. 
This may be related to the different types of illumination (some may be more intense 
and/or homogeneous than others) and/or the quality or resolution that the instrument can 
obtain. In those cases, I tried emphasizing the appearance that corresponds to what I can 
observe by eye, but I was cautious to make strong conclusions because even this 
observation can be misleading (by factors such as heterogeneous background that is hard 
to identify or distinguish sometimes, vision limitation) or biased. In general, I also give 
more credibility to the images obtained in the approximate following order: scanning the 
blot by translucent scanning or by simple scanning, by scanning with the help of a 
halogen lamp, by taking pictures with a Cyber-shot Sony camera and a light box, by 
taking pictures with a low-resolution camera and a light box or by the imager and the UV 
lamp with the white light diffuser. 
In fact, this leads to another concern, which is the methodology used when 
trying to quantify the changes of intensity of the bands. Since methodologies like the 
traditional use of Photoshop to subtract the background can be biased, I used Image J 
established method for Western blot quantitation, which takes the background into 
account. From my experience doing this and the information I have obtained online and 
through colleagues, I can say that this methodology works well when both the 
background is clear and homogeneous and the band intensity is strong enough. I tried 
applying this methodology to most of the films. However, I believe some of them did not 
meet the requirements for being measured through this methodology since they provide 
numbers indicating changes that are very different from what can be observed by eye. A 
reason for this may be the fact that the software needs a large selection area containing 
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the band and a large area of background to be able to take it into account it. However, in 
cases where the background on and/or around the band is heterogeneous, it was 
impossible to avoid including part of it in our selection and I think this affected the 
results. The eye is able to focus only in the region of interest but of course, it is not 
perfect since it can also miss a mildly heterogeneous background that is hard to identify 
or distinguish sometimes or can lead to biased interpretations. However, if the 
observation by eye seems more real than the numbers obtained in a non-optimal blot, I 
gave more credibility to the first one. However, the graphs are shown to illustrate this too. 
The methodology used to quantitate images from scanning the film with the help of a 
lamp or from translucent scanning showed the same tendency but values were relatively 
different. This may be due to the illumination technique or the difference in settings use 
in Image J. As I mentioned before, and this is just speculation, it is conceivable that the 
halogen lamp is somehow illuminating selectively in a way that has a much higher 
illuminating effect in the already clear background areas (left band) than in the darker 
ones. Maybe the illumination from the halogen lamp affects differently different 
backgrounds and even Image J cannot take this into account but we also have quantitation 
from images scanned by translucent scanning which is an optimal way to homogeneously 
illuminate the blots and they show the same tendency. 
I usually preferred to choose images obtained through scanning since they have 
the higher resolution. I also used images obtained through the scanner and the halogen 
lamp. In fact, this was the methodology used to obtain the figures currently shown in the 
paper. I could sometimes observe a dissonance between the numbers obtained from 
images of the same film obtained through these two methodologies. The scanned images 
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have higher resolution. The halogen lamp may not be the optimal method to 
homogeneously illuminate the blot but I made a special effort to manually locate the lamp 
in a way that favored homogeneity. I also believed this illumination method is the one of 
the ones that created a clearer image of the film and I was not aware of the translucent 
scanning method initially. The pictures taken with the low resolution camera and the help 
of a light box probably had homogeneous localization but did not have good resolution so 
I did not use them to quantify the blots. I also took pictures with a better camera but I am 
not sure I was being consistent with the different blots since I did not have a set system to 
fix the camera so I also did not use these images to quantify the blots. The images 
obtained with the imager and the lamp, seem to have less resolution than the scanned 
versions and sometimes the images seem to have difference appearance than what can be 
observed by eye. I used a white light diffuser over a UV lamp that should make the 
illumination homogeneous but is not an established way so I lack information to judge 
how reliable this method is. Also, there was an extra factor with the images obtained 
through the imager, which is the aperture of the light. Representative pictures that were 
taken using different apertures are shown and sometimes the tendency of the band’s 
intensity to increase, remain, or decrease upon c-Src rescue depends on the aperture used. 
There was therefore variability in the numbers obtained depending on the 
methodology used to illuminate the blot and obtain the image. This made the 
interpretations extremely hard to make, even when attempting to quantify. In general, I 
will trust more the quantitation if the blot meets the requirements for proper 
quantification, if the tendency is mostly consistent through the blots obtained through 
different methodologies, if I obtained the image through scanning, and if I believe it 
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reflects what can be observed by eye. 
Finally, I would like to mention that the loading control (IP and Western blot 
with matrin 3 antibody) performed with the non-rescuable cell lines (D388N/ SYF) 
shows a slight decrease in the total amount of matrin 3 (Appendix 1 Figure 13). The 
bands corresponding to phosphorylated matrin 3 in the anti-phosphotyrosine Western blot 
shows no significant difference in intensity (Appendix 1 Figure 13) by eye and one of the 
most reliable images/ quantitation (done trying to avoid the heterogeneous background 
more) (not after quantitation of images obtained by Imager). I believe by eye one could 
observe a mild increase but there is clear heterogenous background interfering with the 
right band. I believe that the fact that the blot does not meet the requirements of 
background and signal intensity for proper quantification by Image J led to the significant 
decreased obtained through quantification. However, if we take into account the decrease 
in the loading control, we could consider there is an increase in matrin 3’s 
phosphorylation too. However, I have mentioned the possible explanation of the decrease 
observed in the blot in Appendix 1 Figure 13, which may respond to a higher (10 ml) 
higher volume of sample loaded in the sample corresponding to the untreated cells. This 
extra volume was not loaded in the anti-phosphotyrosine Western blot (Appendix 1 
Figure 13), and this probably will make the possibility of an increased phosphorylation of 
matrin 3 in non-rescuable cells more unlikely. 
A final attempt was made to reproduce these results, but the reagents used were 
not fresh, and the loading controls and bad quality of the blot made it very difficult to 
make any conclusions. 
After the first sandwich reaction to magnify signals due to phosphorylation, I 
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obtained two blots, using both a shorter and longer exposure. In the one obtained through 
the shorter exposure (Appendix 1 Figure 7) I believe I may see a borderline increase in 
phosphorylation after rescue, but this interpretation is ambiguous and difficult to 
determine because of the faintness of the bands that is not well defined and because of 
heterogeneous background that is mildly apparent but become more apparent after 
observing the longer exposure.  Attempts at quantitation did not confirm such an 
increase.  The only quantification that was possible led to numbers that actually reflect a 
decrease in intensity but I believe the heterogeneous background affected the 
methodology because the Area plots/ curves provided by Image J were not of appropriate 
quality. I would therefore not value this quantitation very much. The longer exposure is 
shown in Appendix 1 Figure 8. The observations made by eye are very similar than the 
ones for Appendix 1 Figure 7, but I believe it is harder to see because the left band is 
more defined and solid than in the previous exposure and the background is more 
apparent and heterogeneous, interfering with the clear visualization of the bands. At the 
same time, the right band seems wider. Again, the only quantitation that was possible 
(image obtained by scanning blot with the help of a halogen lamp and from translucent 
scanning) led to numbers that actually reflect no change or a marginal decrease in 
intensity but I believe the heterogeneous background affected the methodology. 
After washing and redeveloping the blot, we obtained the blot shown in Appendix 
1 Figure 9. The bands are now more defined and the background seems clearer and more 
homogeneous (facilitating quantitation), but it is actually not completely homogeneous. 
Also, the top part of the film is much clearer than the bottom, which may suggest 
excessive washing or other unknown artifact that may lead to a misleading interpretation. 
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By eye, I believe I don’t see a change in intensity in the bands. There may be a slight 
decrease in the intensity but I think the right band is slightly broader and this may 
account for the possible decrease. After scanning the film with a lamp, we quantified and 
still did not observe a significant change in phosphorylation. After scanning the film by 
translucent scanning, we quantified and still did not observe a significant change in 
phosphorylation. The overall results indicate that there is not a significant change in 
intensity between both bands but the very different and much clearer top of the blot 
makes us take this observation also with reservations. 
After performing the second sandwich reaction, the blot became clearer in some 
areas.  For more information about the possible causes of this phenomenon please read 
this manual: http://www.piercenet.com/files/AN0011.pdf. One concern is that this may 
have an effect in the intensity of the band corresponding to phosphorylated matrin 3 from 
the untreated cells (left band). However, the area in the blot that is starting to clear is not 
large enough to really have a major interference with the band. In the first exposure 
(lighter one) I believe that, by eye, I may see a borderline and extremely mild increase in 
the bands corresponding to matrin 3 (especially if the apparent larger area of the right 
band is taken into account) although this is very ambiguous and I am not convinved by it. 
The lightness of the signal made it impossible to make any quantitations by Image J. 
A different exposure is shown in Appendix 1 Figure 11.  Here the bands are very 
sharp and the background around them is relatively homogeneous facilitating the 
quantification. By eye, a mild increase is observed in the intensity of the band 
corresponding to phosphorylated matrin 3.  The clear area in the left side of the blot may 
have an effect in the left band intensity, which may appear weaker. However, even when 
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I take this into account, there may still be a marginal/ mild increase in the intensity of the 
band corresponding to phosphorylated matrin 3 upon s-Src rescue, especially if we look 
at the right side of both bands where the clearing is less prevalent, but this is hard to 
determine. In addition, the surface area of the right band (treated cells) seems to be equal 
or slightly greater than the one in the left (untreated cells). However, the quality of the 
blot makes it hard to make conclusions. Quantitation was performed from images 
obtained from scanning the blot with the help of a lamp and by translucent scanning. A 
mild increase is reflected in this calculation. The quantitation was also performed by 
ImageJ, from images obtained from the imager and a lamp. These images (except for the 
first film) also show an increase, although not so apparent. However, we consider the 
resolution and illumination technique of these images are not optimal and we give them 
less weight than the previous ones. 
A third exposure was obtained and is shown in Appendix 1 Figure 12. The 
observations are similar from the ones made in Appendix 1 Figure 11, although the blot 
was dark and a quality scanned image was hard to obtain. By eye, a very borderline 
increase can be observed again, with the darker band corresponding to rescue of c-Src. 
We quantified the change in the intensity of the bands from the image obtained scanning 
the film with the help of a halogen band, and an increase in intensity is shown upon c-Src 
chemical rescue when we don´t subtract the background. A strong decrease shows 
through quantitation when we subtract the background but we believe this does not 
correspond with what can be visualized by eye and we think it is probably due to the 
nature of the blot which is darker than the one shown in Appendix 1 Figure 11.1, which 
leads to area plots for calculations that are not smooth and can lead to very different 
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outcomes than what we observe by eye. We also quantified the change in the intensity of 
the bands from the image obtained scanning the film by translucent scanning and an 
increase in intensity is shown upon c-Src chemical rescue. We must warn, however, that 
the background was strong and not ideal for the calculations due to the clearing in some 
areas of the blot. Also, the images obtained by the imager are very different and both 
their appearance and the quantitation resulting from them don’t show an increase. Again, 
I think the amount/ homogeneity of illumination affects the appearance of the blot and the 
quantitation. Therefore, the methodology used affects the observations and both the 
resolution and illumination of this last methodology is not ideal so less weight was given 
to this quantitation values. 
 
We performed this experiment to validate the mass spectrometry results that 
revealed matrin 3 as a potential downstream c-Src target. The experiment consistent of an 
immunoprecipitation with matrin 3 antibody, followed by Western blot with matrin 3 
antibody (loading control) and anti-phosphotyrosine antibody (in order to detect the 
changes in matrin 3 phosphorylation upon c-Src chemical rescue). Our initial attempt 
seemed successful but we then realized of the presence of non-specific proteins that have 
probably been pulled down with matrin 3 in the immunoprecipitation. Among other 
reasons, thoroughly described above, some of these non-specific proteins are visualized 
at a molecular weight that is very similar to matrin 3, making the blot unreliable. The 
next attempts to replicate the experiment did no reveal any phosphorylated matrin 3, even 
though the immunoprecipitation worked satisfactorily, based on the anti-matrin 3 
Western blots. If matrin 3 is not heavily phosphorylated, we would need a method to 
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strengthen the signal. For that reason we introduced the sandwich reaction to magnify the 
weak signal. After several attempts to visualize matrin 3 phosphorylation, we were 
encouraged when we observed what we believe is phosphorylation of matrin 3. We had 
to include additional steps to increase the signal in this kind of experiment. In principle, 
the conclusions from images obtained after the first sandwich reaction should be the most 
reliable since they were subjected to less manipulation. Taken into account our 
observations we could only talk about a possible borderline increase in intensity by eye 
(although not clear), with no change in intensity on quantitation. These observation (and 
its quantitation) is limited by the heterogeneous background and the problematic signal-
to-noise so conclusions are hard to make. After washing and developing we should 
observe an even more reliable blot that shows no difference in intensity. However, we see 
no change in intensity (and even a marginal decrease) in the intensity of the bands 
corresponding to phosphorylated matrin 3 upon c-Src rescue. This interpretation is 
limited by the fact that top of the membrane is much brighter than the bottom and it that 
may or may be not homogenous. The fact that is so different from the bottom part of the 
film raises my concerns about the presence of excessive washing or other artifacts. The 
blots obtained after the second sandwich reaction had been subject to more processing, 
but nevertheless, these are the ones that revealed bands that were sharper and easier to 
visualize and quantitate. On average, and based on observation by eye and quantitation of 
scanned images with the help of the lamp and by translucent scanning (and if I don’t 
heavily weight/ take too much into consideration the quantitation done after subtracting 
the background from the images obtained in the third exposure after the second sandwich 
reaction, after scanning the film with the help of a lamp (Appendix 1 Figure 12), nor the 
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quantitation from the images obtained from the imager, due to the reasons described 
above), it could be said that a marginal/ mild increase in the intensity of the band 
corresponding to imidazole- treated cells (rescued c-Src) was observed supporting the 
mass spectrometry results.  The blot used for making the publication figure (Martinez-
Ferrando et al. MCP 2012) was obtained from Appendix 1 Figure 11, after performing 
the second sandwich reaction. This blot reveals clear and sharp bands with relatively 
homogeneous background around them that facilitated quantitation. The quantitation 
values from both Appendix 1 Figures 11 and 12 (except for the quantitation done after 
subtracting the background from the images obtained in the third exposure after the 
second sandwich reaction, after scanning the film with the help of a lamp (Appendix 1 
Figure 12), nor the quantitation from the images obtained from the imager), suggest a 
mild but discernible increase in phosphorylation of matrin 3 upon c-Src rescue. 
Quantitation by Image J takes into consideration the background and even in this case, 
the increase is revealed in the calculations. Apart from the level of processing this blot 
has been subjected to in order to magnify the signal, my other primary concern with the 
analysis of this blot is that the regions where the blot is clearing due to signal loss (maybe 
“ghost-banding”) have an effect in the intensity of the left band and the background 
around it. This effect could impact the observation and the quantitation of the band, 
leading to a misleading conclusion. However, when the observed differences in local 
background are reduced using background correction in Image J, the quantitation of the 
bands still reveals a marginal to mild increase (except for the quantitation done after 
subtracting the background from the images obtained in the third exposure after the 
second sandwich reaction, after scanning the film with the help of a lamp (Appendix 1 
 314 
Figure 12), nor the quantitation from the images obtained from the imager). It is true that 
the described concerns and the fact that I only have a biological replicate showing these 
results make the conclusion less solid and should be interpreted with caution. 
 
In summary, and taking all these considerations into account, we believe that the 
immunoprecipitation and Western blot experiment done to validate the mass 
spectrometry results for matrin 3 has several lingering caveats and may not be the best 
assay to measure matrin 3 phosphorylation, given the technical difficulties to observe 
phosphorylation. Some of the blots showed no response, a mild response or a response 
that is hard to measure. Even though the experiment provided some evidence that 
supports the increase observed in mass spectrometry, each of the obtained blots has its 
own caveats that I have tried to explain here are clearly and thoroughly as possible. The 
second sandwich reaction showed a response that is measurable and has however 
provided modest evidence of a marginal increase in matrin 3 phosphorylation upon c-Src 
rescue (except for the quantitation done after subtracting the background from the images 
obtained in the third exposure after the second sandwich reaction, after scanning the film 
with the help of a lamp (Appendix 1 Figure 12), nor the quantitation from the images 
obtained from the imager), but the caveats and weakness at this stage of the experiment 
(mostly the level of processing and the clearing of the blot in the left side of the left band) 
remain and represent concerns about this result.  
 
The complete set of data is presented here for full transparency. We must warn 
about the weak nature of this set of evidence that provides some evidence about a 
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possible marginal to mild increase in phosphorylation of matrin 3 upon c-Src rescue, but 
presents some lingering concerns and inconsistencies we can not explain, and does not 
contradict as a whole the results obtained in our SILAC experiment at the protein level.  
 
It is evident that if one were to pursue this issue at a later time, additional 
techniques should be used, since standard Western Blot/IP approaches that were valid for 





1 myosin-9 isoform 1 [Mus musculus] gi|114326446 226 kDa 15
2 focal adhesion kinase 1 isoform 1 [Mus musculus] gi|194353972 119 kDa 8
3 keratin, type I cytoskeletal 10 [Mus musculus] gi|112983636 57 kDa 7
4 ephrin type-A receptor 2 precursor [Mus musculus] gi|32484983 109 kDa 7
5 keratin, type I cytoskeletal 17 [Mus musculus] gi|7106335 48 kDa 6
6 rho guanine nucleotide exchange factor 7 isoform b [Mus musculus] gi|165377089 (+1) 80 kDa 6
7 actin, cytoplasmic 1 [Mus musculus] gi|6671509 (+1) 42 kDa 5
8 albumin precursor [Mus musculus] gi|163310765 69 kDa 5
9 tyrosine-protein kinase SgK269 [Mus musculus] gi|157909795 191 kDa 5
10 PREDICTED: similar to SH2/SH3 adaptor protein [Mus musculus] gi|149233948 (+1) 43 kDa 5
11 alpha-2-macroglobulin precursor [Mus musculus] gi|110347469 166 kDa 4
12 ARF GTPase-activating protein GIT1 [Mus musculus] gi|51921285 85 kDa 4
13 sorting nexin-18 [Mus musculus] gi|91598596 68 kDa 4
14 paxillin isoform beta [Mus musculus] gi|114326502 (+1) 65 kDa 4
15 breast cancer anti-estrogen resistance protein 1 [Mus musculus] gi|40254593 94 kDa 3
16 ARF GTPase-activating protein GIT2 isoform 3 [Mus musculus] gi|116517295 76 kDa 3
17 heat shock cognate 71 kDa protein [Mus musculus] gi|31981690 71 kDa 3
18 ATP-dependent RNA helicase DDX3X [Mus musculus] gi|6753620 73 kDa 3
19 mitogen-activated protein kinase 3 [Mus musculus] gi|21489933 43 kDa 3
20 complement C3 [Mus musculus] gi|126518317 186 kDa 3
21 keratin, type II cytoskeletal 5 [Mus musculus] gi|20911031 62 kDa 2
22 vimentin [Mus musculus] gi|31982755 54 kDa 2
23 elongation factor 1-alpha 1 [Mus musculus] gi|126032329 50 kDa 2
24 activated CDC42 kinase 1 isoform 1 [Mus musculus] gi|158711692 117 kDa 2
25 40S ribosomal protein S4, X isoform [Mus musculus] gi|6677805 30 kDa 2
26 neuronal proto-oncogene tyrosine-protein kinase Src isoform 2 [Mus ... gi|70794809 (+1) 60 kDa 2
27 probable ATP-dependent RNA helicase DDX5 [Mus musculus] gi|83816893 69 kDa 2
28 mitogen-activated protein kinase 1 [Mus musculus] gi|6754632 (+1) 41 kDa 2
29 murinoglobulin-1 precursor [Mus musculus] gi|31982171 165 kDa 2
30 keratin, type II cytoskeletal 6A [Mus musculus] gi|54607171 59 kDa 2
31 keratin, type II cytoskeletal 2 epidermal [Mus musculus] gi|124487419 71 kDa 2
32 elongation factor 2 [Mus musculus] gi|33859482 95 kDa 2
33 stress-70 protein, mitochondrial [Mus musculus] gi|162461907 73 kDa 2
34 non-catalytic region of tyrosine kinase adaptor protein 1 [Mus muscul... gi|34328187 43 kDa 2
35 DNA replication licensing factor MCM5 [Mus musculus] gi|112293273 82 kDa 2
36 PREDICTED: similar to Tubulin, beta 4 [Mus musculus] gi|149253488 (+4) 50 kDa 2
37 keratin, type II cytoskeletal 1 [Mus musculus] gi|126116585 66 kDa 2
38 LIM domain-containing protein 1 [Mus musculus] gi|224994267 71 kDa 2
39 phosphatidylinositol 3-kinase regulatory subunit alpha isoform 2 [Mus...gi|117320524 (+1) 84 kDa 2
40 ephrin type-B receptor 4 isoform b [Mus musculus] gi|227330573 (+1) 109 kDa 1
41 mitogen-activated protein kinase 14 isoform 1 [Mus musculus] gi|10092590 41 kDa 1
42 serpin B6 isoform b [Mus musculus] gi|6678097 43 kDa 1
43 protein-L-isoaspartate O-methyltransferase domain-containing prote... gi|23956398 41 kDa 1
44 myosin X [Mus musculus] gi|130507685 237 kDa 1
45 keratin, type I cuticular Ha1 [Mus musculus] gi|145966692 47 kDa 1
46 tensin-like C1 domain-containing phosphatase [Mus musculus] gi|119372288 152 kDa 1
47 tropomyosin alpha-1 chain isoform 3 [Mus musculus] gi|31560030 33 kDa 1
48 PREDICTED: hypothetical protein isoform 1 [Mus musculus] gi|149266991 38 kDa 1
49 keratin, type I cytoskeletal 42 [Mus musculus] gi|154090941 50 kDa 1
50 NCK-interacting protein with SH3 domain [Mus musculus] gi|49258190 79 kDa 1
51 heterogeneous nuclear ribonucleoprotein U [Mus musculus] gi|160333923 88 kDa 1
52 keratin, type I cytoskeletal 13 [Mus musculus] gi|6754480 48 kDa 1
53 PREDICTED: similar to Chain L, Structural Basis Of Antigen Mimicry In A...gi|149255637 (+2) 26 kDa 1
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Appendix 1 Table 1. List of proteins identified with 95% confidence by Scaffold 
pp g p p [ ] g |
55 PREDICTED: hypothetical protein [Mus musculus] gi|149251929 (+6) 33 kDa 1
56 DNA-dependent protein kinase catalytic subunit [Mus musculus] gi|124517706 471 kDa 1
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Experiment: Ferrando_pTyr_Src_ProteinLevelData_v2 95% probability, 1 peptide minimum, displaying Number of Unique Peptides






1 keratin, type I cytoskeletal 10 [Mus musculus] gi|112983636 57 kDa 9
2 focal adhesion kinase 1 isoform 1 [Mus musculus] gi|194353972 119 kDa 22
3 myosin-9 isoform 1 [Mus musculus] gi|114326446 226 kDa 21
4 keratin, type II cytoskeletal 5 [Mus musculus] gi|20911031 62 kDa 10
5 keratin, type I cytoskeletal 17 [Mus musculus] gi|7106335 48 kDa 7
6 actin, cytoplasmic 1 [Mus musculus] gi|6671509 (+1) 42 kDa 11
7 rho guanine nucleotide exchange factor 7 isoform b [Mus musculus] gi|165377089 (+1) 80 kDa 14
8 keratin, type II cytoskeletal 1 [Mus musculus] gi|126116585 66 kDa 2
9 paxillin isoform beta [Mus musculus] gi|114326502 (+1) 65 kDa 5
10 albumin precursor [Mus musculus] gi|163310765 69 kDa 8
11 ephrin type-A receptor 2 precursor [Mus musculus] gi|32484983 109 kDa 11
12 alpha-2-macroglobulin precursor [Mus musculus] gi|110347469 166 kDa 9
13 ARF GTPase-activating protein GIT1 [Mus musculus] gi|51921285 85 kDa 9
14 activated CDC42 kinase 1 isoform 1 [Mus musculus] gi|158711692 117 kDa 4
15 keratin, type II cytoskeletal 2 epidermal [Mus musculus] gi|124487419 71 kDa 3
16 tyrosine-protein kinase SgK269 [Mus musculus] gi|157909795 191 kDa 10
17 PREDICTED: similar to SH2/SH3 adaptor protein [Mus musculus] gi|149233948 (+1) 43 kDa 9
18 sorting nexin-18 [Mus musculus] gi|91598596 68 kDa 6
19 PREDICTED: similar to Ig gamma-2b chain membrane isoform 1 [M... gi|149263750 47 kDa 4
20 breast cancer anti-estrogen resistance protein 1 [Mus musculus] gi|40254593 94 kDa 7
21 elongation factor 1-alpha 1 [Mus musculus] gi|126032329 50 kDa 4
22 PREDICTED: similar to Chain L, Structural Basis Of Antigen Mimicry ... gi|149255637 (+2) 26 kDa 2
23 ARF GTPase-activating protein GIT2 isoform 3 [Mus musculus] gi|116517295 76 kDa 6
24 ATP-dependent RNA helicase DDX3X [Mus musculus] gi|6753620 73 kDa 5
25 keratin, type II cytoskeletal 6A [Mus musculus] gi|54607171 59 kDa 3
26 PREDICTED: similar to Hist1h2bj protein [Mus musculus] gi|149264032 (+16) 14 kDa 1
27 mitogen-activated protein kinase 3 [Mus musculus] gi|21489933 43 kDa 6
28 mitogen-activated protein kinase 1 [Mus musculus] gi|6754632 (+1) 41 kDa 3
29 DNA-dependent protein kinase catalytic subunit [Mus musculus] gi|124517706 471 kDa 1
30 heat shock cognate 71 kDa protein [Mus musculus] gi|31981690 71 kDa 6
31 vimentin [Mus musculus] gi|31982755 54 kDa 5
32 probable ATP-dependent RNA helicase DDX5 [Mus musculus] gi|83816893 69 kDa 3
33 complement C3 [Mus musculus] gi|126518317 186 kDa 5
34 neuronal proto-oncogene tyrosine-protein kinase Src isoform 2 [M...gi|70794809 (+1) 60 kDa 3
35 heat shock 70 kDa protein 1B [Mus musculus] gi|124339826 (+1) 70 kDa 3
36 keratin, type I cuticular Ha1 [Mus musculus] gi|145966692 47 kDa 3
37 gi|163310753-R gi|163310753-R ? 1
38 40S ribosomal protein S4, X isoform [Mus musculus] gi|6677805 30 kDa 4
39 ephrin type-B receptor 4 isoform b [Mus musculus] gi|227330573 (+1) 109 kDa 4
40 mitogen-activated protein kinase 14 isoform 1 [Mus musculus] gi|10092590 41 kDa 3
41 protein-L-isoaspartate O-methyltransferase domain-containing pr...gi|23956398 41 kDa 3
42 tensin-like C1 domain-containing phosphatase [Mus musculus] gi|119372288 152 kDa 2
43 PREDICTED: similar to PTB-associated splicing factor [Mus musculus]gi|149252953 (+1) 70 kDa 1
44 keratin, type I cytoskeletal 42 [Mus musculus] gi|154090941 50 kDa 2
45 Rap guanine nucleotide exchange factor (GEF) 1 isoform 3 [Mus m... gi|16905083 (+2) 122 kDa 3
46 myosin X [Mus musculus] gi|130507685 237 kDa 2
47 intersectin-2 [Mus musculus] gi|46560563 189 kDa 2
48 NCK-interacting protein with SH3 domain [Mus musculus] gi|49258190 79 kDa 2
49 PREDICTED: hypothetical protein [Mus musculus] gi|149251929 (+6) 33 kDa 2
50 thyroid hormone receptor-associated protein 3 [Mus musculus] gi|68533246 108 kDa 1
51 tubulin alpha-1B chain [Mus musculus] gi|34740335 (+8) 50 kDa 1
52 serpin B6 isoform b [Mus musculus] gi|6678097 43 kDa 4
53 non-catalytic region of tyrosine kinase adaptor protein 1 [Mus mu... gi|34328187 43 kDa 3
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55 PREDICTED: similar to Tubulin, beta 4 [Mus musculus] gi|149253488 (+4) 50 kDa 2
56 hypothetical protein LOC239796 [Mus musculus] gi|86262157 56 kDa 1
57 succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitoc...gi|54607098 73 kDa 2
58 murinoglobulin-1 precursor [Mus musculus] gi|31982171 165 kDa 3
59 elongation factor 2 [Mus musculus] gi|33859482 95 kDa 3
60 stress-70 protein, mitochondrial [Mus musculus] gi|162461907 73 kDa 2
61 FCH and double SH3 domains protein 2 isoform 1 [Mus musculus] gi|225579023 (+1) 87 kDa 3
62 tropomyosin alpha-1 chain isoform 3 [Mus musculus] gi|31560030 33 kDa 3
63 PREDICTED: hypothetical protein isoform 1 [Mus musculus] gi|149266991 38 kDa 3
64 LIM domain-containing protein 1 [Mus musculus] gi|224994267 71 kDa 2
65 keratin, type I cytoskeletal 13 [Mus musculus] gi|6754480 48 kDa 2
66 ankyrin 3, epithelial isoform a [Mus musculus] gi|116256491 (+8) 188 kDa 1
67 fibronectin 1 precursor [Mus musculus] gi|46849812 273 kDa 1
68 phosphatidylinositol 3-kinase regulatory subunit alpha isoform 2 [... gi|117320524 (+1) 84 kDa 2
69 PREDICTED: similar to very large inducible GTPase 1 [Mus musculus] gi|149257960 279 kDa 1
70 F-actin-capping protein subunit alpha-2 [Mus musculus] gi|6671672 33 kDa 2
71 gi|124249105-R gi|124249105-R ? 1
72 gi|85861220-R gi|85861220-R ? 1
73 myosin-10 [Mus musculus] gi|33598964 229 kDa 2
74 ATP-binding cassette sub-family F member 2 [Mus musculus] gi|23956078 72 kDa 1
75 heterogeneous nuclear ribonucleoproteins C1/C2 isoform 1 [Mus ... gi|8393544 34 kDa 1
76 heterogeneous nuclear ribonucleoprotein U [Mus musculus] gi|160333923 88 kDa 2
77 bromodomain and WD repeat-containing protein 3 [Mus musculus] gi|125490358 203 kDa 2
78 SH3 and PX domain-containing protein 2A isoform 1 [Mus musculus] gi|181336814 124 kDa 2
79 actin-related protein 3 [Mus musculus] gi|23956222 (+1) 47 kDa 1
80 annexin A2 [Mus musculus] gi|6996913 39 kDa 2
81 poly(rC)-binding protein 1 [Mus musculus] gi|6754994 37 kDa 1
82 glycogen synthase kinase-3 beta [Mus musculus] gi|9790077 47 kDa 1
83 gi|224994231-R gi|224994231-R ? 1
84 gi|226823286-R gi|226823286-R ? 1
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